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Sporadic colorectal cancer (CRC) has been linked to various lifestyle factors, including 
the consumption of alcohol and red meat, smoking, and obesity. CRC is one of most 
extensively characterised cancers, both at a molecular and ‘omic level; nevertheless, the 
precise mechanism driving CRC initiation remains unknown. To date, numerous studies 
have identified changes in the microbial profiles of CRCs compared to adjacent normal 
mucosa and compared to healthy controls; however, CRC-associated bacteria have not 
been concurrently quantified across a single cohort; nor have the relationships between 
CRC-associated bacteria, clinicopathological features of CRC and genomic subtypes of 
CRC been investigated.  
The main aim of this thesis was therefore to gain insight into the potential contribution 
of CRC-associated bacteria in the aetiopathogenesis of CRC by leveraging both host 
genomic and clinicopathological data as well as to investigate patterns of tissue 
colonisation between different CRC-associated bacteria. 
The objectives were 1) to quantify, using quantitative-PCR, CRC-associated bacteria in 
a cohort of 55 paired tumour and adjacent histologically normal samples collected 
during surgical resection as well as in an additional 18 formalin-fixed paraffin-
embedded (FFPE) samples; 2) to determine their relationships to patient age, gender, 
ethnicity, stage of disease, site of disease and MSI status (Chapter 4); 3) to evaluate the 
relationship between each bacterium and host gene expression (Chapter 8) and 
methylation changes (Chapter 6); and 4) to determine genomic subtypes of CRC using 
unsupervised clustering of gene expression data in the context of patient 
clinicopathological features and bacterial quantitation data; and 5) to gain a deeper 
biological understanding of the results from the objectives 1–4 using pathway analyses 
of the genomic subtypes obtained (Chapter 7). 
The main finding of this thesis is that a transcriptomic subtype of colorectal cancer, 
characterised by an increase in CpG island methylation, displays an increased frequency 
of colonisation by Enterococcus faecalis and by high levels of Fusobacterium. At the 
pathway-level, this subtype is enriched for pathways related to DNA and protein 
damage response, infection, inflammation and cellular proliferation; notably, these 
 ii 
findings were confirmed in a well-defined publically available CRC gene expression 
dataset of colorectal adenocarcinomas (N=155). These findings suggest that specific 
bacterial colonisation underlies a distinct genomic subtype of colorectal cancer that is 
characterised by inflammatory-related gene expression changes; these findings however 
require validation in a larger cohort. In addition, novel associations between 
colonisation by specific bacteria and host clinicopathological, transcriptomic and DNA 
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This chapter introduces various aspects of colorectal cancer (CRC) relevant to this 
thesis. The role of pathogenic infection and the microbiome in CRC will be discussed in 
Chapter 2. Chapter 1 starts with a brief overview of the epidemiology of CRC with 
specific reference to risk factors and the South African landscape of the disease. Then, 
colonic physiology will be described while emphasizing host defense mechanisms in 
the colon. Next, the aetiopathogenesis of CRC, with specific reference to proximal vs. 
distal CRCs, which are believed to have distinct aetiopathological features, is described. 
An overview of the role of inflammation in CRC and in irritable bowel disease (IBD) is 
provided, with specific emphasis on the effect of non-steroidal anti-inflammatory drugs 
(NSAIDs) on inflammatory-related diseases of the gastrointestinal tract. The last section 
is dedicated to epigenetic influences in cancer, which is closely linked to chronic 
inflammation. 
Epidemiology of CRC 
CRC is the third most commonly detected cancer in men and the second in women, with 
an estimate of more than 1.2 million new cases and 608,700 deaths occurring in 2008 
worldwide1. Interestingly, CRC incidence varies at least 25 fold between countries, with 
a clear distinction between developed (United States of America, Canada, Japan and 
New Zealand) and developing (South East Asia and Africa) countries2. 
In South Africa, CRC ranks in the top five most common cancers, with a lifetime risk of 
1 in 115 and 1 in 199 in men and women, respectively3. The 5-year survival rate for 
CRC patients is greater than 90% when tumours are detected at a localised, early stage. 
However, that rate drops to 40-65% once the cancer has spread regionally, and to 10% 
after distant metastases of the original tumour are detected4. Unfortunately, only 39% of 
CRCs are in fact diagnosed at an early stage––mainly due to low rates of screening5.  
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Increased rates of colonoscopy-based CRC screening between 2000 and 2008 in the 
United States have been met with a decrease in annual CRC incidence of 2.3–4.2%, 
depending on tumour location, disease stage and gender6. These figures emphasize the 
need for a better understanding of the aetiology of different classes of CRC, which is 
crucial for early prevention and detection. 
CRC risk factors 
Although epidemiological studies have provided valuable clues regarding risk factors 
for CRC, the aetiology of sporadic CRC remains an active area of research. 
CRC is significantly more prevalent in developed countries, a trend linked to lifestyle-
related risk factors, such as red meat- and alcohol- consumption, obesity, physical 
inactivity, type-2 diabetes mellitus, and smoking6–8. Further risk factors include older 
age, male gender and a family history of CRC, polyps or IBD6. Conversely, CRC risk is 
mitigated by increased intake of fiber, NSAIDs, calcium, folate, vitamin D and hormone 
replacement therapy (HRT)6,8. Meanwhile, increasing evidence supports the role of 
specific pathogens9–16, as well as dysbiosis (defined as an imbalance in the intestinal 
microbiome) in tumourigenesis17–19.  
The latest worldwide estimate of the proportion of infection-attributable cancers stands 
at 18%20. Currently, cancers with the largest proportion attributable to infectious agents 
are cervical cancers (100%), liver cancers (70%) and stomach cancers (60%)21. Not 
surprisingly, the rate of infection-attributable cancers is significantly higher in 
underdeveloped countries21,22, underscoring the necessity of continued research, 
especially in sub-Saharan Africa where the proportion of infection-attributable cancers 
is estimated at 32.7%22. Importantly, around 30% of infection-attributable cases occur 
in people younger than 50 years22. 
Southern African CRC landscape 
The incidence of CRC in Southern Africa is highly disparate between different racial 
groups––a phenomenon that appears to mirror the degree of Westernization (especially 
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regarding dietary composition)23,24; this is supported by increased rates of CRC with 
migration to westernized countries, as seen in African Americans23. Black South 
Africans have very low rates of CRC3,25,26 that contrasts starkly with their white 
counterparts3, which appears to be related to diet: Native Africans follow a diet of 
predominantly resistant starch (boiled maize meal) with a significantly lower intake of 
meat protein compared to Westernized populations; this dietary composition is met with 
high levels of microbially-derived butyrate, folate, and biotin23,27––molecules known for 
their protective effect against CRC. Interestingly, intestinal crypt cell proliferation is 
significantly lower in asymptomatic Native Africans compared to African Americans28, 
an observation which is likely explained by the protective effect of butyrate29. The low 
levels of meat protein consumed by Native Africans likely provide further protection. 
Regarding species-level composition of the gut microbiome, Native Africans have 
significantly lower levels of certain Bacteroides spp. (B. vulgatus and B. stercoris) 
compared to high-risk CRC groups, and increased levels of Lactobacillus acidophilus 
530. 
Another intriguing observation among South African CRC patients is the 
disproportionately high number of young black CRC patients; 41–57% of black 
patients25,31,32 compared to only 10% of white patients were under the age of 5031. CRC 
in young black patients do not appear to originate from colonic polyps25 and cannot be 
attributed to IBD or diverticulosis25. Indeed, the majority of these cancers are located in 
the proximal colon25,31,32 (often in the ceacum25), and often display mucinous 
histology32,33 and a higher rate of microsatellite instability (MSI) compared to older 
patients31,33. In comparison to a developed country, in California, 10.6% of African 
Americans vs. 5.5% of white CRC patients presented before the age of 50 years34, and 
black patients were more likely than white patients to develop proximal CRC24,34. 
Therefore, while the difference in the overall CRC incidence between African 
Americans and Native Africans appears to be due to differences in CRC-related lifestyle 
factors, the elevated risk of early-onset CRC appears to be at least partially influenced 
by ethnicity. 
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The relative increase in early-onset CRCs is also common in developing countries 
(where the overall CRC incidence is low) including Lebanon35, Taiwan36, Uganda37, 
Nigeria38, Ethiopia39, Sri-Lanka40, Saudi Arabia41, India42 and Egypt43. Of the 
aforementioned studies, rectal cancers were reported as the predominant site of disease 
in India, Nigeria, Uganda and Ethiopia, while an increase in proximal cancers were 
reported in Saudi-Arabia41, Taiwan36 and South Africa33. While most of these studies 
did not assess MSI status, an increase in the incidence of MSI was reported in early-
onset CRCs in Taiwan36, China44 and South Africa31.  
Because the incidence of late-onset lifestyle-related CRC is lower in developed 
countries, one might expect an increase in the proportion of early-onset CRCs, which 
are more likely due to hereditary factors. However, in many developing countries, the 
rate of early-onset CRCs with a positive family history of CRC is very low (1–
4%)35,36,40,42,43. A Taiwanese study reported no family history of CRC in 81% of early-
onset MSI+ CRCs36 , while a Chinese study reported germline mutations in mismatch 
repair (MMR) genes in 47% of early-onset (< 45 years) CRCs44. Another study 
composed of patients from the US and Scotland demonstrated that 58% of CRC patients 
≤ 35 years exhibited MSI, compared to 12% of patients > 35 years; of the younger 
patients with MSI, 42% had germline mutations in an MMR gene45. In a Scottish cohort, 
28% of CRC patients < 30 years of age had pathogenic mutations in the MMR genes 
MLH1 or MSH2.  
A substantial proportion of early-onset CRCs, especially in developing countries such 
as South Africa, are therefore of unknown aetiological origin, and warrant further 
investigation. 
Physiology of the colon 
Starting from the most apical layer, the colon consist of the mucosa, which includes the 
epithelium, the lamina propria and the muscularis mucosae; the submucosa; the 
muscularis propria; and the serosa46. Longitudinally, the regions of the colon that are 
proximal and distal to the splenic flexure have embryological origins in the mid- and 
hindgut, respectively, with distinct morphological and functional differences between 
these regions. Here, we consider the proximal colon to consist of the caecum, ascending 
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colon, hepatic flexure and transverse colon; and the distal colon consists of the 
descending colon, sigmoid colon, recto-sigmoid junction, splenic flexure and the 
rectum6.  
 
Figure 1: Illustration of different regions of the colon47. The proximal colon consists of the caecum, 
ascending colon, hepatic flexure and transverse colon. The distal colon consists of the descending colon, 
sigmoid colon, recto-sigmoid junction, splenic flexure and the rectum. 
Although the embryological boundary, two-thirds along the transverse colon, guides 
proximal-distal demarcation, many features instead change gradually along the colon. 
LaPointe et al. mapped out gene expression in the healthy colon and found that while 
some genes showed significantly differentially expressed genes between the proximal 
and distal colon, a strict dichotomous model may be too rigid, since as a subset of genes 
are better described by a continuous model, where expression changes gradually along 
the length of the colon48–50. 
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The main functions of the colon are excretion of waste, reabsorption of water and 
electrolytes from the luminal material, and processing resistant carbohydrates via 
fermentation. The latter occurs mainly in the ascending and proximal transverse colon 
through hundreds of saccharolytic and proteolytic bacterial species––mostly obligate 
anaerobes, which produce short chain fatty acids (SCFAs). Together, these SCFAs, 
which include butyrate (15%), propionate (25%) and acetate (60%), constitute 5–15% 
of the total caloric needs of an individual51. Once carbohydrates (the preferred nutrient 
source for most bacteria) are depleted, undigested proteins, originating from both the 
diet, colonic mucous and shed epithelial cells, are fermented in the distal colon. Proteins 
are converted to SCFAs, branched chain fatty acids, amines, ammonia, phenols, indoles 
and sulfurs. Products that are not absorbed by the host are either used by bacteria as a 
nitrogen source or excreted51. In addition to utilisable nutrients, bacteria provide the 
host with essential vitamins, including a variety of B vitamins and vitamin K52. 
Intestinal barrier function 
The colon is home to a rich collection of flora where interaction with the host may be 
symbiotic, commensal or pathogenic. Accordingly, the colon is well equipped to defend 
itself against harmful bacteria––the first line of defense, a 150µm thick mucous layer53 
imposes a physical and chemical barrier, which consists mainly of mucin 2 (MUC2) and 
antimicrobial effector molecules such as antimicrobial peptides, secretory IgAs, 
glycoproteins and trefoil factors, which are secreted by specialised epithelial cells54.  
Structurally, the mucous layer consists of an oligomerised mesh of mucins, with MUC2 
(the only gel-forming mucin expressed in the healthy colon55) as the major constituent. 
The mucous layer consists of a thin sterile inner layer, which is firmly adherent to the 
epithelial cells, and a partially colonised, non-adherent outer layer56. The importance of 
the mucous layer is demonstrated in mice deficient in MUC2, where bacteria are found 
in direct contact with the epithelium and even in colonic crypts, which harbour 
intestinal stem cells; these mice develop colitis57,58 which frequently progresses to 
adenomas and finally adenocarcinomas of the colon and rectum59.  
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Apart from the mucous layer, the intestinal epithelium poses a further physical barrier, 
with the negatively charged glycocalyx deterring bacteria, and tight junctions regulating 
intercellular flux60. The glycocalyx is composed of proteoglycans, glycoproteins and 
glycolipids, and plays an important role in cell-cell recognition, communication and 
intracellular adhesion. 
The integrity of the epithelial barrier may be disrupted by a range of factors (many of 
which are known CRC risk factors), including chronic alcohol consumption, 
psychological stress, chronic use of NSAIDs and specific bacteria (most notably 
pathogenic E. coli strains61). 
Specialised intestinal epithelial cells. 
The harsh environmental factors that rule the intestinal lumen are met with specialised 
epithelial cells; these include microfold (M) cells, goblet cells, Paneth cells and 
endocrine cells, each with specialised functions to maintain homeostasis54. These 
specialised cells differentiate from progenitor cells called transit-amplifying cells, 
which in turn arise from pluripotent stem cells located in the base of intestinal crypts 
(Figure 2). With the exception of Paneth cells, differentiated cells rapidly migrate to the 
luminal border after which they are sloughed off within a few days62,63. Paneth cells, on 
the other hand, migrate to the base of crypts and have a turnover rate of 6–8 weeks62. 
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Figure 2: Organisation of specialised epithelial cells along the crypt villus axis. The intestinal epithelium 
is organised into crypt and villus regions, with the stem and progenitor zone localised in the crypt. 
Transit-amplifying (TA) progenitors arise from the stem cell compartment and differentiate into 
absorptive enterocytes or secretory goblet, enteroendocrine, tuft, or Paneth cells. Most of the 
differentiated cell populations migrate up the villi, but, uniquely, the Paneth cells move downward and 
reside between the stem cells 64. 
Up to 70% of the body’s immunocytes are found in the gut-associated lymphoid tissue 
(GALT), making it one of the body’s largest lymphoid organs65. The GALT consists of 
isolated or aggregated lymphoid follicles, with the latter found in the caecum, colon and 
rectum patches. Aggregated lymphoid follicles are covered by the follicle-associated 
epithelium (FAE), which in turn consists of enterocytes and M cells. As demonstrated 
in germ-free mice, the microbiome is essential for the development of lymph node 
architecture, the GALT, and for antibody production66. This shaping of the mucosal 
immunity serves to establish physiological inflammation: a state of homeostasis where 
immune responses to commensals are down-regulated to avoid excessive and 
potentially self-damaging inflammatory responses, while maintaining low level 
inflammation to allow a rapid response to unwanted antigens54.  
Both the innate and the adaptive immune system possess feedback loops to regulate 
bacterial contact with the mucosal surface. The innate immune system monitors 
mucosa-associated bacterial density by microbial-associated molecular pattern (MAMP) 
concentration, to tailor the activation of epithelial antimicrobial responses67, which 
include secretion of antimicrobial peptides by Paneth cells, and secretion of mucins by 
Goblet cells.  
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Meanwhile, the adaptive immune system uses dendritic cells to sample live bacteria at 
the mucosal surface, which are trafficked to the GALT, where B cells are induced to 
produce bacteria-specific IgAs67, which serve to control the density of specific bacteria 
at the mucosal surface. If homeostasis is disrupted due to host and/or environmental 
factors, dysbiosis (a state associated with the overgrowth of a subset of harmful 
bacteria/single species), loss of epithelial barrier integrity and pathological 
inflammation may ensue (Figure 3). 
 
Figure 3: Colonic epithelial function during physiological vs. pathological inflammation. During 
physiological inflammation, microbial-associated molecular patterns, (MAMPs, green stars) from 
commensal bacteria are sensed by pattern recognition receptors (PRRs), which triggers basal levels of 
antimicrobial peptides (AMP) and interleukin-18 (IL-18) production, which contributes toward tolerance 
intestinal homeostasis. Pathological inflammation occurs when pathogens breach the mucus layer, contact 
intestinal epithelial cells and disrupt epithelial barrier integrity. Pathogens and their products (MAMPs, 
red stars) are also sensed by PPRs and induce expression of a pro-inflammatory cytokines/chemokines 
and AMPs that help limit pathogen propagation and contribute to the recruitment of immune cells. hBD, 
human β-defensin; mBD, mouse β-defensin; HD, human α-defensin. Figure reproduced with permission 
from Muniz et al68. 
Goblet cells 
Goblet cells are primarily responsible for the production of mucins and increase in 
concentration from the duodenum (4%) to the distal colon (16%), mirroring the 
thickness of the mucous layer and microbial density gradient in the intestine69. Notably, 
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MUC12, MUC17, MUC5B and MUC11 were found to be expressed 3.0, 1.5, 2.3 and 1.7 
fold lower, respectively in the proximal colon when compared to the distal colon48. 
Mucins can be broadly classified as either membrane-bound or secretory. Of the 
secretory mucins, MUC2, MUC5AC, MUC5B, and MUC6 are all gel-forming mucins, 
with similar structures localized on chromosome 11.5.5 as a cluster69. Membrane bound 
mucins include MUC1, MUC3A, MUC3B, MUC4, MUC12 and MUC1770. In the 
healthy colon, MUC2 is the dominant mucin, with MUC3 and MUC4 expressed at 
much lower levels71. In a diseased state, including IBD, shigellosis and CRC, several 
mucins including MUC1, MUC5AC, MUC6 may be aberrantly expressed in the 
colon71,72.  
Mucin abundance is regulated by both host- and environmental factors including 
hormones, microbes, cytokines and reactive oxygen and nitrogen species. This 
regulation may target goblet cell differentiation or mucin-synthesis and -secretion69. In 
particular, the recognition of pathogen-associated molecular patterns (PAMPs) via host 
cell pattern recognition receptors (PRRs) play a prominent role in mucin regulation via 
inflammatory pathways, as is evident in germ-free mice, which have significantly fewer 
mucin-secreting Goblet cells69,73. In the case of MUC2, various extracellular stimuli are 
transcriptionally consolidated through pro-inflammatory Nf-κB, which has binding sites 
in the MUC2 promoter69.  
M cells 
Unlike normal enterocytes, M cells lack microvilli, do not secrete mucous or digestive 
enzymes, and have a much thinner glycocalyx, allowing them to readily sample 
antigens from the lumen via endocytosis or phagocytosis, which are then delivered to 
dendritic cells and lymphocytes located in the pocket-like structure on the basolateral 
side of M cells. M cells therefore act as sentinels at the interface between the lumen and 
the lymphoid system65. However, having ready access to the lumen comes at the cost of 
exploitation by certain pathogens, which manage to escape immune detection and use M 
cells as an entry point for infection. 
Dendritic cells themselves can also sample whole bacteria that penetrate the epithelium. 
These antigens are presented to B and T cells, inducing antigen-specific IgA production. 
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IgAs are transported and transcytosed across the epithelium where they may bind to 
complimentary bacteria to prevent bacterial translocation across the epithelium53. 
Paneth cells 
Paneth cells are specialized secretory cells located at the base of intestinal crypts. 
Although Paneth cells are normally only present in the small intestine, they may arise at 
other sites including the colon and oesophagus in some diseased states, and their 
appearance is usually associated with chronic inflammation74,75. Paneth cells secrete a 
variety of antimicrobial factors including α-defensins and lysozyme C (which are active 
against gram-positive and -negative bacteria), as well as secretory group IIA 
phospholipase A2 and REG3A (a C-type lectin), which are effective against gram-
positive bacteria only75.  
Defensins are 30–40 amino acids in length and can be separated into α- and ß-defensins. 
Whereas α-defensins (DEFA5 & DEFA6) are constitutively expressed by Paneth cells 
and neutrophils, ß-defensins are inducibly expressed by a variety of epithelial cells 
including colonocytes (with the exception of ß-defensin-1, which is constitutively 
expressed)75. ß-defensins 2, 3 and 4 are induced by pro-inflammatory and bacterial 
stimuli in the colon and are upregulated in colonocytes of patients with UC, which 
correlates with an increase in TNF-α and IL-876. Similarly, REG3A is inducibly 
expressed by TLR signaling in Paneth cells and enterocytes. 
Regarding site-specific expression, MEP1B, DEFA5 and REG1A were upregulated 1.8, 
2.8 and 2.7 fold respectively, in the proximal compared to the distal colon, according to 
LaPoint et al48. 
CRC aetiopathogenesis  
CRC subtypes 
As previously mentioned, the proximal and distal regions of the colon have different 
embryological origins, and significant morphological and functional differences exist 
between the two. In the early 1980s, epidemiological data highlighted gender- and age- 
disparities in colon cancers of the proximal vs. distal colon77. Subsequent molecular and 
cytogenetic data has supported an aetiopathogenic dichotomy in CRC78–81. Moreover, 
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some environmental risk factors seem to be site-specific, such as smoking in the case of 
proximal CRC and red meat consumption in the case of distal CRC50,82,83. Although this 
dichotomous division is currently the widely accepted working model, in reality many 
molecular features vary gradually along the length of the colon with no clear divide. In 
this regard, Yamauchi et al. propose a paradigm shift towards a continuum model where 
there is a better appreciation of subsite-specific profiles, an idea supported by Benedix 
et al., who demonstrated additional prognostic value by classification according to 
colonic subsite84. However, there is currently very little focus on colonic subsite in 
current research and as such we will adhere to the dichotomous proximal-distal model 
of CRC for the remainder of this discussion. 
The main molecular feature that segregates the majority of proximal from distal cancers 
is the type of genomic instability encountered, with chromosomal instability (CIN) and 
MSI being more prevalent in distal and proximal cancers, respectively85. CIN refers to 
changes in chromosomal copy number and/or structure, which often result in the 
physical loss of genes, referred to as loss of heterozygosity (LOH). Regarding CIN by 
CRC subtype, chromosomal imbalances have been reported in 30% of MSI CRCs, 
compared to 70% of microsatellite stable (MSS) CRCs86. Various mechanisms of CIN, 
including inactivation of genes involved in the mitotic spindle checkpoint, DNA 
damage checkpoints, chromosome metabolism, and centrosome function87, as well as 
global DNA hypomethylation88 have been suggested. DNA hypomethylation is 
associated with large-scale CIN88,89, but not point mutations and short insertions and 
deletions88. In this regard, it is interesting to note that Bond et al. recently defined two 
types of CIN with distinct patterns of instability in MSS cancers: BRAF mutant and 
wild-type cases displayed ‘focal’ or ‘whole arm’ patterns of CIN, respectively90.  
On the other hand, MSI results from a loss of MMR function, which leads to strand 
slippage within repetitive DNA sequence elements and consequent insertions or 
deletions of mono- or dinucleotide repeats (microsatellites). The resulting mutations 
most notably affect tumour suppressors (containing microsatellites), such as TGF-beta 
receptor II (TGFBR2) and BCL2-associated X protein (BAX)91. MSI-positive cancers 
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can be categorized as MSI-high (MSI-H) or MSI-low (MSI-L) according to the degree 
of MSI seen.  
Sporadic MSI-H cancers account for 10–15%92–95 of all CRCs, and an additional 3–10% 
display MSI-L92,95,96. Regarding the prevalence of MSI-L, one study showed by 
examining 377 microsatellite regions that 79% of sporadic CRC showed MSI in 1–11 of 
these regions, and they concluded that the Bethesda panel of microsatellite markers (the 
gold standard for detecting MSI-H) is not very sensitive in detecting MSI-L cases97.  
Around 3% of all CRCs display MSI-H due to a loss-of-function germline mutation98–
100 in the MMR genes MLH1, MSH2 or MSH6, with respective frequencies of 50%, 
39% and 7%101. CRCs originating from germline mutations in MMR genes are referred 
to as hereditary non-polyposis CRCs (HNPCCs)––these patients have an 80% lifetime 
risk of developing CRC91 and patients may develop cancer as early as their teenage 
years. Although colorectal cancer is by far the most common type of cancer associated 
with these mutations, ovarian, gastric, small intestine, brain, urinary and biliary tract 
tumours may also occur101; it is not known why HNPCC patients are specifically 
predisposed to CRC. Loss of MMR function requires inactivation of both alleles, and in 
the case of HNPCC, this occurs via mutation or loss-of-heterozygosity (LOH), and less 
frequently via epigenetic silencing91. Regarding the mechanistic basis of MSI in 
sporadic CRC, Poynter et al. conducted comprehensive mutational screening of MMR 
genes, MLH1 methylation testing, and immunohistochemistry of MMR proteins for 
1061 population-based CRCs. They found that of the MSI-H cases with no mutational 
basis (i.e. sporadic), 60% could be explained by MLH1 methylation (although some 
literature reports are higher), a further 28% showed loss of an MMR protein (MLH1, 
MSH2 or MSH6) by IHC but did not have MLH1 methylation, while 12% were 
unexplained by MLH1 methylation or loss of MLH1, MSH2 or MSH6. In MSI-L cases, 
the MMR proteins MLH1, MSH2 and MSH6 were present by IHC in 100% of cases, 
and only 3% showed promoter MLH1 methylation, leaving 97% of MSI-L 
unexplained102.  
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Stem cells of the colon and CRC initiation 
Despite the seemingly distinct aetiopathogenic foundations of proximal vs. distal CRCs, 
aberrant activation of the Wnt signaling pathway plays a central role in an estimated 
90% of CRCs103,104. Wnt signaling is an evolutionary conserved pathway involved in 
embryonic development and tissue homeostasis105. In the healthy colon, Wnt signaling 
is restricted to colonic crypts with Wnt ligands permanently present in a gradient along 
the crypt–villus axis, facilitating stem cell homeostasis, cell renewal and repair105.  
In about 60% of CRCs, Wnt signaling is activated via loss-of-function mutations in the 
adenomatous polyposis coli (APC) gene106,107, as first discovered in patients with 
germline mutations in APC. These patients develop hundreds of colorectal adenomas 
following inactivation of the remaining wild type allele in a syndrome referred to as 
Familial Adenomatous Polyposis (FAP)108. Almost invariably, some of these adenomas 
will progress to carcinomas. 
In addition to mutation in APC, Wnt signaling may also be activated by activating 
mutations in β-catenin, allowing translocation of β-catenin to the nucleus. Mutations in 
APC or β-catenin seem to be mutually exclusive and common in distal and proximal 
cancers, respectively. Further mechanisms of Wnt signaling activation include 
inflammatory signals through NF-κB-, PI3K-, and Akt-related pathways109, or by 
promoter hypermethylation of Wnt pathway antagonists (especially in sessile serrated 
adenomas and proximal CRCs)110. 
Activation of the Wnt pathway allows β-catenin to translocate to the nucleus where it 
induces expression of an array of genes commonly implicated in CRC pathogenesis, 
including c-MYC, cyclin D1 and Axin 2. Using APC-/- mice, Oshima et al. 
demonstrated that the earliest consequence of loss of APC is an expansion of the 
proliferative zone in crypts––cells remain in a proliferative state instead of 
differentiating and migrating out of the crypt. This results in abnormal tissues 
architecture, which presents as a polyp111,112. Valuable insight regarding the nature of 
cancer initiating cells in CRC was provided by Barker et al., who demonstrated that 
stem-cell-specific loss of APC was required for adenoma formation in a Lgr5-cre mouse 
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line: these cells drove adenoma formation while remaining at the base of the crypt105,113. 
These findings demonstrate the pivotal role of Wnt signaling in CRC initiation, in a 
stem-cell-dependent manner. 
The role of inflammation in cancer 
Acute inflammation is the host’s response to tissue damage as a result of environmental 
insults such as infections, toxins, allergic reactions and autoimmune diseases. This 
response is tightly regulated and usually short-lived. However, persistent activation of 
immune cells leads to chronic inflammation resulting in DNA damage and tissue 
destruction114.  
For centuries, physicians have been aware of a link between inflammation and cancer, 
based on shared characteristics between the two processes. In 1863, Virchow et al. 
observed inflammatory cells in tumour biopsies and noted that tumours often developed 
at sites of chronic inflammation115,116. Meanwhile in 1986, Dvorak et al. described 
tumours as “wounds that do not heal”, highlighting the overlap between cancer and 
inflammation, including immune cell infiltration and angiogenesis116,117.  
The role of inflammation in both tumour initiation and development is now widely 
accepted. Cancer-related inflammation may be intrinsic or extrinsic to malignant 
transformation, although the two pathways are not mutually exclusive, as extrinsic 
inflammation may indirectly cause intrinsic inflammation following malignant 
transformation118. In the intrinsic pathway, an inflammatory response is activated as a 
consequence of malignant transformation. In the extrinsic pathway, chronic 
inflammation, which may be caused by various environmental factors, including 
smoking, exposure to pathogens and a Western style diet, facilitates malignant 
transformation118. 
During chronic inflammation, the balance between pro- and anti-inflammatory 
cytokines is disrupted, creating a pro-carcinogenic environment. Certain pro-
inflammatory cytokines have repeatedly been implicated in tumour initiation and 
progression of various cancers––these include TNF-α, IL-6 and IL-1β118–120. Lack of 
Back to table of contents 18 
anti-inflammatory cytokines is equally detrimental, as demonstrated in IL-10-/- mice, 
which develop colitis and colitis associated cancer (CAC)114.  
Pro-inflammatory cytokines activate transcription factors such as NF-κB and STAT3, 
which in turn trigger genes involved in diverse cellular processes relevant to both 
tumour initiation and progression. In addition to activation through pro-inflammatory 
cytokines (including TNF-α and IL-1β), NF-κB is activated through TLRs that 
recognize microbial signatures114. NF-κB signaling has been causally implicated in 
pathogen-induced cancers such as HBV-related liver cancer and HPV-related cervical 
cancer121; blocking NF-κB signaling has been shown to suppress experimental colitis in 
mice121–123.  
In conclusion, tumour-promoting inflammation is considered one of the enabling 
characteristics of cancer that facilitates acquisition of the hallmarks of cancer described 
by Hanahan et al124. Inflammation can contribute to multiple cancer hallmarks including 
the induction of angiogenesis; invasion and metastasis; sustained proliferative signaling, 
resisting cell death; and evading growth suppressors124. Inflammation is therefore a key 
feature in most cancers. One key question that is particularly relevant to this thesis is the 
degree of inter-individual variation in extrinsic, cancer-promoting and to what extent 
this extrinsic inflammation is caused by host genetic factors or external stimuli such as 
pathogens, smoking and a Western style diet. 
Inflammation, IBD and CRC 
The two major forms of IBD, UC and Crohn’s disease (CD), are strongly linked to 
chronic inflammation. While CD may affect any part of the GIT, it most commonly 
affects the lowest part of the small intestine, the ileum. UC on the other hand is limited 
to the colon and rectum. Increased severity and duration of IBD are accompanied by an 
increased risk of developing CRC with an average risk of 2–3 fold for all IBD 
patients114 
Elevated levels of TNF-α and NF-κB signaling commonly occur in IBD and antibodies 
against TNF-α have proven effective in the treatment of IBD114,121. The aetiology of 
IBD involves the complex interplay between the host and its microbiome: around 100 
genetic loci have been associated with IBD risk and specific bacteria and dietary factors 
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are also associated with the disease114,125. It is generally thought that IBD is the result of 
an inappropriate immune response to commensal bacteria; however, several studies also 
support the role of specific adherent pathogens, and in particular, adherent strains of E. 
coli in the pathogenesis of IBD126,127. The recent surge in metagenomic studies will 
undoubtedly increase our knowledge regarding variability in the human 
microbiome128,129, which may help identify specific microbial profiles that correlate to 
disease susceptibility. 
NSAIDs and inflammatory-related diseases of the gastrointestinal tract 
The ability of aspirin and other NSAIDs to decrease the risk of developing CRC, as well 
as other cancers, has recently received much attention, lending further support to the 
carcinogenic role of inflammation130,131.  
Several studies have demonstrated long-term protection against CRC (including 
HNPCC) with regular use of aspirin130,132–134. The magnitude of the effect appeared 
increase with treatment duration (2.5 years vs. 5 years), rather than the concentration of 
aspirin, with no additional reduction in the 20-year CRC incidence and mortality above 
75mg/day130. Interestingly, the chemopreventive benefit of aspirin also varied by 
colonic site––with at least five years of aspirin use, the risk of developing proximal and 
rectal colon cancers was reduced by 70% and 50%, respectively, while no benefit was 
seen in distal cancers130.  
A host of putative mechanisms underlying the chemopreventive effects of aspirin have 
been proposed135. These mechanisms may be divided into COX-dependent and COX-
independent methods. Aspirin inhibits both COX-1 and COX-2 through acetylation, 
thereby modulating arachidonic acid metabolism and exerting its analgesic and anti-
inflammatory effects via COX-2. Whereas COX-1 is constitutively expressed in most 
tissues, COX-2 is inducibly expressed in response to growth factors, cytokines and 
tumour promoters, and is 50–100 fold less sensitive to aspirin compared to COX-1135. 
COX-2 metabolises arachadonic acid to PGH2, but inhibition by aspirin leads to 
incomplete metabolism with a concomitant shift in metabolites, now favoring, among 
other metabolites, the production of lipoxins, which are known to inhibit cancer cell 
proliferation and angiogenesis135. Further, COX-2’s infamous role in tumour promotion 
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and progression is largely based on the production of the pro-inflammatory prostanoid 
PGE2, that stimulates proliferation, inhibits apoptosis, and promotes motility, invasion 
and angiogenesis135. 
Interestingly, it has been suggested that aspirin promotes apoptosis of MSI-H cells, 
where critically unstable cells are removed from the population, resulting in a largely 
MSS population, even in the presence of a dysfunctional MMR system, as evidenced 
from MMR deficient CRC cell lines and a mouse model of HNPCC133,136. Using a 
mouse model of HNPCC, Mcilhatton et al. recently demonstrated a reduction in MSI 
upon long-term administration of aspirin, with a concomitant 18–21% increase in life 
span. Although the difference did not reach statistical significance, untreated HNPCC 
mice showed MSI-L and MSI-H in 39% and 33% of cases, whereas aspirin-treated mice 
showed MSI-L and MSI-H in 56% and 22% of cases. This effect was however obtained 
in homozygous null MSH2 mice, whereas HNPCC patients are heterozygous carriers of 
MMR mutations, suggesting that the effect on preventing MSI might be increased under 
long-term, low dose aspirin use in HNPCC carriers, compared to the 400mg/kg dose 
that was required in the HNPCC mouse model133. The finding that aspirin is more 
effective in preventing proximal cancers lends further credence to an MSI-based 
mechanism of protection.  
The mechanism whereby aspirin might prevent MSI is still unclear, but it seems 
plausible that it is related to a reduction in inflammation and oxidative stress, since 
these conditions are known to promote MSI137–139. In relation to HNPCC carriers, Kloor 
et al. recently found that MSI+, MMR-deficient crypt foci (where bi-allelic MMR gene 
inactivation has occurred) are prevalent in the colons and small bowels of HNPCC 
patients: about one per 1 cm2 or 2 cm2, respectively140; this is in stark contrast to the low 
number of clinically manifest HNPCC cancers, a discrepancy that suggests that most 
MMR deficient crypt foci do not progress to cancer136. Indeed, despite the prevalence of 
MMR-deficient crypt foci in the small bowel, only ±4% of patients with HNPCC 
developing small bowel cancers141. Since the vast majority of MMR mutational carriers 
develop CRC specifically, it seems plausible that the colonic environment somehow 
potentiates tumourigenesis, either by putting extra pressure on an already MMR 
Back to table of contents 21 
deficient system thereby inducing MSI, or by an MSI-independent mechanism. In such 
a pro-inflammatory and -tumourigenic environment regular use of aspirin may tip the 
scales towards an anti-inflammatory environment, thus abrogating chronic inflammation 
that may be caused by chronic pathogenic infection or other environmental stimuli. 
However, this still does not explain why a relatively short course (~5 years) of treatment 
with aspirin confers long-term protection (10–20 years follow up) against CRC in 
HNPCC patients. 
Given the preventative role of regular aspirin use in CRC, together with the association 
between inflammation, IBD and CRC, one would reasonably expect NSAIDs to have a 
similarly preventative effect on IBD-related diseases. However, the data regarding the 
association between NSAID use and IBD are conflicting7,142,143, and appear to depend in 
part on the type of NSAID used143. These results may also be confounded by the 
accuracy of IBD diagnosis, which may be confused with drug-induced colitis, where 
NSAIDs cause IBD-like ulceration144,145. Irrespective of whether NSAIDs increase the 
risk of IBD, regular use appears to be at least moderately protective against CRC in IBD 
patients142,146. 
Epigenetic influences in cancer 
According to the classical model, cancer arises from an initiating mutation, which is 
followed by a series of mutations in tumour suppressor genes and oncogenes, resulting 
in clonal selection and tumour heterogeneity. With increasing knowledge of the role of 
epigenetics in health and disease, it is becoming apparent that not only mutations but 
also epigenetic modifications play a pivotal role in various cancers. 
The epigenetic landscape is sculpted by post-translational modifications to DNA and 
histones, which are essential to normal processes such as cellular differentiation, X-
chromosome inactivation and genomic imprinting147.  
Of the epigenetic marks, changes in DNA methylation has received most attention, with 
a growing body of evidence supporting a causal role for various environmental factors, 
including alcohol consumption, caloric intake, cigarette smoking and pesticides in 
aberrant methylation, which in turn has been associated with various diseases including 
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diabetes, asthma, cancer, Alzheimer’s and atherosclerosis148,149. Furthermore, both 
bacterial and viral pathogens have been linked to aberrant methylation of host DNA: 
Helicobacter pylori induces aberrant DNA methylation in gastric cells; this 
phenomenon is most likely triggered by an inflammatory response to H. pylori rather 
than directly by the bacteria since the immunosuppressive drug cyclosporin A blocks 
aberrant DNA methylation in H. pylori-infected mice without affecting H. pylori 
colonisation150. Furthermore, Epstein-Bar virus+ gastric cancers have distinct patterns 
of methylation151. 
Aberrant methylation is a common occurrence in CRC, with global hypomethylation, 
and region-specific hypermethylation associated with CIN+ and MSI+ CRCs, 
respectively152–154. About 70% of proximal cancers with MSI exhibit aberrant 
hypermethylation of CpG islands (referred to as the CpG island methylator phenotype 
(CIMP))155 and hypermethylation of the promoter region of MLH1 is the main cause of 
sporadic MSI CRCs102.  
Global hypomethylation occurs particularly in non-CpG-island regions of the genome, 
including repetitive sequences, and in CpG island shores156. While hypomethylation has 
been associated with activation of tumour suppressors in a few genes (e.g. CDH3), the 
most apparent consequence of global hypomethylation is CIN88,89. This occurs when 
pericentromeric regions are demethylated, which facilitates recombination and altered 
chromosomal replication156. 
An epigenetic basis for cancer was suggested by Feinberg et al. who suggested that 
cancer has a fundamentally common basis that is grounded in a polyclonal epigenetic 
disruption of stem/progenitor cells; these changes are mediated by ‘tumour-progenitor 
genes’ which increase the capacity for self-renewal and pluripotency157. Hypothetical 
tumour progenitor genes would have a direct effect on a) DNA with both genetic and 
epigenetic consequences (e.g. APOBEC), b) stem cell genes (e.g. OCT4, FOXD3, 
NANOG) or c) genes that affect chromatin e.g. (EZH2)157. 
These epigenetic changes set the stage for initiating mutations as well as genetic and 
epigenetic plasticity157. This model is supported by in vitro and in vivo studies where 
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tumour cells demonstrate reversibility of phenotype, indicating epigenetic control. 
Furthermore, global hypomethylation, and in many cases promoter hypermethylation, 
precedes initial mutations in cancer, with epigenetic alterations found even in benign 
neoplasms157.  
In conclusion, epigenetic modifications undoubtedly play a crucial role in 
carcinogenesis, particularly during the initiation stage. However, whole-genome 
epigenetic research is still in its infancy and at this stage it is unclear to what extent 
aberrant epigenetic changes in progenitor/stem cells drive cancer initiation and to what 
extent epigenetic mechanisms contribute to each of the hallmarks of cancer124. 
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Chapter 2: The infectious link to colorectal cancer 
 
Abstract  
Oncogenic pathogens have been discovered in numerous cancers, including cervical, 
lung, liver and gastric cancer. At least 18% of all cancers were attributed to infection in 
a global report on infection-associated cancers in 2002, a number that is expected to 
grow.  
From other infection-attributable cancers, we know that only a small proportion of 
individuals initially infected with the relevant pathogen will develop cancer, and that 
this progression is dependent on chronic long-term infection. Further, genetic, 
environmental and strain-specific factors modify the susceptibility to the oncogenic 
potential of these microbes. 
In the case of CRC, pathogenic shifts in the microbiome (dysbiosis) and/or infection 
with specific pathogens may play a role in the aetiopathogenesis of CRC. Although 
there is ample epidemiological and/or in vitro evidence for an association between 
specific bacteria and CRC, causality has not been established thus far.  
This chapter outlines established oncogenic pathogens, and their shared characteristics, 
followed by a discussion of factors that influence the composition of the colonic 
microbiome and possible links to CRC aetiopathogenesis. Finally, CRC-associated 
bacteria and their putative oncogenic mechanisms are described.  
The role of microbes in cancer  
Although several cancer-microbial associations have been documented, only a handful 
of pathogens have been unequivocally established as oncogenic thus far158. Even so, 
18% of all cancers were attributed to infection in a global report on infection-associated 
cancers in 200220. Given the steady increase of cancer-microbial associations being 
uncovered, this is likely an underestimate of the true fraction of infection-dependent 
cancers. However, establishing causality is no easy task: certain bacteria may induce 
tumour growth, but subsequently decline once the tumour forms; others may 
opportunistically infect existing tumours without contributing to disease progression159; 
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while some may even selectively kill tumour cells. In fact, the observation that 
advanced tumours spontaneously regress in certain cancer patients following an 
infection prompted inquiry into the use of bacteria as a cancer therapeutic tool160. A 
multitude of bacterial strains across diverse genera have now been explored for both 
their standalone therapeutic potential, as well as their potential to be used as vectors for 
cancer therapy160.  
Clearly, one needs to sift through numerous cancer-microbe associations to uncover any 
true oncogenic pathogens. Further, an oncogenic pathogen, even if present at very low 
concentrations, may affect the system in a manner analogous to the butterfly effect, so 
that one cannot readily pinpoint the original trigger. As summarized in the keystone-
pathogen hypothesis, certain low-abundance microbial pathogens can orchestrate 
inflammatory disease by remodeling a normally benign microbiota into a dysbiotic one. 
This is based on the observation that certain species have disproportionately large 
effects on their communities, given their abundance, and are thought to form the 
‘keystone’ of the community’s structure161. As an example, it has been proposed that 
Porphyromonas gingivalis, a minor constituent of periodontal biofilms (which is not 
able to induce periodontitis by itself), impairs the host’s innate immune response, 
leading to dysbiosis-induced inflammation, which manifests as periodontitis161. Similar 
scenarios may exist in the case of IBD and CRC. 
Established oncogenic pathogens 
Established oncogenic viruses and the cancers they cause include Epstein–Barr virus 
and Burkitt’s Lymphoma; Hepatitis C and B viruses and hepatocellular carcinoma; 
Human Herpesvirus 8 and Kaposi’s sarcoma; and Human papillomavirus (HPV) and 
cervical cancer158,162. Among bacteria, only Helicobacter pylori has been established as 
oncogenic, through evidence from large-scale epidemiological studies with long-term 
follow up data158,163.  
In the case of HPV, which expresses oncogenic proteins that transform infected host 
cells164, the pathogenic mechanisms involved are very clear. In many cases however, 
multiple pathogenic methods may be implicated. With Helicobacter pylori for instance, 
although chronic inflammation appears to be a major oncogenic driving force, the H. 
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pylori effector protein, CagA, which is injected directly into host cells, induces multiple 
cancer-related pathways in the host, including ERK-MAPK signaling pathway, which 
likely further contributes to oncogenesis165.  
Despite diverse pathogenic mechanisms, certain shared characteristics between 
oncogenic pathogens are worth noting: Firstly, only a small proportion of individuals 
initially infected with the relevant pathogen will develop cancer, and secondly, this 
progression is dependent on chronic, long-term infection. For example, 10–90% of the 
population is chronically infected with H. pylori, depending on geographical location166, 
of which 10–15% will experience recurrent gastroduodenal ulceration, but only 1–2% 
of infected individuals will eventually develop gastric cancer166. These figures point to 
obvious genetic, environmental and strain-specific risk modifiers that govern 
susceptibility to the oncogenic potential of these microbes. Finally, the proportion of a 
given cancer type that may be ascribed to the relevant infectious agent is variable: 
virtually 100% in the case of HPV-related cervical cancers worldwide5,20, and at least 
60% of all gastric cancer cases (and 75% in the case of noncardia gastric cases), in the 
case of H. pylori20,21.  
The CRC-associated microbiome 
The human microbiome consists of approximately tenfold as many cells as the human 
body and collectively weighs 1–2kg56, with the colon containing an estimated 1011–1012 
cells/g of luminal contents167. Through two major initiatives––the Human Microbiome 
Project, and the Metagenomics of the Human Intestinal Tract (MetaHIT) consortium, 
the relationship between the human microbiome, the environment and host genetics is 
steadily being uncovered, revealing possible intricate links to various diseases, 
including cancer, diabetes and obesity168.  
Factors influencing the composition of the colonic microbiome 
In the healthy colon, the immune system tolerates antigens derived from commensal 
flora169, the mucosal barrier provides a robust barrier to colonisation by pathogens, and 
beneficial bacteria dominate over potentially harmful bacteria––this state is referred to 
as eubiosis. On the other hand, dysbiosis is described as qualitative and quantitative 
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changes in microbial composition, changes in microbial metabolic activity and changes 
in the local distribution of specific microbes170; dysbiosis may occur due to various 
environmental insults including antibiotics, long-term dietary patterns128,171 and 
psychological stress172,173. Dysbiosis is correlated with various chronic disease states 
including diabetes174, IBD175 and CRC16,176,177. Based on next generation sequencing 
efforts, temporal associations between microbiota and developing tumours in CRC have 
been described178; similarly, a progressive decrease in SCFAs and a change in microbial 
profile from healthy controls to adenomas to CRCs have been noted, which suggests 
that dysbiosis occurs at the adenoma stage or earlier, and intensifies with tumour 
development179. The question of whether dysbiosis is a cause or a consequence of 
disease is at least partially answered by transplantation experiments where microbiota is 
transplanted from diseased to germ-free healthy animals, an event which is 
accompanied by transference of the donor disease phenotype. This has been 
demonstrated in the case of obesity, metabolic syndrome and colitis180. 
Long-term dietary patterns, particularly regarding the proportion and type of fats and 
polysaccharides, directly affect microbial composition due to substrate specificity128. 
While Prevotella spp. dominate under carbohydrate-rich diets, Bacteroides spp. are 
associated with diets high in proteins and animal fat171. The bacterial metabolite profile 
produced under different diets directly impact host health; under sulfate-rich diets for 
example, sulfides are produced by sulfate-reducing bacteria, leading to the production 
of hydrogen sulfide which damages the colonic mucosa and increases mucosal 
permeability170. Intriguingly, microbial composition might explain some of the risk 
modulatory effects of diet on CRC. O’ Keefe et al. found that Native Africans (risk 
cancer incidence < 1:100 000), who consumed more resistant starch and less red meat 
and animal products, had significantly higher levels of butyrate (and total SCFA) when 
compared to African Americans (risk 65:100 000) and Caucasians (risk 50:100 000) 
who consumed a high animal-protein and -fat diet23,27. Since the presence of butyrate 
can be wholly attributed to bacterial activity, it can be concluded that the natural 
microbiota may be mediating a proportion of the risk associated with consuming a high 
animal-protein and -fat diet. In terms of microbial composition, Prevotella spp. and 
Bacteroides spp. (corresponding to different gut enterotypes)181, predominate in Native 
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Africans and African Americans, respectively27. Together with a decrease in SCFAs, a 
Western-style diet rich in animal fats, red meat and alcohol (known CRC risk factors) 
promote microbial production of carcinogens182 and decreases barrier function, which 
facilitates E. coli colonisation183. 
Psychological stress can also affect microbial composition172,173; mechanisms that may 
explain this effect include impairment of intestinal barrier function184–186(which is 
partially explained by reduced production of mucins187); decreased production of 
immunoglobulin A (IgA); as well as the production of various catecholamines, which 
increase dramatically in response to stress and encourage the growth of potentially 
pathogenic microbes170––norepinephirine in particular has been linked to overgrowth 
and increased expression of E. coli virulence factors170,188,189.   
Finally, host-genetic factors influence the composition of the gut microbiome. This has 
been most evident in the case of IBD susceptibility genes. Determining to what extent 
microbial variation depends on the host genome as a whole has been more challenging. 
Studies comparing the microbiome of dizygotic vs. monozygotic twins, have thus far 
failed to identify a significant host-genotype effect, perhaps due to lack of statistical 
power180. Examples, of single gene effects include carcinoembryonic antigen-related 
cell adhesion molecule 6 (CEACAM6), which is often overexpressed in patients with 
Crohn’s disease; CEACAM6 acts as a receptor for adherent-invasive E. coli (AIEC) that 
subsequently colonise the intestinal mucosa and induce inflammation190; in mice, 
NOD2-dependent dysbiosis predisposes mice to transmissible colitis and CRC by 
creating a pro-inflammatory environment and disrupting epithelial barrier function. The 
microbiota of NOD2-deficient mice, which are transferrable to wild type mice, 
sensitizes the colonic mucosa to injury191; finally fucosyltransferase 2 (FUT2), is 
responsible for the synthesis of an oligosaccharide moiety (H antigen) that acts as an 
attachment site as well as a carbon source for bacteria. Loss-of-function mutations in 
FUT2 increase susceptibility to Crohn’s disease, through altering microbial composition 
(which leads to chronic inflammation)192,193. Other disease-predisposing genes that 
affect microbial composition include defensin genes, MYD88 and HLA genes180. 
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CRC-associated bacteria 
Given the current evidence, at least three theories can explain a causative role of 
bacteria in CRC: 1) Dysbiosis creates a pro-carcinogenic environment due to the lack of 
beneficial bacteria and a relative increase in pro-carcinogenic bacteria with non-specific 
oncogenic effects such as inflammation, and the production of pro-carcinogenic 
metabolites; 2) Chronic infection with a single oncogenic pathogen causes CRC in 
susceptible individuals (e.g. H. pylori infection in gastric cancer) through directly 
manipulating host cellular signaling and/or non-specific effects such as chronic 
inflammation or 3) A combination of 1) and 2), where dysbiosis promotes a pro-
carcinogenic environment, and facilitates colonisation by opportunistic pathogens (with 
oncogenic potential) due to disruption of mucosal barrier function.  
Recent studies, either through epidemiological and/or in vitro results, have linked 
Enteropathogenic E. coli (EPEC)9,10, Fusobacterium.16,194–196, Streptococcus 
gallolyticus12,13,197, Enterococcus faecalis198–202, Enterotoxigenic Bacteroides fragilis 
(ETBF)14,15,203, as well as viruses (polyoma viruses (JC and SV40), human 
papillomavirus, Epstein Barr virus, and cytomegalovirus)204,205 to CRC. The oncogenic 
potential of the bacteria, as well as suspected bacterial components implicated in the 
aetiopathogenesis of CRC are summarised in Table 1 in Chapter 4. 
Escherichia coli and CRC 
While E. coli has a core genome of ~2000 genes, the average E. coli genome consists of 
4721 genes, with a complete pool of around 8000 genes; a high rate of recombination 
underpins the adaptability of E. coli strains and results in the high level of strain 
diversity. Although up to 300 E. coli strains may be present in any individual, each 
person is commonly colonised by a single dominant strain that constitutes more than 
half the colonies isolated from faeces206. The dominant strain is usually also the resident 
strain, which may be present for months or years206.  
Both IBD and CRC patients are commonly colonised by E. coli strains with adherent 
and/or invasive properties127,207,208. Using 16S rRNA sequence analysis, Swidsinski et al. 
showed that while only 3% of biopsy specimens from healthy controls contained any 
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type of bacteria (that had successfully colonised the epithelium), ~90% of patients with 
adenomas or carcinomas had 103–105 bacteria in both malignant and macroscopically 
normal samples. E. coli was the dominant bacterial species in 3%, 62% and 77% of 
patients who were asymptomatic, had adenomas, or carcinomas, respectively; further, E. 
coli was partially intracellular in 87% of E. coli-positive patients207.  
These findings are supported by Martin et al. who demonstrated the presence of 
intramucosal E. coli in 33% and 14% of colon cancer tumour and matched normal 
biopsies respectively vs. in 9% of controls127. They further demonstrated that strains 
isolated from tumour or normal biopsies from a given patient were identical. 
Only recently has further characterization identified a specific group of E. coli strains 
associated with CRC: These strains, first identified in patients with Crohn’s disease, 
were classified as adherent-invasive E. coli (AIEC)––a new pathogenic group––in 1999, 
based solely on phenotypic traits, and the absence of genes previously related to 
invasion in pathogenic strains of E. coli209. With no AIEC-specific genes identified, 
these strains are identified by their ability to adhere to and invade intestinal epithelial 
cells; the ability to survive and replicate in macrophages without triggering host cell 
death; and the ability to trigger TNF-α release by infected macrophages210.  
AIEC 
Recent studies have identified E. coli virulence factors commonly found in AIEC that 
might be relevant to CRC; these include pks, afaC, lpfA and cnf1. The polyketide 
synthases (pks) genomic island encodes the colibactin (clb) genotoxin, which induces 
DNA double-strand breaks in an ex vivo mouse intestinal model11. In vitro, epithelial 
cells infected with pks+ strains displayed increased mutation frequency and anchorage-
independent colony formation, which suggests oncogenic potential11. Moreover, pks-
positive E. coli promote CRC progression in colitis-susceptible interleukin-10–deficient 
(Il10−/−) mice, through its genotoxic capabilities211.  
Clinically, these results are supported by the finding that E. coli strains expressing afaC, 
lpfA or pks (or a combination thereof) were significantly more common in CRC cases 
compared to healthy controls212,213.  
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EPEC 
EPEC causes severe watery diarrhea, particularly among infants in developing countries, 
and asymptomatically infects an unknown proportion of adults. EPEC is closely related 
to enterohaemorrhagic E. coli (EHEC) and Citrobacter rodentium, which are 
collectively referred to as attaching/effacing E. coli (AEEC) (not to be confused with 
AIEC), due to their ability to attach to epithelial cells and cause loss of microvilli 
(effacement). C. rodentium infects small animals and is widely used to model human 
EPEC and EHEC infection in mice. EPEC can be divided into typical and atypical 
EPEC (aEPEC); where aEPEC lack the EPEC adherence factor (EAF) plasmid214. 
The first clue that AEEC might have oncogenic potential is that C. rodentium causes 
transmissible colonic hyperplasia in immunocompetent mice215. Recent in vitro 
evidence, suggest that MSI-positive CRCs may be caused by EPEC infection in 
susceptible individuals by downregulating MMR proteins (MLH1 and MSH2) in CRC 
cell lines, in an attachment-dependent manner9,10. Following EPEC-infection of normal 
colonic mucosa samples, bacteria were able to enter ~10% of colonic crypts and 
subsequently attach to areas that contain undifferentiated proliferative epithelial cells9, 
which are believed to be the cells-of-origin for CRC113. Maddocks et al. found AEEC in 
25% (5/20) of formalin-fixed paraffin-embedded (FFPE) CRC samples and in none of 
the matched normal samples, as measured by PCR detection of the intimin (eae) gene; 
AEEC were present at tens to tens of thousands of bacteria/FFPE section judged by 
immunofluorescence staining9. 
More recently, Maddocks et al. showed that in vitro EPEC-induced depletion of the 
mismatch repair proteins occurs at the protein level and that depletion of MLH1 and 
MSH2 was dependent on mitochondrial targeting of the EPEC effector protein EspF, 
which caused depletion of mismatch repair proteins and increased mutational frequency 
of infected cells10.  
In a proteomic analysis of the response of intestinal epithelial cells to EPEC infection, 
MSH6 protein levels were increased more than 7-fold in a Caco-2 EPEC-infected cell 
line compared to a type III secretion-deficient mutant EPEC infection, while MLH1- 
and MSH2-proteins were not reported. In the same system, DNA-damage binding 
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protein 1 (DDB1) was downregulated two-fold in wild type EPEC-infected cells216. 
Notably, DDB1 is involved in host-virus interaction e.g. EB-virus, which has been 
noted as a causal factor in gastric cancer205.  
Many EPEC effectors have been studied in detail and, in terms of their potential to 
promote tumourigenesis, exhibit disparate effects: NIeC and NIeD inhibit NF-kB and 
AP-1 respectively, both oncogenes. On the other hand NIeH1 activates the oncogene 
Bax-inhibitor-1, while EspG and EspZ activate p21-activated kinase (PAK) and focal 
adhesion kinase (FAK), respectively. A recent review by Wong et al. provides a 
complete overview of all 27 EPEC effectors that have been identified to date, and their 
cellular function217.  
Fusobacterium spp. 
An association between Fusobacterium spp. and CRC was discovered via metagenomic 
analyses; multiple independent studies have now confirmed enrichment with 
Fusobacterium spp. in biopsy samples from CRC patients compared to the adjacent 
normal mucosa and compared to healthy controls16,194,195. McCoy et al. also found 
significantly higher numbers of Fusobacterium spp. in the normal mucosa of patients 
with adenomas compared to healthy controls, suggesting a possible early role for 
Fusobacterium in CRC195. In the APCMin/+ mice, F. nucleatum infection accelerated 
tumourigenesis, characterised by infiltration of specific myeloid cell subsets into 
tumours and an Nf-kB pro-inflammatory signature (which included COX-2, TNF-α and 
IL-8) that is shared in human Fusobacterium-infected CRC tissue218. However, F. 
nucleatum infection alone may not be oncogenic since it stimulates proliferation in CRC 
cell lines but not in non-neoplastic cell lines. Further, F. nucleatum is found at 
significantly higher levels in tumours compared to the adjacent normal mucosa16,194,219, 
which suggests that the tumour provides a niche environment that is exploited by these 
bacteria. 
Streptococcus gallolyticus 
Streptococcus bovis, which is present in 2.5–15% of healthy individuals159, causes 10–
15% of bacterial endocarditis cases197. An association between Streptococcus bovis-
Back to table of contents 33 
bacteraemia/endocarditis and CRC was first investigated in the 1950’s220. Subsequently, 
a multitude of retrospective studies and case control studies have reported this 
association, but with varying incidence rates (6–67%)13,197. 
S. bovis has since been sub-classified as S. gallolyticus ssp. gallolyticus (S. bovis I), S. 
infantarius ssp. infantarius (S. bovis II⁄1) and S. gallolyticus ssp. pasteurianus (S. bovis 
II⁄2)221. S. bovis associated CRC was subsequently found to be much more strongly 
associated with S. gallolyticus ssp. gallolyticus compared to the other subtypes (pooled 
odds ratio = 7.26; 95% confidence interval = 3.94–13.36)13.  
A study investigating the incidence of S. gallolyticus ssp. gallolyticus infection among 
CRC patients with or without a history of S. gallolyticus/bovis bacteremia, found 
infection in 48.7% and 32.7% of tumours, respectively; similar levels of S. gallolyticus 
were detected in the corresponding normal tissue samples, while only 2% of control 
biopsies were infected12. Interestingly, these results were limited to tissue samples (with 
no significant difference between groups in feacal or mucosal infection), which indicate 
intimate adherence/invasion in CRC patients. S. gallolyticus infection was not 
associated with stage, grade, or location of the tumours, or with age or gender12. 
S. gallolyticus has the following pro-carcinogenic traits: S. gallolyticus or its wall 
extracted antigens (WEA) stimulates COX-2 expression in rats pretreated with the 
carcinogen azoxymethane, thereby triggering MAPK signaling and the progression of 
preneoplastic lesions4; this is supported by the increased expression of the pro-
inflammatory cytokines (IL-1 and COX-2) in S. gallolyticus-positive CRC patients in 
both tumour and normal tissues compared to S. gallolyticus-negative CRC patients12. 
Enterococcus faecalis 
Traditionally classified as a human commensal, E. faecalis, is in fact one of the most 
common causes of nosocomial infections222. E. faecalis has been linked to CRC due to 
significantly higher fecal levels of the bacterium in CRC patients compared to healthy 
controls198. 
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Mechanistic ties to oncogenesis include the production of extracellular reactive oxygen 
species (ROS) and induction of COX-2 expression, which leads to inflammation and 
CRC in IL-10 knockout mice199,202,223, which induces aneuploidy and tetraploidy in an 
in vitro model of infection223. 
Enterotoxigenic Bacteroides fragilis (ETBF) 
ETBF is a pathogenic strain of the commensal B. fragilis, which secretes a heat-labile 
metalloprotease (B. fragilis toxin (BFT)) and causes human inflammatory diarrhea in 
susceptible individuals. In faecal samples, ETBF is found in ±12% of healthy 
controls14,224, 27% of patients with diarrhea224, and 38% of patients with CRC14. 
However, infection rates appear to vary largely by geographical location225. 
In addition to causing diarrhea in susceptible individuals, ETBF induces colitis and 
colonic tumours in Apc/+ min mice15; BFT cleaves the extracellular domain of E-
cadherin, which triggers ß-catenin nuclear signaling, followed by c-MYC expression 
and cellular proliferation203; ETBF-induced colitis, colonic hyperplasia and tumour 
formation could be prevented by inhibiting the inflammatory cytokines IL-23 and IL-17. 
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Chapter 3: Study design, clinicopathological characterisation, 
and sample processing 
 
Abstract 
In this chapter, the aims and objectives of this thesis are stated and a schematic 
representation of the study design is supplied. 
Next, the clinicopathological characteristics of our CRC cohort, sample preparation and 
storage methods, as well as sample size and power calculations are presented.  
Our cohort consists mainly of mixed ancestry patients (70%), with around 90% of cases 
of sporadic origin, and a remaining 10% of cases of confirmed hereditary non-polyposis 
CRC (HNPCC). Regarding site of disease, 60% of CRCs were located in the rectum, 
18% in the proximal colon and 22% in the distal colon. Furthermore, 81.6% of our 
cohort presented with stage II or III CRCs. We further recorded patient gender, age, 
BMI, familial history of cancer, smoking or alcohol consumption, as well as 
histopathological features noted in pathology reports and chemotherapy and/or radiation 
treatment received. 
In order to minimize the effect of intra-sample heterogeneity for the fresh-frozen cohort 
(N=55), we simultaneously extracted DNA, RNA and protein from a single tissue 
sample, and bacterial detection and whole genome analysis (including transcriptomic 
and epigenomic analyses presented in Chapters 6–8) were conducted on these samples, 
when possible. In some instances, these could not be used do to lack of sample 
availability, poor sample quality or the nature of downstream applications (e.g. the 
extraction of DNA from gram-positive bacteria in tissue samples required a modified 
protocol). In addition to the main cohort (N=55), 18 formalin-fixed paraffin-embedded 
(FFPE) CRC tissues were sourced from Groote Schuur Hospital’s archival materials in 
order to increase the number of MSI+ samples available for bacterial detection. Only 
Fusobacterium and EPEC (which had previously been associated with MSI in the 
literature) were measured in these samples. 
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Finally, an a priori sample size calculation was initially used as a rough estimate of the 
required sample size for a paired tumour vs. normal gene expression analysis. We then 
conducted post-hoc power analyses to evaluate the power to detect differential gene 
expression for the various bacteria-specific comparisons of interest (e.g. genes 
differentially expressed in EPEC+ vs. EPEC– groups or in groups with high or low/no 
colonization by Fusobacterium).  
Study aims and objectives 
The main aim of this thesis was to gain insight into the potential contribution of CRC-
associated bacteria in the aetiopathogenesis of CRC by leveraging both host genomic 
and clinicopathological data as well as to investigate patterns of tissue colonisation 
between different CRC-associated bacteria. 
As described in Chapter 2, several bacterial species have been linked to colorectal 
cancer, but these species have not been concurrently quantified across a single cohort, 
nor have any bacteria been studied in parallel with the host genomic and 
clinicopathological features. The aim of this study was to address these issues using a 
South African cohort of CRC patients in order to 1) gain insight into the potential 
contribution of CRC-associated bacteria in the aetiopathogenesis of CRC and 2) 
determine the quantitative relationship of tumour and adjacent normal tissue 
colonisation between the various CRC-associated bacteria studied here. 
The objectives were to 1) quantify CRC-associated bacteria in a cohort of 55 paired 
tumour and adjacent histologically normal samples collected during surgical resection, 
as well as in an additional 18 FFPE CRCs (17 of which were MSI+) for the detection of 
EPEC and Fusobacterium; 2) to determine their relationships to patient age, gender, 
ethnicity, stage of disease, site of disease and MSI status (Chapter 4); 3) evaluate the 
relationship between each bacterium and host gene expression (Chapter 8) and 
methylation changes (Chapter 6); and 4) to determine genomic subtypes of CRC using 
unsupervised clustering of gene expression data in the context of patient 
clinicopathological features and bacterial quantitation data; and 5) to gain a deeper 
biological understanding of the results from the objectives 1–4 using pathway analyses 
of the genomic subtypes obtained (Chapter 7). The study design is outlined in Figure 1.  
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Figure 1: Thesis outline describing the use of samples from the primary cohort (fresh-frozen samples). T: 
tumour samples; N: normal samples. FFPE samples were used to supplement the number of MSI+ 
samples (N=17) for bacterial detection as described in Chapter 4. 
 
Materials and methods 
Sample collection and storage 
This study consists of two cohorts: The main cohort consists of 55 paired colorectal 
patient samples (adenocarcinoma tissue and adjacent macroscopically normal mucosa) 
together with patient blood samples (for MSI testing) that were collected during surgical 
resection at the Groote Schuur Hospital, as part of a previous study in our laboratory by 
Dr. Amirtha Ganesh. The samples were frozen immediately in liquid nitrogen and 
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stored at -80.0°C; the second cohort was sourced in order to obtain more patients with 
sporadic microsatellite instability (MSI-H). For this cohort, 18 adenocarcinoma samples 
were selected from archival formalin-fixed paraffin embedded (FFPE) specimens that 
had previously been screened for MSI by immunohistochemistry of the mismatch repair 
genes MLH1, MSH2 and MSH6; these patients were referred for MSI testing if CRC 
was diagnosed under the age of 50, or if CRC was diagnosed in two or more first or 
second degree relatives with an HNPCC-related tumor. For our purposes, we selected 
patients with MSI (absence of staining of one or more MMR proteins), who also had 
mutational screening data available so that we could distinguish sporadic from HNPCC 
cases. Of the 18 patients, two had confirmed mutations in the MLH1 mismatch repair 
gene and were therefore classified as HNPCC. Although the main focus of this study is 
to characterize CRC-associated bacteria in sporadic CRCs, HNPCC patients were 
included, because they provide a valuable reference for investigating the putative role of 
EPEC and Fusobacterium in causing MSI (because MSI is linked to specific mutations 
in HNPCC). 
Ethical consent was obtained for the collection of samples (UCT HREC REF 416/2005) 
and each patient provided written and informed consent to collect tissue and blood 
samples during surgical resection. Ethical consent has subsequently been renewed to 
collect additional patient samples and to continue analyses of the existing cohort (UCT 
HREC REF 366/2010). 
A priori sample size calculation 
Our initial estimate of the sample size for gene expression analyses was based on a 
standard paired tumour vs. normal comparison and performed in R using the 
Bioconductor package SizePower226; accordingly, a minimum of 17 paired patient 
samples were required in order to detect a minimum fold change of 2 at a false negative 
rate of 0.05–the parameters used are specified in Table 1. The anticipated standard 
deviation of the difference in log-expression between matched tumour and normal 
samples (σ = 0.7) was based on a conservative estimate from the literature227.  
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1The acceptable probability of a type I error for any single gene (false positive rate). 
2The acceptable probability of a type II error for any single gene (false negative rate). 
3Absolute mean difference in log-expression between treatment and control units as postulated under the 
alternative hypothesis H1 (equates to a fold change of two in this case). 
4Anticipated standard deviation of the difference in log-expression between matched treatment and 
control units. 
Post-hoc power analysis for detection of bacterially-associated differential gene 
expression 
As detection of CRC-associated bacteria in tissue samples was conducted after gene 
expression analysis of 19 sample pairs, post-hoc power analyses were conducted to 
assess the power to detect bacterially-associated differential gene expression for each of 
the six bacterial species investigated. 
In sample size and power calculations it is usually assumed that the two groups being 
compared are of equal size; in practice however, this is rarely the case. We therefore 
estimated an adjusted ‘equal sample size’ for each comparison of interest, using the 
online resource StatsToDo228. We show the actual and adjusted sample sizes for the 
comparison between high-level colonisation by a particular bacterium compared to low-
level or no infection for tumours (Table 2a) and normal samples (Table 2b). The 
distinction between high- and low-level infections was set based on the quantitative 
distribution of bacteria across all samples, where samples that fell in the third quartile 
were graded as high-level (see Chapter 4 for further detail).  
Table 2a. Description of sample groups for gene expression analysis, tumour samples: comparing high-
level colonisation to low/no infection. 
 High level colonisation 






Fusobacterium 7 12 8 
afaC+ AIEC 5 14 7 
ClB+ AIEC 1 18 n/a 
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EPEC n/a n/a n/a 
ETBF 3 16 5 
E. faecalis 2 15 3 
 
Table 2b. Description of sample groups for gene expression analysis, normal samples: comparing high-








Adjusted sample  
 size/group 
Fusobacterium  2 17 3 
afaC+ AIEC 1 18 n/a 
ClB+ AIEC 1 18 n/a 
EPEC n/a n/a n/a 
ETBF 2 17 3 
E. faecalis 1 13 n/a 
 
Next, we show the actual and adjusted sample sizes for the comparison of samples with 
or without colonisation by a particular bacterium for tumours (Table 2c) and normal 
samples (Table 2d). 
Table 2c. Description of sample groups for gene expression analysis, tumour samples: comparing 
infection-positive vs. –negative samples. 
 Infection+ 






Fusobacterium 18 1 n/a 
afaC+ AIEC 11 8 9 
ClB+ AIEC 6 13 8 
EPEC 3 16 5 
ETBF 10 9 9 
E. faecalis 7 10 8 
 
Table 2d. Description of sample groups for gene expression analysis, normal samples: comparing 
infection-positive vs. –negative samples. 
 Infection+ 




Adjusted sample  
size/group 
Fusobacterium  16 3 5 
afaC+ AIEC 10 9 9 
ClB+ AIEC 6 13 8 
EPEC 2 17 3 
ETBF 10 9 9 
E. faecalis 4 10 5 
 
Back to table of contents 41 
These adjusted samples sizes were used as input for power calculations using the R 
package sizepower226, where we calculated the power to detect genes differentially 
expressed at fold changes of two (effect size = 1) or three (effect size = 1.6), for equal-
size group comparisons. We arbitrarily selected group sizes of 3, 6 or 9, in order to 
obtain an estimate of power at each level (Table 3). The acceptable number of false 
positives (α) was specified as 0.001 and the variance term (σ2d) was calculated as 0.66, 
from the median residual standard deviation across all probes when comparing two 
randomly chosen treatment and control samples (using the R package limma229), as 
recommended in the sizepower package. 
Table 3. Post-hoc power analyses for varying effect and sample sizes. 
Number of samples per group* Effect size (μ) Estimated power  
3 1 25% 
6  1 65% 
9  1 89% 
3 1.6 80% 
6 1.6 99% 
9 1.6 100% 
*Due to unequal sample sizes between classes, an adjusted sample size/group was calculated and used for 
power calculation228. 
Sample preparation 
For MSI testing, DNA was isolated from tumour and adjacent normal colonic mucosal 
samples and from peripheral blood lymphocytes for each patient; DNA from tissue was 
isolated from ~6 mm3 of tissue using the Gentra Puregene Tissue Kit (Qiagen). Briefly, 
after adding cell lysis solution, the samples were incubated at 65°C for 15 minutes. In 
order to obtain maximum yield, Proteinase K was added to each sample followed by 
continued lysis at 55° C for 3 hours. If the tissue was not completely lysed after 3 hours, 
samples were incubated overnight at 55° C. Blood DNA was extracted from peripheral 
blood lymphocytes using the Gentra Puregene Blood Kit (Qiagen), according to the 
manufacturer’s instructions.  
Subsequent to the extraction of DNA for MSI testing, DNA, RNA and protein were 
simultaneously isolated from paired patient samples using a Dounce homogenizer and 
the AllPrep DNA/RNA/Protein kit (Qiagen), according to the manufacturer’s 
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instructions. These DNA and RNA amplicons were used for genomic analysis (gene 
expression and methylation arrays, and for the detection of gram-negative bacteria). For 
the detection of gram-positive bacteria, a separate extraction had to be performed where 
DNA was extracted from ~6 mm3 of tissue using the QIAamp® DNA Mini Kit 
(Qiagen). Briefly, each sample was incubated in 180 μl of lysozyme (20mg/ml) for 40 
min at 37°C; after adding 20 μl of proteinase K, samples were incubated at 56°C until 
the tissue was completely lysed (at least 4 hours, or overnight if tissue was still visible 
after 4 hours); samples were next incubated for 30 min in Buffer AL (supplied with 
QIAamp® DNA Mini Kit), and thereafter DNA was isolated according to the 
manufacturer’s instructions.  
For FFPE samples, DNA was extracted using the RecoverAll Total Nucleic Acid 
Isolation Kit (Ambion). FFPE slides were prepared from the Groote Schuur Hospital 
archival FFPE wax blocks. Of the 17 patients for whom FFPE material was requested, 
only 6 were successfully retrieved due to lack of sample availability; FFPE slides were 
prepared, and tumour margins were demarcated using hematoxylin and eosin guide 
slides, by the department of Anatomical Pathology at UCT. Fourteen additional patients’ 
FFPE slides (that had previously been prepared from archival FFPE wax blocks) were 
obtained from the Human Genetics Laboratory at UCT; unfortunately, tumour margins 
had not been demarcated for the majority of these slides. In cases where tumours had 
been demarcated, tissue inside or outside of the demarcated area was processed 
separately. Samples were prepared by scraping the tissue from the glass slides using a 
sterile scalpel blade and transferring it to a 2mL Eppendorf tube. After 
deparraffinization in 100% xyleen, samples were incubated in 180 μl of lysozyme 
(20mg/ml) for 40 min at 37°C, followed by incubation for 42 hours at 50°C in 
Proteinase K. For the remainder of the protocol, DNA was isolated according to the 
manufacturer’s instructions. Of the 20 FFPE samples obtained, 18 had sufficient DNA 
quantity and quality for downstream analyses, and 17 were MSI+. 
Microsatellite instability (MSI) testing 
MSI testing was conducted on DNA extracted from paired tissue samples, as well as the 
corresponding blood samples for each patient, using allelic profiling of the Bethesda 
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panel of microsatellite markers, which includes two mononucleotide repeats (BAT25 
and BAT26) and three dinucleotide repeats (D2S123, D17S225 and D5S314). Samples 
were classified as microsatellite stable (MSS), microsatellite instable-low (MSI-L) or 
microsatellite instable-high (MSI-H) if they had 0, 1 or at least 2 of the 5 markers 
showing instability, respectively230, based on electrophoretic analysis of PCR products, 
which was conducted on an ABI PRISM® 3130xl Genetic Analyzer. Primer sequences 
were taken from Loukola et al.231, and are indicated in Table 4. The five primers sets 
were divided into two multiplex PCRs; the optimized parameters are shown in Table 5. 
For each pair, the forward primer was labeled with one of the fluorescent markers 6-
carboxyfluorescein (FAM), tetrachloro-6-carboxyfluorescein (TET) or 
hexachlorofluorescein (HEX). 
Table 4. Primers used for MSI testing according to the Bethesda panel of markers. 
Microsatellite marker Primers (3’–5’) Size range (bp) 
BAT25 (F) HEX-TCGCCTCCAAGAATGTAAGT 90–125 
 (R) TCTGGATTTTAACTATGGCTC  
BAT26 (F) FAM-TGACTACTTTTGACTTCAGCC 80–120 
 (R) AACCATTCAACATTTTTAACCC  
D2S123 (F) FAM-AAACAGGATGCCTGCCTTTA 197–227 
 (R) GGACTTTCCACCTATGGGAC  
D5S346 (F) TET-ACTCACTCTAGTGATAAATCG 96–122 
 (R) AGCAGATAAGACAGTATTACTAGTT  
D17S250 (F) FAM-GGAAGAATCAAATAGACAAT 140–170 
 (R) GCTGGCCATATATATATTTAAACC  
For each pair, the forward primer was labeled with one of the fluorescent markers 6-carboxyfluorescein 
(FAM), tetrachloro-6-carboxyfluorescein (TET) or hexachlorofluorescein (HEX). 
Table 5. Cycling conditions used for multiplexed PCR MSI testing. 
Step Duration Temperature Cycles 
Denaturation 60 sec 95°C  
Denaturation 1 sec 96°C x35 
Annealing/extension* 10 sec 49.9°C or 57.5°C  
Final extension 10 sec 72°C  
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*An annealing/extension temperatures were 49.9°C for the BAT25/26 multiplex and 57.5°C for the 
D2S123/D5S346/D17S250 multiplex. 
For the FFPE cohort immunohistochemistry (IHC) had previously been performed for 
MSH2, MSH6 and MLH1 by the division of Anatomical Pathology at the Groote 
Schuur Hospital. Samples that displayed absence of staining for any of the mismatch 
repair proteins evaluated were considered to have MSI-H. IHC of MMR proteins has 
been shown to have high sensitivity (92.7%) and specificity (100%) in detecting MSI232. 
Originally, patients were referred for IHC analysis if CRC was diagnosed under the age 




We retrieved clinical information from patient hospital folders for 61 of the 68 patients 
initially sourced by Dr. Amirtha Ganesh. We recorded patient demographics, treatment 
summaries, pathology reports, and chemo- and radiotherapy treatment records in a 
MySQL database. We further recorded patient age, BMI, familial history of cancer, 
smoking or alcohol consumption, as well as histopathological features and 
chemotherapy and radiation treatment received.  
The clinicopathological characteristics of the 55 fresh-frozen paired samples (of the 68 
collected) used in this study are summarized in Table 6. The mean age of patients was 
59 (SD±15.3), while gender was divided equally. MSI testing was performed for the 32 
patients who had not received preoperative radio- or chemotherapy: 7 were MSI-H (of 
which 4 were HNPCC), 3 MSI-L, while the remaining 22 were MSS. For comparisons 
using MSI status, missing cases (where MSI status was not determined were excluded). 
The majority of cases were stage II or III cancers (81.6%), while stage I- and IV-cancers 
accounted for 12.2% and 6.1% of cases, respectively. The cohort consisted of 60% 
rectal and 40% colon cancers, with proximal cancers accounting for 45% of colon 
cancers. The majority of our cohort was of mixed-ancestry (70.4%), while patients of 
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Caucasian (14.8%), black (11.1%) and Indian ethnicities (3.7%) made up the rest of the 
cohort.  
Table 6: Clinicopathological characteristics of the cohort of fresh-frozen tissues (N=55).  
Feature (patients with missing data) Number of patients N=55 
Mean age (2) 59 (SD±15.3)  
BMI (4) 26.8 (SD±4.7)  
Gender (1)  
Female 27 (50%) 
Male 27 (50%) 
MSI status (23)  
MSS 22 (68.8%) 
MSI-H 7 (21.9%) 
MSI-L 3 (9.4%) 
CRC Type   
HNPCC 6 (10.9%) 
Sporadic 49 (89.1%) 
Tumour stage (6)  
I 6 (12.2%)  
II 18 (36.7%) 
III 22 (44.9%) 
IV 3 (6.1%) 
Tumour site (5)  
Ceacum 4 (8%) 
Ascending colon 1 (2%) 
Hepatic flexure 1 (2%) 
Transverse colon 3 (6%) 
Splenic flexure 1 (2%) 
Descending colon 3 (6%) 
Sigmoid colon 3 (6%) 
Rectosigmoid junction (RSJ) 4 (8%) 
Rectum 30 (60%) 
Radiation/Chemo received before resection (2)  
Yes 22 (41.5%) 
No 31 (58.5%) 
Ethnicity (1)  
Black 6 (11.1%) 
Caucasian 8 (14.8%) 
Indian 2 (3.7%) 
Mixed-Ancestry  38 (70.4%) 
In the case of age and BMI, mean values and their standard deviations (SD) are reported. The numbers in 
column 1 in brackets represent the number of patients with missing data in that category. 
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Microsatellite instability testing  
Forty-eight of the 68 patients had tumour, normal, and blood samples available, and we 
performed MSI testing on the 32 patients who did not receive pre-operative chemo- or 
radiotherapy (the vast majority of these tumours were located in the colon). Of the 5 
HNPCC patients, 4 were classified as MSI-H (≥ 2/5 markers show instability). Of the 
sporadic CRCs, 3 patients (9%) were classified as MSI-H, and an additional 3 as MSI-L, 
which is comparable to previous reports of MSI in 10–18% of CRCs92,94. An example 
of an electrophoretogram for 1 of the 5 markers evaluated for each sample can be seen 
in Figure 2; in this example microsatellite instability presents as additional peaks on the 
left, which indicate an insertion. 
 
Figure 2: Capillary electrophoresis of a MSI positive cancer. Electropherograms of the D17S250 loci 
from normal colonic mucosa (N), blood (B) and tumour (T) tissues. The presence of additional peaks in T 
indicate that an increased proportion of T vs. N/B cells have an insertion in this marker which is caused 
by a dysfunctional mismatch repair system.  
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Discussion 
In order to minimize the effect of intra-sample heterogeneity, we simultaneously 
extracted DNA, RNA and protein for each patient, and bacterial detection and whole 
genome analysis (including transcriptomic and epigenomic analyses presented in 
Chapters 6–8) were conducted on these samples, when possible.  
Regarding sample size calculations, we initially estimated sample size based on a 
standard paired analysis between tumour and normal samples. However, given the 
design of our study, where we screened for multiple CRC-associated bacteria, the power 
to detect differences in gene expression or methylation across the genome depended on 
the number of positive and negative samples for a given species. Accordingly, post-hoc 
power analyses were conducted for the various comparisons of interest. In order to 
detect a fold change of 2, at least 9 samples per group are required. On the other hand, a 
fold change of 3 could be detected with 80% and 90% power with 3 or 6 samples per 
group, respectively. 
Our cohort consists mainly of patients of mixed ancestry––it is important to note 
however that the racial distribution of our cohort largely mirrors the segment of the 
population who attend the Groote Schuur Hospital, rather than a representative sample 
of all CRCs in South Africa. The majority of our cohort has cancers of sporadic origin, 
but about 10% of our cohort has confirmed HNPCC. Regarding pathological 
characteristics, around 60% of our cohort has rectal cancers, and of the remaining 40%, 
proximal and distal colon cancer occurred in 45% and 55% of cases, respectively. 
Further, the majority of our cohort presented with stage II/III CRCs.  
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Chapter 4: Quantitative profiling of colorectal cancer-
associated bacteria reveals associations between 
Fusobacterium spp., enterotoxigenic Bacteroides fragilis 
(ETBF) and clinicopathological features of CRC 
 
Abstract 
Various studies have presented clinical or in vitro evidence linking bacteria to colorectal 
cancer, but these bacteria have not previously been concurrently quantified by qPCR in 
a single cohort. Here, many of these bacteria (Fusobacterium spp., Streptococcus 
gallolyticus, Enterococcus faecalis, Enterotoxigenic Bacteroides fragilis (ETBF), 
Enteropathogenic Escherichia coli (EPEC), and afaC- or pks-positive E. coli) are 
quantified in paired tumour and normal tissue samples from 55 colorectal cancer 
patients. Further, associations between a) the presence and b) the level of colonisation 
by each bacterial species and site and stage of disease, age, gender, ethnicity and MSI-
status are determined. 
With the exception of S. gallolyticus, we detected all bacteria profiled here in both 
tumour and normal samples at varying frequencies. ETBF (FDR=0.001 and 0.002 for 
normal and tumour samples) and afaC-positive E. coli (FDR=0.03, normal samples) 
were significantly enriched in the colon compared to the rectum. ETBF (FDR=0.04 and 
0.002 for normal and tumour samples, respectively) and Fusobacterium (FDR=0.03 
tumour samples) levels were significantly higher in late stage (III/IV) colorectal cancers. 
Fusobacterium was by far the most common bacteria detected, occurring in 82% and 
81% of paired tumour and normal samples. Fusobacterium was also the only bacterium 
that was significantly higher in tumour compared to normal samples (p=6e-5). 
Significant associations between high-level colonisation by Fusobacterium and MSI-H 
(FDR=0.05); age (FDR=0.03); or pks-positive E. coli (FDR=0.01) were also discovered. 
Furthermore, the EPEC detected here was exclusively identified as atypical EPEC, 
which has not been previously reported in association with colorectal cancer. 
By quantifying colorectal cancer-associated bacteria across a single cohort, inter- and 
intra-individual patterns of colonisation not previously recognised were uncovered and 
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important associations with clinicopathological features were identified for 
Fusobacterium and ETBF. 
Introduction 
A causal link between specific pathogens and numerous cancers has now been firmly 
established. Clear evidence exists that the vast majority of cervical cancers are directly 
caused by colonisation by human papillomavirus (HPV)233. Similarly, Helicobacter 
pylori is a known risk factor for the development of gastric cancer and is considered a 
class I carcinogen by the WHO 234,235. 
The possibility of oncogenic bacteria in the colon was already evident in the 1950s 
when a clinical association between Streptococcus bovis bacteraemia/endocarditis and 
CRC was discovered236. Subsequently, multiple studies have demonstrated enrichment 
with specific bacterial pathogens in faecal or tissue samples of CRC patients, including, 
Fusobacterium194,195,237, S. gallolyticus12,13,197, E. faecalis198 and Enterotoxigenic 
Bacteroides fragilis (ETBF)238.  
Previously, 16S rRNA profiling of CRC paired tumour and normal biopsies has 
revealed that while only 3% of biopsy specimens from healthy controls contained any 
type of bacteria, ~90% of patients with adenomas or carcinomas had bacterial 
concentrations of 103–105 colony-forming units per microliter in both malignant and 
macroscopically normal samples207. This clearly demonstrates the susceptibility of these 
patients to pathogenic colonisation of the normally sterile colonic epithelium––not only 
in existing tumour tissue, but also in the surrounding macroscopically normal tissue, 
which may suggest a pre-existing risk to colonisation/infection. 
Based on both in vitro and in vivo observations, bacterially-driven oncogenic 
mechanisms in CRC have been proposed to include activation of Wnt signaling 
(ETBF203, EPEC239, Fusobacterium196), pro-inflammatory signaling (E. faecalis200,201, S. 
gallolyticus240,241) and genotoxicity (EPEC10, AIEC11,212,213).  
The oncogenic potential of these bacteria, as well as suspected bacterial components 
implicated in the aetiopathogenesis of CRC were discussed in Chapter 2 and are 
summarized in Table 1. 
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Table 1: Summary of the putative oncogenic mechansims and the bacterial components implicated in 
CRC pathogenesis for the six bacterial species quantified in this study. 
Bacterial species Support for putative oncogenic mechanism  Suspected bacterial 
components 
implicated 
EPEC Downregulates mismatch repair proteins in vitro9,10; 
increases mutational frequency in vitro10. 
espF10  
Escherichia coli with 
adherent/and or 
invasive properties. 
Enriched in CRC patients207,208,242; CRC-associated 
strains commonly have genes related to M-cell 
translocation (lpfA)213; genotoxicity (pks)11,211–213, 
or cell cycle modulation (cnf1)212. 
pks11,212,213, afaC213, 
lpfA213  
cnf1212 and cdt212. 
Fusobacterium Multiple independent metagenomic studies identify 
Fusobacterium as overrepresented in CRC tissue 
compared to matched normal mucosa and healthy 
controls194,195,237. F. nucleatum increases tumour 
multiplicity in an APC Min/+ mouse model218; 
Triggers ß-catenin nuclear signaling196. 
FadA196  
ETBF Enriched in faecal samples from CRC patients238; 
Triggers ß-catenin nuclear signaling; induces c-
Myc expression and cellular proliferation203; 
increases colitis and tumour in a Min/+ mice 
model15. 




Enriched in CRC patients with12,13,197,243 and 
without bacteremia12. S. infantarius or its wall 
extracted antigens promote progression of 
preneoplastic lesions in rats and promotes pro-
inflammatory COX-2 signaling240,241. 
Cell wall extracted 
antigens 
E. faecalis Enriched in faecal samples from CRC patients198; 
Produces extracellular superoxide199, promotes 
inflammation and CRC in IL-10 knockout 
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To date, however, the presence and levels of multiple CRC-associated bacteria have not 
been examined across a single cohort. Further, to our knowledge, ETBF and E. faecalis 
have only been quantified by quantitative PCR (qPCR) in feacal samples of CRC 
patients, and EPEC has only been quantified in a small CRC cohort with archival FFPE 
samples9. Here qPCR was used to measure the presence of six bacteria, previously 
reported in association with CRC, in paired adenocarcinoma and adjacent normal 
mucosal samples; these include Fusobacterium, Streptococcus gallolyticus, 
Enterococcus faecalis, ETBF, EPEC and afaC- or pks-positive E. coli. Detailed 
participant-level characteristics are presented in Appendix A (Tables 1 & 2). 
Materials and Methods 
Cohort selection 
Cohort selection for bacterial quantification is described in Chapter 3. Briefly, the 
primary cohort consists of 55 paired colorectal patient samples (adenocarcinoma tissue 
and adjacent normal mucosa), whilst the second cohort was sourced in order to obtain 
more patients with sporadic microsatellite instability (MSI-H). For this cohort, 18 
adenocarcinoma samples were selected from archival FFPE specimens that had 
previously been screened for MSI by immunohistochemistry of the mismatch repair 
proteins MLH1, MSH2 and MSH6. 
Sample preparation and MSI testing 
DNA isolation protocols used for the extraction of gram-negative or gram-positive 
bacterial DNA from host tissue samples or from FFPE sections are described in Chapter 
3. MSI testing performed for tissue samples and for FFPE sections are also described in 
Chapter 3. 
Primers and control DNA 
Primers for the detection of each bacterial species were sourced from the literature or 
designed in-house, and their specificity was confirmed using Primer BLAST244. All 
primers, along with their limits of detection (LODs) and qPCR efficiencies, are listed in 
Table 2. 
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Table 2: Primers used for bacterial detection together with their annealing temperatures, efficiencies and LODs.  














EPEC eaeA9 F-GTGACGATGGGGATCGAT 
R1-ACGGCTGCCTGATAATGTT 
150 70–60 87 0.010 4 
(20fg) 
73 
 eaeA (intimin 
epsilon, gamma, 
zeta, alpha, pi, 
rho, beta, lambda, 
iota, kappa, eta, 
delta, xi, mu, 
kapp, jota) 
R2-GGAACTGCATTGAGTAAAGGAG 70 70-60 80 0.055 4 
(20fg) 
100 
 eaeA (intimin 
theta) 
R3-GAAGCTGCATTGAGTAAAGAAG 70 60 ND ND ~ 10# ND 
 bfp245 F-GGAAGTCAAATTCATGGGGGTAT 
R-GGAATCAGACGCAGACTGGTAGT 
299 70–64 92 0.010 20 
(100fg) 
100 




114 70–60 86 0.008 16 
(100fg) 
83 
 stx2246 F-ATGACAACGGACAGCAGTTAT 
R-CTGAACTCCATTAACGCCAGATA 
116 70–60 89 0.015 16 
(100fg) 
100 
AIEC Clb211 (pks) F-GCGCATCCTCAAGAGTAAATA 280 60 80 0.022 20 50 
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R-GCGCTCTATGCTCATCAACC (100fg) 
 afaC247  F-GCGCTATGTGGTGCAGAGTA 
R-AAAACCGGTATTCACCAGGA 
185 65–60 86 0.026 20 
(100fg) 
53 
E. faecalis 16S rRNA248 F-CCGAGTGCTTGCACTCAATTGG 
R-CTCTTATGCCATGCGGCATAAAC 
137 60 80 0.017 3 (10 
fg) 
87 
S. gallolyticus sodA12 F-CAATGACAATTCACCATGA 
R-TTGGTGCTTTTCCTTGTG 









294 65-55 78 0.020 4 
(20fg) 
70 
Fusobacterium 16S rRNA250 F-CGGGTGAGTAACGCGTAAAG 
R1-GCCGTGTCTCAGTCCCCT 
228 60 85 0.026 2 (5fg)  75 
  R2-GCATTCGTTTCCAAATGTTGTCC 61 60 83 0.020 2 (5fg)  79 
FFPE QC COX1 F-TATGGCGTTTCCCCGCATAA 
R-GCGAGCAGGAGTAGGAGAGA 
69 57 98  N/A N/A 
ND: not determined; #The LOD for the specific detection of intimin theta could not be accurately determined since an intimin theta+ control strain was not 
available at the time; *LOD: limit of detection (bacterial copies) where positive identification was made in at least 50% of replicates.
 
 
The following reagents were obtained through the NIH Biodefense and Emerging 
Infections Research Resources Repository, (NIAID, NIH) as part of the Human 
Microbiome Project: Streptococcus gallolyticus subsp. gallolyticus, Strain TX20005, 
HM-272D; Genomic DNA from Bacteroides fragilis, Strain 3_1_12, HM-20D, 
Genomic DNA from Clostridium difficile, Strain NAP07 (CDC#2007054), HM-88D; 
Genomic DNA from Enterococcus faecalis, Strain HH22, HM-200D; Genomic DNA 
from Escherichia coli, Strain B171, NR-9297; and Genomic DNA from Fusobacterium 
nucleatum subsp. polymorphum, Strain F0401. ETBF genomic DNA (ATCC43858) was 
kindly provided by Dr Annalisa Pantosti from the Istituto Superiore di Sanità, Italy. 
DNA from enterohemorrhagic E. coli (to confirm EPEC identity) was kindly supplied 
by Dr. Anthony Smith at the National Institute for Communicable Diseases, South 
Africa. DNA from AIEC (strains HM358, HM229 and HM334) was kindly provided by 
Dr. Barry Campbell from the University of Liverpool, UK. 
qPCR amplification conditions 
Experiments were performed in triplicate on a Roche LightCycler® 480 Real-Time 
PCR System in 96-well format, using 50 ng patient DNA per well. Separate assays were 
performed for each bacterial gene detected; the cycling conditions are specified in 
Appendix A (Table 3). EPEC (eaeA, bfpA and stx1 and stx2), ETBF and S. gallolyticus, 
were each detected in 20 μl reactions using SensiFAST SYBR No-ROX Kit (Bioline); 
AIEC, Fusobacterium and E. faecalis were each detected in 25 μl reactions using 
Maxima SYBR green qPCR Master Mix (Thermo Scientific). In order to increase 
specificity, it was necessary in some cases to perform touchdown PCR, whereby the 
annealing temperature is lowered in a stepwise manner to discourage amplification of 
off-targets during the first 10 cycles of PCR251,252; touchdown qPCR was performed for 
detection of EPEC (bfpA and eaeA), S. gallolyticus, ETBF, EHEC (stx1 and stx2) and 
AIEC (afaC).  
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qPCR quantification 
For each qPCR assay, absolute quantification was performed using a standard curve 
constructed from serially diluted genomic DNA for each of the positive control strains. 
The concentration of bacterial DNA found was expressed in terms of genome copies by 
calculating the weight of one genome copy for each species as used by Dolezel et al.253: 
DNA content (pg) = genome size (bp)/(0.978 x 109). 
For example, Fusobacterium have an estimated genome size of 2.2 Mb and since one 
picogram of DNA equals approximately 978 Mb, a single Fusobacterium genome 
weighs approximately 2.25 fg (2.2Mb/978Mb/pg) and therefore 1 ng of DNA from 
Fusobacterium equates to about 445k copies (1000pg/(2.2Mb/978Mb)) of the bacterium 
(Table 3). 
Table 3: Estimates of bacterial genome copies per nanogram of bacterial DNA. 
 Strain, genome size Estimated bacterial 
copies/ng bacterial 
DNA.  
EPEC (eaeA/bfp) E2348/69, 4.97 Mb 2 x 105 
ETBF (bft) 3_1_12, 5.49 Mb 1.8 x 105 
E. faecalis (16s rRNA) V583, 3.34 Mb 3 x 105 
Fusobacterium (16s 
rRNA) 
NA, 2.2 Mb 4.5 x 105 
AIEC (afaC) LF82, 4.88 Mb210 2 x 105 
AIEC (ClB) LF82, 4.88 Mb 2 x 105 
S. gallolyticus (sodA) UCN34, 2.35254 4 x 105 
EHEC (stx1)  O157:H7, 5.6 1.8 x 105 
EHEC (stx2) O157:H7, 5.6 1.8 x 105 
 
In the case of AIEC strains, genome size may vary substantially between strains, since 
these strains are classified according to phenotypic traits and not sequence similarity. 
We opted to use the prototypical LF82 AIEC strain, which has a genome size of 4.88 
for quantification. 
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Positive control standards were spiked with the same amount of human genomic DNA 
(extracted from uninfected human cell cultures) used in the patient sample reactions 
(50ng DNA). The LOD was defined as the lowest concentration at which a positive 
result (correct meltcurve) could be obtained in at least 50% of replicates (Table 1). For 
all assays except ClB and afaC at least 70% of replicates were positive at the relevant 
LOD. In cases where results were inconsistent (1/3 replicates positive), samples were 
retested and taken as positive if a positive meltcurve was obtained in both runs (the 
results were then averaged across the two runs to obtain quantitative data). Negative 
controls were included in each assay. 
qPCR quantification in FFPE samples 
We first evaluated the quality of DNA extracted from archival FFPE slides (which had 
been stored between 2 and 23 years) using three primer pairs designed to amplify 100bp, 
200bp and 300bp amplicons of the GAPDH gene255. For most samples we detected 
either a very faint or no visible band at 100bp, whilst a 200bp amplicon could only be 
amplified in a few samples. On testing a shorter amplicon (69bp) of the COX1 gene 
(which we found to be stably expressed in our cohort and is therefore assumed to have 
no significant differences in copy number between samples), all samples could be 
amplified by qPCR; the difference in cycle threshold (Ct) between the highest and 
lowest quality sample was 9.3. We therefore redesigned the reverse primers for bacterial 
detection to shorten the resulting amplicons to 60–70bp, and used the COX1 results to 
account for degradation in our bacterial quantification. In the case of eaeA, two reverse 
primers were designed, one that detects intimin subtypes epsilon, gamma, zeta, alpha, pi, 
rho, beta, lambda, iota, kappa, eta, delta, xi, mu, kappa and jota; while the second was 
designed to specifically detect intimin theta (which was found in both EPEC-positive 
MSI-H samples from the fresh-frozen cohort). The efficiencies for the COX1 qPCR was 
calculated using 5-fold serial dilutions constructed using a high- and low quality patient 
sample, as 1.96 and 2, respectively. A ‘fold change’ value was then calculated for 
COX1 in each sample, using the ΔΔCt method and the mean Ct across 6 randomly 
selected DNA samples from the fresh-frozen (high-quality DNA) sample cohort was 
used as reference (the maximum ΔCt between fresh-frozen samples was 1.8). These 
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sample-specific ‘fold change’ values for COX1 between FFPE samples to be tested and 
the reference set of fresh-frozen samples were used as a correction factor to adjust for 
DNA sample quality. A theoretical limit of detection was also calculated for each 
sample by multiplying the correction factor for each sample with the LOD that had 
previously determined for high quality DNA. A theoretical limit of detection was also 
calculated for each sample by multiplying the correction factor for each sample with the 
LOD that had previously determined for high quality DNA. After performing absolute 
quantification, the result was multiplied by the correction factor for each sample. The 
validity of this method was assessed by comparing Fusobacterium quantitation obtained 
from DNA extracted from fresh frozen samples to that of matched FFPE samples 
(which we had available for four patients); after removing a single outlier sample, the 
Pearson’s correlation coefficient was 0.94, and the median fold change between 
matched fresh-frozen and FFPE samples was 1. FFPE samples that tested negative for 
Fusobacterium were set to ‘NA’ for downstream analysis, since the negative results 
could be due either to sample quality or to absence of the bacterium. 
Statistical analyses 
In order to assess quantitative differences between paired tumour and normal samples 
for each bacterium, the Wilcoxon signed rank test was applied to the subset of samples 
that had at least one positive sample in a pair (tumour or normal).  
To assess the association between each bacterium and clinicopathological features, we 
compared a) samples with vs. without colonisation by a particular bacterium and b) 
samples with high vs. low/no-colonisation by a particular bacterium. Except for 
Fusobacterium, all other bacterial quantitative data had a large proportion of 
colonization-negative cases, which lead to non-normal distributions and unequal 
variances between groups. To address this issue, we converted the quantitative data to 
categorical data where for each bacterium, samples were categorised as ‘no-infection’, 
‘low-infection’ or ‘high-infection’. Quantitative data (copies/50ng) were log2 
transformed and samples with no-colonisation were arbitrarily set to 1 before log2 
transformation; the third quartile (calculated across infection-positive cases only) was 
used to discriminate low- and high-colonisation cases (see Figure 2 for categories). 
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Associations with clinicopathological features were examined using Fisher’s exact test. 
Meanwhile, in the case of Fusobacterium (where the data was normally distributed), we 
used the Kruskal-Wallis test to evaluate differences between groups stratified by the 
clinicopathological parameter of interest. In order to investigate which CRC stages were 
significantly different in terms of the level of colonisation by Fusobacterium we used 
Dunn’s test to compare individual stages in a pairwise manner. Results with an FDR ≤ 
0.05 after applying multiple testing correction (Benjamini-Hochberg method) over all 
clinicopathological comparisons made for each species, were considered significant.  
Results 
Bacterial quantification 
CRC-associated bacteria were quantified in adenocarcinoma and matched normal 
mucosal samples by qPCR, using a serial dilution of genomic DNA from each 
bacterium as standards. With the exception of S. gallolyticus, all species were present in 
tumour and normal samples at varying frequencies. While the association between S. 
gallolyticus bacteremia or infective endocarditis and CRC is well established13, only 
one study, by Abdulamir et al.12, has measured S. gallolyticus in CRC patients without a 
history of bacteremia or infective endocarditis. That study found that 4% of healthy 
controls but 48.7% and 32.7% of CRC patients with or without bacteremia were 
infected with S. gallolyticus in the relevant colonic tissue12. In contrast, we did not 
detect S. gallolyticus in any of our adenocarcinoma or matched normal mucosa samples 
using the same primers used by Abdulamir et al.12who used these primers for both for 
conventional PCR and qPCR. It should be noted that the levels reported in that study 
were typically very low and that none of our cohort had any reported history of 
bacteremia/bacterial-endocarditis. It is important in this regard that our qPCR assay was 
very sensitive (LOD = 5 copies/50ng DNA) and allowed for the detection of gram-
positive bacteria such as S. gallolyticus by the addition of lysozyme to the homogenized 
human tissue prior to DNA extraction; we can therefore only speculate that the 
discrepancy between our results and those of Abdulamir et al. could be explained by a) 
differences in sample preparation, b) ethnic differences in the susceptibility to 
colonisation by S. gallolyticus or c) geographical differences in S. gallolyticus strains 
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found in Southern Africa that may have precluded detection of the bacterium in our 
cohort. Further investigation is therefore required to clarify this discrepancy. 
Of the bacteria that we detected, Fusobacterium was by far the most common, occurring 
in 82% and 81% of paired tumour and normal samples, respectively, with 80% 
concurrent colonisation in paired samples. Fusobacterium was also the only bacterium 
that occurred at significantly higher levels in tumour compared to normal samples (p = 
6e-5, Wilcoxon signed rank test), which is in agreement with previous studies194,219,237. 
The qPCR results are summarized in Figure 1 and Table 4.  
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Figure 1: qPCR quantification of bacteria in paired patient samples, expressed as log10 bacteria/50ng of 
patient DNA. Each bar represents one samples (either tumour or normal) and the order of samples are the 
same for each bacterium. Red (tumour); blue (normal); *(Not determined, the majority of these, block of 
* on the left of figure were FFPE samples, where only Fusobacterium was successfully measured). 
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Table 4: Quantification of bacteria in colorectal cancer and adjacent normal tissues 
Pathogen Colonisation rate T 
(%) 
Colonisation 
rate N (%) 
Concurrent 
colonisation 




58/71 (82%) 48/59 (81%) 43/54 (80%) 
AIEC (afaC) 19/53 (36%) 17/54 (31%) 16/20 (80%) 
AIEC (pks) 12/54 (22%) 13/55 (24%) 9/16 (56%) 
E. faecalis 11/40 (28%) 7/38 (18%) 5/10 (50%) 
ETBF 14/54 (26%) 15/53 (28%) 12/17 (71%) 
EPEC 6/54 (11%) 3/54 (6%) 3/6 (50%) 
S. gallolyticus 0/45 (0%) 0/45 (0%) 0/45 (0%) 
T and N denote adenocarcinoma and adjacent normal mucosa, respectively. Rates of concurrent 
colonisation in T and N samples were calculated as a fraction of the number of patients who were infected 
in T and/or N with a particular bacterium. 
In our cohort, ETBF was detected in 14/54 (26%) of colorectal adenocarcinomas and 
15/53 (28%) of adjacent normal mucosa samples. This is largely consistent with 
previous studies on faecal samples, which have reported ETBF in ±12% of healthy 
controls224,238, 27% of patients with diarrhea224, and 38% of patients with CRC238 with  
colonisation rates appearing to vary widely by geographical location15. Further, 71% of 
ETBF+ patients were infected in both adenocarcinoma and matched adjacent normal 
samples. 
Although Balamurugan et al. demonstrated significantly higher levels of faecal E. 
faecalis in CRC patients compared to healthy controls198, this is the first study to 
quantitatively measure E. faecalis in paired adenocarcinoma (28% E. faecalis-positive) 
and normal mucosa samples (18% E. faecalis-positive) with 50% of infected patients 
being infected in both adenocarcinoma and matched normal mucosa samples. However, 
no significant clinical associations with E. faecalis colonisation were found. 
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To investigate the presence of E. coli genes that are commonly found in AIEC in IBD 
and CRC patients, presence of ClB (part of the pks genomic island) and afaC (present in 
all operons of the afimbrial adhesin family) were evaluated in paired CRC samples. 
pks+ E. coli has previously been detected in 55–67% of CRC patients213,256, compared 
to 8% of healthy controls213. By contrast, in our cohort, 22% of adenocarcinomas and 
24% of adjacent normal mucosa samples were pks+, and 56% of pks+ patients were 
infected in both adenocarcinoma and matched normal mucosa samples. Meanwhile, 
afaC was detected in 36% and 31% of adenocarcinoma and normal mucosa samples, 
respectively, and found 80% of afaC+ patients were infected in both adenocarcinoma 
and matched normal mucosa samples. These rates are much lower than that found by 
Prorok-Hamon et al., who found 67% of CRC patients to be afaC+ compared to 17% of 
controls213. This discrepancy could be explained by our relatively high LOD for afaC 
and pks (Table 1). In contrast to Buc et al.256, who found pks to be more common in 
distal compared to the proximal colon, no significant association between the presence 
of pks and site of disease was found. Lastly, it should be noted that in addition to pks 
and afaC many other AIEC-related genes including cyclomodulins256 and lpfA213 have 
been noted for their relevance to CRC. 
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Figure 2: Colonisation levels for each bacterium/gene were categorized using the third quartile taken 
across infection-positive samples as a cutoff for high- or low-level infection. Categories: 1 (No infection), 
2 (low infection, any positive result < third quartile), 3 (high infection, any positive results ≥ third 
quartile). In the case of EPEC, because there were so few EPEC-positive patients (N=6), samples were 
analysed as positive or negative only. EF: E. faecalis; FB: Fusobacterium. 
 
ETBF and afaC-positive E. coli are significantly enriched in the colon compared to the 
rectum of CRC patients 
As shown in Figure 3, the presence of ETBF and afaC-positive strains were 
significantly associated with the colon compared to the rectum in normal samples (FDR 
= 0.001 and 0.03, respectively), as well as in tumour samples in the case of ETBF (FDR 
= 0.002). No significant differences were found between the proximal and distal colon 
for any of the bacteria in this study. 
Back to table of contents 64 
 
Figure 3: ETBF and afaC is significantly more prevalent in colon vs. rectal cancers. This applies to both 
tumour and normal tissue in the case of ETBF (FDR = 0.002, 0.001, respectively) and normal tissue only 
in the case of afaC (FDR = 0.03). 
Colonisation by ETBF or high-level colonisation by Fusobacterium are associated with 
late-stage CRC 
As shown in Figure 4, the presence of ETBF was significantly associated with stage of 
disease (Fisher’s exact FDR=0.04 and 0.002 for normal and tumour samples, 
respectively). Similarly, in the case of Fusobacterium, late stage (III/IV) tumour 
samples were significantly associated with high-level colonisation by Fusobacterium 
(Kruskal-Wallis, FDR=0.03). In order to investigate which CRC stages were 
significantly different in terms of the level of colonisation by Fusobacterium we used 
Dunn’s test to compare individual stages in a pairwise manner. Fusobacterium levels 
were significantly higher in stage III CRCs compared to stage I or II CRCs (p=0.002 for 
both comparisons). For ETBF, for which we found a difference in the presence or 
absence of ETBF between stages, individual stages were compared in a pairwise 
manner using Fisher’s exact test. ETBF was found more frequently in stage III or IV 
CRCs compared to stage I or II CRCs (stage I vs. IV p=0.01; stage II vs. stage IV 
p=0.01; stage II vs. stage III p=0.003) as well as in the normal mucosa of stage IV 
CRCs compared to stage I CRCs (stage I vs. IV p=0.01; stage II vs. IV p=0.01). 
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High-level colonisation by Fusobacterium also seems to correlate with chronic 
inflammation in CRC. For example, McCoy et al. found a significant positive 
correlation between Fusobacterium abundance and local inflammation in adenoma 
cases195 whilst we found that there is a trend towards high-level colonisation by 
Fusobacterium in patients with noted inflammation in normal tissue (Kruskal-Wallis, p 
= 0.01, FDR = 0.07, Figure 5), and tumour tissue (Kruskal-Wallis, p = 0.18, FDR = 0.2). 
We also found a positive association between high levels of colonisation by 
Fusobacterium and pks-positve E. coli in normal tissue (Fisher’s exact, FDR = 0.007) or 
EPEC in tumour tissue (Fisher’s exact, p = 0.08, FDR = 0.2). These data suggest that 
certain individuals may be more susceptible to infection, irrespective of the bacterial 
species. The finding that invasive strains of Fusobacterium are more prevalent in 
inflamed tissue in IBD, therefore suggests a possible inflammation-driven role of 
Fusobacterium in CRC development that warrants further investigation. 
 
Figure 4: ETBF and Fusobacterium are found at significantly higher levels in late stage (III/IV) 
cancers. For Fusobacterium, individual stages were compared in a pairwise manner using Dunn’s test. 
For ETBF, individual stages were compared in a pairwise manner using Fisher’s exact test. 
Fusobacterium is found at significantly higher levels in stage III CRCs compared to stage I or II CRCs. 
ETBF is found more frequently in stage III or IV CRCs compared to stage I or II CRCs; and in the 
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Further clinical associations with high-level Fusobacterium colonisation  
A significant relationship between high-level colonisation by Fusobacterium and MSI-
H, compared to samples that were MSS or MSI-L (Kruskal-Wallis, FDR=0.05) was 
found, Figure 5. Furthermore, a significant increase in Fusobacterium levels in CRCs of 
younger patients (< 60 years), (Kruskal-Wallis, FDR=0.03) was noted, with 31% vs. 
11% of patients under or over the age of 60 falling into the Fusobacterium-high group 
of colonisation (Figure 5). In normal samples, there was a trend towards high-level 
colonisation in males compared to females (Kruskal-Wallis, p=0.09, Figure 5). 
In order to objectively assess the levels of colonisation by Fusobacterium between 
different ethnic groups, age-matched subsets of the data were used to account for the 
significant difference in patient age by ethnicity (ANOVA p=7.2e-6); across all patients, 
the mean age of black patients was 36, that of mixed ancestry patients was 58, and that 
of white patients was 77. Two age- and gender-matched comparisons were therefore 
performed: a) black patients (mean age=35, N=6) vs. mixed ancestry patients under the 
age of 50 (mean age=42, N=10) and b) caucasian patients (mean age=77, N=8) vs. 
mixed ancestry patients over the age of 70 (mean age=72, N=19). Fusobacterium was 
found at significantly higher levels in black patients compared to their age-matched 
mixed ancestry counterparts in adjacent normal samples, (Kruskal-Wallis, p=0.03, 
Figure 5), but not in tumour samples (Kruskal-Wallis, p=0.6). No significant differences 
were found between age-matched caucasian and mixed ancestry patients in terms of 
Fusobacterium colonisation levels. 
Finally, the Fusobacterium-high group was also significantly associated with the 
presence of pks-positive E. coli in normal samples (Fisher’s exact, FDR=0.01) and two 
of the three EPEC+ tumours were also infected with Fusobacterium-high (Fisher’s exact, 
p=0.08, FDR=0.2), Figure 5. 
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Figure 5: Fusobacterium clinicopathological associations. High-level colonisation by Fusobacterium is 
significantly more prevalent in younger patients, males and patients of black ethnicity. Due to the 
disproportionately high number of young, black patients seen in our cohort the relationship between 
ethnicity and levels of colonisation by Fusobacterium was assessed using the subset of patients ≤ 50 years. 
A borderline significant relationship was seen between high-level colonisation by Fusobacterium and 
MSI-H compared to MSS/MSI-L (In our cohort three MSI-L cases were included with the MSS cohort). 
The vertical and horizontal dotted lines in the bottom right figure represent the cutoff for high-level 
colonisation by pks+ E. coli and Fusobacterium, respectively (see methods for further detail). FB: 
Fusobacterium; T: CRC tumour tissue; N: adjacent normal mucosa; F: Female; M: Male; |nflammation 
noted: yes (Y), no (N). 
EPEC detection and characterisation 
In the fresh-frozen cohort, eaeA was detected in 11% and 6% of tumour and normal 
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Colonisation levels varied from ±13–3037 bacteria/50ng of DNA extracted. The eaeA 
gene is found in EPEC and in enterohemorrhagic E. coli (EHEC). In our cohort, all 
eaeA-positive cases (N = 6) lacked the bfpA gene, which is present in typical EPEC, but 
not atypical EPEC (aEPEC) or EHEC. All eaeA+ samples were then identified as 
aEPEC and not EHEC due to the absence of stx1 (present in EHEC, but not aEPEC). 
aEPEC has not been previously reported in association with CRC, although the EPEC 
detected in FFPE CRC samples by Maddocks et al.9 could be aEPEC since they only 
profiled eaeA, and not bfpA or stx1. 
No significant clinical associations were found for EPEC––this is not surprising given 
the small number of EPEC positive patients (N=6). However, of the six patients 
infected with EPEC, 67% (2/3) of sporadic MSI-H cases (fresh-frozen cohort), and only 
9% (2/22) of MSS were EPEC-positive; the remaining two EPEC-infected patients were 
of unknown MSI status. Therefore, similar to Fusobacterium, there seems to be a trend 
towards EPEC- colonisation in sporadic MSI-H patients. Furthermore, in light of the 
effect of intimin subtype (of which there are currently 27 known variants257) on tissue 
tropism258–260 we sequenced the 150bp amplicon amplified during intimin detection, 
which is located in the variable region of intimin and identified intimin theta exclusively 
in the two EPEC-positive MSI-H cases and in one case with unknown MSI-status. In 
the remaining EPEC-positive samples, intimin subtype could not be conclusively 
identified based on the 150bp product, but produced equal BLAST scores for the 
intimin subtypes: zeta 2&3, alpha 2, pi, iota 1, delta, beta 2, epsilon 2&8, jota and 
lambda in all of the remaining samples. In samples with concurrent colonisation in 
paired samples, the 150bp product sequences were identical. Intimin sequencing results 
are summarized in Table 5. 
Table 5: Summary of BLAST search query to identify intimin subtypes. Samples highlighted in bold 
were used to determine the effect of FFPE fixation on the ability to detect EPEC by qPCR. 
Sample Highest scoring BLAST 
hits 








44T theta 100 MSI-H Y Y 
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44N theta 99 MSI-H N Y 
63T theta 100 MSI-H Y NA 
34N zeta 2&3, alpha 2, pi, 
iota 1, delta, beta 2, 
epsilon 2&8, jota, 
lambda 
100 MSS N Y 
34T zeta 2&3, alpha 2, pi, 
iota 1, delta, beta 2, 
epsilon 2&8, jota, 
lambda 
100 MSS N Y 
22T theta, gamma 98 ND ND NA 
45T zeta 2&3, alpha 2, pi, 
iota 1, delta, beta 2, 
epsilon 2& 8, jota, 
lambda 
97 ND ND NA 
29N zeta, alpha 2, pi, iota 1, 
delta, beta 2, epsilon, 
jota, lambda 
100 MSS ND Y 
29T zeta 2&3, alpha 2, pi, 
iota 1, delta, beta 2, 
epsilon2& 8, jota, 
lambda 
100 MSS ND Y 
ND: not determined; NA: not applicable. 
Our finding that intimin theta was exclusively identified in MSI-H EPEC positive cases 
(both located in the caecum), and in one case of unknown MSI status (located in the 
rectum) is interesting. Moreover, the two MSI-H patients infected with intimin-theta 
aEPEC were also the only two patients (with available MSI data) where MLH1 was 
hypermethylated, as determined by methylation-specific qPCR. Both these patients 
were also infected with high levels of Fusobacterium (2730 and 68700 copies/50ng in 
tumour samples). Our data support the finding by Maddocks et al. that EPEC may 
decrease MMR functionality, but the implied mechanisms thereof appear to contrast: 
Maddocks et al. demonstrated in vitro EPEC-induced depletion of the mismatch repair 
proteins occurring at the protein level, despite an apparent increase in MLH1 and MSH2 
mRNA following infection of HT29 cells with EPEC (strain E2348/69)10. Maddocks et 
al. concluded that EPEC-induced depletion of MLH1 and MSH2 proteins was 
dependent on mitochondrial targeting of the EPEC effector protein EspF and that this 
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depletion significantly increased the mutational frequency of infected cells10. On the 
other hand, we identified decreased MMR functionality, which is based on epigenetic 
silencing of mlh1 in intimin theta+ aEPEC+ samples. Further work therefore seems 
needed to reconcile the apparently differing molecular origins of MLH1 depletion 
suggested by the cell-line-based studies of Maddocks et al. and our studies on clinical 
samples.  
Lastly, although we did not sequence the entire intimin gene, the 150bp amplified 
sequences were consistently identical within but not between patients, suggesting that 
strains isolated from tumour or normal biopsies from a given patient are identical, in 
agreement with the findings by Martin et al. concerning E. coli strains in paired CRC 
samples242. 
Next, given the reported relationship between EPEC and MSI in vitro9,10 as well as the 
relationship between intimin theta+ aEPEC and MSI seen here, we sourced 18 
additional MSI-H samples from archival FFPE samples. However, none of which tested 
positive for EPEC, but because the median level of EPEC colonisation across EPEC-
positive samples from the fresh-frozen cohort was relatively low (51 copies/50ng DNA), 
we investigated whether the level of degradation in the FFPE samples precluded 
detection in these samples. To this extent we compared the qPCR results from fresh-
frozen (150bp amplicon) and matched archival FFPE samples (70bp amplicon) for three 
EPEC-positive patients (5 EPEC-positive T or N samples). EPEC could only be 
detected in one of the five matched FFPE samples––the sample that displayed the 
highest level of colonisation (3037 copies/50ng) in the fresh frozen tissue. Further, the 
median estimated LOD for the FFPE samples was 191 copies/50ng DNA (see Methods 
for further details), which is higher than the median level detected in fresh frozen 
samples (51 copies/50ng DNA). We therefore conclude that if EPEC were present in the 
MSI-H FFPE samples at levels similar to that seen in fresh-frozen samples, the level of 
degradation in the FFPE samples would have precluded detection of EPEC, even when 
attempting to amplify a 70bp amplicon. 
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Discussion 
By quantifying multiple CRC-associated bacteria in one cohort, we uncovered inter- 
and intra-individual patterns of colonisation not previously recognised. We further 
identified significant associations with clinicopathological features including MSI-H 
(Fusobacterium), stage of disease (ETBF and Fusobacterium), tumour location (ETBF 
and afaC-positive E. coli), age (Fusobacterium), as well as a positive association 
between Fusobacterium and pks-positive strains. 
Notably, the finding that late stage (III) tumour samples were significantly associated 
with high-level colonisation by Fusobacterium is consistent with previous studies 
demonstrating a positive association between high-level colonisation by Fusobacterium 
and regional lymph node metastases194,219. Bonnet et al. found a similar trend between 
cyclomodulin-positive E. coli, and stage III/IV colon cancers, which we however did 
not observe here261. Tumour tissue provides a nutrient-rich surface that is not protected 
by an intact mucosal layer, and the tumour-homing activity of certain bacteria is well 
documented159; but this does not necessarily imply oncogenic potential. However, in 
addition to the enrichment of Fusobacterium in tumour vs. normal tissues and in late 
stage CRCs, Fusobacterium spp. are also enriched in irritable bowel disease (IBD) 
patients (who have a 2–3 fold increased risk of developing CRC)114 compared to healthy 
controls. Interestingly, Fusobacterium spp. isolated from inflamed tissue in IBD patients 
were significantly more invasive in a subsequent in vitro assay compared to non-
inflamed tissue from IBD patients or healthy controls262, possibly suggesting an active 
role for Fusobacterium in gastrointestinal diseases. 
Tahara et al. have previously observed an association between high-level colonisation 
by Fusobacterium and MSI-H, MLH1 methylation as well as the CpG island methylator 
phenotype (CIMP)219 suggesting that Fusobacterium might promote MSI by inducing 
MLH1 hypermethylation. Importantly, the association between MSI and Fusobacterium 
observed in our study was independent of the origin of MSI in our cohort, with 4/8 
HNPCC adenocarcinoma samples falling into the Fusobacterium-high group of 
infection. HNPCC requires inactivation of both alleles of the affected mismatch-repair 
gene and it is tempting to speculate that Fusobacterium precipitates loss of the wild-type 
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allele through methylation. However, the role of aberrant methylation in the 
aetiopathogenesis of HNPCC remains questionable: Kaz et al. found promoter 
methylation of MLH1 in 53% of HNPCC adenomas263, compared to only 4% of 
sporadic adenomas, whilst Speake et al. found 40% and 25% of hyperplastic polyps of 
sporadic or HNPCC origin to be CIMP-H264. However, LOH or gene conversion are the 
most frequent mechanism of inactivation of the wild type MLH1 allele in HNPCC 
tumours265–269. Further, HNPCC and sporadic MSI-H cancers have distinct histological 
and molecular features: While, both cancer types display lymphocytic infiltration, 
mucin secretion and poor differentiation270, HNPCCs tends to originate from classical 
adenomas compared to sessile-serrated adenomas in the case of MSI-H CRCs271 whilst 
on a molecular level, HNPCCs are strongly associated with mutations in APC or ß-
catenin and/or KRAS270,271, while MSI-H sporadic CRCs instead exhibit BRAF 
mutations, which are present in CRC precursor lesions271. Therefore, while it is 
tempting to speculate that Fusobacterium might cause MSI (and thereby CRC), it seems 
more likely that Fusobacterium preferentially flourishes in MSI-H compared to MSS 
cancers, perhaps due to the altered glycosylation profile in MSI-H cancers272, that could 
facilitate adherence of certain bacteria273. Additionally, F. nucleatum infection has been 
shown to stimulate proliferation in CRC- but not in non-neoplastic-cell lines196 and 
Fusobacterium stimulates cellular proliferation following an initial oncogenic hit 
(affecting a component of the WNT signaling pathway) in mice274 and in CRC cell 
lines196. Taken together, it therefore seems most likely that Fusobacterium is not 
oncogenic itself, but may contribute to tumourigenesis by promoting inflammation and 
cancer cell proliferation. 
It has long been appreciated that certain individuals are more susceptible to aberrant 
pathogenic colonisation of the gut epithelium, which may be accompanied by chronic 
inflammation, for example in patients with IBD. However, our finding that colonisation 
by certain bacteria are significantly associated with clinicopathological features in 
CRC–including the stage and site of disease–is new and might be linked to differential 
susceptibilities in relation to clinical features, such as age and ethnicity; these 
associations do not necessarily imply oncogenicity since many of the CRC-associated 
bacteria investigated in this study are asymptomatically present in a significant 
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percentage of the population 224,238. One might therefore expect a pathogenic trend 
similar to that of H. pylori where genetic, environmental and strain-specific risk 
modifiers govern susceptibility to bacterially-mediated oncogenesis in the colon and 
where only a small fraction of individuals infected with the bacterium will eventually 
develop cancer. Evaluating the distribution of bacteria in relation to ethnicity, lifestyle- 
and clinicopathological factors is the first step in evaluating host-susceptibility to 
infection and putative bacterially-mediated oncogenic mechanisms. Furthermore, 
bacterial abundance is not the only factor that may be correlated with 
clinicopathological features since low-abundant bacteria may exert a significant effect 
on the host through the secretion of toxins at high levels. For example, Dutilh et al. 
showed that Enterobacterial toxins were among the most highly expressed in 
metatranscriptomic sequencing data from CRC paired tumour and normal tissues 275, 
including toxins from E. coli, Salmonella enterica and Shigella flexneri 275. Evaluating 
the presence of bacterial toxins with oncogenic potential at the transcriptional or 
proteomic level will thus provide an additional layer of information to unravel complex 
host-pathogen interactions with relevance to CRC in the future. Future studies should 
also be aimed at validating our findings in a larger cohort (particularly in MSI-H CRCs 
in the case of EPEC); and at profiling Fusobacterium at the species level, as well as 
other AIEC toxins implicated in CRC not examined here, such as lpfA.  
Establishing causality for any of the bacteria examined here remains a challenge and 
would require rigorous investigation in animal models as well as large scale 
epidemiological data, as was used in establishing causality in the case of H. pylori and 
gastric cancer. However, by evaluating the distribution of bacteria in relation to 
ethnicity, lifestyle- and clinicopathological factors in a South African cohort, we have 
taken a first step towards this goal and we expect that our data will facilitates the 
development of targeted research questions for future studies. 
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Chapter 5: Quality assessment and data handling methods for 




One of the primary objectives of this thesis was to conduct gene expression analysis on 
paired CRC samples to investigate host-signaling pathways in the context of specific 
bacterial colonisation. However, clinical samples often have variable RNA integrity due 
to a range of factors from host factors (type of tissue/sample, disease state etc.) to 
sample collection and storage, which have important implications for downstream gene 
expression analyses. RNA and microarray quality assessment form an integral part of 
gene expression analysis and, although methods such as the RNA integrity number 
(RIN) algorithm reliably asses RNA integrity, the relevance of RNA integrity in gene 
expression analysis as well as analysis methods to accommodate the possible effects of 
degradation requires further investigation.  
We investigated the relationship between RNA integrity and array quality on the 
commonly used Affymetrix Gene 1.0 ST array platform using reliable within-array and 
between-array quality assessment measures. The possibility of a transcript specific bias 
in the apparent effect of RNA degradation on the measured gene expression signal was 
evaluated after either excluding quality-flagged arrays or compensation for RNA 
degradation at different steps in the analysis.  
Using probe-level and inter-array quality metrics to assess 34 Gene 1.0 ST arrays 
derived from historical, paired tumour and normal primary colorectal cancer samples, 7 
arrays (20.6%), with a mean sample RIN of 3.2 (SD = 0.42), were flagged during array 
quality assessment while 10 arrays from samples with RINs < 7 passed quality 
assessment, including one sample with a RIN < 3. We detected a transcript length bias 
in RNA degradation in only 5.8% of annotated transcript clusters (p-value 0.05, FC ≥ 
|2|), with longer and shorter than average transcripts under- and overrepresented in 
quality-flagged samples respectively. Applying compensatory measures for RNA 
degradation performed at least as well as excluding quality-flagged arrays, as judged by 
hierarchical clustering, gene expression analysis and Ingenuity Pathway Analysis; 
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importantly, use of these compensatory measures had the significant benefit of enabling 
lower quality array data from irreplaceable clinical samples to be retained in 
downstream analyses. 
Here, we demonstrate an effective array-quality assessment strategy, which will allow 
the user to recognize lower quality arrays that can be included in the analysis if 
appropriate measures are applied to account for known or unknown sources of variation, 
such as array quality- and batch- effects, by implementing ComBat or Surrogate 
Variable Analysis. This approach of quality control and analysis will be especially 
useful for clinical samples with variable and low RNA qualities, with RIN scores ≥ 2. 
 
The results from this Chapter were published in BMC genomics in 2013276 (Appendix 
D).  
Introduction 
RNA degradation is a common concern in gene expression analysis, especially for 
clinical samples where RNA degradation may occur before sample collection277. A 
wealth of archival material, either snap frozen or formalin fixed and paraffin embedded 
(FFPE), could potentially be used for gene expression analysis, given an appropriate 
method to evaluate and account for the effect of RNA degradation on the quality of 
downstream gene expression data. Methods such as the RNA integrity number (RIN) 
algorithm reliably assess RNA integrity by extracting features from the RNA 
electropherogram. The RIN algorithm was developed using learning tools to identify 
regions (features) indicative of RNA integrity in the electropherogram, which are then 
used to compile the RNA integrity number on a scale of 1 to 10. However, the relevance 
of RNA integrity in gene expression analysis, especially when there is large variability 
between samples, requires further investigation and validation on a platform specific 
basis. The impact of RNA integrity on gene expression analysis has been investigated 
on both qRT-PCR and certain microarray platforms278–283. Opitz et al. investigated the 
impact of RNA degradation on Agilent 44 k gene expression profiling by subjecting 
RNA from clinical biopsies to temperature-induced RNA degradation and comparing 
gene expression to the original, intact samples. Notably, less than 1% of genes were 
affected, even after substantial RNA degradation, where control and test samples had 
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RINs of 9 and 5 respectively. The affected transcripts were relatively shorter, had lower 
GC content, or had probes relatively closer to the 5' region of the gene compared to 
more robust genes282. Although the process of RNA degradation is not fully understood, 
both exonuclease and endonuclease activity is likely to play an important role282. 
Classical oligo-dT based cDNA synthesis, which starts at the poly-A tail, will most 
certainly be compromised by exonuclease activity. In contrast random priming does not 
rely on full length mRNA and therefore is in theory at least partially relieved from the 
affects of RNA degradation282–285. 
When using semi-degraded RNA for gene expression studies, reliable measures of array 
quality provide valuable information that can be used to guide downstream analysis. 
Microarray data quality may be defined in terms of accuracy (systematic bias between 
the true and measured value), precision (the uncertainty in replicated measures), 
specificity (the selective power of the measurement to respond only to the specific 
targets) and sensitivity (the expression range potentially covered by the 
measurement)286. Any attempt to utilise array quality results to guide downstream 
analysis should ideally take into account the possible effects of RNA degradation on 
sensitivity, specificity and accuracy. In previous work, Binder et al. proposed a single-
array preprocessing method that allows correction for systematic biases such as RNA 
degradation by utilising information on the 3'/5'-amplification bias and the sample-
specific calling rate286. Lassmann et al. proposed using a data adjustment method to 
allow comparative analysis of microarray datasets derived from fresh frozen vs. FFPE 
samples by centering the log intensities of each probe set independently to a mean of 
zero in both groups284. Chow et al. evaluated the suitability of different quality control 
and preprocessing strategies for use with partially degraded RNA samples on the 
Illumina DASL-based gene expression assay using mean inter-array correlation and 
multivariate distance matrix regression (MDMR) as a measure of success287. 
Unfortunately none of these studies are directly applicable to one of the most commonly 
used human transcriptomic microarray platforms, namely Affymetrix Gene 1.0 ST 
arrays, either because they do not use a random priming approach or because the design 
of the microarray platform differs substantially from Gene 1.0 ST arrays. We therefore 
identified two alternative approaches that might be used as compensatory methods: 
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Firstly, Johnson et al. developed an empirical Bayes algorithm, ComBat, to directly 
adjust for non-biological experimental variation. As the name implies, this method is 
most often used to adjust for batch effects i.e. when microarrays are processed on 
different dates288. Secondly, Leek et al. developed a method called Surrogate Variable 
Analysis (SVA), which examines the contribution of sources of signal due to unknown 
(surrogate) variables in high-dimensional data sets, which may confound the biological 
signal of interest289. The surrogate variables are constructed directly from the gene 
expression data where groups of genes that are affected by each source of variation are 
identified, factors are then estimated for each array which can be included in a linear 
model to adjust for unknown sources of noise e.g. RNA- or array-quality. 
Here, we investigate the relationship between RNA integrity and array quality on 
Affymetrix Gene 1.0 ST arrays for 34 paired colorectal tumour and adjacent normal 
biopsies of highly variable RNA integrity. We assume that at a certain point on the RIN 
scale, RNA will be degraded to the extent where fragments are too small to analyse 
reliably and for the purpose of this analysis we arbitrarily select a RIN cutoff of 2. We 
describe the within- and between-array quality control measures and analysis methods 
that we found most relevant for gene expression analysis of samples with highly 
variable RINs on Affymetrix Gene 1.0 ST arrays. We then investigate the possibility of 
a transcript-length dependency in RNA degradation. Finally, we apply array quality 
information to either exclude quality-flagged arrays, to directly adjust the data using the 
ComBat algorithm, or to account for unknown sources of variation (such as RNA 
integrity or array quality) in the model fitting process using SVA. The data discussed, 
have been submitted to ArrayExpress, with accession number E-MEXP-3715. 
Materials and Methods 
Sample preparation and quality control 
Frozen samples were transitioned to RNA®later -ICE (Ambion), an RNA stabilisation 
solution, using dry ice to prevent thawing of the tissue at any stage. RNA was extracted 
using a Dounce homogenizer and the AllPrep DNA/RNA/Protein kit (Qiagen) including 
DNAse treatment. RNAseZap (Ambion) was used to eliminate RNAse from the work 
surface, pipettes and glassware. RNA integrity assessment was conducted on an Agilent 
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Bioanalyser 2100. 
Quantitative real-time PCR 
From a biological perspective, we used the stability of expression of housekeeping 
genes to investigate the effect of RNA integrity on array- and qRT-PCR performance. 
Gene candidates were selected from those previously been specifically identified as 
good reference genes for colorectal cancer290–294. Expression stabilities were ranked 
using the Normfinder algorithm295 and three genes were selected for use as reference 
genes. All primers except those for B2M296 were designed using Primer-BLAST; 
sequences are shown in Table 4.  
Table 4: Primers used for qRT-PCR analysis. 
 
 
Experiments were performed in triplicate on a Roche LightCycler® 480 Real-Time 
PCR System in 96-well format. Efficiency was determined for each primer pair using a 
two-fold dilution series across five points for five patient samples of varying RNA 
integrity. For each patient, tumour vs. normal fold change was determined based on the 
method of Antonov et al. whereby the Ct of the test gene is normalised by the geometric 
mean of multiple control genes285. Since our efficiencies were quite low in some cases, 












where 𝑡  represents the test gene, 𝑒  represents efficiency and 𝑖  represents the control 
gene(s). 
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Microarray analysis 
Affymetrix HuGene 1.0 ST expression arrays 
Thirty-four samples with A260/230 ratios of at least 1.6, RINs of at least 2 and no sign 
of genomic DNA contamination, were selected for microarray analysis. The samples 
were amplified from 200ng of total RNA in accordance with the Ambion® WT 
Expression assay kit and fragmented and end labeled in accordance with the 
Affymetrix® GeneChip® WT Terminal Labeling protocol. The prepared targets were 
hybridized overnight to Affymetrix Human Gene 1.0 ST arrays. Following 
hybridization, the arrays were washed and stained using the GeneChip Fluidics Station 
450 and scanned using the GeneChip® Scanner 3000 7G. Arrays were processed in two 
batches - batch one had 10 arrays, and batch two 24. Individual patient pairs were not 
split across batches. 
 
Microarray quality assessment and data analysis 
Standard Affymetrix quality control was conducted using Expression Console® 
Software: The quality of cDNA preparation and array hybridisation was assessed using 
appropriate spike-in controls at each stage. 
Raw array quality was investigated at the probe level by 1) the difference between the 
mean of the perfect match probes and the mean of the background probes for each array 
as well as 2) the coefficient of variation (CV) across all probes for each array. A 
threshold for the CV across probes was set as two standard deviations from the mean 
CV, where the mean was calculated from arrays with RINs > 6. The data were 
preprocessed in R using the Bioconductor packages frma297, oligo298, and the ComBat 
algorithm for batch correction288. Preprocessed data quality was assessed using the 
global normalised, unscaled standard error (GNUSE)299. The SE estimates are 
normalized such that for each probe set, the median standard error across all arrays is 
equal to 1. Since most genes are not expected to be differentially expressed, boxplots 
for each array should be centered around 1. Samples with a median GNUSE of greater 
than 1.25 were flagged for downstream analysis. This threshold is fairly arbitrary and 
has not been validated for the Gene 1.0 ST platform but roughly equates to having a 
precision that is on average 25% worse than the average Gene 1.0 ST array299. 
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Five comparative methods for analysis of differential expression were individually 
applied to the preprocessed data: 1) The arrayWeights function in the Bioconductor 
package limma229 was used to estimate array quality weights which were then included 
in the linear model fit; 2) Arrays that were flagged in array quality assessment were 
excluded from the analysis; 3) The ComBat algorithm for batch correction was applied 
to directly adjust the data according to quality, where arrays were divided into two 
categories according to the array quality assessment; 4) “Quality” and “batch” were 
included as a factors in the linear model together with disease status; 5) Surrogate 
variable analysis was applied to frma-processed data without any direct adjustment, the 
output from SVA being incorporated into the linear model fit289. 
To rank genes by evidence for differential expression, the eBayes function in limma 
was applied to compute moderated t-statistics, moderated F-statistic, and log-odds of 
differential expression by empirical Bayes shrink- age of the standard errors towards a 
common value229. Next, using the topTable function in limma, p-values were adjusted 
for multiple hypothesis testing using the Benjamini and Hochberg method300. Transcript 
clusters were annotated in R using the Bioconductor package 
hugene10sttranscriptcluster.db (Affymetrix Human Gene 1.0-ST Array 
Transcriptcluster Revision 8 annotation data, assembled using data from public 
repositories). 
The subset of genes differentially affected by RNA quality was similarly obtained, now 
using array quality for grouping, instead of disease status. Genes with adjusted p-values 
≤ 0.05 and FCs ≥ |2| were included in the analysis. Transcript length was obtained for 
all annotated transcript clusters using the Bioconductor package goseq301. Hierarchical 
clustering with average linkage and Euclidian distance as distance measure was 
performed in R using the hclust function. 
For Ingenuity Pathway Analysis, genes that were found to be significantly differentially 
expressed for each method (adjusted p-value ≤ 0.01), were used as input for IPAs “Core 
Analysis”. Here, statistically significant over-representation of our listed genes in a 
given process such as “colorectal tumour” or “infection of embryonic cell lines” is 
scored by p-value, using the right-tailed Fisher’s Exact Test. In the case of upstream 
regulators, the predicted activation state and activation z-score is based on the direction 
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of fold change values for genes in the input dataset for which an experimentally 
observed causal relationship has been established. Performance was assessed using the 
top 10 functions in terms of p-values for each method while taking into account the 
relevance of the function to colorectal cancer. 
The data analysis pipeline which can be divided into three phases: quality control; data 





Figure 1: Summary of the full data analysis pipeline which consists of three phases: 1) Quality control 
(QC), 2) data adjustment and/or analysis and 3) performance evaluation. 




We assessed array quality using within- and between-array measures––the former to 
assess raw data quality (Figures 2a & 2b), and the latter to assess the quality of an array 
relative to a large publically available collection of high quality Gene 1.0 ST arrays 
(Figure 2c). Raw array quality was investigated at the probe level by calculating the 
difference between the means of perfect match- and background-probes for each array 
as well as the coefficient of variation (CV) across all probes for each array. 
Preprocessed data quality was assessed using the global normalised, unscaled standard 
error (GNUSE)299. See Methods section for details. 
 
Figure 2: Array quality metrics. a) Raw coefficient of variation across all probes by sample, the red line represents our chosen 
threshold which is calculated as 2SD from the mean of CVs for arrays with RINs > 6. Samples labeled in red denote samples that 
were eventually flagged for downstream analysis because they failed ≥ two of the three quality measures b) Raw perfect match 
mean - background mean c) Global normalised unscaled errors (GNUSE) across probes for each array. Samples with a median 
GNUSE greater than 1.25 were flagged for downstream analysis. 
 
The 34 RNA samples used in this study had mean RIN of 6.3 and a standard deviation 
of 2.0. Samples that failed all three measures of quality had RINs between 2 and 3.3 as 
summarised in Table 1. Samples were ranked by GNUSE median and we found a good 
concordance in terms of ranking between the different quality control metrics. Samples 
that failed at least two out of the three quality measures were flagged for downstream 
analysis, resulting in 7 out of 34 samples being flagged (mean RIN = 3.2; SD = 0.42, 
samples represented in red in Figure 2). Interestingly, for one sample with a RIN of 2.6, 
array quality was not compromised, judged by our quality measures. The possibility of 
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a RIN-independent RNA quality factor, such as chemical purity, was investigated by 
performing a two-tailed Student’s t-test, comparing A260/230 ratios between quality-
flagged and quality-passed sample groups but no significant association was found (p-
value = 0.14). 
Table 1: Array quality assessment summary. 
 
Array performance is ranked for each measure with 1 considered the worst quality. Samples highlighted 
in bold were flagged for downstream analysis.  
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Transcript-dependent effects of RNA degradation on accuracy 
To investigate a possible probe-positional intensity bias related to RNA integrity, we 
plotted the mean probe intensity from the 5'- to 3' end of the sequence using 4644/32321 
(14.4%) of transcript clusters for Gene 1.0 ST arrays and 54130/54675 (99%) of 
probesets for HGU133-plus2 arrays. The number of probes per set varies for GeneST 
arrays, so we selected the largest group (N = 4664), which had exactly 25 probes/set. 
Interestingly, from the 4644 transcript clusters displayed in Figure 3, Gene ST 1.0 
arrays, do not display the same probe-positional intensity bias typically seen in oligo-dT 
based arrays such as the HGU133-plus2 arrays. 
 
Figure 3: Mean probe intensity by probe position, where each line represents an array for a) Gene 1.0 ST 
arrays: transcript clusters with exactly 25 probes (N = 4644) and b) HGU133-plus2 arrays previously 
analysed with a subset of the cohort: probesets with exactly 11 probes per probeset. 
 
We next investigated which genes were most affected in our quality-flagged category 
and identified 1994 out of 21943 annotated transcript clusters (with 1172 uniquely 
identified genes) that were significantly different (fold change ≥ |2|, adjusted p-value ≤ 
0.05) between the two quality categories previously discussed. Of the 1172 uniquely 
identified genes, 1032 and 140 showed decreased or increased intensity in the quality-
flagged category respectively (Figure 4a). To investigate transcript characteristics in the 
genes most affected, we compared transcript lengths (taken as the median cDNA length 
for each gene) between the different groups. Compared to the unaffected genes, median 
cDNA lengths of genes that showed increased intensity were significantly shorter (p-
value < 2.2𝑒 − 16) while those with decreased intensity significantly longer (p-value = 
2.9𝑒 − 9) with regards to quality, judged using the Mann Whitney test (Figure 4b). 
RNA degradation plot
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Figure 4: Characteristics of genes most affected by RNA degradation (adjusted p-value ≤ 0.01, |fold 
change| > 2) when comparing samples that either passed or were flagged during QC. a) Fold change 
distribution of annotated transcript clusters comparing samples that were flagged vs. samples that passed 
QC b) Gene lengths of uniquely identified genes. Expression signal significantly increased (Up) or 
decreased (Down) with respect to the ‘Unaffected’ group, judged using a Mann-Whitney test. 
 
Quality dependent methods of data adjustment and analysis 
After assigning samples to two categories according to array quality measures, we next 
assessed the performance of the five preprocessing and analysis methods. Broadly 
speaking, the data was either directly adjusted for quality effects using ComBat, or 
quality-flagged samples were excluded from the analysis, or possible quality effects 
were addressed by including known or unknown sources of non- biological variance in 
the linear model fit to assess differential expression.  
The five methods of data preprocessing and analysis, further detailed in the Methods 
section, were: 1) Estimating array quality weights which were then included in the 
linear model fit; 2) Excluding quality-flagged arrays from the analysis; 3) Applying a 
batch correction algorithm, ComBat288, to directly adjust the data according to quality, 
where arrays were divided into two categories according to the array quality 
assessment; 4) “Quality” and “batch” were included as a factors in the linear model 
together with disease status; 5) Possible unknown sources of non-biological variance, 
such as quality, was estimated by SVA, with the output incorporated into the linear 
model fit289. 
To assess the effect of using ComBat for direct data adjustment, hierarchical clustering 
using Euclidian distance was performed before and after direct adjustment (Figure 5). 
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We chose to use Euclidian distance based on research by Gibbons et al. who 
demonstrated that, for log-transformed expression data, using Euclidian distance is 
more appropriate than Pearson’s correlation coefficients302.  
Figure 5: Samples’ expression profiles were clustered using average linkage hierarchical clustering. The 
dissimilarity measure (height) used was 1- Pearson correlation of the log2-transformed expression values. 
a) Sample clustering after preprocessing. b) Sample clustering after preprocessing and correction for 
batch and quality using ComBat. Samples that were flagged during quality assessment are highlighted in 
red. 
 
Before adjustment, samples that were flagged during quality assessment cluster closely 
together, irrespective of the disease status of the samples. After adjustment, the 
maximum distance between samples is greatly reduced, and quality-flagged samples no 
longer cluster together. Also, samples segregate more clearly by disease status after 
adjustment. 
Furthermore, applying ComBat clearly has a stabilising effect on the transcript clusters 
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Figure 6: Boxplots of frma-normalised expression values. a) All transcript clusters. b) Genes most 
affected by quality (adjusted p-value ≤ 0.01, |fold change| > 2. c) Genes most affected by quality after 
adjustment for batch- and quality-effects using ComBat. Samples that were flagged during quality 
assessment are highlighted in red. 
 
SVA identified two surrogate variables that were subsequently used in downstream 
analysis. Plotting the estimates of these surrogate variables for each sample revealed a 
pattern whereby samples were clearly grouped by batch and quality (Figure 7). 
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Figure 7: Surrogate variable analysis results. Two latent variables were identified by SVA. Samples 
highlighted in triangles or circles were from two different batches. Samples that were flagged during 
quality assessment are highlighted in red. 
 
To evaluate the performance of each method, we first compared the number of 
differentially expressed genes detected between tumour and normal samples at a 
stringent p-value of 0.01. For our analysis, we did not use a fold change cutoff since we 
feel that artificial fold change cutoffs, which exclude subtle changes in the expression of 
many genes, may result in the loss of valuable biological information, or worse, affect 
the interpretation of the data––this is particularly true for applications such as 
network/pathway analysis303. 
SVA and ComBat detected 2137 and 1945 genes (p-value ≤ 0.01), respectively. The top 
four methods had 1117 differentially expressed genes in common (Figure 8). At the 
commonly used p-value- and fold change-cutoffs of 0.05 and 2 respectively––SVA, 
Combat, ArrayWeights and excluding arrays, produced 447, 475, 461 and 521 
differentially expressed genes – suggesting similar performance under these criteria. We 
next assessed the relevance of these differentially expressed genes, in colorectal cancer, 
using Ingenuity Pathway Analysis where, statistically significant over-representation of 
our listed genes in a given process such as colorectal tumour or infection of embryonic 
cell lines is scored by p-value. 
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Figure 8: Venn diagram of unique differentially expressed genes (tumour vs. normal) with adjusted p-
values ≤ 0.01 for the four best-performing methods. A) removing quality-flagged arrays before analysis. 
B) applying SVA to batch corrected data. C) ComBat used to correct for batch and quality. D) Array 
weights included in the linear model. 
 
We considered the top 10 functions for each method (Table 2) from which it was clear 
that the 615 and 423 additional genes identified as differentially expressed by SVA and 
ComBat, compared to that obtained when excluding quality-flagged arrays, were 
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Table 2: P-values for evidence for overrepresentation in the functions listed for each method.  
 
 
A) excluding quality-flagged arrays from the analysis; B) applying SVA to batch corrected data; C) 
ComBat used to correct for batch and quality; D) Array weights included in the linear model; E) 
including batch and quality as factors in the linear model. 
 
Using IPA, we considered the top 10 upstream regulators (highest absolute activation z-
scores) when comparing tumour vs. normal samples, to further investigate the utility of 
SVA or ComBat as suitable analysis methods when including low-RIN samples (Table 
3). We found considerable overlap in the identity and direction of activation of these 
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Table 3: Top 10 IPA-derived upstream regulators, by absolute activation z-score. A) excluding quality-
flagged arrays from the analysis; B) applying SVA to batch corrected data; C) ComBat used to correct for 




qRT-PCR validation of select genes 
In order to ascertain whether or not data obtained by microarray analysis with low-RIN 
samples were comparable to the results obtained using the method designed by Antonov 
et al. for qPCR analysis of low-RIN samples, we selected two genes, dipeptidase 1 
(DPEP1) and claudin 1 (CLDN1), for qRT-PCR validation. Given that our microarray 
data analysis suggests ~95% of genes are unaffected by RNA integrity, we wished to 
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compare microarray and qPCR data for genes that were apparently unaffected by RNA 
integrity; DPEP1and CLDN1 were found to be significantly differentially expressed in 
our microarray data by all of the five methods used and, in addition, there is strong 
literature evidence for their differential expression between tumour and normal samples. 
From reference genes previously cited as suitable for colorectal cancer studies, we 
selected those most stably expressed in our cohort using the Normfinder algorithm 
(UBC, B2M, ATP5E)290–294. We found good correlations, for both CLDN1 (Adjusted 
R2 = 0.81) and DPEP1 (Adjusted R2 = 0.83), between qRT-PCR- and microarray-based 
fold change values (Figure 9), irrespective of RIN score. 
 
Figure 9: DPEP1 and CLDN1 tumour vs. normal fold change (FC) results for qRT-PCR and microarray 
results. Samples that were flagged during quality assessment are highlighted in red. 
 
Discussion and conclusions 
RNA is extremely vulnerable to degradation and as such has the potential to introduce a 
systematic bias in gene expression measures. Reliable measures of sample and data 
quality are therefore essential to evaluate the effects of RNA integrity on accuracy, 
sensitivity and specificity of gene expression results. From previous studies as well as 
our own, it is now clear that the level of acceptable RNA degradation within an 
experiment depends largely on the experimental design, platform and application. 
Multiple studies have demonstrated an improvement in microarray and qRT-PCR 
performance by using random priming when RNA integrity is in doubt. Here we 
observed a direct association between RINs and array quality in the majority of cases. 
To gauge the consequences of using these arrays in downstream analysis, we compared 
quality-flagged to quality-passed arrays and found a relatively small subset of genes, 
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1172/20019, to be significantly affected (p-value 0.05, FC ≥ |2|) in our samples on the 
Gene 1.0 ST platform. It is of course possible that the exact identity and proportion of 
the affected genes may differ between studies on Gene 1.0 ST arrays but, based on our 
data, we suggest that the overall proportion of affected genes is unlikely to be 
significantly different to that observed here. Depending on the application, this may or 
may not have an effect on the study outcome. However, the most common microarray 
applications such as finding differentially expressed genes between two conditions, 
pathway analysis, and clustering do not rely on interrogating specific genes and appear 
to be largely robust to the effects of RNA degradation on this platform (Table 2). 
Using within- and between-array quality measures, we investigated the relationship 
between RNA integrity and array quality on Affymetrix Gene 1.0 ST arrays. We found 
a combination of within- and between-array quality measures useful to rank samples by 
array quality. However, the single most useful array quality measure appears to be 
GNUSE, since it provides a more general measure of array quality relative to a large set 
of publically available arrays. We found that 86% of samples with RINs ≤ 3.3 were 
flagged by at least two of our quality control measures. One sample with RIN score < 3 
passed all three quality measures, although it did have relatively low array quality 
weight. Furthermore, 10 out of 17 samples with RIN scores ≤ 7 passed at least 2 out of 
3 quality measures, suggesting that the widely used RIN cutoff of 7 is too stringent for 
Gene 1.0 ST arrays.  
We then examined the genes most affected by RNA degradation and demonstrated a 
relationship between accuracy and length of the original transcript, with both longer 
than average, and very short transcripts being under- and overrepresented in quality-
flagged samples respectively. This is in contrast to the findings by Opitz et al. who 
found that short transcripts were more vulnerable to the perceived effects of degradation, 
whereas long transcripts were more stable relative to the average length transcript282. 
Interestingly, of the genes that were overrepresented in quality-flagged samples, 70% 
were small non-protein coding RNAs, including 94 small nucleolar RNAs, and 4 
microRNAs, consistent with reports that microRNAs are more robust to RNA 
degradation compared to mRNA304, perhaps because they are more thermodynamically 
stable than mRNAs.  
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Without excluding any genes, we then compared the orthogonal approaches of either 
excluding quality-flagged arrays or compensating for RNA degradation at different 
steps in the analysis. Sample clustering showed that when using ComBat adjustment, 
quality-flagged samples no longer clustered together. Furthermore, samples tend to 
segregate more clearly by disease status following adjustment, which suggests that the 
algorithm is not introducing artifacts. It is worth noting that patients 13, 4 and 18 were 
diagnosed with a hereditary form of CRC (HNPCC)––it is therefore not surprising that 
the ‘normal’ samples from these patients form a separate cluster.  
Irrespective of sample/array quality, applying compensatory measures for RNA 
degradation performed at least as well as excluding arrays that were flagged during 
quality assessment, as judged by gene expression analysis and IPA. At a p-value of 0.01, 
SVA and Combat detected the highest number of differentially expressed genes 
between tumour and normal samples and the top four methods applied here had 1117 
differentially expressed genes in common. To evaluate the biological plausibility of the 
genes deemed significantly differentially expressed between tumour and normal 
samples, we harnessed the results from IPA to show that, in terms of the top scoring 
biological functions and upstream regulators, there is considerable overlap in the 
identity and direction of biological activation when comparing analysis methods that 
either excluded or included quality-flagged arrays. These results suggest that our 
analysis strategies are biologically sound and not biased by non-biological variance. 
The relevance of each method will depend on the downstream application and the 
proportion of quality-flagged arrays: If a small percentage of arrays are flagged, there 
might not be much benefit in including them for downstream analysis. However, if a 
large proportion of the arrays are affected by RNA quality––which is likely to often be 
the case where the RNA is derived from irreplaceable historical clinical samples––the 
ability to retain all arrays and to account for these effects in the analysis will be valuable. 
Here, ComBat may be useful if direct data adjustment is required, e.g. for sample/gene 
clustering. On the other hand, for analysis of differential expression, especially when 
the source of non-biological variance is not immediately apparent, SVA may be most 
useful since it does not require supervision; notably, in our hands SVA was able to 
identify two surrogate variables which closely corresponded to “batch” and “quality” 
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factors, judged by the grouping of samples. To establish whether the measures used here 
to compensate for quality-effects are superior to excluding these arrays from the 
analysis will require a controlled study with known true- and false-positives where the 
discriminatory power of each method can be objectively investigated. However, the 
significant overlap observed between the differentially expressed genes identified by the 
different approaches used here, combined with the considerable overlaps in both 
biological function and upstream regulators identified by pathway analysis of the 
resultant data, argues against a simple expansion of false positives when lower quality 
array data is included in the analyses. The quality assessment and data analysis methods 
discussed here should in principle be as useful for Affymetrix Exon ST array analysis as 
well.  
 
In conclusion, array quality measures can be used to set quality thresholds, to provide 
valuable information that can be used to improve the linear model of differential 
expression, or to correct expression signal prior to assessing differential expression. We 
suggest that accounting for known or unknown sources of variation, such as variable 
RNA integrity and batch, by implementing ComBat or Surrogate Variable Analysis for 
analysis of differential gene expression enables robust analysis of microarray datasets 
derived from variable and low quality RNA, thereby extending the range of clinical 
samples that are suitable for microarray analysis.  
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Chapter 6: Whole-genome methylation analysis of CRC 




Whole-genome methylation analysis was conducted on 24 pairs of colorectal 
adenocarcinoma and matched normal mucosal samples (19 of these 24 pairs were also 
analysed by whole-genome gene expression analysis, Chapters 7 and 8).  
In this Chapter a brief overview of DNA methylation in general and in the context of 
CRC is provided. Next, whole-genome methylation technologies are reviewed, with a 
detailed description of the Illumina HumanMethylation450 BeadChip technology used 
thereafter. 
Methylation patterns were assessed using a model-based approach to unsupervised 
clustering in our cohort both before and after merging our cohort with a large publically 
available dataset of colorectal adenocarcinomas (N=361), with confirmed CpG island 
methylator phenotype (CIMP) annotation, available from The Cancer Genome Atlas 
(TCGA). 
In the merged dataset (N=385), four clusters with varying levels of CpG island 
methylation were obtained: two clusters were dominated by CIMP-low (L) samples, 
another by CIMP-high (H) samples, while the fourth cluster was almost entirely 
composed of CIMP-stable samples. Clinically relevant features included the enrichment 
of MSI-H samples in the CIMP-H cluster and the predominance of proximal cancers 
and stage I/II cancers in the two clusters displaying the highest level of CpG island 
methylation. 
CIMP-status in our cohort was predicted using unsupervised clustering of CpG island 
probes mapping to a published five-gene array-based marker panel; 9 of 24 samples 
were classified as CIMP-L, 1 as CIMP-H and 14 as CIMP-stable.  
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Analysis of variance by CIMP-status revealed 2172 probes associated with CIMP-status 
(p ≤ 0.05, |Δ beta| ≥ 0.2), 93% of which mapped to CpG islands and 99.8% of which 
showed increased methylation in CIMP+ vs. CIMP– samples; moreover, of the 94 genes 
significantly associated with CIMP status (FDR ≤ 0.25), at least 23% (22/94) had 
previously been found to show increased CpG island methylation in CIMP+ vs. CIMP– 
tumours305; of these, BDNF306 and KCNK13305 have been used in published CIMP-
marker panels. 
In addition to array-based methylation analyses, MLH1 methylation (the main cause of 
MSI-H in sporadic CRCs) was validated by methylation-specific PCR. Two samples 
tested positive for MLH1 methylation, both of which were sporadic MSI-H CRCs that 
were predicted to be CIMP+. 
Lastly, any patterns of methylation associated with CRC associated pathogens 
(including Fusobacterium, Enterococcus faecalis, Enterotoxigenic Bacteroides fragilis 
(ETBF), Enteropathogenic Escherichia coli (EPEC), ClB+ E. coli and afaC+ E. coli) 
were determined. EPEC was associated with altered patterns of host methylation in 
tumour samples, but the majority of CpG sites were not significantly associated with 
EPEC- colonisation after multiple testing correction. This is not surprising since there 
were only three EPEC+ samples in this cohort, and multiple testing correction imposed 
a substantial penalty on the p-values, given that ~300 000 probes were analysed 
concurrently. Nevertheless, two of the three EPEC+ samples had confirmed MLH1 
promoter methylation by methylation-specific PCR, and all three EPEC+ samples were 
predicted to be CIMP+. Taken together, these results point towards a possible link 
between EPEC and aberrant methylation in the colon, which warrants validation in a 
larger cohort. 
Introduction 
DNA methylation–the covalent addition of a methyl group to cytosine–is catalyzed by 
DNA methyltransferases (DNMTs), a family that includes members with de novo- and 
maintenance-methylation functions. 
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CpG dinucleotides (a cytosine followed by a guanosine) are the most frequent site of 
methylation, with ~80% methylated in healthy cells. Because methylated cytosines tend 
to be deaminated to thymine over evolutionary time, CpG dinucleotides occur at a 
frequency of 20–25% less than expected by chance307. However, more than 60% of 
genes contain CpG-rich regions, referred to as CpG islands; these regions are 300–
3000bp in length and have a GC percentage of at least 50%, and an observed-to-
expected CpG ratio of at least 0.6, where the observed-to-expected CpG ratio is 
calculated by the formula ((Number of CpG/(Number of C × Number of G)) × Total 
number of nucleotides in the sequence)308. The cutoffs for this definition are however 
quite arbitrary and may vary between studies309.. In contrast to CpG poor regions, CpG 
islands are typically unmethylated. DNA methylation across the genome therefore 
follows a bimodal distribution, with the majority of CpG sites methylated at very high 
levels (>85%), and CpG islands largely unmethylated (<15%)310. 
Although DNA methylation is commonly associated with gene silencing, its function is 
more accurately region-specific. While DNA methylation serves to immobilise 
transposable elements genome-wide311, CpG-island-based methylation may activate or 
repress transcription of specific genes. Methylation of promoter-based CpG islands is 
strongly associated with transcriptional repression due to the inhibition of binding of 
methylation-sensitive transcriptional activators, or to affects on the binding of proteins 
that orchestrate changes in chromatin conformation312. On the other hand, 
developmentally programmed methylation of CpG islands in 3’ regions have been 
associated with tissue- and cell-type-specific transcriptional activation312. Further, non-
CpG island methylation in gene bodies is even thought to affect gene splicing313. It is 
therefore becoming apparent that DNA methylation is not simply an on-off switch for 
transcription, but has various, more subtle roles across different regions of the genome. 
Methylation patterns in CRC 
Aberrant methylation is a common occurrence in CRC, with global hypomethylation, 
and region-specific hypermethylation associated with chromosomal instability (CIN) 
and microsatellite instability (MSI), respectively152–154. About 70% of proximal MSI+ 
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cancers exhibit frequent hypermethylation of CpG islands155, and hypermethylation of 
the promoter region of MLH1 is the main cause of MSI-H in sporadic CRCs102.  
Prior to the development of technologies for evaluating methylation genome-wide, 
Toyota et al. defined 33 markers that were differentially methylated between Caco-2 
cells and normal mucosal samples314. These markers were subsequently divided into 
cancer-specific and age-related markers315. The subset of CRCs that displayed 
methylation of cancer-specific markers was referred to as CIMP315. Five genes were 
subsequently selected as surrogate markers of CIMP (CDKN2A, MLH1, MINT1, MINT2 
and MINT31) that could be used to classify samples as CIMP+ or CIMP-stable. This 
panel has since been updated based on analysis of a larger number (195) of CpG loci. 
The new panel consists of CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1155,306, and 
is commonly used for PCR-based detection of CIMP. 
The classification of samples as CIMP+ has since been subdivided into CRCs with 
high- (CIMP-H) or intermediate/low (CIMP-L) levels of CpG island methylation. 
Importantly, CIMP-H and CIMP-L CRCs appear to have heterogeneous molecular and 
clinicopathological features: CIMP-H CRCs are associated with the proximal colon, 
older age, female sex, frequent BRAF mutation, MLH1 methylation, MSI and rarely 
KRAS and TP53 mutations; meanwhile CIMP-L CRCs are associated with KRAS 
mutation, but not MSI, or mutations in BRAF or TP53316. The mechanisms underlying 
these associations remain unclear. Regarding the mechanistic basis of CIMP, the DNA 
methyltransferase DNMT3B as well as SNPs in folate metabolizing enzymes have been 
implicated316 but additional clarification is required. Further, numerous studies have 
investigated CRC prognosis according to MSI, CIN, CIMP and BRAF/KRAS mutation 
status, but the relationship between these factors appears complex. 
Unsupervised clustering of whole-genome methylation data supports the association 
between the degree of CpG island methylation encountered and specific 
clinicopathological and molecular features317. Using a model-based approach to 
unsupervised clustering, Hinoue et al. identified four classes of methylation (determined 
across 125 CRCs): a relatively small subset of CRCs displayed a particularly high-level 
and -frequency of CpG island methylation, along with frequent mutations in BRAF, 
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MLH1 promoter methylation, MSI-H and proximal colonic location––these cases were 
classified as CIMP-H; the remaining three clusters were defined as: CIMP-L 
(characterised by hypermethylation of a subset of CIMP-H markers), cluster 3 (which 
displayed less CpG island methylation compared to the CIMP-L clusters), and cluster 4 
(which displayed even less CpG island methylation compared to cluster 3). Hinoue et al. 
developed two diagnostic DNA methylation gene marker panels, each consisting of five 
genes, based on Illumina Infinium DNA methylation data of 125 CRCs; one panel is 
used to identify CIMP (CIMP-H or CIMP-L), and the other is used to segregate CIMP-
H tumors from CIMP-L tumors317.  
Meanwhile, global hypomethylation occurs particularly in non-CpG-island regions of 
the genome, including repetitive sequences and in CpG island shores156. While 
hypomethylation has been associated with activation of a handful of tumour supressors 
(e.g. CDH3), the most apparent consequence of global hypomethylation is chromosomal 
instability88,89,153. This occurs when pericentromeric regions are demethylated, which 
facilitates recombination and altered chromosomal replication156. 
While certain disease-related methylation patterns such as global DNA hypomethylation 
are quite obvious, whole-genome methylation analysis is still in its infancy, and it is 
essential to first establish a baseline tissue-specific methylation profile, as well as the 
extent of inter-individual and temporal variations in methylation profiles, before more 
subtle disease-related methylation patterns can be appreciated147. For example, age-
related methylation occurs in the majority of tissues, where a subset of genes undergo 
hyper- and hypomethylation in CpG-rich and -poor regions, respectively147. In cancer, 
cigarette smoking and body mass index have been associated with increased 
methylation of CpGs, which was attenuated by hormone replacement therapy or aspirin 
use318.  
Finally, numerous pathogens can induce aberrant methylation in host cells, including H. 
pylori150,319,320 and Epstein Barr in gastric cancer151, as well as Influenza virus, 
Pseudomonas syringae, Wolbachia pipientis321 and Campylobacter rectus322. Whether 
or not microbially-induced methylation plays a role in CRC remains unknown. 
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Methylation analysis technology overview 
Although DNA methylation testing has been conducted on a per-gene basis for over 20 
years, microarray and sequencing technologies have only recently been implemented 
allowing cost-effective, whole-genome methylation analysis. 
Methylation patterns can be captured in a high-throughput manner following one of two 
strategies to record methylation sites: 1) bisulfite conversion of DNA, which 
specifically mutates unmethylated cytosines (through deamination) to uracil, allowing 
genotype-based analysis of methylation (using microarrays or sequencing) at single 
nucleotide level, or 2) enrichment-based methods that employ DNA-methylation-
specific antibodies, methyl-binding domain proteins, or restriction enzymes to enrich 
for a fraction of highly methylated (or unmethylated) DNA fragments. Enrichment of 
specific fragments are then quantified by next-generation sequencing323. 
An overwhelming variety of platforms are currently available for DNA methylation 
testing, selection from which should be guided by the nature of the sample to be 
analysed (specifically regarding the amount and integrity of DNA available), as well as 
the tradeoff between cost and genomic coverage.  
Because enrichment-based methods require relatively large amounts of intact (in the 
case of restriction enzyme methods) DNA, bisulfite-based methods are most suitable for 
clinical samples, which often have variable quality (e.g. FFPE-derived DNA) and 
quantity (e.g. scarce clinical samples). Bisulfite-based methods are also more accurate 
and reproducible, as long as bisulfite conversion and PCR efficiencies are consistent. 
Further, bisulfite-based methods allow profiling of CpG-poor regions that are largely 
excluded by CpG-enrichment based methods324. 
One disadvantage of bisulfite-based methods is the inability to distinguish between 
bisulfite-induced deamination of unmethylated cytosines to uracil, and single nucleotide 
polymorphisms (SNPs), which are particularly prevalent in CpG dinucleotides, since 
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methylated cytosine are naturally deaminated to thymine over evolutionary time. One 
solution is to exclude known SNPs from the downstream analysis. In the case of 
bisulfite-sequencing, both the forward and reverse strand can be sequenced to allow 
discrimination between SNPs and unmethylated CpGs, since the opposing strand would 
have been propagated as an A as opposed to a G in the case of a true SNP324. 
Bisulfite-based microarrays in particular are commercially available only for human 
samples, and although they are more cost-effective and require less technical expertise 
than sequencing, this comes at the cost of genomic coverage. 
Lastly, enrichment-based methods efficiently assess genome-wide methylation on a 
broad scale, but they do not yield information on individual CpG dinucleotides, and 
quantification may be biased by copy number variations (particularly in cancer 
samples)324. In the case of enzyme-based methods, this may be remedied by measuring 
the ratio between methylated and unmethylated versions of a sequence, as opposed to 
either on their own324. The main advantage of enrichment-based methods is that they 
provide cost-effective assessment of genome-wide DNA methylation, albeit at relatively 
lower resolution and with higher susceptibility to experimental bias323. 
Illumina HumanMethylation450 BeadChips 
The Illumina HumanMethylation450 BeadChip was selected for this study. This is a 
bisulfite-based array, which covers selected areas of 99% of Refseq genes, with an 
average of 17 CpG sites per gene region, where each gene region is divided into six 
feature types (Figure 1). Further, 94% of CpG islands are covered, with similar 
coverage for adjacent regions (Figure 2). 
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Figure 1: Coverage of NM and NR transcripts from UCSC database. Each transcript is divided into 
function regions: TSS200 is the region from the transcription start site (TSS) to –200 nt upstream of the 
TSS; TSS1500 covers –200 nt to –1500 nt upstream of TSS; 5’ untranslated region (5’UTR), 1st exon, 




Figure 2: Coverage of regions in relation to CpG islands. The 2 kb regions immediately upstream and 
downstream of the CpG island boundaries are referred to as CpG island shores, and the 2 kb regions 
upstream and downstream of the CpG island shores are referred to as CpG island shelves. N: north; S: 
south. Figure reproduced with permission325.  
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Regions covered outside CpG islands include non-CpG methylated sites, sites 
differentially methylated in various tumour versus normal samples and across several 
tissue types, CpG islands outside coding regions, and miRNA promoter regions. 
The assay includes whole-genome amplification of bisulfite-converted DNA, followed 
by fragmentation and hybridization to the array. For each locus, the percentage of 
methylation is determined using a combination of sequence-specific hybridization 
capture and allele-specific single-base primer extension. One of two array chemistries 
are used to achieve this (Figure 3): Infinium I beadtypes consist of an unmethylated and 
a methylated bead for each locus examined; if the locus happens to be methylated, it can 
only bind to a methylated bead type (and vice versa), upon which a single, fluorescently 
labeled nucleotide (A or T (red), and C or G (green)) is incorporated immediately after 
the CpG locus. Infinium II beadtypes (which make up 72% of probes on the array) have 
one bead for both methylated and unmethylated loci; the nucleotide that binds reveals 
the methylation status since it completes the CpG locus; if an A (red) or G (green) is 
incorporated, the locus was unmethylated or methylated, respectively. Importantly, type 
I probes map to more CpG islands (57%) compared with type II probes (21%)326.  
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Figure 3: Illumina bead chemistries used to detect methylation. A: Infinium I beadtypes consist of an 
unmethylated and a methylated bead for each locus examined; if the locus happens to be methylated, it 
can only bind to a methylated bead type (and vice versa), upon which a single, fluorescently labeled 
nucleotide (A or T (red), and C or G (green)) is incorporated immediately after the CpG locus. B: 
Infinium II beadtypes have one bead for both methylated and unmethylated loci; the nucleotide that binds 
reveals the methylation status since it completes the CpG locus; if an A (red) or G (green) is incorporated, 
the locus was unmethylated or methylated, respectively. Figure reproduced with permission325. 
The level of methylation, on a scale of 0–1 at a particular CpG site, is summarized as a 
beta-value, where the ith interrogated CpG site is defined as, 
ß =  
max (𝑦𝑖,𝑚𝑒𝑡ℎ𝑦, 0)
max(𝑦𝑖,𝑚𝑒𝑡ℎ𝑦, 0) + max (𝑦𝑖,𝑢𝑛𝑚𝑒𝑡ℎ𝑦) + 𝛼
 
 
where yi,methy and yi,unmethy are the intensities measured by the i
th methylated and 
unmethylated probes respectively, and any negative values after background adjustment 
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are set to 0. A constant offset α (by default, α = 100) is added to the denominator to 
regularise beta when both methylated and unmethylated probe intensities are low327. 
The beta-statistic ranges between 0 (100% unmethylated) and 1 (100% methylated).  
Performance-wise, precision and accuracy on the Illumina HumanMethylation450 
BeadChip is very good, with R > 0.98 between technical replicates; the maximum 
sensitivity measured is a beta value of 0.2 (<1% false positive rate). 
Quality may be assessed by a total of 850 control bead types on the array, about 70% of 
which are ‘negative’ controls used by Illumina’s GenomeStudio software for 
background correction328. The control probes include non-specific binding controls, 
staining controls, extension controls, target removal controls, and hybridization controls. 
Differential methylation analysis considerations 
Unlike gene expression analysis, averaging methylation values across a given gene has 
little biological meaning since each gene consists of multiple functional regions, each of 
which may be differentially affected by methylation. Differential analysis can therefore 
either be conducted for individual CpG sites (which have been annotated as CpG island 
or non-CpG island), or by region of interest (e.g. TSS200, 1st exon, gene-body) after 
calculating region-specific methylation values. 
The beta distribution of methylation, together with the natural heterogeneity in overall 
intensity between samples, presents a further challenge to analysis––the widely used 
statistical framework for preprocessing and analysing gene expression data (which is 
based on the assumption of normality and similar average intensities between samples) 
may not be suitable. Statistical methods for differential methylation analysis is therefore 
an active area of investigation, which will no doubt see much change over the next few 
years. Wilhelm-Benartzi et al. have reviewed current processing and analysis methods 
for DNA methylation array data329. 
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Materials and methods 
Methylation analysis of MLH1 using methylation specific PCR 
MLH1 promoter methylation was determined by methylation specific PCR (MSP) in 
DNA extracted from tumour, normal and blood samples for 30 of the 32 patients for 
whom MSI testing was conducted. DNA was first bisulfite converted using the EZ 
DNA Methylation-Gold KitTM (Zymo Research), where DNA was denatured for 10 
minutes at 98ºC (since bisulfite only reacts with single stranded DNA), followed by 
incubation for 4 hours at 64ºC with bisulfite. The resulting bisulfite converted DNA was 
cleaned and desulphonated using spin columns.  
The MYOD gene is considered to be constitutively methylated and was therefore 
selected as a positive control to assess DNA integrity, bisulphite conversion efficiency, 
and to normalize DNA input. Serial dilutions were constructed for MYOD and MLH1 
plasmids to include 106, 105, 104, 103, 102, 50 and 25 copies of each gene for 
quantification purposes. Samples in which at least 1000 copies of the MYOD template 
were detected passed quality control––this equates to a minimum analytical sensitivity 
of 2.5% of all alleles. Samples that had a negative result for both MYOD and MLH1 
were repeated. Appropriate controls were included throughout the protocol, which are 
listed in Table 1. The primers used for MSP of MLH1, and the control gene MYOD are 
listed in Table 2. 
Table 1. Positive and negative controls included in the methylation detection protocol. 
Control type Stage where used 
No template control Bisulfite conversion 
Human methylated DNA standard (Zymo 
Research) 
Bisulfite conversion 
No template control Methylation specific PCR 
Human Bisulfite converted methylation DNA 
standard (Zymo Research) 
Methylation specific PCR 
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Table 2. Primers used for MLH1 and MYOD MSP. 






PCRs were conducted in 20 μl reactions in 96-well plates, using 1μl forward and 1μl 
reverse primer (from 6mM stock), 10μl BIORAD IQ supermix (from 2x stock), 2.5μl 
bisulfite converted DNA or 2μl plasmid standard and 5.5μl water. The cycling 
conditions are specified in Tables 3a (MYOD) and 3b (MLH1), and qPCR was 
conducted on a Bio-Rad C1000 Thermocycler. 
Table 3a: Cycling protocol for MYOD MSP. 
Step Duration Temperature Cycles 
Denaturation 60 seconds 95 °C 1 
Denaturation 30 seconds 95 °C  
Annealing 30 seconds 59 °C 37 
Extension 30 seconds 72 °C (plate read)  
Melt curve 5 seconds 65°C to 95°C (increment 0.5 °C) 1 
 
Table 3b: Cycling protocol for MLH1 MSP. 
Step Duration Temperature Cycles 
Denaturation 60 seconds 95 °C 1 
Denaturation 30 seconds 95 °C  
Annealing 30 seconds 61.5 °C 39 
Extension 30 seconds 72 °C   
Extension 20 seconds 74 °C (plate read)  
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Melt curve 5 seconds 65°C to 95°C (increment 0.5 °C) 1 
 
Whole genome array-based methylation analysis 
For whole-genome array-based methylation analsyis, samples were bisulfite converted 
using the EZ DNA Methylation-Gold KitTM, as described for MSP-based detection of 
MLH1 methylation; again bisulfite conversion efficiency was assessed using MYOD as 
a positive control. Bisulfite-converted DNA was whole genome amplified and 
enzymatically fragmented prior to hybridization to Illumina HumanMethylation 450k 
BeadChip arrays, according to the manufacturer’s instructions330. Arrays were scanned 
on an Illumina HiSeq 2000 using Illumina’s iScan technology.  
Data preprocessing  
Raw data was extracted and overall quality was assessed using Illumina’s 
GenomeStudio Data Analysis software. Further quality checks were performed using 
the R package minfi’s ‘qcreport’ function331. All samples passed quality control 
assessment. Further exploration using multivariate analysis showed a clear distinction 
between tumour and normal samples by hierarchical clustering, even when using raw ß-
values. 
Data was normalized using beta mixture quantile normalisation (BMIQ)332 implemented 
in the R package wateRmelon333. BMIQ addresses the difference in distributions seen 
between type I and II Infinium probes by using quantiles to normalize the type II probes 
to a distribution comparable to type I probes, using a ß-mixture model fit to the type I 
and type II probes separately332.  
Next, sites were filtered using the IMA334 filter function IMA.methy450PP, where 
probes that had ≥10% of samples with detection P-value > 0.05 were excluded, as well 
as probes on the X and Y chromosomes, and probes containing known SNP sites. The 
results were as follows: 11847 sites with missing values were removed, 90401 sites 
contained SNPs and were removed, 10417 sites on the X and Y chromosomes were 
removed; 372912 sites were retained from the original 485577 sites.  
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Differential methylation analysis 
Differential methylation analyses were conducted in CIMP+ vs. CIMP– tumours and by 
specific bacterial colonisation in tumour and normal samples, using the R package 
CpGassoc335, which implements an analysis of variance (ANOVA) model. The 
Benjamini-Hochberg method was used for multiple testing corrections300. The 
magnitude of change between groups was estimated by calculating the difference in 
median beta values between the two groups. These analyses were conducted on the 
subset of CpG probes which had previously been shown to provide the most accurate 
results for the Illumina HumanMethylation450 BeadChips by comparison to bisulfite 
sequencing data336. Using this subset (294840 of the 372912 filtered probes) reduces the 
risk of false discovery, while maximizing the power to detect differential methylation. 
Multivariate analysis 
We used unsupervised clustering to explore patterns of methylation using recursively-
partitioned mixture model (RPMM) clustering337. RPMM is a hierarchical, model-based 
clustering method that determines cluster membership by recursively comparing the 
model goodness-of-fit between n-class and n+1-class mixture models (starting with 
n=1). If, for example, the 2-class model fits the data better than the 1-class model, these 
classes are further split into 2 new classes and compared to the previous split in terms of 
model goodness-of-fit. Recursion continues until the algorithm arrives at the most 
parsimonious representation of the data. This procedure results in an estimate of the 
number of clusters, as well as the posterior probabilities of class membership338. 
RPMM-based analysis was conducted in R, and based on a script from Hinoue et al.339. 
The top 1% (3707) most variable probes by median absolute deviation was used as 
input for RPMM. Following assignment of class membership, samples within each 
cluster were ordered for heatmap-display using the R package seriation340. Heatmaps 
were generated using the function ‘aheatmap’ from the R package NMF341. 
In order to provide a visual representation of the underlying pattern (regarding 
similarities/dissimilarities) among samples, multidimensional scaling (MDS) was 
conducted using the mdsPlot function from the R package minfi331 to visually explore 
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the relationship between samples and to investigate the effect of varying the number of 
CpG probes used for clustering. 
Cohort integration and analysis 
In order to evaluate methylation patterns in a broader context, our cohort was merged 
with a large publically available dataset of whole-genome methylation data (also run on 
HumanMethylation450 BeadChips), which was generated from 361 colorectal 
adenocarcinomas. 
Raw data, together with clinical sample annotations, were downloaded from The Cancer 
Genome Atlas (TCGA). The merged dataset was normalized and filtered and quality 
control (QC) was conducted using the ‘qcreport’ function in minfi, and all samples 
passed QC. Samples were normalized using BMIQ normalization, as previously 
described. A filtering step was applied to the BMIQ-normalised data based on the 
detection p-value of probes using the R package wateRmelon, with default settings: 
sites where more than 5% of samples had a beadcount < 3; sites with a detection p-value 
> 0.05; samples where > 1% of sites had a detection p-value > 0.05; and sites where > 
1% of samples had a detection p-value > 0.05 were removed. 
The TCGA dataset consists of several different batches (samples processed separately). 
Unfortunately, batch identifiers are not available for these samples. Notably though, 
given that 85% of the TCGA cohort is Caucasian, while the majority of our cohort is 
mixed ancestry, batch correction could erase biologically relevant differences between 
our cohort and the TCGA cohort. However, there is a possibility that batch-specific 
variation remains in the dataset. Nevertheless, hierarchical clustering (Euclidian 
distance, complete linkage) showed a clear distinction between tumour and normal 
samples, irrespective of cohort, except for four tumour samples from our cohort, which 
clustered closely with the normal samples (10T, 15T, 1T, 4T). 
Ingenuity Pathway Analysis (IPA) 
IPA was used to conduct pathway-level analysis of probes associated with the 
phenotype of interest at a p-value ≤ 0.05. IPA is described in more detail in Chapters 7 
and 8. 
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Results 
Detection of MLH1 methylation by methylation-specific PCR 
Methylation-specific PCR of the promoter region of the MLH1 gene was conducted on 
DNA extracted from tumour, normal and blood samples of 30 patients, including all of 
patients for whom array-based DNA methylation analysis was performed.  
Two patients, 44 and 63, had MLH1 promoter methylation in tumour samples, while the 
remaining 28 patients did not have MLH1 promoter methylation in tumour, normal or 
blood samples, as judged by quantification against the MLH1 standard curve. Three of 
the 84 samples (tumour, normal and blood for the 28 negative patients) failed QC. 
Characterisation of CRC methylation by multivariate analysis 
Whole-genome profiling was conducted for 24 pairs of tumour and matched normal 
samples using Illumina HumanMethylation450k BeadChips. Nineteen of these pairs 
were also run on Affymetrix Gene 1.0 ST arrays for transcriptomic profiling (See 
Chapters 5, 7 and 8). 
Multidimensional scaling of the 1000, 10000 and 100000 most variable probes across 
tumour and normal samples were conducted to visually examine the relationship 
between samples, and to gauge the role of the number of probes used on the clustering 
outcome (Figure 4).  
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Figure 4. MDS of the 1000 (left), 10000 (middle) and 100000 (right) most variable probes across tumour 
and normal samples, using BMIQ normalized data. T: Tumour samples (orange); N: adjacent normal 
samples (green). 
The most striking feature is the high degree of similarity between normal samples, 
which excludes the majority of tumour samples. There was no appreciable improvement 
in clustering when increasing the number of probes used, so the top 1% (N=3077) most 
variable probes (by median absolute deviation) was therefore arbitrarily selected for 
RPMM-based clustering. Due to the size of the overall dataset, the smaller subset was 
favoured to limit the computational power required to execute downstream analyses. 
RPMM-based clustering of the top 1% most variable probes revealed four methylation 
clusters across tumour samples, with varying levels of CpG island methylation (Figure 
5).  
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Figure 5: RPMM based clustering of the top 1% (N=3077) most variable methylation probes for tumour 
samples in our cohort. The row annotation on the left of the heatmap indicates whether the probe 
interrogates a CpG island (CGI), black=CpG island, white=non-CpG island. The scale on the right of the 
heatmap indicates beta values (0–1). 
The relationship between individual tumour samples for the top 1% most variable 
probes was also explored by multidimensional scaling (Figure 6), which confirmed the 
RPMM-derived clusters.  
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Figure 6: MDS of the top 1% (3707) most variable probes by MAD. Samples have been coloured 
according to the RPMM clusters to which they belong.  
Most of the MSI-H samples fell into the two RPMM clusters with the least amount of 
CpG island methylation; however four of the five MSI-H samples in these two clusters 
are of hereditary origin (confirmed HNPCC)––these are 13T, 18T, 20T, 4T. Although 
the role of CpG island methylation across the genome is unclear in HNPCC samples, 
the majority of studies indicate that MLH1 methylation does not play an appreciable 
role in the pathogenesis of these cancers265,267–269,342. Meanwhile, there were several 
samples that displayed a relative increase in CpG island methylation but no MSI in the 
rLL and rLR clusters. 
Determining patterns of methylation alongside a large external cohort 
In order to address the limitations of our cohort (i.e. small sample size and lack of 
CIMP status annotation), tumour samples from our cohort were merged with the TCGA 
cohort (N=361) for downstream analysis. This allowed us to a) increase sample size and 
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to b) to make inferences regarding CIMP status for our cohort based on the clustering 
alongside the TCGA samples, which had available molecularly determined CIMP 
classifications. 
Of the 353 adenocarcinoma samples that had site of disease information, 25.5% were 
rectal, 46.7% proximal, and 27.7% distal. Regarding patient ethnicity (of whom 324 had 
available information), 85.5% were Caucasian, while 10.8% were black or African 
American, and 3% were Asian. Gender was roughly equal, with 45% female and 55% 
male. Regarding MSI status (where 347 cases had available information), 69% were 
MSS, 15.3% were MSI-H, and 15.6% were MSI-L. Meanwhile, 343 cases had available 
CIMP classifications (by MSP): 9% were classified as CIMP-H, 48.8% as CIMP-L and 
31.2% as CIMP–stable. This cohort was therefore enriched for Caucasian patients, 
cancers of the proximal colon, and CIMP+ cancers.  
RPMM-based clustering of the top 1% (N=4614) most variable probes across the 361 
(TCGA) plus 24 (our cohort) adenocarcinoma samples resulted in four clusters (rLL, 
rLR, rRL and rRR), Figure 7.  
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Figure 7: RPMM based clustering of the top 1% (N=4614) most variable methylation probes for tumour 
samples in the merged cohort (N=385). RPMM-based clustering of the top 1% (4614 probes). The row 
annotation on the left of the heatmap indicates whether the probe interrogates a CpG island (CGI), 
black=CpG island, white=non-CpG island. The scale on the right represents row-scaled beta values 
(scaling was done to assist visualization across a large cohort of samples). The legend categories on the 
right are in the same order as the row annotations at the top of the graph. 
The rRR cluster displayed the highest level of CpG island methylation, followed by 
progressively less frequent and less intense methylation of CpG islands in the rRL, rLL 
and rLR clusters. The rRR, rRL, rLL and rLR clusters most likely correspond to the 
CIMP-H, CIMP-L, cluster 3 and cluster 4 of Hinoue et al. However, both the rRL and 
the rLL clusters are considered to be CIMP-L here, based on the enrichment of CIMP-L 
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samples in both these clusters; on the other hand Hinoue et al. referred to one of these as 
CIMP-L and the other as CIMP-stable. 
A summary of descriptive characteristics by cluster is presented in Table 4.  
Table 4: Summary of descriptive characteristics by RPMM cluster 
 rLL (N=136) rLR (N=100) rRL (N=90) rRR (N=60) 
Gender (ND=4)     
Female 41% 49% 38% 57% 
Male 59% 51% 62% 43% 
Ethnicity 
(ND=38) 
    
Caucasian 82.6% 81.5% 74% 86% 
Black 11.6% 7.6% 14.3% 8.6% 
Mixed ancestry 4.1% 8.7% 3.9% 0% 
Indian 0.8% 0% 0% 0% 
Asian 0.8% 2.2% 7.8% 5.2% 
BMI (ND=105)     
< 25 38.5% 24.3% 36% 36% 
≥ 25 61.5% 75.7% 64% 64% 
Stage (ND=19)     
I/II 42.5% 42.7% 61.6% 69% 
III/IV 57.5% 57.3% 38.4% 31% 
Site of disease 
(9=ND) 
    
Proximal colon 34.3% 24.5% 62.5% 86% 
Distal colon 32.8% 43.9% 21.6% 12.3% 
Rectum 32.8% 31.6% 15.9% 1.8% 
MSI status 
(ND=15) 
    
MSI-H 9.2% 12.2% 10.6% 47.4% 
MSI-L 12.2% 13.3% 22.4% 12.3% 
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MSS 78.6% 74.5% 67% 40.4% 
CIMP status 
(ND=44) 
    
CIMP-H 0% 0% 2.5% 57.9% 
CIMP-L 72.3% 1.2% 95% 42.1% 
CIMP-stable 37.7% 98.8% 2.5% 0% 
Percentages were calculated based on the cases with available information in that category; percentages 
may not add up due to rounding. ND: indicates the number of cases for whom that particular information 
was not available. 
There was little variation in gender, ethnicity and BMI across the four clusters. As 
anticipated, the distribution of CIMP-H and CIMP-L samples––defined by MSP of a 
CIMP marker panel––varied greatly by cluster: the rRR cluster was heavily enriched for 
CIMP-H samples, which occurred at a frequency of 57.9% and 94% of all CIMP-H 
samples were present in this group; CIMP-L samples occurred at frequencies of 72.3% 
and 95% in the rLL and rRL clusters, while 98.8% of the rLR cluster consisted of 
CIMP-stable samples. As expected from the literature, CIMP+ rRL and rRR clusters 
were enriched for MSI+ cancers of the proximal colon, with notable enrichment of 
MSI-H samples and female gender in the rRR cluster. Regarding CIMP status according 
to CRC stage, early stage CRCs (I/II) were significantly more frequent in the CIMP-
enriched rRL and rRR clusters compared to the CIMP-poor rLL and rLR clusters 
(Fisher’s exact p-value=0.0001). By comparison, in the Hinoue et al. cohort, 41% of 
CIMP-L (corresponding to our rRL cluster) and 66% of CIMP-H (corresponding to our 
rRR cluster) CRCs compared to 41% of their cluster 3 (our rLR cluster) and 52% of 
CIMP-stable (our rLL cluster) CRCs were stage I/II317. The reason for this discrepancy 
is not clear. To our knowledge, a difference in CIMP status between early and late stage 
CRCs has not previously been reported in the literature, and is perhaps uncovered here 
due the use of whole-genome methylation profiles as opposed to five-gene CIMP panels. 
The basis for the difference seen here is not known–one hypothesis is that aberrant CpG 
island methylation is an early event in a subgroup of CRCs and that these regions are 
again demethylated with increasing tumour progression. 
Regarding our cohort, 12 samples clustered with the predominantly CIMP-L rLL cluster, 
8 with the CIMP-stable rLR cluster, and 4 with the CIMP-L rRL cluster. The CIMP-
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stable cluster included three of five HNPCC patients, while two of three sporadic MSI-
H patients clustered with the CIMP-L clusters. 
Predicting CIMP status using an array-based marker panel 
RPMM-based clustering of our samples alongside a larger CIMP-defined cohort 
provided a good indication of CIMP status for our cohort according to cluster 
membership. However, the Hinoue et al. array-based CIMP panel was utilized in an 
attempt to further refine the classification of samples. 
As previously mentioned, Hinoue et al. published a CIMP-defining marker panel 
(B3GAT2, FOXL2, KCNK13, RAB31, and SLIT1) that identifies CIMP-H or CIMP-L 
tumours with 100% sensitivity and 95.5% specificity, with 2.4% misclassification using 
the condition of DNA methylation of three or more markers with a ß-value threshold of 
≥ 0.1. They also defined a CIMP-H-specific marker panel (FAM78A, FSTL1, KCNC1, 
MYOCD, and SLC6A4) that identified CIMP-H tumours with 100% sensitivity and 
specificity, using the condition of DNA methylation of three or more markers with a ß-
value of ≥ 0.1. However, because the majority of probes mapping to the CIMP-marker 
panel had ß-values of ≥ 0.1 in the present study a ß-value threshold of 0.1 could not be 
used as a meaningful threshold to define CIMP status. This could be due to differences 
in array chemistries between the HumanMethylation27 BeadChip used by Hinoue et al. 
(who used a ß-value threshold of 0.1) and the HumanMethylation450k BeadChip used 
in our study. CIMP status was therefore evaluated by RPMM-based subtyping of probes 
mapping to CpG islands of the Hinoue et al. CIMP+ marker panel of genes (Figure 8).  
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Figure 8: Predicting CIMP-status using an array-based marker panel. RPMM-based clustering of probes 
mapping to CpG islands in the Hinoue CIMP marker panel (B3GAT2, FOXL2, KCNK13, RAB31, and 
SLIT1). Samples in the rL cluster are considered to be CIMP+. The legend categories on the right are in 
the same order as the row annotations at the top of the graph. The scale on the right of the heatmap 
indicates beta values (0–1). EF: E. faecalis; FB: Fusobacterium. 
Three clusters were obtained, two of which (rRL and rRR) more closely resembled each 
other compared to the rL cluster. An increased frequency of CpG island methylation 
was seen in the rL cluster–the ten samples in this cluster were therefore considered to be 
CIMP+. These ten samples (along with 37T, which was classified as CIMP-stable 
according to Figure 8) were the only samples where at least three of the five genes in 
the panel had gene-level methylation ß values of ≥ 0.3 (gene-level methylation ß values 
were obtained by calculating the median ß value of probes mapping to a particular gene). 
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The predictive ability of this panel is demonstrated in Figure 9, where RPMM clustering 
of the CIMP marker panel probes was performed on the merged dataset, which included 
343 samples with MSP-confirmed CIMP status (CIMP-H, CIMP-L or CIMP-stable).  
Figure 9: Predicting CIMP-status using an array-based marker panel after merging our cohort (N=24) and 
the TCGA cohort (N=361). RPMM-based clustering of probes matching to CpG islands in the Hinoue 
CIMP marker panel (B3GAT2, FOXL2, KCNK13, RAB31, and SLIT1) using a large cohort of CRC 
samples with confirmed CIMP status. The legend categories on the right are in the same order as the row 
annotations at the top of the graph. The scale on the right of the heatmap indicates beta values (0–1). F: 
female; M: male; CIMP.neg: CIMP-stable. 
 
Five RPMM clusters were obtained: the rLL cluster was composed of 78% CIMP-L and 
22% CIMP-stable samples; the rLR cluster was composed of 87.5% CIMP-stable and 
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12.5% CIMP-L samples; the rRL cluster was composed of 92.9% CIMP-L, 4.3% 
CIMP-H and 2.9% CIMP-stable samples; and the rRRL and rRRR clusters combined 
were composed of 68% CIMP-H and 32% CIMP-L samples. These results were 
comparable to the cluster membership obtained when using the top 1% most variable 
probes, with regards to the distribution of CIMP-H, CIMP-L and CIMP-stable samples 
(Figure 7). 
We compared CIMP classifications when using a) the CIMP marker panel of genes 
(Figure 8) to b) the top 1% most variable probes of the merged cohort (N=385) (Figure 
7). The two classifications were largely in agreement, except for six samples (15T, 14T, 
37T, 16T, 3T and 4T) that were classified as CIMP-stable using the CIMP marker panel, 
but CIMP-L when using the top 1% most variable probes across the merged cohort. 
These six samples were classified as CIMP-stable on the basis that (with the exception 
of 37T) they all had less than three genes with ß values of ≥ 0.3. 
When applying the Hinoue et al. CIMP-H panel (which specifically identifies CIMP-H 
tumours) to our cohort, only one sample, 63T, was identified CIMP-H (Appendix B, 
Figure 1); Sample 63T is MSI-H and displays hypermethylation of the MLH1 promoter, 
as confirmed by PCR-based analysis, and it is therefore not surprising that this sample 
displayed a relative increase in CpG island methylation compared to the CIMP-L 
samples.  
In summary, ten samples, for which methylation data was generated here, were 
classified as CIMP+ using the Hinoue et al. CIMP panel (13T, 8T, 23T, 63T, 44T, 41T, 
34T, 17T, 48T, 11T), one of which (63T) is likely CIMP-H. The remaining 14 samples 
(14T, 15T, 56T, 3T, 37T, 16T, 20T, 1T, 55T, 10T, 4T, 33T, 18T, 60T) were classified 
as CIMP-stable. All samples classified as CIMP+ had gene-level methylation ß values 
of ≥ 0.3 in at least three of the five genes in the CIMP+ marker panel. The sample 
classification is largely supported by evaluation against cluster membership obtained by 
RPMM-clustering of the top 1% most variable probes, with the exception of six samples 
that display very low levels of CpG methylation, which were therefore classified as 
CIMP-stable. 
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Genome-wide methylation analyses 
The CpGassoc package was used to detect probes associated with a) CIMP-status and b) 
specific bacterial infection.  
Evaluation of CIMP-associated methylation 
Analysis of variance by CIMP-status revealed 2172 probes (mapping to 1027 unique 
genes) that were associated with CIMP status in our cohort at a p-value cutoff of 0.05, 
and an absolute difference in median beta values between CIMP+ and CIMP– samples 
of 0.2 (which according to Illumina, can be detected with a FDR of < 1%). However, 
after multiple testing correction, only 5 probes were significantly associated with 
CIMP-status at an FDR cutoff of 0.05 and a Δ beta cutoff of 0.2; even at a more relaxed 
FDR of 0.25, only 124 (mapping to 94 unique genes) probes were associated with 
CIMP status. Nevertheless, an increase in CpG island methylation is evident in CIMP+ 
cancers, since 93% of the 2172 probes associated with CIMP-status mapped to CpG 
islands, and 99.8% showed increased methylation in CIMP+ vs. CIMP– samples. 
Moreover, of the 94 genes significantly associated with CIMP status at an FDR ≤ 0.25 
and Δ beta ≥ 0.2, at least 23% (22/94) had previously been found to show increased 
CpG island methylation in CIMP+ vs. CIMP– tumours305 (Table 3); of these, BDNF306 
and KCNK13305 have been used in published CIMP-marker panels. 
Table 3: Overlap in CpG probes (representing 22 genes) significantly associated with CIMP-status (FDR 
≤ 0.25, Δ beta ≥ 0.2) between our cohort and Hinoue et al.305. 
Probe ID Gene 
symbol 
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Probes mapping to CpG islands are noted as ‘1’; Δ beta = median beta difference between CIMP+ vs. 
CIMP– tumours; All except cg22410750 map to CpG island regions of the genome. 
Evaluation of bacterially-associated methylation 
For each bacterial species quantified in our cohort, differential host methylation analysis 
was conducted for a) high-level vs. low/no colonisation and b) positive- vs. negative- 
colonisation status in both tumour and normal samples, on the condition that each group 
had at least three samples. High- and low-level colonisation categories were determined 
in Chapter 4. The results for all comparisons made for tumour and normal samples are 
presented in Tables 4a and 4b respectively.  
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Table 4a: Summary of differential methylation analyses conducted for tumour samples showing the 
number of probes (that mapped to annotated genes) differentially methylated for each comparison made 
(|Δ beta| ≥ 0.2).  
Model specified Sample number p ≤ 0.05 FDR ≤ 0.25 FDR ≤ 0.05 
EF+ vs. EF- 7 vs. 15 315 0 0 
FB-H vs. FB-L/N 7 vs. 17 403 7 0 
afaC-H vs. afaC-L/N 6 vs. 18 62 0 0 
afaC+ vs. afaC- 14 vs. 10 85 0 0 
ClB+ vs. ClB- 7 vs. 17 331 0 0 
ETBF-H vs. ETBF L/N 4 vs. 20 488 17 0 
ETBF+ vs. ETBF- 14 vs. 10 215 0 0 
EPEC+ vs. EPEC- 3 vs. 21 1019 141 62 
EF: E. faecalis; FB: Fusobacterium. 
Table 4b: Summary of differential methylation analyses conducted for normal samples showing the 
number of probes (that mapped to annotated genes) differentially methylated for each comparison made 
(|Δ beta| ≥ 0.2).  
Model specified Sample number p ≤ 0.05 FDR ≤ 0.25 FDR ≤ 0.05 
ETBF+ vs. ETBF- 14 vs. 10 2 0 0 
ETBF-H vs. ETBF-L/N 4 vs. 20 4 0 0 
ClB+ vs. ClB- 8 vs. 16 1 0 0 
afaC+ vs. afaC- 13 vs. 11 3 0 0 
afaC-H vs. afaC-L/N 3 vs. 21 9 0 0 
EF+ vs. EF- 4 vs. 15 9 0 0 
FB-H vs. FB-L/N 3 vs. 21 22 1 1 
EF: E. faecalis; FB: Fusobacterium. 
Only the comparison between EPEC+ and EPEC– CRCs yielded significant results at 
an FDR ≤ 0.05; for this comparison, 141 or 62 CpG sites were significantly methylated 
in association with EPEC colonisation at FDR cutoffs of 0.25 or 0.05, respectively. This 
is considerable given that the CIMP+ vs. CIMP– comparison produced only 124 CpG 
probes at an FDR cutoff of 0.25. EPEC-associated CpG sites with an FDR ≤ 0.05 are 
presented in Table 5. These results should however be interpreted with caution, given 
the unbalanced comparison (3 EPEC+ vs. 21 EPEC– samples) that is more susceptible 
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Table 5: CpG sites significantly associated with EPEC colonisation in tumours (FDR ≤ 0.05, |Δ beta| ≥ 




CpG island P value FDR EPEC+ vs. 
EPEC- 
cg19778944 A4GALT 1 3.9E-06 1.4E-02 0.29 
cg03940620 B3GAT1 1 8.3E-06 2.3E-02 0.22 
cg19104475 CABP7 1 2.6E-08 1.0E-03 0.34 
cg23614229 CACNA1G 1 3.5E-07 3.8E-03 0.26 
cg16111791 CACNB4 1 1.6E-05 3.4E-02 0.21 
cg07131655 CAMKV 1 9.0E-10 2.2E-04 0.23 
cg14469019 CAPSL 0 2.6E-05 4.4E-02 0.25 
cg00879447 CCDC85A 1 3.0E-05 4.8E-02 0.24 
cg02299940 CHP2 1 9.5E-06 2.3E-02 0.21 
cg12120327 COL2A1 1 8.8E-06 2.3E-02 0.28 
cg07295964 CPLX2 1 2.2E-06 1.1E-02 0.40 
cg04986675 CPQ 1 4.6E-06 1.6E-02 0.20 
cg06531007 CR2 1 1.2E-05 2.8E-02 0.22 
cg14557714 CTSL1 1 2.3E-05 4.0E-02 0.24 
cg26267854 CXCL12 1 5.6E-08 1.3E-03 0.30 
cg17267805 CXCL12 1 1.7E-06 9.0E-03 0.40 
cg06048524 CXCL12 1 2.1E-06 1.0E-02 0.40 
cg14948279 DCLK2 1 2.1E-05 3.7E-02 0.27 
cg02934930 EPHB1 1 6.9E-06 2.0E-02 0.40 
cg24183261 EYA1 1 7.2E-06 2.1E-02 0.24 
cg02102020 FAM5B 1 8.4E-08 1.5E-03 0.26 
cg20509780 FBLN1 1 2.8E-05 4.6E-02 0.32 
cg14778074 GABRA2 1 1.6E-05 3.4E-02 0.20 
cg10451078 GATA4 1 8.7E-07 5.8E-03 0.33 
cg05412333 GATA4 1 1.7E-05 3.5E-02 0.23 
cg17816394 GNG4 1 5.2E-06 1.8E-02 0.24 
cg10154926 HAP1 1 1.5E-05 3.2E-02 0.22 
cg05660795 IGFBP1 1 7.2E-07 5.4E-03 0.27 
cg14093886 INHBA-
AS1 
1 9.9E-07 6.0E-03 0.24 
cg22063259 ISLR2 1 6.3E-07 5.4E-03 0.27 
cg24766308 JAKMIP2 0 8.1E-06 2.3E-02 0.23 
cg15811719 KCNJ6 1 1.7E-05 3.5E-02 0.20 
cg27147871 LOC400891 1 3.0E-06 1.2E-02 0.27 
cg10004574 LOC400891 1 9.7E-06 2.3E-02 0.22 
cg05328197 MAPK4 1 9.0E-06 2.3E-02 0.34 
cg25803927 MN1 1 3.4E-06 1.3E-02 0.38 
cg23791592 MSI1 1 2.0E-05 3.7E-02 0.35 
cg01425670 NEGR1 1 2.8E-05 4.6E-02 0.28 
cg18834338 NEUROG3 1 2.0E-07 2.7E-03 0.25 
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cg05886671 NEUROG3 1 2.1E-05 3.7E-02 0.25 
cg14005139 NKX2-1 1 2.0E-05 3.7E-02 0.24 
cg03666741 NRIP3 1 5.1E-06 1.7E-02 0.37 
cg07140751 P2RX5 1 4.0E-06 1.4E-02 0.27 
cg26244952 PRDM6 1 2.3E-06 1.1E-02 0.31 
cg15193171 PRDM6 1 1.9E-05 3.6E-02 0.28 
cg20416031 PRKG1 1 3.0E-05 4.8E-02 0.23 
cg23123909 RAB3C 1 1.6E-05 3.4E-02 0.32 
cg08621203 RAET1G 1 7.3E-07 5.4E-03 0.31 
cg05680085 RHBDD1 1 1.9E-05 3.6E-02 0.23 
cg13364903 SCUBE3 1 1.1E-05 2.6E-02 0.24 
cg19671026 SELV 0 3.9E-08 1.2E-03 0.29 
cg18586919 SELV 0 1.1E-07 1.8E-03 0.30 
cg03703707 SHC4 1 4.5E-09 3.6E-04 0.27 
cg23637124 SHC4 1 6.0E-08 1.3E-03 0.25 
cg22967284 SLIT1 1 3.0E-05 4.8E-02 0.22 
cg21110939 SV2B 1 8.2E-06 2.3E-02 0.25 
cg05003791 SYNGR1 1 2.2E-06 1.1E-02 0.26 
cg00786658 TSHZ3 1 3.2E-05 4.9E-02 0.21 
cg26226202 WNT9B 1 4.3E-09 3.6E-04 0.26 
cg26217504 XKR5 1 2.1E-05 3.7E-02 0.51 
cg14156581 ZFPM2 1 9.7E-06 2.3E-02 0.27 
cg05629186 ZNF391 1 6.0E-07 5.4E-03 0.22 
 
Of the 62 probes significantly associated with EPEC infection, 95% mapped to CpG 
islands and 100% displayed increased methylation in EPEC+ CRCs. Many of these 
genes have previously been found to be methylated in various cancers: WNT9B and 
GNG4 are both members of the Wnt signaling pathway, and GNG4 is specifically 
methylated in BRAF mutant CRCs343; GATA4 is often methylated in CRCs and is 
proposed to have diagnostic potential344; epigenetic silencing of CXCL12 has been 
shown to promote metastasis in breast345, non-small cell lung346, and colon cancer347; 
FBLN1 is methylated in various cancers348–350; CTSL1 is methylated in HPV+ vs. HPV- 
oral squamous cell carcinoma351,352; and CACNA1G is a member of the CIMP panel 
proposed by Weisenberger et al.155,306. 
Next, the degree of correspondence between EPEC-associated changes in gene 
methylation and downstream gene expression (using the results of differential gene 
expression analysis for EPEC+ vs. EPEC– samples, described in Chapter 8) was 
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assessed. The 1019 probes associated with EPEC- colonisation status (p ≤ 0.05, |Δ beta| 
≥ 0.2) mapped to 701 unique genes, of which 35 also showed differential gene 
expression in an EPEC-specific manner (p ≤ 0.05; Chapter 8), as shown in Table 6. The 
relatively low level of correspondence between genes differentially methylated and 
differentially expressed (35/701, 5%) is similar to the findings of Hinoue et al., who 
showed that 7.3% of genes that showed hypermethylation (|ß| > 0.20) in CIMP-H 
tumours also showed at least a two-fold reduction in gene expression317.  
Table 6: Genes with altered methylation and gene expression in association with EPEC colonisation (P ≤ 
0.05; |Δ beta| ≥ 0.2) in alphabetical order. Consistent, yes: direction of change in gene expression 
consistent with the expected downstream effect of increased or decreased methylation. 
Gene  
symbol 













C12orf68 chromosome 12 
open reading 
frame 68 
2.2E-02 -1.49 1.6E-02 0.23 yes 
C6orf223 chromosome 6 
open reading 
frame 223 
4.5E-03 1.87 4.0E-02 -0.27 yes 
C7orf50 chromosome 7 
open reading 
frame 50 




2.7E-02 1.95 4.9E-03 -0.25 yes 





2.2E-02 -1.59 3.5E-03 0.25 yes 




8.6E-03 -1.40 3.6E-03 0.21 yes 
EFNB2 ephr n-B2 1.3E-02 -1.89 4.4E-02 0.23 yes 
EPDR1 ependymin 
related protein 1 
(zebrafish) 
2.8E-02 -1.44 1.2E-02 0.46 yes 
EPHB1 EPH receptor 
B1 
2.3E-02 -1.47 2.6E-04 0.31 yes 




1.4E-02 -1.93 7.1E-04 -0.21 no 






2.7E-02 1.57 2.2E-02 0.27 no 
HDAC9 histone 
deacetylase 9 
2.7E-02 -1.49 3.4E-02 0.32 yes 








e mai tenance 
domain 
containing 2 





1.1E-02 -1.37 2.2E-02 0.32 yes 




3.6E-03 -2.40 2.1E-02 0.26 yes 
NAV1 neuron 
navigator 1 
8.9E-03 -1.49 2.1E-02 0.24 yes 
NFASC neurofascin 1.5E-02 -1.47 4.4E-03 0.25 yes 








2.3E-02 -2.18 3.5E-03 0.26 yes 











1.3E-02 -1.47 1.5E-02 0.37 yes 
SCUBE3 signal peptide, 
CUB domain,
EGF-like 3 
3.7E-03 1.71 6.4E-03 0.22 no 
SOX1 SRY (sex 
determining 
region Y)-box 1 








3.9E-03 -1.42 2.0E-02 0.23 yes 
TLX2 T-cell leukemia 
homeobox 2 
1.9E-02 -1.36 2.0E-02 0.40 yes 
WSCD1 WSC domain 
containing 1 
7.6E-03 -1.60 2.2E-04 0.29 yes 
ZNF287 zinc finger 
protein 287 
1.8E-03 -1.55 3.2E-02 0.24 yes 
ZNF419 zinc finger 
protein 419 
4.7E-03 -1.43 9.0E-03 0.35 yes 
ZNF546 zinc finger 
protein 546 
3.6E-04 -1.78 3.5E-02 0.32 yes 
ZNF606 zinc finger 
protein 606 
7.9E-03 -1.33 1.6E-03 0.33 yes 
ZNF83 zinc finger 
protein 83 
4.5E-03 -1.82 3.7E-05 0.32 yes 
 
The 35 genes presented in Table 6 encompassed 51 probes on the methylation array, 
which primarily mapped to CpG islands (36/51, 71%). Regarding gene regions, 35 
probes (69%) mapped to TSS1500, TSS200, 5’UTR or 1st Exon gene regions, while 16 
probes (31%) mapped to gene body or 3’UTR regions. Detailed methylation analysis 
and annotation results for the 35 genes with concomitant changes in gene expression are 
listed in Appendix B, Table 1. In cases where more than one probe per gene showed 
differential methylation, median p- and Δ beta-values were calculated across probes. 
Given the enrichment of probes mapping to CpG islands in the promoter region 
(including TSS1500, TSS200, 5’UTR and 1st Exon), the resulting gene-level 
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methylation values are considered to be reasonable predictors of promoter methylation 
and hence gene silencing.  
Thirty-two of 35 genes (91%) displayed gene expression changes that were consistent 
with the underlying methylation change (Table 5), and 31 genes (89%) had increased 
methylation in EPEC+ samples. 
Pathway analysis was conducted using the 1019 probes associated with EPEC 
colonisation in CRCs (p ≤ 0.05) and, since fold-change values are not applicable to 
methylation data, only p-values were used as input. The top 10 most significant 
canonical pathways associated with EPEC colonisation are listed in Table 7.  
Table 7: Top 10 IPA canonical pathways associated with EPEC+ CRCs. The Ratio indicates the 
proportion of genes significantly associated with EPEC compared to the full list of genes in each pathway. 
Ingenuity Canonical Pathways  -log(p-
value) 
Ratio 
Axonal Guidance Signaling 7.93 9.03E-02 
Ephrin Receptor Signaling 5.34 1.09E-01 
Glutamate Receptor Signaling 4.85 1.75E-01 
Neuropathic Pain Signaling In Dorsal Horn Neurons 3.36 1.10E-01 
Ephrin B Signaling 3.21 1.23E-01 
CREB Signaling in Neurons 2.81 8.19E-02 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.66 7.61E-02 
BMP signaling pathway 2.47 1.05E-01 
Embryonic Stem Cell Differentiation into Cardiac Lineages 2.45 3.00E-01 
G Protein Signaling Mediated by Tubby 2.38 1.52E-01 
 
Notably, the pathways Ephrin Receptor Signaling, Ephrin B Signaling and BMP 
signaling pathway are all major players in intestinal stem cell maintenance and 
differentiation353. This is relevant to CRC since crypt stem cells are thought to be the 
cells-of-origin of intestinal cancer113. Moreover, EPEC has been shown to enter colonic 
crypts in normal colonic mucosa co-cultured with EPEC9, which supports to the 
possibility of EPEC-dependent epigenetic manipulation of intestinal stem cells. 
The top ten upstream regulators most significantly associated with EPEC+ CRCs are 
presented in Table 8.  
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Table 8: Top 10 IPA upstream regulators associated with EPEC+ CRCs. 
Upstream 
Regulator 
Molecule Type p-value of 
overlap 
REST transcription regulator 4.08E-10 
Calmodulin group 9.04E-09 
TWIST1 transcription regulator 3.49E-07 
POU4F1 transcription regulator 8.99E-07 
ESR2 ligand-dependent nuclear 
receptor 
1.11E-06 
CTNNB1 transcription regulator 3.61E-06 
FGF8 growth factor 3.85E-06 
HTT transcription regulator 5.52E-06 
decitabine chemical drug 6.13E-06 
NANOG transcription regulator 1.02E-05 
 
Amongst these, the transcription factors β-catenin (CTNNB1) and NANOG both have 
critical roles in stem cell homeostasis, which is in agreement with the canonical 
pathways results. Interestingly, the DNA methyltransferase inhibitor Decitabine, which 
is used in epigenetic cancer therapy354, is also listed as an upstream regulator in EPEC+ 
CRCs, which further alludes to a role of EPEC in epigenetic manipulation of host cells. 
Discussion 
Whole-genome methylation patterns in CRC and adjacent normal mucosa samples were 
evaluated using unsupervised RPMM clustering. By merging our smaller cohort with a 
large, well-annotated, publically available dataset, we were able to draw inferences 
across a large pool of samples, which facilitated methylation subtyping of our samples 
with greater statistical confidence. Four clusters with varying levels of CpG island 
methylation were obtained from the merged dataset; two clusters were dominated by 
CIMP-L samples, another by CIMP-H samples, while the fourth cluster was almost 
entirely composed of CIMP-stable samples. Clinically relevant features included the 
enrichment of MSI-H samples in the CIMP-H cluster, the predominance of proximal 
cancers, and stage I/II cancers in the CIMP-H and one of the CIMP-L clusters. 
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Samples were classified as CIMP+ or CIMP– using a published array-based marker 
panel of CIMP-status, and all samples classified as CIMP+ had gene-level methylation 
ß-values of ≥ 0.3 in at least three of the five genes in the CIMP+ marker panel. The 
marker panel-based classification of CIMP is largely supported by comparison against 
cluster membership obtained by RPMM-clustering of the top 1% most variable probes 
for the merged dataset. 
Analysis of variance by CIMP-status revealed 2172 probes associated with CIMP-status 
(p ≤ 0.05, |Δ beta| ≥ 0.2), 93% of which mapped to CpG islands and 99.8% of which 
showed increased methylation in CIMP+ vs. CIMP– samples; moreover, of the 94 genes 
associated with CIMP status at an FDR ≤ 0.25, at least 23% (22/94) had previously been 
found to show increased CpG island methylation in CIMP+ vs. CIMP– tumours305; of 
these, BDNF306 and KCNK13305 have been used in published CIMP-marker panels. 
Cancer-specific CpG island methylation of specific genes has been associated with a 
distinct clinicopathological and molecular features of CRC. However, with the 
exception of a few key genes, including DNA repair genes (MLH1), Wnt antagonists 
(SFRPs) and tumour suppressors (CDKN2A)355, the mechanistic relevance of CpG 
island methylation of these genes remains largely obscure. One obvious hurdle in 
delineating the role of gene methylation in CRC is the often poor correlation between 
promoter methylation and transcriptional silencing. For instance, we demonstrate in 
Chapter 7 that a specific transcriptomic subtype of CRC is associated with increased 
promoter-methylation (and therefore presumably silencing) of several WNT pathway 
inhibitor genes; however, these effects do not appear to translate to decreased 
transcription of these genes.  
Apart from the etiological contribution of DNA methylation in CRC, another clinically 
relevant question, which is perhaps easier to address is: to what extent does the 
epigenetic landscape change from tumour initiation to progression and metastasis, and 
what are the pathological, diagnostic and prognostic implications thereof? In the present 
study, a significant difference in the proportion of early (I/II) vs. late (III/IV) stage 
CRCs was identified between methylation clusters with higher (rRL, rRR) or lower 
(rLR, rLL) levels of CpG island methylation (p=0.0001). This difference has not 
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previously been reported and requires further study to uncover the basis and putative 
clinical implications thereof. There is currently great interest in identifying DNA 
methylation biomarkers for CRC risk, diagnosis, treatment and prognosis355,356. DNA 
methylation biomarkers are potentially more robust compared to gene expression 
biomarkers due to the cancer-specific methylation patterns found in certain genes; 
indeed and a handful of biomarkers including SEPT9 (ColoVantage®) and VIM 
(ColoSure™) are already commercially available356. 
This is the first study to investigate the putative association between specific CRC-
associated pathogens and genome-wide DNA methylation in paired CRC tissue samples. 
Although no specific methylation changes were found for the majority of bacteria 
examined here, EPEC-infected tumours displayed significantly altered patterns of host 
methylation in 62 CpG sites (FDR≤0.05). Further, of the 35 genes that were 
differentially methylated and differentially expressed in EPEC+ samples (p≤0.05), 91% 
displayed gene expression changes that were consistent with the underlying methylation 
change and 89% had increased methylation in EPEC+ samples. Moreover, two of the 
three EPEC+ samples had confirmed MLH1 promoter methylation by MSP, and all 
three EPEC+ samples were predicted to be CIMP+. Although certainly intriguing, these 
results should be interpreted with caution, since we only had three EPEC+ samples 
available in this study. Maddocks et al. previously demonstrated that EPEC infection 
can cause decreased expression of MLH1 in vitro; however, this observed reduction 
apparently occurred at the protein level, not at the mRNA level10; this apparent 
discrepancy between our clinical data showing EPEC-associated epigenetic inactivation 
of MLH1, and the in vitro data of Maddocks et al. showing protein-level depletion of 
MLH1, requires further clarification. 
At the pathway level, EPEC+ CRCs show methylation of genes belonging to pathways 
related to stem cell homeostasis and, although we have not proven a causal link between 
EPEC and aberrant methylation of host DNA here, the fact that EPEC can colonise 
stem-cell rich intestinal crypts9 increases the probability of these effects being mediated 
by EPEC. Future studies should validate our findings in a larger cohort of EPEC+ CRCs 
and in adjacent normal samples as well as in in vitro infection models.  
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Chapter 7: Specific bacterial infection, inflammation, and 
DNA and protein damage responses underlie a distinct 
genomic subtype of CRC  
 
Abstract 
In this chapter, unsupervised clustering of gene expression data together with 
integrative network analysis of whole-genome gene expression and methylation data 
was used to investigate a) possible CRC subtypes in our cohort (which consisted of 19 
adenocarcinomas) and b) the biological basis for these subgroups. In addition, the same 
workflow was applied to a well-defined publically available CRC gene expression 
dataset (GSE13294) of 155 colorectal adenocarcinomas to evaluate the relevance of the 
findings in our cohort to a larger CRC cohort.  
A subtype of CRC that is associated with a relative increase in the frequency of 
colonisation by E. faecalis and high-level colonisation with Fusobacterium as well as 
CpG island methylation and microsatellite instability (MSI) was identified. Comparison 
of our classification of the larger cohort (GSE13294) to previous classifications of this 
cohort revealed a substantial overlap with the de Sousa et al.357 CCS2/3 subtypes and 
the inflammatory subtype of Sadanandam et al.358. Pathway-level analyses of genes 
differentially expressed between the two CRC subtypes identified here revealed an 
increased response to DNA and protein damage, infection, inflammation and 
proliferation in one of these subtypes. Various genes and pathways linked to increased 
metastasis and CRC progression were also highlighted in this subtype. 
 
Introduction 
Established CRC subtypes 
Colorectal cancers (CRCs) are frequently classified by the type of genomic instability 
encountered, with chromosomal instability (CIN) and microsatellite instability (MSI) 
being more frequent in the distal and proximal colon, respectively. Recent studies have 
refined CRC subtype classification using unsupervised clustering of whole-genome 
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transcriptome, methylome and copy number variation data to describe clinically and 
biologically relevant CRC subtypes104,357,358. 
In a comprehensive molecular characterisation of CRCs (encompassing whole-genome 
copy number variation, methylation, miRNA, mRNA expression and mutation data) 
The Cancer Genome Atlas (TCGA) divided CRCs into hypermutated (around 16% of 
CRCs) and non-hypermutated, which could be further subdivided into two classes by 
mRNA expression data and other molecular data104. Hypermutated CRCs had near-
diploid genomes and were highly enriched for MLH1 hypermethylation, CpG island 
methylator phenotype (CIMP) and BRAF (V600E) mutations. Interestingly, in the non-
hypermutated tumours copy-number variation, gene expression and methylation data 
were very similar between different sites (proximal, distal, rectal). Furthermore, only 
the hypermutated class showed a high agreement between mRNA expression- and 
methylation-derived clusters, while none of the non-hypermutated classes showed good 
agreement between copy number variation methylation or mRNA-derived clusters. Four 
methylation subgroups were identified: CIMP-H, CIMP-L and two CIMP stable clusters 
that were predominantly non-hypermutated and showed some difference by tumour 
location and KRAS mutation status104.  
De Sousa et al. identified three CRC subtypes based on unsupervised clustering of gene 
expression data: one is characterised by a high frequency of proximal, MSI- and CIMP-
positive CRCs (CSS2), another by distal CIN-positive CRCs (CCS1) and a third, novel 
category, that is heterogeneous with regards to MSI- and CIMP-status, as well as site of 
disease (CSS3)357. 
Sadanandam et al. applied a similar method to de Sousa to classify 445 CRCs, but 
instead defined five CRC subtypes, each of which show similarities to different cell 
types along the colonic crypt, with concomitant degrees of ‘stemness’ and Wnt 
signaling358. The five transcriptional CRC subtypes were named as goblet-like, 
enterocyte, transit-amplifying, inflammatory or stem-like, according to the degree of 
correspondence to a published gene signature that discriminates terminally 
differentiated cells (at the normal colon crypt top) from crypt stem cells (at the normal 
crypt base). The enterocyte- and goblet-like subtypes were significantly associated with 
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the top of the crypt, and the stem-like type was significantly associated with signatures 
of the base of the crypt. Meanwhile, the inflammatory subtype was not associated with 
the position in the crypt, and samples in the transit-amplifying type could be divided 
between the bottom and the top of the crypt. In relation to MSI status, 94% of the 
inflammatory subtype samples were MSI+, whereas 14% and 33% of the transit-
amplifying and stem-like subtypes were MSI+, respectively358. 
Interestingly, both de Sousa et al. and Sadanandam et al. demonstrated that their CRC 
subtypes (4/5 in the case of Sadananadam et al.) could be matched to existing CRC cell 
lines and that these cell lines maintained their original classification in mouse 
xenografts, which may imply a cell-type-specific etiological basis357,358, propagated via 
epigenetic modifications. 
Given the discrepancy in classification between the de Sousa et al. and the 
Sadananadam et al. studies (five vs. three subtypes), these groups compared and 
reconciled their results, stating that although specifying k=3 provided the most robust 
clustering solution, k=5 had similar stability and was therefore also valid359. By 
swapping their datasets to compare the two different subgroup classification schemes, 
they found that the Sadanandam et al. enterocyte and transit amplifying types could be 
collapsed into the CIN+ CSS1 type of de Sousa et al.; the inflammatory and goblet type 
could be collapsed into the MSI+/CIMP+ CSS2 type of de Sousa et al.; and the stem-
like type matched the CSS3 type of de Sousa et al.359.   
Numerous additional studies have described similar CRC subtype classification systems 
based on gene expression and/or other whole-genome data, which will not be discussed 
here305,360–362. 
Data analysis workflow 
Unsupervised clustering of gene expression data together with integrative network 
analysis of whole-genome gene expression and methylation data was used to investigate 
a) possible CRC subtypes in our cohort (which consisted of 19 adenocarcinomas) and b) 
the biological basis for these subgroups. In addition, the same workflow was applied to 
a well-defined publically available CRC gene expression dataset (GSE13294) of 155 
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colorectal adenocarcinomas to evaluate the relevance of our results in a larger cohort. A 
summary of this workflow is presented in Figure 1. 
 
Figure 1: CRC subgroup classification and biological interpretation workflow. This method flowchart 
was applied to our cohort as well as to an external cohort of 155 CRC samples (for which mRNA 
expression profiles (GSE13294) and MSI status was available). Numbers indicated on the figure relate to 
our cohort. Median absolute deviation (MAD); integrated pathway level (IPL); colorectal cancer (CRC); 
Ingenuity Pathway Analysis (IPA). 
Briefly, a mixture-model based approach called recursively-partitioned mixture model 
(RPMM)337 was used for unsupervised clustering. One advantage of RPMM compared 
to other methods is that it does not require specification of the number of expected 
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subgroups. The data was next assessed using multidimensional scaling (MDS) in order 
to visualize the relationship between all samples and to confirm the RPMM-based 
subgroups.  
Established subgroups were next evaluated from a network-level perspective using 
PARADIGM363––a pathway-activity inference approach which infers patient-specific 
alterations in genes, complexes and abstract processes by modeling each gene by a 
factor graph as a set of interconnected variables encoding the expression and known 
activity of a gene and its products, and allowing the incorporation of many types of 
omics data as evidence363. PARADIGM has been suggested as an alternative method of 
identifying cancer subtypes363, having the advantage of producing pathway-level results 
on a per-patient basis. However, for the sake of comparing our subtypes to previously 
established subtypes derived from gene-expression data, subtypes were defined here 
solely on the basis of gene expression data. 
Next, in order to investigate the underlying biology of these subgroups, differential gene 
expression analysis was performed to compare the two RPMM-derived groups using the 
R package limma364. Ingenuity pathway analysis (IPA) was then applied to the subset of 
significantly differentially expressed genes. These results were compared to those 
obtained through differential analysis of PARADIGM integrated pathway levels (IPLs) 
between subtypes.  
The CRCassigner-786358–a gene signature subtype classifier that separates the five 
subtypes proposed by Sadananamdam et al.–was also used to evaluate our subgroups in 
the context of an external classification system. Conversely, RPMM-based classification 
was applied to the GSE13294 dataset (which had previously been classified by 
Sadanandam et al. and de Sousa et al.), and the three sets of classifications were 
compared. As with our cohort, IPA and PARADIGM were used to investigate 
biological features of the resultant RPMM-based subgroups, and the results were 
compared to those obtained through subgroup analyses of our cohort.  
Lastly, the contribution of CpG island methylation in our CRC subgroups was evaluated 
by determining the frequency of CIMP+ in each subgroup (Chapter 6), as well as CpG 
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island methylation of Wnt pathway antagonists––a known mechanism of Wnt pathway 
activation in CIMP+ CRCs. Analysis of variance was used to find CpG sites associated 
with CRC subtypes. 
Methods 
Establishing patient subtypes 
All data analyses described here, except PARADIGM, were conducted in the R 
statistical framework. 
Recursively-partitioned mixture model (RPMM) clustering implemented in the R 
package RPMM337 was used to identify tumour subtypes based on mRNA expression 
data (RPMM is explained in broader detail in Chapter 6). RPMM was applied to the 
third quartile most variable gene expression data by median absolute deviation (MAD), 
which left 8325/33297 transcript clusters in our cohort (Affymetrix Human Gene 1.0 ST 
arrays) and 13669/54675 probesets in the Jorissen cohort (GSE13294, Affymetrix 
HGU133-plus2 arrays). A Gaussian distribution was specified to suit the distribution of 
gene expression data. The gene expression data used for RPMM was ComBat-
corrected365 to adjust for batch and quality factors, while specifying the disease status 
(tumour vs. normal) as the phenotype of interest. 
Multidimensional scaling (from the R package minfi331) was applied to the 8325 
transcript clusters used as input for RPMM to visually explore the underlying pattern 
(regarding similarities/dissimilarities) among samples, using Euclidian distance as a 
measure of similarity.  
Established subgroups were next evaluated from a network level in PARADIGM. Data 
were prepared for input to PARADIGM by median-centering the log2 gene expression 
data across samples for each gene, as recommended by the authors of PARADIGM363. 
Preprocessing and quality control of gene expression data is described in Chapter 5. For 
the methylation data, beta values in the 1500 bp region upstream from the transcription 
start-site were summarized from probe-level beta values, for each gene, using the 
IMA334 package function indexregionfunc. These values were then inverted, since 
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PARADIGM relates high values to increased gene expression, and low values to 
decreased gene expression (and promoter methylation is generally associated with 
decreased gene expression); the inverted values were median-centered across samples 
and used as input to PARADIGM alongside gene expression data. The online version of 
PARADIGM, which is available on request at https://dna.five3genomics.com was used. 
Default analysis settings were used, except for decreasing the log-likelihood percent 
threshold from 0.05 to 0.01% as recommended by the authors of PARADIGM for 
smaller cohorts (personal communication). 
To evaluate patient subgroups, hierarchical clustering (Euclidian distance, complete 
linkage) was performed on the subset of IPLs where at least 75% of samples had 
absolute activation scores of ≥ 0.25363, which left 5334/17348 IPLs. 
Biological interpretation of CRC subtypes 
Once subgroups were established, all downstream analyses were conducted on gene 
expression data that had been corrected for batch and quality factors using ComBat365, 
while specifying the RPMM-subgroups as the phenotype of interest (as opposed to 
disease status). This allows conservation of biologically meaningful subgroup-specific 
variation, while adjusting the data for known sources of technical variation. 
Bacterial subgroup associations were evaluated using Fisher’s exact test applied to 
categorical data (which was derived in Chapter 4). For Fusobacterium the level of 
colonisation by Fusobacterium rather than the absence or presence of Fusobacterium 
was compared since the majority of samples are colonised by Fusobacterium; for the 
rest of the bacteria positive vs. negative- colonisation status was evaluated between 
subgroups. 
Differential gene expression analyses of RPMM-based subgroups were conducted using 
the R package limma364, and the R package hugene10sttranscriptcluster.db366 was used 
for annotation. Genes with an FDR ≤ 0.05 and an absolute fold change ≥ 1.25 were used 
to investigate pathway-level alterations that define CRC subtypes using IPA. For each 
cohort genes significantly altered between subtypes were used to investigate the IPA 
categories: canonical pathways, upstream regulators and diseases and functions. 
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IPA’s canonical pathways, and diseases and functions analyses compute a right-tailed 
Fisher’s exact test, considering a) the number of differentially expressed genes that 
participate in a given pathway/function, and b) the total number of genes known to 
participate in this pathway/function in the selected reference set (i.e. the full set of genes 
for the array platform used). 
IPA’s upstream regulator analysis predicts which genes, chemical drugs or toxicants act 
as upstream regulators, based on downstream gene expression data and prior knowledge 
of expected effects between upstream regulators and their target genes stored in the 
Ingenuity® Knowledge Base. Two statistical measures are produced: the overlap p-
value is used to infer whether there is a statistically significant overlap between the 
dataset genes and the genes that are regulated by a transcriptional regulator (using 
Fisher’s exact test), and the activation z-score is used to infer likely activation states of 
upstream regulators based on comparison with a model that assigns random regulation 
directions. 
To assess the difference between established subgroups based on PARADIGM results, 
the R package limma was used to identify IPLs that showed differential activity 
between RPMM-based subgroups; IPLs with an FDR ≤ 0.05 and an absolute difference 
in median activity score between groups of at least 0.25 were deemed significant.  
To apply the CRCassigner-786 to our cohort, each of the 786 genes in the panel were 
assigned to the Sadanandam subtype that had the maximum Prediction Analysis of 
Microarrays (PAM) score (specified by Sadanandam et al.358) for that gene. Hierarchical 
clustering (Euclidian distance, complete linkage) was applied to the gene expression 
data for each subset, to evaluate which of our samples most closely resembled a given 
subtype. 
For methylation analyses, the CpGassoc335 package was used to test for associations 
between CpG sites and CRC subgroups. To evaluate the effect of CpG island 
methylation on the activity of the Wnt signaling pathway, Wnt antagonists that were 
reported to be methylated in CRCs, including SFRP1, SFRP2, SFRP5103, DKK-1367, 
DKK2, DKK4368, WIF1369, WNT5A370, SOX17371, APC1A372 and APC2372, were selected 
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and RPMM-based clustering was performed on the methylation and gene expression 
data for these genes. 
Results 
Identifying tumour subtypes  
RPMM-based clustering of the top quartile most variable transcript clusters (8325 
transcript clusters) was applied whereby two main RPMM groups were obtained, one of 
which had two subgroups (Figure 2). The related clusters “rLL” (Left-Left) and “rLR” 
(Left-Right) were designated as group A, while the cluster “rR” (Right) was designated 
as group B.  
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Figure 2: RPMM-based clustering of the top quartile (N=8325) most variable transcript clusters. Levels 
of bacterial colonisation (as determined in Chapter 4) are indicated on the figure legend, where 3: high-
level infection, 2: low-level infection, 1: no infection. ETBF: Enterotoxigenic Bacteroides fragilis; ClB: 
ClB/pks+ E. coli, FB: Fusobacterium., afaC: afaC+ E. coli; EF: Enterococcus faecalis. The legend 
categories on the right are presented in the same order as the row annotations at the top of the graph. The 
scale on the right represents log2 expression values. 
Multidimensional scaling (MDS) was applied to the same 8325 probes used for RPMM, 
which showed good agreement with the RPMM subgroups (Figure 3, left). MDS of the 
adjacent normal samples (Figure 3, right) demonstrated a moderate degree of 
correspondence with the tumour-derived subgroups, but there were no distinct clusters. 
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Figure 3: Multidimensional scaling of the top quartile (N=8325) most variable transcript clusters in 
tumour (left figure) and normal (right figure) samples. The RPMM-derived groups A and B are 
highlighted in green and orange, respectively. The tumour-derived subgroups are also highlighted in the 
adjacent normal samples (right figure) to evaluate the level of agreement between clustering of normal 
samples with the tumour-derived subgroups. 
The subgroups obtained from RPMM-based gene expression clustering was compared 
to those obtained through hierarchical clustering of PARADIGM IPLs (using the top 
5334/17348 IPLs), as shown in Appendix C. Two distinct clusters were obtained, and 
with the exception of one sample (18T), the clusters obtained for PARADIGM were 
identical to the two main RPMM-based gene expression clusters.  
Applying our data analysis pipeline to a large external dataset with previously defined 
subtypes 
The same RPMM-based subtyping method was applied to a publically available CRC 
expression dataset (GSE13294), which will be referred to as the Jorissen cohort361. This 
cohort had already been classified into subgroups by de Sousa et al.357 and Sadanandam 
et al.358. Three RPMM clusters were obtained here, two of which were more closely 
related (rRL and rRR) and were therefore combined for downstream analysis––this 
group will be referred to as group B (Figure 4). 
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Figure 4: RPMM-based clustering of the most variable quartile of probesets (N=13669) for the Jorissen 
cohort (N=155). RPMM clusters are displayed alongside the previously established de Sousa and 
Sadanandam subtypes and MSI-status for each sample. Here, only the top 1000 most variable probes are 
displayed, although clustering was conducted on the top 25% most variable probes. The legend categories 
on the right are presented in the same order as the row annotations at the top of the graph. The scale on 
the right represents log2 expression values. 
 
Multidimensional scaling again confirmed the RPMM-based clusters, which provided 
good separation of the data (Figure 5). 
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Figure 5: Multidimensional scaling of the top quartile (N=13669) most variable probesets used for RPMM clustering of the Jorissen cohort. The three figures 
are identical apart from the difference in annotation, where samples have been coloured by the de Sousa (left), Sadanandam (middle) or RPMM (right) 
subgroups. 
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Group B contained 84/155 samples and was heavily enriched for the de Sousa et al. 
CCS2- and CCS3-type samples, with 82% (32/39) and 72% (23/32) of CCS2 and CCS3 
samples present in this group; meanwhile 72.5% (58/80) of the CCS1 group fell in 
group A. Regarding MSI-status, 79% of MSI+ patients fell in the B group. 
Most of the inflammatory-like samples (85% (29/34)) and the stem-like samples (60% 
(12/20)), which have been reported to agree with the CCS3 subtype359, fell into group B. 
However, goblet-like samples, which together with inflammatory-like samples have 
been reported to agree with the CCS2 subtype359, were fairly equally distributed 
between groups A and B, with 43% (9/21) of goblet-like samples in group B. Further, 
71% (17/24) of the Enterocyte-like samples and 14% (5/36) of the transit-amplifying-
like type (which together corresponded to the CCS1 subtype359) fell into the B group.  
To summarise, 40% of group B was composed of inflammatory-like samples (94% of 
which fell into the rRR subgroup of group B), 17% were stem-like samples, 12.5% were 
goblet-like, 24% were enterocyte-like and 7% were transit amplifying-like. Group B 
thus has an overrepresentation of: inflammatory-, stem- and enterocyte-like samples; 
CCS2 and CCS3 subtype samples; and MSI+ samples.  
Biological features that distinguish CRC subtypes 
No significant differences in clinical characteristics between group A and group B 
CRCs in our cohort were found; however, there was a trend for increased cancers of the 
proximal colon, and for patients of white or black ethnicity (as opposed to mixed 
ancestry) in group B patients (Table 1). 
Table 1: Descriptive characteristics by CRC subtype. 
 Group A (N = 9) Group B (N = 10) P (Fisher’s exact) 
MSI-H 3 4 1.00 
HNPCC+ 2 2 1.00 
Stage*    
I/II 2 5 0.37 
III/IV 6 5 0.37 
Site    
Proximal colon 2 5 0.35 
Distal colon 5 2 0.35 
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Rectum 2 3 1.00 
Age*    
≤ 60 2 4 0.63 
> 60 6 6 1 
Gender    
Male 5 4 0.66 
Female 4 6 0.66 
Ethnicity    
Mixed ancestry 8 5 0.14 
Black 0 2 0.47 
White 0 3 0.2 
Indian 1 0 0.47 
*One case had missing information 
Visual inspection of annotated heatmaps (Figure 2), suggested an overrepresentation of 
certain bacteria in group B. Using Fisher’s exact test a) the number of Fusobacterium-
high vs. Fusobacterium-low/negative cases between group A and group B, and b) 
positive vs. negative- colonisation status for the rest of the bacteria were compared. The 
frequency of high-level colonisation by any bacterium between the two groups was also 
compared. E. faecalis, Fusobacterium-high and EPEC had the strongest association with 
group B (p-values: 0.05, 0.06, 0.2), but this association was not significant after 
Benjamini-Hochberg multiple testing correction. There was also an increased frequency 
of high-level colonisation by any bacterium in group B (p=0.1, FDR=0.3) (Table 2). 
Table 2: Comparison of bacterial colonisation between group A and group B samples using Fisher’s exact 
test. 




P (Fisher’s exact 
test) 
FDR 
FB-H  1 6 0.06 0.2 
EF+ * 1 6 0.05 0.2 
ETBF+  5  5  1 1 
ClB+  3  3  1 1 
afaC+  5  6 1 1 




5 13 0.1 0.3 
*Two samples did not have data available. FB-H: Fusobacterium-high; EF: E. faecalis; ETBF: 
Enterotoxigenic B. fragilis; ClB+: colibactin+ E. coli; EPEC: Enteropathogenic E. coli; Colonisation-H: 
samples that had one or more high-level colonisations by any of the species tested. 
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CpG island methylation by subgroup   
In Chapter 6 CIMP status was predicted using an established array-based marker panel 
of CIMP305. Interestingly, although the RPMM clustering did not take methylation data 
into consideration, the majority of CIMP+ samples fall in group B and in group B 80% 
of cases were CIMP+.  
Next, given the central role of Wnt pathway activation in CRC, methylation of CpG 
islands in Wnt pathway antagonist genes that had previously been reported as 
methylated in CRC were evaluated. These included SFRP1, SFRP2, SFRP5103, DKK-
1367, DKK2, DKK4368 ,WIF1369, WNT5A370, SOX17371, APC1A372 and APC2372. Since 
CpG islands are frequently located at the 5’ promoter of genes, CpG island methylation 
was used as a proxy for gene silencing. Wnt antagonists showed increased CpG island 
methylation in 7/10 group B cancers (Figure 6). However, these changes did not appear 
to translate to decreased expression of these genes (Appendix C). 
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Figure 6: RPMM-based clustering of CpG islands in Wnt pathway antagonists known to be methylated in 
CRC. The legend categories on the right are presented in the same order as the row annotations at the top 
of the graph. The scale on the right represents methylation beta values (0–1). EF.cat: E. faeclis 
colonisation category (1=negative; 2=low-level; 3=high-level); FB.cat: Fusobacterium colonisation 
category (1=negative; 2=low-level; 3=high-level); ND: not determined. 
Analysis of variance of genome-wide methylation between group A and group B 
cancers produced only 37 differentially methylated CpG sites at a relaxed FDR cutoff of 
0.25 (Table 3). Even when analysing CIMP+ vs. CIMP- tumours (Chapter 6), the list of 
sites significantly associated with CIMP status was relatively small (124 sites with FDR 
≤ 0.25). This is largely due to the drastic effect of multiple testing correction on this 
platform, the degree of which is proportional to the number of probes evaluated (in this 
case ~300 000). Nevertheless all 37 probes indicated increased methylation in group B 
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cancers, and 33 of 37 mapped to CpG islands, which supports the predicted CIMP+ 
status found in the majority of group B samples. 
Table 3: Analysis of variance of CpG sites between group A and group B samples. 












S1PR1 1 0 1.57E-07 0.04 0.27 
cg0231594
0 
CLSTN2 3 1 5.37E-07 0.06 0.39 
cg0675867
0 
GRIN2A 16 1 1.05E-06 0.06 0.25 
cg1358910
8 
FAM5B 1 0 1.44E-06 0.06 0.30 
cg2615668
7 
PAX2 10 1 1.58E-06 0.06 0.30 
cg2710651
3 
RGS20 8 1 1.76E-06 0.06 0.26 
cg0327953
5 
GALNT14 2 1 2.24E-06 0.07 0.46 
cg2362480
8 
ZSCAN30 18 0 2.57E-06 0.07 0.20 
cg0678120
9 





17 1 4.44E-06 0.10 0.21 
cg1277752
0 
LMX1B 9 1 7.02E-06 0.13 0.31 
cg1391674
0 
ZNF582 19 1 8.24E-06 0.14 0.39 
cg1884438
2 
EFS 14 1 1.10E-05 0.16 0.32 
cg2710002
2 
RAB39A 11 0 1.04E-05 0.16 0.28 
cg0663447
3 
KCNK10 14 1 2.20E-05 0.20 0.26 
cg1030463
7 
NRN1 6 1 1.77E-05 0.20 0.31 
cg1811919
2 
GATA4 8 1 2.32E-05 0.20 0.20 
cg1838715
6 
NRG1 8 1 2.66E-05 0.20 0.20 
cg1839175
8 
GRIN2A 16 1 2.33E-05 0.20 0.17 
cg1949244
6 
CELF4 18 1 1.79E-05 0.20 0.15 
cg2101386
6 
EFS 14 1 1.66E-05 0.20 0.29 
cg2309282
3 
PODN 1 1 2.21E-05 0.20 0.20 
cg0973696
8 
ECEL1 2 1 3.01E-05 0.21 0.26 
cg0031954
5 
ASTN1 1 1 3.40E-05 0.22 0.23 
cg0736919
0 
PCP4L1 1 1 3.82E-05 0.22 0.35 
cg0966985
3 
TLL1 4 1 3.81E-05 0.22 0.22 
cg1185552
6 
MPPED2 11 1 3.67E-05 0.22 0.41 
cg1658075
9 
XKR5 8 1 4.02E-05 0.23 0.22 
cg0751450
5 
HS6ST3 13 1 4.32E-05 0.23 0.26 
cg1707868
6 
POU3F3 2 1 4.21E-05 0.23 0.34 
cg1725070
1 
PTPN5 11 1 4.32E-05 0.23 0.24 
cg1181542
5 
ONECUT1 15 1 4.82E-05 0.25 0.30 
cg1334707
1 
UNC80 2 1 4.96E-05 0.25 0.16 
cg1771676
5 
APBA2 15 1 5.07E-05 0.25 0.22 
cg1864217
7 
WNT3A 1 1 5.01E-05 0.25 0.26 
cg0995588
6 
ITIH5 10 1 5.50E-05 0.25 0.14 
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cg2615818
0 
NTRK3 15 1 5.35E-05 0.25 0.22 
The Δ beta value was calculated for each CpG site by subtracting the median beta value across group A 
samples from that of group B samples. 
CRCassigner-786 subtypes 
In order to assess our CRC subtypes in the context of the Sadanandam et al. subgroups, 
and to gain biological insight into their defining characteristics, the CRCassigner-786 
classifier was applied to our dataset as follows: each of the five subtypes was allocated 
the subset of the 786 genes that had maximum Prediction Analysis of Microarrays 
(PAM) scores (published by Sadanandam et al.) for that subtype. For each of the five 
resulting sub-classifiers, hierarchical clustering was performed in order to visually 
assess the degree of correspondence to each of the five subtypes; samples with 
increased gene expression relative to the rest of the cohort suggests increased 
correspondence to that subtype. For the transit amplifying-like panel of genes there was 
very little discernable difference between samples (Appendix C). For the remaining four 
subtypes (Figure 7), two main subgroups were clearly visible from the clustering 
dendrograms.  
 





Figure 7: CRC classification according to the CRCassigner-786 classifier of Sadanandam et al. EF.cat: E. 
faecalis colonisation level category (1=negative; 2=low-level; 3=high-level); FB: Fusobacterium 
colonisation level category (1=negative; 2=low-level; 3=high-level). The legend categories on the right 
are presented in the same order as the row annotations at the top of the graph. The scale on the right 
represents log2 expression values. 
Four samples showed a relative increase in stem-like expression (14T, 41T, 13T, 8T), 
three of which had been classified as group B samples; in accordance with the literature, 
most (3 of 4) of these samples were of distal origin358. Seven samples (44T, 23T, 63T, 
13T, 11T, 4T, 18T) had a relative increase in goblet-like expression, and most MSI+ 
samples (5 of 7) belonged to this cluster––these included both HNPCC and sporadic 
MSI+ samples. Five of seven goblet-like samples were also predicted to be CIMP+, and 
6 of 7 were located in the proximal colon. Meanwhile, the inflammatory classifier 
separated 9 of 10 group B samples from the rest of the cohort and included 44T, 8T, 
34T, 23T, 63T, 20T, 18T, 41T and 13T––this group included 8 of 10 CIMP+ samples 
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and 5 of 7 MSI+ samples. With the enterocyte-like classifier it was more difficult to 
define subgroups: the six samples showing the lowest expression (44T, 41T, 14T, 23T, 
37T, 33T) mostly belonged to group B, whereas samples that displayed the highest 
expression (60T, 34T, 15T, 56T, 20T, 18T, 4T, 10T) mostly belonged to group A. 
Both the inflammatory samples and the goblet-like samples were enriched for high-level 
colonisation by Fusobacterium, with 6 of 7 of Fusobacterium-high infected samples 
present in the goblet-like cluster. Further, 6 of 7 E. faecalis+ samples fell in the 
inflammatory cluster.  
The inflammatory/goblet characteristics of group B samples are supported by tumour 
biopsy pathology reports since 5 of 9 patients (9 of 10 group B samples had available 
records) displayed signs of inflammation and/or had a visible mucinous component. 
Two more patients in the inflammatory-subtype presented with diverticular disease and 
mucinous metaplasia of the appendix, respectively. In group A, only one patient (8 of 9 
group A samples had available records) had a reported mucinous component (4T), while 
another had diverticulae (10T). 
Our results thus agree with the merging of the goblet and inflammatory subtypes into 
one subtype (CCS2), as proposed by Sadanandam et al.359, and demonstrate that many 
of these samples are MSI-H (5/7) or CIMP+. It can be concluded that our infection-
dominated subtype (group B) most closely resembles the inflammatory subtype of 
Sadanandam et al., with certain samples presenting with features of the stem-like or 
goblet type. Group A samples are more likely of the enterocyte-type.  
Gene- and pathway-level CRC subtype comparison 
Patients belonging to group B of our cohort and of the Jorissen cohort were suspected to 
have similar biological features, since both were enriched for inflammatory-like 
samples, and likely also for CIMP+ samples, given the enrichment with CCS2 and 
CCS3 samples in group B of the Jorissen cohort. Gene expression and pathway-level 
differences between the two RPMM-derived subgroups were therefore compared 
between the cohorts. For each cohort a) differential gene expression analysis between 
subgroups, followed by b) IPA of the significantly differentially expressed genes, and c) 
differential analysis of IPLs obtained through PARADIGM were performed. Finally, 
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the overlap between the two cohorts regarding subgroup-specific gene- and pathway-
level alterations was established. 
Gene expression analysis between group A and group B of our cohort produced 4671 
genes at an absolute fold change cutoff of 1.25, and 296 genes at an absolute fold 
change cutoff of 2 (FDR ≤ 0.05). For the Jorissen cohort, 5771 genes were differentially 
expressed at an absolute fold change cutoff of 1.25, and 546 genes at a fold change 
cutoff of 2 (FDR ≤ 0.05). Of the 4671 genes differentially expressed in our cohort, 1619 
overlapped with Jorissen subgroup comparison results, 78% (1266/1619) of which were 
consistently up- or down-regulated in both cohorts. Meanwhile, 19 genes were 
differentially altered in both cohorts at an absolute fold change ≥ 2 (FDR ≤ 0.05), 18 of 
which were consistently up- or down-regulated in group B of both cohorts (Table 4). 












C10orf99 3.3E-02 -2.5 4.3E-03 -2.4 yes 
COL12A1 1.4E-03 3.6 4.8E-06 2.1 yes 
CXCL10 4.9E-02 2.8 2.3E-06 2.8 yes 
FCGR2A 1.0E-02 2.5 7.1E-14 2.4 yes 
HSPA4L 1.6E-02 2.8 9.1E-11 2.6 yes 
IL1B 7.0E-03 3.2 8.9E-09 2.7 yes 
IL8 5.4E-03 4.1 6.1E-06 2.9 yes 
MMP1 4.6E-02 3.0 2.7E-05 2.6 yes 
MMP12 1.3E-03 4.4 5.0E-08 3.0 yes 
NR4A2 1.5E-02 2.2 4.8E-06 2.1 yes 
PKIB 4.1E-03 -2.2 7.7E-05 2.0 no 
PLA2G4A 3.2E-02 2.4 1.9E-04 2.3 yes 
PLK2 5.8E-04 2.0 3.8E-11 2.8 yes 
POSTN 1.8E-02 3.7 2.1E-07 3.0 yes 
PTGS2 2.6E-03 3.9 1.2E-08 3.0 yes 
REG1A 3.3E-02 6.2 3.2E-02 2.5 yes 
TDO2 4.1E-02 3.2 7.5E-06 2.0 yes 
TNFAIP6 3.7E-03 3.0 5.1E-09 2.3 yes 
VCAN 2.1E-02 2.4 7.1E-08 2.3 yes 
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The biological roles of many of the 18 genes supported the relevance of inflammation in 
the pathogenesis of group B cancers: the pro-inflammatory chemokine CXCL10 and 
cytokines IL-8 and IL-1B, along with the infamous prostaglandin-endoperoxide 
synthase 2 (PTGS2 or COX-2), which is induced by IL-1B373, were all upregulated in 
group B cancers. Two downstream targets of these inflammatory genes were also 
upregulated in group B cancers: regenerating islet-derived 1 alpha (REG1A) is 
upregulated by IL-8374, and nuclear receptor 4A2 (NR4A2) is upregulated by COX-2 
and rescues cells from undergoing programmed cell death375. Further, polo-like kinase 2 
(PLK2), also upregulated in group B cancers, is upregulated in response to ROS-
induced oxidative stress, where it facilitates cell survival by promoting the NRF2 
antioxidant pathway376.  
IL-8 expression is of particular importance, since it is a central element of the innate 
immune response that is regulated by a number of different stimuli, including 
inflammatory signals (TNF-α, IL-1β), chemical and environmental stress (such as 
hypoxia), steroid hormones377, infection with certain viruses378,379 and bacteria. Bacteria 
known to induce IL-8 include Fusobacterium196,380,381 and H. pylori––which induces IL-
8-dependent REG1A expression374. Intriguingly, both REG1A and REG3A were 
potently upregulated in cancers with high levels of Fusobacterium infection, and to a 
lesser extent IL-8 (Chapter 8).  
Given their role in inflammation, it is not surprising that many of the genes in Table 4 
are implicated in the pathogenesis of irritable bowel disease (IBD) and/or are linked to 
host response to infection. For instance, FCGR2A polymorphisms modify susceptibility 
to IBD382, and IL-8383, COX-2, REG3A, REG1A384, IL-1B385, MMP1386, MMP-12387,388 
and POSTN389 are all overexpressed in patients with IBD.  
Extracellular matrix proteoglycans versican (VCAN) and lumican (LUM) are both 
significantly upregulated in group B cancers (lumican with fold changes of 4 and 1.7 in 
our cohort and the Jorissen cohort, respectively). In addition to their structural role in 
the extracellular matrix, proteoglycans act as signaling molecules by virtue of the their 
complex structures, which facilitate interaction with ligands and receptors390 of 
endogenous or exogenous origin. In their soluble form, proteoglycans can act as danger 
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signals, acting as damage-associated molecular patterns (DAMPs), which induce non-
pathogen mediated inflammation through TLR signaling upon tissue stress391. 
Accordingly, proteoglycans have established roles in various cancers390, including 
CRC392. Versican in particular regulates cell adhesion and survival, cell proliferation, 
cell migration and extracellular matrix assembly393, and activates TLR2 and TLR6 in a 
CD14-dependent manner, inducing the expression of TNFA, IL6 and several growth 
factors391. Further, glycosaminoglycans linked to proteoglycans are an important 
element of the host-pathogen interface that can mediate pathogenic infection with 
viruses, bacteria and parasites394. Lumican binds and presents bacterial 
lipopolysaccharide (LPS) to CD14, which initiates an immune response leading to 
increased phagocytosis391. 
Many of the genes upregulated in group B cancers also have roles in tumour 
progression and metastasis; these include matrix metalloproteases (MMPs) 1 and 12, 
which have opposing roles in promoting and inhibiting tumour progression, 
respectively395,396; CXCL10 also elicits seemingly contradictory effects on tumour 
progression since it is antiangiogenic and antiproliferative in CRC397, yet is associated 
with advanced cancer and may promote invasion through the induction of cell 
migration398; Periostin (POSTN) promotes metastatic CRC growth by increased cell 
survival399; IL-8 promotes angiogenesis400 and lastly; REG1A expression in CRC has 
been linked to poor prognosis and correlates with recurrence and/or distant metastasis in 
MSI+ patients401. 
Lastly, tryptophan 2,3-dioxygenase (TDO) is an important mediator of immune 
tolerance, and its overexpression may contribute to tumoral immune resistance to 
tumour-specific antigens in group B cancers402.  
Pathway-level CRC subgroup comparison 
Ingenuity Pathway Analyses 
IPA was used to investigate pathway-level alterations that define CRC subtypes. For 
each cohort genes significantly altered between subtypes (FDR ≤ 0.05, FC ≥ 1.25) were 
used to investigate a) canonical pathways b) upstream regulators and c) diseases and 
functions that defined CRC subtypes. 
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Canonical pathway analyses 
Fifty-four and 96 canonical pathways showed significant overrepresentation (p ≤ 0.05) 
in group B cancers in our cohort and in the Jorissen cohort, respectively. In our cohort, 
EIF2 signaling was the top scoring canonical pathway, while numerous pathways 
related to DNA and protein damage response were altered between subtypes (Table 5a). 
In the Jorissen cohort, top-scoring pathways included Antigen Presentation Pathway, 
IGF-1 Signaling and Protein Ubiquitination Pathway (Table 5b). 
Table 5a: Top 20 most significant IPA canonical pathways in group B vs. group A samples of our cohort. 
Ingenuity Canonical Pathways  -log(p-
value) 
Downregulated  Upregulated  
EIF2 Signaling 13.4 8/169 (5%) 109/169 
(64%) 
Role of BRCA1 in DNA Damage Response 10.6 0/60 (0%) 46/60 (77%) 
Protein Ubiquitination Pathway 9.27 20/249 (8%) 126/249 
(51%) 
Cell Cycle Control of Chromosomal Replication 9.25 1/27 (4%) 25/27 (93%) 
Cell Cycle: G2/M DNA Damage Checkpoint 
Regulation 
8.48 1/48 (2%) 32/48 (67%) 
Mitotic Roles of Polo-Like Kinase 8.32 4/63 (6%) 39/63 (62%) 
Hereditary Breast Cancer Signaling 7.29 7/111 (6%) 61/111 
(55%) 
Role of CHK Proteins in Cell Cycle Checkpoint 
Control 
6.52 4/55 (7%) 36/55 (65%) 
tRNA Charging 5.72 0/38 (0%) 26/38 (68%) 
RAN Signaling 5.61 0/16 (0%) 15/16 (94%) 
Mismatch Repair in Eukaryotes 5.61 0/16 (0%) 13/16 (81%) 
Cell Cycle: G1/S Checkpoint Regulation 4.86 7/63 (11%) 32/63 (51%) 
Regulation of eIF4 and p70S6K Signaling 4.54 10/141 (7%) 72/141 
(51%) 
Cyclins and Cell Cycle Regulation 4.46 10/77 (13%) 36/77 (47%) 
ATM Signaling 4.09 2/59 (3%) 31/59 (53%) 
Telomere Extension by Telomerase 4.09 0/15 (0%) 14/15 (93%) 
Purine Nucleotides De Novo Biosynthesis II 4.03 1/11 (9%) 8/11 (73%) 
DNA Double-Strand Break Repair by Homologous 
Recombination 
3.60 0/14 (0%) 10/14 (71%) 
DNA Double-Strand Break Repair by Non-
Homologous End Joining 
3.60 0/14 (0%) 11/14 (79%) 
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DNA damage-induced 14-3-3“€ Signaling 3.47 3/19 (16%) 11/19 (58%) 
Estrogen-mediated S-phase Entry 3.45 3/24 (13%) 16/24 (67%) 
 
Table 5b: Top 20 most significant IPA canonical pathways in group B vs. group A samples of the 
Jorissen cohort. 
Ingenuity Canonical Pathways  -log(p-
value) 
Downregulated  Upregulated  
Antigen Presentation Pathway 9.28 1/34 (3%) 28/34 (82%) 
IGF-1 Signaling 8.40 14/96 (15%) 46/96 (48%) 
Glucocorticoid Receptor Signaling 8.38 24/256 (9%) 106/256 
(41%) 
Role of NFAT in Regulation of the Immune 
Response 
8.31 14/158 (9%) 74/158 
(47%) 
CD28 Signaling in T Helper Cells 7.83 9/107 (8%) 55/107 
(51%) 
OX40 Signaling Pathway 7.71 2/46 (4%) 32/46 (70%) 
Role of Tissue Factor in Cancer 7.35 11/107 (10%) 52/107 
(49%) 
Cdc42 Signaling 7.21 8/121 (7%) 61/121 
(50%) 
B Cell Receptor Signaling 7.17 16/167 (10%) 73/167 
(44%) 
Leukocyte Extravasation Signaling 6.76 13/191 (7%) 85/191 
(45%) 
Integrin Signaling 6.68 18/194 (9%) 81/194 
(42%) 
Protein Ubiquitination Pathway 6.54 21/251 (8%) 101/251 
(40%) 
Virus Entry via Endocytic Pathways 6.51 10/89 (11%) 43/89 (48%) 
Caveolar-mediated Endocytosis Signaling 6.19 6/71 (8%) 38/71 (54%) 
HGF Signaling 6.16 12/104 (12%) 47/104 
(45%) 
PI3K/AKT Signaling 6.14 13/120 (11%) 53/120 
(44%) 
IL-17 Signaling 5.94 4/72 (6%) 40/72 (56%) 
Type I Diabetes Mellitus Signaling 5.63 3/100 (3%) 53/100 
(53%) 
Prostate Cancer Signaling 5.61 7/80 (9%) 40/80 (50%) 
PKCëü Signaling in T Lymphocytes 5.60 7/107 (7%) 52/107 
(49%) 
 
Next, the overlap between subtype analyses for the two cohorts was established, which 
resulted in 15 significantly overrepresented canonical pathways, all of which were 
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predicted to be activated in group B samples. Included were pathways related to DNA 
and protein damage response, as well as cell cycle regulation (Table 5c). 
Table 5c: Canonical pathways predicted to be significantly altered in both cohorts in group B vs. group A 


































































































































dTMP De Novo 
Biosynthesis 
1.86 0/5 (0%) 4/5 
(80%) 
1.35 0/5 (0%) 4/5 
(80%) 




























Upstream regulator analyses 
As described in the Materials and Methods section, IPA’s upstream regulator analysis 
predicts which genes (including transcriptional regulators) act as upstream regulators 
based on downstream gene expression data and prior knowledge of expected effects 
between transcriptional regulators and their target genes. Two statistical measures are 
produced: the p-value of overlap, and the activation z-score (where negative and 
positive scores indicate inhibition or activation by the upstream regulator). 
There were 150 and 894 IPA upstream regulator entries in our CRC cohort and the 
Jorissen cohort, respectively, that showed significant overrepresentation between 
subgroups (p-value of overlap ≤ 0.05). The top 20 scoring upstream regulators in our 
cohort included multiple transcription factors that were predicted to be activated (E2F1, 
E2F2, MYC, MYCN, XBP1, NFE2L2, TBX2 and CCND1) or deactivated (RB1, 
CDKNA2, KDM5B and NUPR1) in group B cancers (Table 6a). Meanwhile, in the 
Jorissen cohort, top-scoring subtype-specific upstream regulators were dominated by 
various cytokines, including TNF, IFNG and IFNA2 and growth factors including 
TGFB1 and HGF (Table 6b). 
Table 6a: Top 20 most significant upstream regulators predicted to be significantly altered in group B vs. 
group A samples in our cohort, with absolute activation z-scores ≥ 2. Chemical upstream regulators were 
excluded. 
































PTGER2 G-protein coupled 
receptor 
5.092 4.28E-09 







miR-1 (and other miRNAs w/seed 
GGAAUGU) 




RICTOR Other -7.97 4.30E-07 





Table 6b: Top 20 most significant upstream regulators predicted to be significantly altered in group B vs. 
group A samples in the Jorissen cohort, with absolute activation z-scores ≥ 2. Chemical upstream 
regulators were excluded. 
Upstream Regulator Molecule Type Activation z-score p-value of overlap 
TGFB1 growth factor 7.62 4.62E-43 
IFNG cytokine 11.73 9.13E-42 
TP53 transcription regulator 4.115 1.14E-41 
TNF cytokine 11.051 7.45E-33 
IL2 cytokine 6.836 3.86E-26 
STAT3 transcription regulator 6.512 1.81E-23 
IFNA2 cytokine 8.837 7.99E-23 
OSM cytokine 7.171 1.63E-22 
CD40LG cytokine 7.058 9.83E-22 
IL4 cytokine 5.298 4.38E-21 
CD3 complex -4.992 5.04E-21 
IL1B cytokine 10.491 1.23E-20 
HRAS enzyme 2.703 1.50E-20 
IL6 cytokine 8.821 8.31E-20 
HGF growth factor 5.829 1.13E-19 
APP other 4.657 1.50E-19 
Interferon alpha group 8.861 1.51E-19 
NFKBIA transcription regulator 4.071 2.99E-19 
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Vegf group 7.696 2.77E-18 
CSF2 cytokine 8 3.87E-18 
 
Of the 68 upstream regulators that overlapped between the two datasets, 67 had 
consistent direction of predicted activation state. The upstream regulators (excluding 
molecules of chemical origin such as chemical toxicants and chemical drugs) with 
consistent direction of activation between the two cohorts are listed in Table 6c.  
Table 6c: Upstream regulators predicted to be significantly altered in our cohort and the Jorissen cohort in 
group B vs. group A samples, with absolute activation z-scores ≥ 2. Chemical upstream regulators are not 
shown. 








BAX Transporter 3.223 0.0103 3.471 9.67E-06 
CD28 transmembrane 
receptor 
-6.198 0.0313 -3.741 4.54E-13 
KDM5B transcription 
regulator 
-5.879 3.53E-06 -4.241 3.05E-07 
TSC22D1 transcription 
regulator 
2.236 0.00386 2.449 0.00112 
E2F2 transcription 
regulator 
2.5 2.75E-07 2.63 0.00495 
SREBF1 transcription 
regulator 
3.145 0.00983 2.371 0.00225 
ATF4 transcription 
regulator 
4.22 0.000396 3.736 0.000108 
FOXM1 transcription 
regulator 
4.498 1.65E-05 3.503 0.000101 
E2F1 transcription 
regulator 
5 1.91E-15 3.969 3.23E-08 
NFE2L2 transcription 
regulator 
6.705 3.33E-10 4.295 5.58E-07 
XBP1 transcription 
regulator 
7.864 5.63E-14 7.336 1.58E-10 
Irgm1 Other -4.101 0.00292 -4.208 5.15E-06 
BID Other 2.121 0.0136 3.302 0.000496 
Back to table of contents 165 
APP Other 2.403 0.00363 4.657 1.50E-19 
PRNP Other 2.714 0.034 2.283 2.34E-05 
RAB1B Other 2.864 0.00401 2.469 0.00657 
SCAP Other 3.59 0.00525 2.652 0.0429 
GAST Other 4.8 0.0156 3.616 0.00011 
CD24 Other 5.385 0.0145 2.853 4.10E-10 
let-7 microRNA -7.67 2.62E-13 -2.755 5.97E-07 





-8.019 3.20E-05 -7.563 3.17E-12 




-7.472 1.92E-07 -6.004 3.74E-12 










-5.855 0.00501 -5.971 4.12E-15 





-5.81 0.00016 -4.682 4.68E-09 





-5.531 0.0158 -2.946 0.00713 





-4.991 0.0457 -2.811 0.000176 





-3.312 0.0471 -4.289 8.14E-05 





-2.707 0.0207 -2.88 2.14E-06 
PIM1 Kinase 2.113 0.0221 2.175 0.0018 
ATM Kinase 2.685 0.000793 2.635 1.93E-06 
ANGPT2 growth factor 5.468 0.000382 5.213 2.70E-10 
HGF growth factor 7.825 0.00285 5.829 1.13E-19 
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caspase Group 2.538 0.016 2.55 0.0373 
Jnk Group 3.323 0.0293 5.8 8.19E-12 
PTGER2 G-protein 
coupled receptor 
5.092 4.28E-09 2.702 0.0102 
CAT Enzyme -2.745 0.025 -3.046 7.31E-12 
PLA2G2A Enzyme 2.228 0.0108 2.559 0.00036 
PIN1 Enzyme 2.534 0.0128 2.107 0.00232 
CD38 Enzyme 4.713 0.0189 5.897 5.13E-07 
IL3 Cytokine 3.316 0.0132 4.617 4.88E-08 
IL5 Cytokine 5.279 0.0306 7.804 1.99E-14 
CSF2 Cytokine 8.068 0.000137 8 3.87E-18 
CD3 Complex -7.035 0.00874 -4.992 5.04E-21 
 
One transcription regulator that may regulate the DNA damage response noted in the 
canonical pathways results is forkhead box protein M1 (FOXM1), which is predicted to 
be activated in group B of both cohorts. This is supported at the mRNA level in our 
cohort where FOXM1 is upregulated 2.3 fold (FDR=3.5e-4). FOXM1 is upregulated in 
response to oxidative stress (via the TNF-α/reactive oxygen species/HIF-1 pathway)403, 
and triggers upregulation of ROS scavenger genes including superoxide dismutase 
(SOD), PRDX3 and catalase (CAT)404, which is confirmed by gene expression data in 
both cohorts (Table 7). 









SOD1 1.5 4.3E-03 1.2 5.7E-06 
CAT N/A N/A 1.2 6.9E-05 
PRDX3 1.3 5.0E-02 1.4 3.6E-08 
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Interestingly however, catalase was predicted to be a deactivated upstream regulator in 
B group CRCs of both cohorts (Table 6c), which may suggest increased oxidative 
damage, despite FOXM1 activation. Through its response to oxidative stress, FOXM1 
facilitates tumour cell survival405–407 by inducing proliferation and increasing resistance 
to apoptosis403. FOXM1 expression in CRC is associated with poor prognosis408 and 
tumour metastasis is promoted through upregulation of MMPs and pro-angiogenic 
VEGF406.  
Another transcription factor related to oxidative stress and inflammation that might be 
relevant to the pathogenesis of group B cancers is X-box binding protein 1 (XBP1). 
XBP1 is a mediator of endoplasmic reticulum (ER) stress, which is induced by the 
accumulation of misfolded proteins. Cells with secretory functions, including Paneth 
and Goblet cells, are therefore particularly dependent on a competent unfolded protein 
response (UPR)409; its role in Paneth- and Goblet-cell function is underscored by the 
occurrence of unresolved colitis in XBP1 deletion mice, as well as the increased risk of 
IBD conferred by hypomorphic variants of XBP1410. Activation of XBP1 in B group 
CRCs therefore suggests that these experience increased ER stress, which is mediated 
by XBP1-related mechanisms, which is in contrast with the overall inflammatory 
features of this group.  
Additional predicted upstream regulators of interest, that are related to tumour initiation 
and progression in group B cancers, include PIN1 (correlated with CRC progression411), 
ANGPT2 (induces angiogenesis412), PIM1 (a proto-oncogene413) and Jnk kinases414. 
Interestingly, several miRNAs, including the tumour suppressor let-7, and miRNA145, 
which suppresses the oncogene ANGPT2415, are predicted to be deactivated in group B 
cancers. 
Diseases and functions analyses 
In our cohort, 110 diseases and functions showed significant activation/deactivation 
between subgroups (p ≤ 0.05, |activation z-score| ≥ 2). The top 20 scoring diseases and 
functions by p-value in our cohort were dominated by DNA Replication, Recombination, 
Repair, Cell Cycle and Infectious Disease categories (Table 8a). Meanwhile, in the 
Jorissen cohort the top 20 (of 261) significant diseases and functions categories 
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included Cellular Growth and Proliferation, Infectious Disease, and Cancer, while the 
more detailed annotations (column 2, Table 8b) revealed functions related to tumour 
progression and metastasis in B group CRC (Table 8b). 
Table 8a: Top 20 most significantly different IPA diseases and functions group B vs. group A samples in 
our cohort. A p-value of overlap of 0.05 and |z-score| cutoff of 2 was used. 




Cell Cycle, DNA Replication, Recombination, 
and Repair 
checkpoint control 7.43E-16 3.38 
DNA Replication, Recombination, and Repair DNA replication 5.96E-14 2.439 
DNA Replication, Recombination, and Repair repair of DNA 1.05E-11 3.485 
Cell Cycle cell cycle progression 5.97E-11 3.578 
Infectious Disease infection of cells 7.81E-09 9.811 
Gene Expression, Protein Synthesis translation of RNA 1.02E-08 -3.348 
Cell Cycle M phase 1.28E-08 3.17 
Gene Expression, Protein Synthesis translation of mRNA 1.93E-08 -3.348 
Cellular Compromise, DNA Replication, 




DNA Replication, Recombination, and Repair metabolism of DNA 6.24E-08 3.059 
Cellular Compromise, DNA Replication, 




Cell Cycle interphase 2.32E-07 3.233 
Cell Cycle cycling of centrosome 5.55E-07 2.759 
Infectious Disease infection by RNA virus 5.75E-07 10.075 
Infectious Disease infection by HIV-1 5.77E-07 9.176 
Infectious Disease infection of tumor cell 
lines 
6.62E-07 7.739 
Infectious Disease, Reproductive System 
Disease 
infection of cervical 
cancer cell lines 
6.76E-07 7.737 
Cell Cycle, DNA Replication, Recombination, 
and Repair 
S phase checkpoint 
control 
6.85E-07 2.23 
Cell Cycle, DNA Replication, Recombination, 
and Repair 
checkpoint control of 
tumor cell lines 
7.64E-07 2.059 
Cell Cycle senescence of cells 1.17E-06 -3.239 
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Table 8b: Top 20 most significantly different IPA diseases and functions group B vs. group A samples in 
the Jorissen cohort. A p-value of overlap of 0.05 and |z-score| cutoff of 2 was used. 







Cellular Growth and Proliferation proliferation of cells 6.09E-46 Increased 6.123 
Cellular Movement cell movement 2.13E-35 Increased 7.194 
Cellular Movement migration of cells 1.42E-33 Increased 7.233 
Cellular Movement invasion of cells 3.58E-32 Increased 4.663 
Hematological System 




1.71E-31 Increased 5.323 
Cell Death and Survival cell death of immune 
cells 
8.35E-30 Increased 3.67 
Hematological System 
Development and Function, 
Tissue Morphology 
quantity of blood 
cells 
1.50E-28 Increased 4.982 
Cell Death and Survival cell death of blood 
cells 
1.52E-28 Increased 3.468 
Cancer advanced malignant 
tumor 
2.44E-28 Increased 2.61 
Cancer growth of tumor 6.45E-28 Increased 3.179 
Infectious Disease Viral Infection 9.93E-28 Increased 5.851 
Cancer metastasis 3.59E-27 Increased 2.61 
Cellular Function and 
Maintenance 
function of blood 
cells 
7.51E-26 Increased 2.927 
Cellular Development, Cellular 
Growth and Proliferation, 
Hematological System 
Development and Function 
proliferation of 
immune cells 
1.34E-25 Increased 2.709 




2.27E-25 Increased 2.715 
Cellular Development, Cellular 
Growth and Proliferation 
proliferation of tumor 
cell lines 
8.51E-25 Increased 3.402 
Cellular Movement cell movement of 
tumor cell lines 
4.11E-24 Increased 4.435 
Cellular Movement cell movement of 5.40E-24 Increased 8.081 
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blood cells 
Cellular Development, Cellular 
Growth and Proliferation 
proliferation of blood 
cells 
6.64E-24 Increased 2.627 
Cellular Movement migration of blood 
cells 
9.14E-24 Increased 8.181 
 
Next, cohort comparison identified 11 diseases and functions that overlapped between 
the two data sets, six of which fell into the Infectious Disease category (Table 8c).  
Table 8c: IPA diseases and functions categories shared between subgroups in our cohort (columns 3&4) 
and that of the Jorissen cohort (columns 5&6). A p-value of overlap of 0.05 and |z-score| cutoff of 2 was 
used.  























3.648 1.25E-11 2.364 
Cell Death and Survival cell viability 




7.672 3.49E-14 4.475 
Cell Death and Survival cell survival 0.003
93 
8.121 6.58E-22 7.171 






8.856 6.09E-46 6.123 




9.31 4.27E-08 7.254 
Infectious Disease HIV infection 4.09E
-06 
9.419 6.95E-08 7.356 




9.423 5.37E-08 7.442 




9.811 1.49E-11 7.583 




10.075 2.01E-10 7.491 
Infectious Disease Viral Infection 9.10E
-05 
10.224 9.93E-28 5.851 
 
Interestingly increased Viral Infection was indicated in B group CRCs of both cohorts 
as well as decreased Bacterial Infection in the Jorissen cohort (p = 2e-10, z-score = -3). 
It is not immediately apparent whether the predicted increase in the Viral Infection 
category is based on a) a relative decrease in viral response mechanisms, which 
translates to increased viral infection, or b) a relative increase in viral response 
mechanisms, which is indicative of increased viral infection. Heatmaps of the 
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underlying gene expression data show a general increase in genes implicated in Viral 
Infection (which is predicted to be increased in group B) and in Bacterial Infection 
(which is predicted to be decreased in group B) in B group CRCs. The Viral and 
Bacterial Infection functions were based on 912 and 218 genes, respectively that were 
differentially expressed between group A and B cases of the Jorissen cohort, and 124 
genes overlapped between Viral and Bacterial Infection functions. 
Additionally, cellular proliferation and cell viability, as well as metabolism and 
transport of proteins, were predicted to be increased in B group CRCs of both cohorts. 
PARADIGM analysis 
In addition to using IPA to compare CRC subtypes at the pathway-level, PARADIGM 
was applied in a similar manner since PARADIGM has the advantage of allowing 
integration of multiple omics data types, as well as providing results on a per-patient 
basis.  
Regarding our cohort, differential analysis of PARADIGM IPLs produced 1464 IPLs 
that were differentially activated (FDR ≤ 0.05, |difference in group medians| ≥ 0.25) 
between group A and B samples, including 712 genes or gene families (Appendix C, 
Table 1), 711 complexes (Appendix C, Table 2), and 41 abstract processes (Appendix C, 
Table 3). In the Jorissen cohort 3619 IPLs were differentially activated between groups 
(FDR ≤ 0.05, absolute difference in group medians ≥ 0.25), including 1922 genes or 
gene families (Appendix C, Table 4), 1609 complexes (Appendix C, Table 5), and 88 
abstract processes (Appendix C, Table 6).  
Of the 1464 IPLs differentially activated between subtypes in our cohort, 570 were also 
present in the Jorissen cohort analysis, 499 (88%) of which had a consistent direction of 
activation- or deactivation between the two cohorts. Of the 499 IPLs, the shared abstract 
processes included DNA damage response-related pathways, activation of caspase 
activity by cytochrome c and prostaglandin biosynthesis (Table 9). The results from 
PARADIGM therefore support the results from IPA, and provide an additional layer of 
validation for the subtypes defined here. 
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Table 9. PARADIGM-derived abstract processes significantly altered (FDR ≤ 0.05, absolute median 
difference between subgroups ≥ 0.25) between RPMM-subgroups in our cohort as well as the Jorissen 
cohort.  








negative_regulation_of_DNA_binding_(abstract) 6.31E-03 2.7 7.76E-16 2.6 
anoikis_(abstract) 3.66E-02 2.2 3.68E-16 3.3 
protein_catabolic_process_(abstract) 8.22E-04 1.9 3.81E-15 1.2 
G2/M_transition_DNA_damage_checkpoint_(abstr
act) 
2.26E-02 1.9 7.77E-15 1.6 
response_to_radiation_(abstract) 4.74E-02 1.7 8.62E-17 2.3 
DNA_damage_checkpoint_(abstract) 1.27E-03 1.6 1.99E-04 0.9 
regulation_of_transcription_(abstract) 1.21E-03 1.6 7.59E-04 0.6 
prostaglandin_biosynthetic_process_(abstract) 2.36E-02 1.3 3.58E-07 0.7 
spindle_assembly_(abstract) 1.99E-02 1.2 1.37E-02 0.6 
regulation_of_mitotic_centrosome_separation_(abs
tract) 
3.72E-03 1.2 3.22E-02 0.3 
protein_folding_(abstract) 2.24E-03 1.2 7.27E-04 0.9 
G1/S_transition_checkpoint_(abstract) 8.83E-03 1.0 1.59E-03 0.4 
Golgi_organization_(abstract) 8.32E-03 1.0 4.35E-02 0.6 
activation_of_caspase_activity_by_cytochrome_c_
(abstract) 
2.64E-02 0.8 3.34E-16 1.0 
cell_cycle_arrest_(abstract) 3.09E-02 -1.2 2.08E-06 -0.5 
ribosome_biogenesis_(abstract) 3.24E-02 -2.9 8.79E-13 -2.7 
Subgroup diff.: median difference in PARADIGM activity score between each subgroup. The first two 
columns represent the FDR and difference in medians for our cohort  
DNA and protein damage response: exogenous or endogenous triggers? 
Since previous studies have shown that E. faecalis induces DNA damage and 
chromosomal instability in vitro through ROS generation223,416,417, the contribution of E. 
faecalis to the upregulation of DNA and protein damage response pathways identified 
using pathway analyses was assessed. Heatmaps of the canonical pathways including 
Role of BRCA1 in DNA damage response, Cell cycle G2/M DNA damage checkpoint 
regulation, and Protein Ubiquitination were produced using the list of genes predicted 
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to be altered in group B samples for each pathway in IPA. Figure 8 shows the result for 
the Cell cycle G2/M DNA damage checkpoint regulation pathway, which was the top 
scoring canonical pathway when comparing E. faecalis+ to E. faecalis–CRCs, using 
genes differentially expressed with a p-value ≤ 0.05 (results not shown) as input. 
 
Figure 8: Hierarchical clustering of genes implicated in the Cell cycle G2/M DNA damage checkpoint 
regulation pathway in IPA. The legend categories on the right are presented in the same order as the row 
annotations at the top of the graph. The scale on the right represents row-scaled expression values. EF.cat: 
E. faecalis colonisation level category (1=negative; 2=low-level; 3=high-level); FB: Fusobacterium 
colonisation level category (1=negative; 2=low-level; 3=high-level); EPEC.cat: EPEC colonization 
(1=negative; 2=positive); ND: not determined. 
Clearly, although six of the seven E. faecalis+ samples fall in the cluster where the Cell 
cycle G2/M DNA damage checkpoint regulation pathway is upregulated, this response 
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is not exclusive to E. faecalis+ samples, but rather to group B samples in general. It is 
thus conceivable that ROS might instead be produced by neutrophils and macrophages 
through the induction of oxidant-generating enzymes including the NOX (NADPH 
oxidase) and DUOX (Dual oxidase) enzymes, as well as myeloperoxidase (MPO) and 
inducible nitric oxide synthase (iNOS)418. However, no up-regulation of oxidant-
generating enzymes was seen in B group CRCs, and in fact NOX1 was significantly 
downregulated in Jorissen G group cancers (FC=–2.3) and NOXA1 was significantly 
downregulated in B group CRCs of both cohorts (both with FCs of ~ –1.3), which could 
support the contribution of exogenous ROS by bacteria in B group CRCs. However, 
since there is no direct evidence of increased ROS and/or NOS in these cancers, it is 
also possible that the DNA damage response is activated by factors other than increased 
ROS and/or NOS.  
Do MSI-specific antigens trigger the biological response seen in B group cancers? 
Compared to their microsatellite-stable counterparts, MSI+ CRCs have a heightened 
immune response that is evident macroscopically and at the molecular level419. This 
tumour-specific immune response is caused by antigenic MSI-induced frameshift 
mRNAs and/or peptides420,421. The contribution of MSI to subtype-specific alterations 
in immune-related functions were therefore investigated by comparing canonical 
pathways of particular biological interest in B group CRCs (related to inflammation, 
infection and oxidative stress) between a) MSI vs. MSS cancers (using genes 
differentially expressed between MSI vs. MSS cancers as input (|FC| ≥ 1.25, FDR ≤ 
0.05) and b) B group vs. A group cancers of the Jorissen cohort (|FC| ≥ 1.25, FDR ≤ 
0.05). The results (presented in Table 10) clearly demonstrate that the increase in 
inflammation, oxidative stress response, and antigen presentation in B group cancers is 
not specific to MSI+ cancers, since stronger evidence for upregulation of these 
pathways is seen in B group CRCs as a whole (of which 21% are MSS). 
 
 
Table 10: comparison of canonical pathways with particular biological interest in B group vs. A group 
CRCs compared to MSI vs. MSS status in the same cohort. 
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An important consequence of the anti-tumoural immune response in MSI+ CRCs is 
selective pressure towards immune evasion421. Mechanisms that contribute towards 
immune evasion in MSI+ CRCs include alteration in antigen-presentation machinery, 
specifically in HLA class I-mediated antigen presentation, which can be compromised 
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by mutations in B2M (30–60% of MSI+ CRCs) or through loss or downregulation of 
HLA class I heavy chains (~60% of MSI+ CRCs)421. Further, alterations in antigen 
processing machinery may also facilitate immune evasion421. HLA gene expression was 
therefore compared between a) MSI vs. MSS cancers, and b) B group vs. A group 
CRCs in the Jorissen cohort. Strikingly, multiple HLA class II (HLA-D) genes were 
preferentially upregulated in B group CRCs, while no HLA class I genes were 
differentially expressed in either comparison (Table 11). These results suggest induction 
of MHC class II antigen presentation in B group CRCs (most likely by tumour 
infiltrating lymphocytes), which is not specific to MSI+ cancers. These findings provide 
further support for the presence of foreign antigens in B group CRCs, which may well 
be of microbial origin. 
Table 11: Comparison of HLA genes significantly differentially expressed in a) MSI vs. MSS cancers and 






















3.0E-06 2.4 4.0E-14 3.6 increased 
203932_at HLA-DMB 3.3E-09 2.3 3.1E-10 2.4 increased 
205671_s_at HLA-DOB 3.7E-05 1.6 1.4E-02 1.3 decreased 








2.3E-06 2.3 1.2E-12 3.3 increased 




























4.0E-06 2.6 1.9E-07 2.8 increased 












7.8E-08 3.0 4.4E-10 3.4 increased 




8.2E-04 1.6 3.3E-03 1.5 decreased 
Relative subtype-specific effect indicates a relative increase or decrease in the result comparing the CRC 
subtype-specific effect to the MSI-specific effect. 
Discussion 
Specific bacterial infection, inflammation and DNA and protein damage responses 
underlie a distinct genomic subtype of CRC  
A subtype of CRC that is associated with a relative increase in the frequency of 
colonisation by E. faecalis and high-level colonisation with Fusobacterium, CpG island 
methylation (predicted using a CIMP-specific array-based marker panel) and MSI (as 
judged from the Jorissen cohort) was identified. These cancers are most similar to de 
Sousa et al. CCS2/3 subtypes and the inflammatory subtype of Sadanandam et al., 
which is supported by clinical observations in these patients. Moreover, pathway 
analyses of gene expression data in our cohort, as well as a larger publically available 
cohort (GSE13294), revealed increased response to DNA and protein damage, infection, 
inflammation and proliferation in these cancers. Various genes and pathways linked to 
increased metastasis and CRC progression were also highlighted in B group CRCs. 
One clinically relevant feature of inflammatory group B cancers is the significant 
upregulation of the COX-2 in both cohorts, which suggests that aspirin (which inhibits 
COX-2) might be particularly useful in preventing these cancers––an idea supported by 
pathway analysis of the Jorissen cohort, which lists aspirin as a ‘deactivated’ upstream 
regulator (z-score –4.4 p-val 9.6e-8). Moreover, regular prophylactic aspirin use 
specifically reduces the risk of developing CRCs that overexpress COX-2422. On the 
other hand, aspirin apparently helps prevent BRAF wild type but not BRAF mutant 
CRCs423, and the latter is strongly associated with CIMP-H cancers, which may be more 
frequent in group B cancers. Nevertheless, the level of protection conferred by aspirin in 
relation to CRC subtypes is certainly intriguing and warrants further investigation, 
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especially since recent studies offer compelling evidence for the use of aspirin as an 
adjuvant therapy for CRC––aspirin use (before or after diagnosis) improved patient 
survival and reduced the risk of metastatic CRC131.  
Given the occurrence of MSI-specific antigens, which is accompanied by an increased 
immune response in these cancers, the contribution of MSI to the activation of pathways 
related to antigen presentation, inflammation, DNA and protein damage response, and 
infection (seen in group B cancers) was investigated. Numerous HLA class II genes 
were preferentially upregulated in B group CRCs, indicating the presence of antigens 
unrelated to MSI-status in these tumours, which may be of microbial origin, given the 
increased subtype-specific response to inflammation and infection.  
In addition to increased inflammation and response to infection in B group CRCs, these 
cancers exhibit an increased DNA and protein damage response at the pathway level. 
The transcription factors FOXM1 and XBP1 likely play important roles in regulating 
oxidative damage and inflammation in these samples, and overexpression of FOXM1 
may facilitate tumour survival and progression in spite of DNA damage. The DNA and 
protein damage response seen in B group CRCs was not specific to E. faecalis+ samples, 
where one might expect ROS-induced DNA damage. However, the finding that oxidant-
generating enzymes were not upregulated in B group CRCs supports the possibility of 
exogenous bacterially-produced ROS. However, it is also possible that the DNA 
damage response is activated by factors other than ROS and/or NOS. The DNA damage 
response and protein ubiquitination was preferentially activated in B group CRCs, as 
opposed to MSI+ cancers, and it is therefore unlikely that MSI-induced mutations alone 
cause this response. One intriguing alternative is the well-established link between viral 
infection and the DNA damage response, which is exploited by several viruses to 
facilitate incorporation into the host genome424. However, a study that examined the 
distribution of JC polyoma virus (JCV), human adenovirus (AdV), Epstein–Barr virus 
(EBV), Kaposi sarcoma-associated herpesvirus (KSHV/HHV8) and human 
papillomavirus (HPV) across a cohort of 185 sporadic CRCs found no association 
between CIMP status and any of the viruses425. Since CIMP+ cancers are 
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overrepresented in B group CRCs, it seems less likely that the DNA damage response is 
virally-induced, at least not by the viruses examined in the Karpinski et al. study.  
While there appears to be a large-scale transcriptional response that links inflammation, 
DNA damage response, protein ubiquitination and immune response in group B cancers, 
it is unclear whether this translates to increased or decreased inflammation/oxidative-
induced damage in group B relative to group A cancers. Since oxidative stress can cause 
an array of DNA damage, including MSI (through mRNA or protein-level 
downregulation of the MMR system)137,138, mutations in non-microsatellite regions, 
DNA double strand breaks and CIN418,426, it is tempting to speculate that oxidative 
stress might contribute to mutations and/or chromosomal instability in group B cancers. 
However, this requires further investigation. 
Collectively, the role of infection, inflammation and oxidative stress in B group CRCs, 
bears resemblance to the pathogenesis of IBD-associated CRCs, where host 
susceptibility factors underlie an inappropriate response to bacteria, which results in 
increased inflammation and oxidative stress and an overrepresentation of specific 
bacterial families and species. Further, several genes previously linked to IBD were 
consistently upregulated in B group CRCs. Although there are distinct differences 
between IBD-associated and sporadic CRC427, there are clearly also similarities at the 
level of infection, bacterial colonisation and oxidative stress, at least in a subset of 
cancers. Presumably, there is a continuum in the degree of chronic colonic 
inflammation across a population, in which case it is reasonable to assume that, similar 
to IBD-associated CRC, subclinical inflammation accompanied by shifts in microbial 
composition also confer an increased risk of developing CRC.  
Importantly, the increase in IL-8 signaling and COX-2 expression in group B CRCs 
closely resembles the NF-κB pro-inflammatory signature (which included COX-2, 
TNF-α and IL-8) described by Kostic et al. that is amplified in human Fusobacterium-
infected CRC tissue218. They also found, using IPA, that the Fusobacterium-associated 
gene expression signature in human CRCs was highly enriched for the inflammatory 
response gene ontology category218. These findings provide support for the role of 
Fusobacterium in B group CRCs. 
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In Chapter 4, high-level colonisation by Fusobacterium was associated with both pks-
positive E. coli, and Enteropathogenic E. coli. Interestingly Warren et al. revealed a 
subset of microbes (including Leptotrichia and Campylobacter spp.) that were 
significantly associated with F. nucleatum in CRC biopsies, using co-occurrence 
network analysis of metagenomic signatures428,429. Importantly, this polymicrobial 
signature was associated with over-expression of numerous host genes, including IL-
8428. F. nucleatum is known to provide a scaffold for secondary bacterial colonisers in 
dental plaque, resulting in a structured biofilm429–431. Notably, H. pylori is known to 
selectively adhere to Fusobacterium432, and E. faecalis co-aggregates with F. nucleatum 
in endodontic infections433. These findings suggest that Fusobacterium could facilitate 
colonisation of potentially oncogenic pathogens. Incidentally, F. nucleatum is able to 
adapt to oxidative stress434,435 and in fact shows enhanced pathogenicity in mice under 
these conditions436, with F. nucleatum strains originating from inflamed biopsy tissue of 
IBD patients being significantly more invasive in a Caco-2 cell invasion assay than 
strains that were isolated from healthy tissue from either IBD patients or control 
patients262. Moreover, this adaptation of F. nucleatum to oxidative stress can be 
conferred to other more strict anaerobes437. 
Study limitations and future recommendations 
The major limitation of our study is the relatively small sample size, which limits 
statistical confidence in our findings. This issue was addressed retrospectively by 
applying our data analysis pipeline to a large publically available cohort where our 
method produced broadly similar results to the classifications of de Sousa et al. and 
Sadanandam et al. Further, closely related RPMM clusters were merged for ease of data 
analysis, but we recognize that there are likely more than two valid CRC subtypes. 
However, certain biologically relevant features appear to be shared by more than one 
subtype, as demonstrated by gene expression and pathway analyses between group A 
and B cancers. 
There does not seem to be consensus in the literature regarding a variability cutoff to 
use to select the subset of genes used for clustering. This parameter affects the resulting 
clusters to a certain extent and the decision of using the top 25% most variable genes 
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(by median absolute deviation) was based on the results from MDS of the Jorissen 
cohort, which demonstrated better separation of clusters when using the top 25% of 
clusters compared to using a very stringent cutoff of the 1000 most variable probesets.  
Nevertheless, biologically important features that distinguish the CRC subtypes defined 
here were identified that are likely applicable to the published subtypes of de Sousa et al. 
and Sadanandam et al.  
Regarding the establishment of CIMP-status in our cohort, a published array-based 
marker panel, for which high sensitivity and specificity has been reported339, was used. 
However, the gold standard for CIMP classification is by methylation-specific PCR and 
the agreement between array-based vs. molecular classification was not confirmed here. 
Future work should thus be aimed at validating these findings in a larger cohort, which 
includes more rectal samples (since only 5/19 from our study and 25/155 of the Jorissen 
study were rectal samples). Investigating the level of ROS and NOS by CRC subtype, 
and the association between subgroups and CRC risk factors that have inflammatory or 
pro-oxidative potential other than bacteria (including viral infection, cigarette smoking, 
alcohol- and red meat-consumption), may shed further light on the pathogenesis of B 
group CRCs. In addition, screening patients for single nucleotide polymorphisms 
known to modify IBD risk may shed light on the cursory resemblance between type B 
CRCs and IBD observed here, particularly regarding the host’s susceptibility to 
infection and the ability to control inflammation and oxidative stress. Any significant 
associations could have clinical utility for identifying individuals with an increased risk 
of developing type B CRC. 
Conclusion 
Here, direct evidence of altered CRC pathogenesis associated with increased bacterial 
colonisation by high levels of Fusobacterium and by E. faecalis in our group B cohort is 
provided. The relative importance of infection in B group CRCs is also supported by 
pathway analysis in the Jorissen cohort where an elevated host-response to infection, 
which is accompanied by an increased inflammatory response, is predicted at the 
pathway level. Further, although not exclusively linked to E. faecalis, this bacterium 
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may contribute to oxidative stress in these samples by production of superoxide. This is 
supported by the lack of evidence for overexpression of oxidant generating host 
enzymes in B group CRCs.  
Given the positive association between colonisation with Fusobacterium and several 
other bacteria that was identified in this study and elsewhere, we hypothesize that 
colonisation by Fusobacterium (particularly at high levels) could facilitate colonisation 
with secondary (potentially oncogenic) pathogens in the colon; moreover, a pro-
oxidative environment–which is likely found in group B CRCs–could increase the 
pathogenic potential of Fusobacterium, as indicated by previous reports. 
We propose that a subtype of CRC (which generally corresponds to the de Sousa 
CCS2/3 subtypes) is associated with a relative increase in colonisation by E. faecalis, 
high-level Fusobacterium (and likely other bacteria not examined here), inflammation, 
CpG island methylation and microsatellite instability, as well as an increased response 
to oxidative DNA and protein damage. This subtype is further characterised by a 
significant upregulation of COX-2, which suggests that aspirin in combination with 
selective antibiotics might be particularly useful in preventing and treating these cancers. 
This is the first study to link colonisation by specific bacteria to a transcriptomic 
subtype of colorectal cancer. The enrichment with both E. faecalis and Fusobacterium, 
together with the relative increase in inflammatory pathways in this subtype, suggests 
that polymicrobial colonisation of the colonic epithelium and/or tumour may be an 
important aspect of colonic tumourigenesis that warrants further investigation. Our 
findings underscore the value of quantifying suspected oncogenic bacteria alongside 
transcriptomic data in elucidating molecular origins and optimal therapeutic strategies 
by colorectal cancer subtype.  
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Chapter 8: Gene expression analyses reveals E. faecalis- and 
Fusobacterium-associated genomic alterations in colorectal 
cancer  
Abstract 
In addition to characterising the genomic subtypes of CRC, and investigating the 
relevant patterns of bacterial colonisation, described in Chapter 7, we were interested in 
identifying transcriptomic and pathway-level changes that were specific to CRCs 
colonised by each of the bacteria studied here. 
Whole-genome differential gene expression analysis was therefore performed for 
nineteen pairs of tumour and adjacent normal colorectal cancer (CRC) samples and 
bacteria-associated gene expression profiles were investigated for Fusobacterium, 
Enterococcus faecalis, Enterotoxigenic Bacteroides fragilis, Enteropathogenic 
Escherichia coli, ClB+ E. coli and afaC+ E. coli.  
A relatively large subset of genes was differentially expressed in E. faecalis-infected 
CRCs (489 at an FDR ≤ 0.05); included in this subset were various small leucine-rich 
proteoglycans (SLRPs), CXCL10, and BMI1. 
Meanwhile comparison between samples with high-level Fusobacterium infection 
compared to low-level or no colonisation by Fusobacterium revealed differential 
expression of the regenerating islet-derived-family genes REG1A, REG3A and REG1P 
(FDRs ≤ 0.05)–these were the only genes differentially expressed in association with 
high-level colonisation by Fusobacterium. 
Pathway analysis of genes differentially expressed in association with E. faecalis 
colonisation uncovered pathways related to immune function (in particular antigen 
presentation and microbial pattern recognition), inflammation and CRC progression, 
which may indicate an important role in the pathogenesis of a subset of CRCs. 
Introduction 
Previous studies have successfully demonstrated pathogen-induced alterations of the 
host transcriptome in vitro438 and in vivo439, using microarray-based gene expression 
analysis. Upon infection of the host, one might expect a) a virulence factor-specific 
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response in a particular host signaling pathway (e.g. as a result of injected bacterial 
effectors) or b) a more general immune/inflammatory response in the host that is not 
necessarily limited to the presence of a single pathogen, and may be linked to dysbiosis.  
In in vitro models of infection438, or in mono-associated mouse models440, differential 
expression analysis together with pathway analysis can be used to identify any 
genes/pathways that are specifically altered in response to the bacterium. Potentially 
confounding factors in clinical CRC samples include the plethora of interspecies 
interactions in the gut microbiome, cancer-specific gene expression changes (that may 
overlap with bacterially-induced immune-related response), inter-individual variation, 
site-specific variation, as well as sampling and technical variation. Therefore, although 
one may not be able to determine bacterially-induced alterations in clinical CRC 
samples, any bacterially-associated signatures obtained provide a true reflection of the 
system in question that cannot be readily mimicked in vitro or in mouse models. These 
bacterially associated signatures will hopefully provide novel insights and drive 
hypotheses regarding the poorly understood role of CRC-associated bacteria in the 
pathogenesis of the disease. 
In this study, building a profile of CRC-associated bacteria across a single CRC cohort 
comes at the cost of variable statistical power to detect species-specific gene expression 
signatures. In a small cohort such as ours (N=19), one would expect to miss smaller fold 
change effects, especially for species that are underrepresented in our cohort. 
The putative oncogenic mechanisms of CRC-associated pathogens were discussed in 
Chapter 4. Here, host gene expression changes previously reported for E. faecalis and 
Fusobacterium will be briefly discussed. 
Enterococcus faecalis: an overview 
Enterococci are normal human commensals that inhabit the gastrointestinal tract, the 
oral cavity and the vagina441, yet are ranked among the top three nosocomial (hospital-
acquired) bacterial pathogens. Up to 90% of Enterococci infections are caused by E. 
faecalis and antibiotic resistance poses a major problem in the treatment of these 
infections442. Moreover, E. faecalis is known for its capacity to transfer antibiotic 
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resistance to other pathogens442. Enterococci are incredibly resilient pathogens that can 
withstand and adapt to a variety of harsh environmental conditions that may provide 
them with a competitive advantage441. 
Several virulence factors are more frequently detected in patients with pathogenic E. 
faecalis infection compared to faecal isolates from healthy controls; these include 
aggregation substance (AS), surface adhesins, sex pheromones, lipoteichoic acid, 
extracellular superoxide, gelatinase, hyaluronidase, and cytolysin441. AS facilitates 
adhesion and phagocytosis by macrophages and neutrophils, allowing intracellular 
survival of E. faecalis.  
As discussed in Chapter 7, E. faecalis produces DNA-damaging superoxide, the level of 
which is strain-specific441. Additionally, E. faecalis infection of neutrophils or 
macrophages results in an increase or decrease in host-derived superoxide production, 
respectively441. 
Cell extracts of AS- and bacteriocin-positive E. faecalis induce T-cell proliferation, with 
subsequent release of TNF-β and IFN-γ; these cell extracts also activate macrophages to 
release tumor necrosis factor alpha TNF-α. Similarly, lipoteichoic acid, a structural cell-
wall component present in many gram-positive bacteria including E. faecalis, stimulates 
leukocytes to release inflammatory TNF-α, IL-1β, IL-6 and IL-8441.  
In IL-10-/- mice, Enterococcus spp. (E. faecalis and E. faecium) induce an inflammatory 
response similar to that seen in IBD440. Compared to control mice, genes differentially 
expressed in response to Enterococcus spp. infection were associated with pathways 
related to inflammatory disease, immune response, antigen presentation (particularly 
major histocompatability complex Class II), fatty acid metabolism and detoxification440. 
E. faecalis is found at significantly higher levels in stool samples from CRC patients 
compared to healthy controls198 and oncogenic potential has been suggested based on its 
production of extracellular superoxide which leads to inflammation, DNA damage and 
CRC in IL-10 knockout mice199,202,223. E. faecalis also induces aneuploidy and 
tetraploidy in vitro223. 
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Fusobacterium: an overview 
Fusobacteria are well known for their role in periodontal disease. More recently, 
Fusobacterium spp., and in particular F. nucleatum, has been identified as a common 
bacterium in CRC patients, with a marked increase in the colonisation of tumour 
compared to adjacent normal mucosal tissue 16,194,219. This relationship was confirmed 
in our cohort, where Fusobacterium occurred at significantly higher levels in tumour 
samples (p=0.0003). In Chapter 7, the ability of F. nucleatum to provide a scaffold for 
secondary bacterial colonisers429–431, including E. faecalis433 was discussed. Moreover, 
co-aggregation structures may be relevant in the pathogenesis of CRC, since a subset of 
microbes are significantly associated with F. nucleatum in CRC biopsies428,429. In 
addition to providing a structural scaffold for secondary colonisers, F. nucleatum is also 
able to invade and replicate in epithelial cells443.  
Regarding its oncogenic potential, APCMin/+ mice infected with F. nucleatum show 
accelerated tumourigenesis, characterised by infiltration of specific myeloid cell subsets 
into tumours and an NF-kB pro-inflammatory signature (including COX-2, TNF-α and 
IL-8); these findings were confirmed by Kostic et al. in human Fusobacterium-infected 
CRCs218. They utilized a deep transcriptome sequencing data set (i.e., RNA-seq) 
including 133 colon tumors, generated by The Cancer Genome Atlas, to profile both 
Fusobacterium spp. colonisation and host gene expression profiles. They identified 
Fusobacterium-associated genes by calculating the Spearman’s rank correlation 
coefficient of the relative abundance of Fusobacterium transcripts with host gene 
expression; these included COX-2, IL-1β, IL-6, IL-8, TNF-α, and MMP3218.  
Methods 
Sample preparation and microarray-based gene expression analysis 
Nineteen paired tumour and normal samples were selected for gene expression analysis, 
based on (i) the availability of tumour, normal and blood samples, as well as complete 
consent forms for each patient and on (ii) site of disease, radiotherapy-status, ethnicity, 
tumour stage and recurrence. Patients who had preoperative radiotherapy were excluded 
in order to avoid any additional confounding factors.  
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RNA preparation and gene expression analysis on Affymetrix Human Gene 1.0 ST 
arrays, as well as data preprocessing and quality control, are described in Chapter 5. 
Differential gene expression analysis 
ComBat-based batch and quality correction (described in detail in Chapter 5) was 
performed for each bacterial comparison individually, by specifying the comparison of 
interest in the model. Differential expression analysis was then performed on the subset 
of transcriptclusters that mapped to Entrez Gene Symbols, using the R package 
limma229. This left 21934 of the original 33297 transcriptclusters for analysis, which 
excluded control probes and transcripts with poor annotation. Differential analyses in 
tumour and normal samples were conducted separately and we compared a) samples 
with vs. without colonisation by a particular bacterium and b) samples with high vs. 
low/no-colonisation by a particular bacterium. Comparisons were only made where at 
least three samples per group were available, as summarized in Tables 1a and 1b.  
Pathway analysis 
Ingenuity Pathway Analysis (IPA) was applied to the subset of genes significantly 
altered between groups of interest (FDR ≤ 0.05; |FC| ≥ 1.25). The IPA categories: 
canonical pathways, upstream regulators and diseases and functions are included here.  
PARADIGM analysis was conducted on tumour samples using whole-genome gene 
expression and methylation data as input, as described in Chapter 7. To assess the 
difference between groups of interest using PARADIGM pathway analysis results, the 
R package limma229 was used to identify IPLs that showed differential activity between 
groups of interest; IPLs with an FDR ≤ 0.05 and an absolute difference in median 
activity score between groups of at least 0.25 were deemed significant. 
Results 
Bacteria-associated gene expression analysis 
To investigate the putative effect of CRC-associated bacteria on host gene expression, 
differential analyses were conducted separately in tumour and normal samples to 
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compare, for each bacterium a) samples with vs. without colonisation and b) samples 
with high vs. low/no-infection. The comparisons made, and the number of transcript 
clusters differentially expressed for each comparison, are listed in Table 1a (tumour 
samples) and Table 1b (normal samples). 
After correcting for multiple testing, only the analysis by E. faecalis infection-status in 
tumour samples produced significant results where 509 transcript clusters corresponding 
to 489 unique genes, were differentially expressed at an FDR ≤ 0.05. At a more relaxed 
FDR cutoff of 0.25, the afaC+ vs. afaC– comparison in normal samples produced 3811 
transcript clusters, and Fusbacterium-high vs. Fusobacterium-low/neg in normal 
samples produced 210 transcript clusters; in tumour samples Fusbacterium-high vs. 
Fusobacterium-low/neg and EPEC+ vs. EPEC– both produced 13 transcript clusters. 
However, downstream analyses and interpretations were only conducted on results with 
an FDR ≤ 0.05, and an absolute fold-change of at least 1.25. 
Table 1a: Summary of differential gene expression analyses conducted for tumour samples showing the 
number of transcript clusters differentially expressed for each comparison made.  
Model specified Number of 
samples/category 
p ≤ 0.05 FDR ≤ 0.25 FDR ≤ 0.05 
EF+ vs. EF– 7 vs. 10 6032 4216 509 
FB-H vs. FB-L/N 7 vs. 12 2184 13 3 
afaC-H vs. afaC-L/N 5 vs. 14  860 7 0 
afaC+ vs. afaC– 13 vs. 8 1596 0 0 
ClB+ vs. ClB– 6 vs.13 1719 0 0 
ETBF-H vs. ETBF L/N 3 vs. 16 1000 1 0 
ETBF+ vs. ETBF– 10 vs. 9 1584 1 0 
EPEC+ vs. EPEC– 3 vs. 16 1720 13 0 
H: high-level infection; L: low-level infection; N: no infection; FB: Fusobacterium; EF: E. faecalis 
Table 1b: Summary of differential gene expression analyses conducted for normal samples showing the 
number of transcript clusters differentially expressed for each comparison made. 
Model specified Number of 
samples/category 
p ≤ 0.05 FDR ≤ 
0.25 
FDR ≤ 0.05 
ETBF+ vs. ETBF- 10 vs. 9 611 0 0 
ETBF-H vs. ETBF-L/N 4 vs. 20 400 0 0 
ClB+ vs. ClB- 6 vs. 13 1140 0 0 
afaC+ vs. afaC- 10 vs. 9 4185 3811 1 
afaC-H vs. afaC-L/N 3 vs. 16 718 0 0 
EF+ vs. EF- 4 vs. 10 1503 0 0 
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FB-H vs. FB-L/N 3 vs. 16 2461 210 0 
FB+ vs. FB- 16 vs. 3 797 0 0 
H: high-level infection; L: low-level infection; N: no infection; FB: Fusobacterium; EF: E. faecalis 
Enterococcus faecalis-associated genomic alterations in CRCs 
Genes differentially expressed in association with E. faecalis colonisation 
The top 50 most significantly differentially expressed genes by E. faecalis colonisation 
status are presented in Table 2; given the overrepresentation of E. faecalis in group B 
CRCs (Chapter 7), genes that were also significant in the comparison between group A 
vs. group B CRCs are highlighted in boldface for clarity. 
Table 2: The top 50 most significantly differentially expressed genes by E. faecalis colonisation status. 
Boldface entries were also significant in the comparison between group A vs. group B CRCs in Chapter 7. 
Gene ID Gene 
symbol 
GeneName P value FDR FC (EF+ 
vs. EF–) 
8166906 GPR34 G protein-coupled receptor 34 2.6E-07 3.9E-03 2.4 
8126784 PLA2G7 phospholipase A2, group VII 
(platelet-activating factor 
acetylhydrolase, plasma) 
4.3E-07 3.9E-03 2.7 
8138289 ETV1 ets variant 1 5.3E-07 3.9E-03 2.3 
7965410 DCN decorin 2.5E-06 8.6E-03 3.9 
8100541 IGFBP7 insulin-like growth factor 
binding protein 7 
2.6E-06 8.6E-03 2.9 
8101126 CXCL10 chemokine (C-X-C motif) 
ligand 10 
2.6E-06 8.6E-03 5.8 
8102792 PCDH18 protocadherin 18 3.1E-06 8.6E-03 3.7 
7957737 TMPO thymopoietin 3.1E-06 8.6E-03 2.1 
7965403 LUM lumican 4.1E-06 9.4E-03 6.1 
8076292 DNAJB7 DnaJ (Hsp40) homolog, 
subfamily B, member 7 




complex, class II, DP alpha 1 
5.0E-06 9.4E-03 3.6 
8017210 AP1S2 adaptor-related protein complex 
1, sigma 2 subunit 
5.2E-06 9.4E-03 2.2 
7898988 CLIC4 chloride intracellular channel 4 6.3E-06 1.0E-02 2.1 
7919815 CTSK cathepsin K 6.7E-06 1.0E-02 3.5 




complex, class II, DP alpha 1 
7.4E-06 1.1E-02 3.5 
8001800 CDH11 cadherin 11, type 2, OB-
cadherin (osteoblast) 
7.9E-06 1.1E-02 3.1 
8094625 KLHL5 kelch-like family member 5 9.3E-06 1.1E-02 2.6 
8160238 PSIP1 PC4 and SFRS1 interacting 
protein 1 
9.4E-06 1.1E-02 1.7 
8157890 PBX3 pre-B-cell leukemia homeobox 
3 
1.0E-05 1.2E-02 1.9 
7926609 BMI1 BMI1 polycomb ring finger 
oncogene 
1.1E-05 1.2E-02 2.0 
8145470 DPYSL2 dihydropyrimidinase-like 2 1.2E-05 1.2E-02 2.1 




complex, class II, DP alpha 1 
1.5E-05 1.4E-02 2.8 
8140840 STEAP4 STEAP family member 4 1.6E-05 1.4E-02 2.4 
8127563 COL12A1 collagen, type XII, alpha 1 1.9E-05 1.6E-02 4.1 
8128007 GJB7 gap junction protein, beta 7, 
25kDa 
2.0E-05 1.7E-02 -1.6 
8091032 FOXL2 forkhead box L2 2.3E-05 1.8E-02 -1.7 
8046895 FAM171B family with sequence similarity 
171, member B 
2.5E-05 1.9E-02 2.9 
8174322 MORC4 MORC family CW-type zinc 
finger 4 
2.7E-05 2.0E-02 2.3 
7981377 ANKRD9 ankyrin repeat domain 9 2.8E-05 2.0E-02 -1.5 
7957260 GLIPR1 GLI pathogenesis-related 1 2.8E-05 2.0E-02 2.8 
8036324 ZNF260 zinc finger protein 260 3.1E-05 2.0E-02 2.3 
8053882 DUSP2 dual specificity phosphatase 2 3.1E-05 2.0E-02 -1.6 
8121319 SOBP sine oculis binding protein 
homolog (Drosophila) 
3.1E-05 2.0E-02 2.1 
8173732 TAF9B TAF9B RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 31kDa 
3.2E-05 2.0E-02 2.1 
8176263 TAF9B TAF9B RNA polymerase II, 
TATA box binding protein 
3.2E-05 2.0E-02 2.1 
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(TBP)-associated factor, 31kDa 
8143040 SLC35B4 solute carrier family 35, 
member B4 
3.8E-05 2.1E-02 1.7 
8143054 AKR1B1 aldo-keto reductase family 1, 
member B1 (aldose reductase) 
3.9E-05 2.1E-02 2.1 
8157605 STOM stomatin 3.9E-05 2.1E-02 1.5 
7936322 GPAM glycerol-3-phosphate 
acyltransferase, mitochondrial 
3.9E-05 2.1E-02 1.6 
7959761 FAM101A family with sequence similarity 
101, member A 
4.0E-05 2.2E-02 -1.6 
8042439 ANTXR1 anthrax toxin receptor 1 4.4E-05 2.3E-02 3.3 
7930833 KCNK18 potassium channel, subfamily 
K, member 18 
4.6E-05 2.3E-02 -1.6 
8089714 LSAMP limbic system-associated 
membrane protein 
4.7E-05 2.3E-02 2.1 
7958913 OAS2 2'-5'-oligoadenylate synthetase 
2, 69/71kDa 
5.0E-05 2.3E-02 2.3 
7912852 EIF1AX eukaryotic translation 
initiation factor 1A, X-linked 
5.0E-05 2.3E-02 1.7 
8115234 ANXA6 annexin A6 5.1E-05 2.3E-02 1.7 
8169473 PLS3 plastin 3 5.1E-05 2.3E-02 3.1 
8138805 CPVL carboxypeptidase, vitellogenic-
like 
5.6E-05 2.4E-02 2.0 
8135734 CPED1 cadherin-like and PC-esterase 
domain containing 1 
5.6E-05 2.4E-02 2.4 
EF: E. faecalis 
The chemokine CXCL10 was upregulated 5.8-fold (FDR=0.009) in E. faecalis+ CRCs. 
Importantly, Enterococcus spp. have been shown to upregulate CXCL10 in IL-10-/- 
mice440,444, which may imply E. faecalis-induced transcription of CXCL10 in our cohort. 
CXCL10 is secreted by cells stimulated with type I and II interferons or 
lipopolysaccharide (LPS) and plays an important role in the recruitment of T cells to 
sites of inflammation445. 
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In CRC, CXCL10 exerts antiangiogenic and antiproliferative effects397, yet is also 
associated with advanced cancer397 and may promote invasion through the induction of 
cell migration398. 
Another interesting observation is the upregulation of various SLRPs–a family of 
secreted proteoglycans that are involved in regulating matrix assembly and cellular 
growth446. Co-regulation for 12 of the 13 known SLRPs have been predicted on the 
basis of a common HOX-Runx module in these genes446, which might explain the 
significant and concurrent upregulation of lumican, decorin, biglycan (FDR=0.06), and 
asporin in E. faecalis+ CRCs. Of these SLRPs, only lumican was also significantly 
differentially expressed in group B cancers, at a slightly lower p-value (p=0.003), but 
with a lower fold change of 4, compared to the fold change of 6.1 in E. faecalis + CRCs. 
Both decorin and biglycan act as endogenous ligands of TLR4 and TLR2 following 
tissue damage and their release from the extracellular matrix391. TLR4/2 activation 
stimulates an inflammatory response through NF-κB, with downstream induction of IL-
1B and IL-10. Lumican, on the other hand, is not an endogenous TLR4/2 ligand, but 
presents LPS to the TLR4/2-adaptor molecule CD14, whereby it induces an immune 
response to LPS and increased bacterial phagocytosis391. 
Certain pathogens express adhesins that bind to glycosaminoglycans which are linked to 
proteoglycans––this interaction can a) facilitate cell invasion, and/or b) enhance 
virulence via shedding of proteoglycans that lead to the release of effectors that weaken 
host defenses447. Notably, E. faecalis utilizes both these mechanisms, a) to gain entry 
into macrophages448 and b) to weaken host defense through the degradation of the 
proteoglycan decorin, which leads to the inactivation of α-defensins449. 
Lastly, it is interesting to note that BMI1 polycomb ring finger oncogene was 
upregulated 2-fold in E. faecalis-infected CRCs. BMI1 is an intestinal stem cell 
marker450 that is overexpressed in various cancers451. The oncogenic potential of BMI1 
has been attributed to its potent negative regulation of the tumour suppressor p16INK4, 
which suppresses senescence in primary cells451. High expression of BMI1 is 
significantly associated with metastasis452,453 and poor survival454 in CRC patients. 
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Importantly, aberrant BMI1 expression has been found in premalignant gastrointestinal 
lesions451, which points to its possible role in cancer initiation. 
Pathway-level alterations associated with E. faecalis infection 
Pathway analyses were conducted using IPA and PARADIGM. These methods are 
discussed in broader detail in Chapter 7. IPA takes a list of differentially expressed 
genes (together with their FDRs and FCs) as input, whereas PARADIGM uses the 
actual gene expression and methylation data as input and therefore infers activity on a 
per-patient basis. Both methods are very useful in facilitating biological interpretation 
of large-scale omics data. Regarding the output, IPA produces statistical measures of 
confidence in the differential overrepresentation (represented as a p-value) and/or 
change in activity (represented by a z-score) of canonical pathways, upstream regulators 
and diseases and functions. Meanwhile, PARADIGM provides an activity score for 
each integrated pathway level (IPL), which consists of genes, complexes and abstract 
processes, on a per-patient basis. 
The IPA results that were significantly altered in E. faecalis+ CRCs (p ≤ 0.05, |z-score| 
≥ 2) are presented in Tables 3a–3c for canonical pathways, upstream regulators, and 
diseases and functions, respectively. Meanwhile, differential analysis of PARADIGM 
IPLs by E. faecalis colonisation status did not provide any significantly altered genes, 
complexes or abstract processes. 
 
In order to identify pathways that are specifically altered in E. faecalis+ CRCs as 
opposed to group B cancers as a whole (described in Chapter 7), the overlap between 
pathway analyses for these two sets of results was established––overlapping entries are 
italicized in Tables 3a–3c. Although E. faecalis may significantly contribute to these 
overlapping pathways, the focus in this chapter is on the subset of pathways for which 
alteration was more evident in E. faecalis+ CRCs, as opposed to group B CRCs in 
general. 
IPA results revealed an increase in immune-related canonical pathways in E. faecalis+ 
CRCs (Table 3a).  
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Table 3a: Ingenuity Canonical Pathways significantly associated with E. faecalis colonisation in CRCs 
(p≤0.05). Boldface entries were also significant in the comparison between group A vs. group B CRCs in 
Chapter 7. 






Antigen Presentation Pathway 2.88 0/33 (0%) 15/33 
(45%) 








Leukocyte Extravasation Signaling 2.06 15/190 (8%) 48/190 
(25%) 




Allograft Rejection Signaling 1.91 0/36 (0%) 11/36 
(31%) 
T Helper Cell Differentiation 1.71 4/62 (6%) 13/62 
(21%) 
Aryl Hydrocarbon Receptor Signaling 1.68 7/135 (5%) 41/135 
(30%) 
Chondroitin Sulfate Biosynthesis (Late Stages) 1.65 6/43 (14%) 5/43 (12%) 
L-dopachrome Biosynthesis 1.60 1/1 (100%) 0/1 (0%) 
Glucocorticoid Receptor Signaling 1.58 18/252 (7%) 67/252 
(27%) 
Antiproliferative Role of TOB in T Cell Signaling 1.57 0/26 (0%) 14/26 
(54%) 
Role of Pattern Recognition Receptors in Recognition of 
Bacteria and Viruses 
1.56 11/116 (9%) 28/116 
(24%) 
OX40 Signaling Pathway 1.55 0/46 (0%) 17/46 
(37%) 
Growth Hormone Signaling 1.53 6/69 (9%) 15/69 
(22%) 




Cdc42 Signaling 1.48 11/121 (9%) 32/121 
(26%) 
Chondroitin Sulfate Biosynthesis 1.41 8/51 (16%) 6/51 (12%) 




Calcium-induced T Lymphocyte Apoptosis 1.36 3/53 (6%) 18/53 
(34%) 
Dermatan Sulfate Biosynthesis 1.36 8/53 (15%) 7/53 (13%) 
Role of JAK2 in Hormone-like Cytokine Signaling 1.34 2/32 (6%) 5/32 (16%) 
Granulocyte Adhesion and Diapedesis 1.32 12/159 (8%) 35/159 
(22%) 
Hypusine Biosynthesis 1.30 1/2 (50%) 0/2 (0%) 
Cardiolipin Biosynthesis II 1.30 1/2 (50%) 0/2 (0%) 
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The most significant finding was the activation of the Antigen Presentation Pathway, 
which was largely based on the increased expression of several HLA type II genes––this 
is in agreement with the findings by Barnett et al. regarding E. faecalis and E. faecium 
infection of IL10-/- mice440. Together with the overrepresentation of genes related to the 
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses pathway, 
these data provide evidence for an elevated host immune response to foreign antigens in 
these tumours that could be due to microbial- or cancer-specific antigens. This is 
supported by the fact that LPS is predicted to be an active upstream regulator in E. 
faecalis-infected CRCs, based on the differential expression of CXCL10, proteoglycans 
and various other genes (Table 3b). 
In accordance with the predicted active role of LPS, SOCS1 (a negative regulator of 
host response to LPS), is predicted to be deactivated in E. faecalis+ CRCs (Table 3b). 
SOCS-1 plays a crucial role in dampening host response to LPS to avoid excessive 
tissue damage. Furthermore, SOCS-1 deficient mice are highly sensitive to LPS-
induced shock and produce increased levels of inflammatory cytokines455.  
LPS is found in the outer membrane of gram-negative bacteria, whereas E. faecalis is 
gram-positive. Plausible scenarios that could explain the LPS-like response seen here 
include the presence of lipoteichoic acid (an immunogenic cell wall component of 
gram-positive bacteria456) activation of TLR2/4 by endogenous ligands, such as decorin 
and biglycan391 or the presence of increased levels of mucosally associated gram-
negative bacteria. 
In accordance with an increased immune response to foreign antigens, an inflammatory 
response is implied by the predicted increase in Leukocyte Extravasation Signaling–the 
process responsible for transporting leukocytes from the blood to tissue at sites of 
inflammation. Moreover, various cytokines were predicted to be activated in association 




Back to table of contents 196 
Table 3b: Upstream regulators predicted to be altered in EF CRCs (p≤0.05, |z-score| ≥2), sorted by 
molecule type. Italicised entries were also significant in the comparison between group A vs. group B 
CRCs in Chapter 7. 
 






tretinoin chemical - 
endogenous 
mammalian 
Activated 3.2 7.4E-05 
hyaluronic acid chemical - 
endogenous 
mammalian 
Activated 2.3 4.9E-03 
D-glucose chemical - 
endogenous 
mammalian 
Activated 2.5 3.1E-02 
SB203580 chemical - kinase 
inhibitor 
Inhibited -3.2 8.8E-03 
PD98059 chemical - kinase 
inhibitor 
Inhibited -2.4 3.7E-02 
lipopolysaccharide chemical drug Activated 4.4 1.3E-03 
decitabine chemical drug Activated 3.9 4.9E-03 
bleomycin chemical drug Activated 2.1 6.3E-03 
phorbol myristate 
acetate 
chemical drug Activated 3.3 7.3E-03 
epigallocatechin-
gallate 
chemical drug Inhibited -3.1 8.1E-03 
mifepristone chemical drug Inhibited -2.5 4.4E-02 
N-acetyl-L-cysteine chemical drug Inhibited -2.2 4.5E-02 
trichostatin A chemical drug Activated 2.2 4.7E-02 
SB-431542 chemical reagent Inhibited -2.6 8.5E-04 
metribolone chemical reagent Activated 2.9 1.9E-03 
hexachlorobenzene chemical toxicant Activated 2.0 3.8E-02 
TNF cytokine Activated 3.7 6.1E-03 
CD40LG cytokine Activated 2.9 7.6E-03 
CSF2 cytokine Activated 2.9 1.0E-02 
IFNG cytokine Activated 2.9 1.2E-02 
IL1B cytokine Activated 3.1 2.6E-02 
IFNA2 cytokine Activated 2.6 3.1E-02 
IL6 cytokine Activated 2.0 3.6E-02 
IL5 cytokine Activated 2.7 3.9E-02 
TGM2 enzyme Activated 2.4 8.3E-03 
PTGER2 G-protein coupled 
receptor 
Activated 2.6 1.1E-02 
Alpha catenin group Inhibited -3.8 1.7E-07 
Back to table of contents 197 
Ifnar group Activated 2.6 1.9E-03 
estrogen receptor group Inhibited -2.7 9.5E-03 
IFN Beta group Activated 2.2 2.8E-02 
TGFB1 growth factor Activated 3.4 1.4E-05 
FGF2 growth factor Activated 2.4 3.7E-03 
WISP2 growth factor Inhibited -2.0 1.1E-02 
AGT growth factor Activated 2.8 2.7E-02 
miR-124-3p (and other 
miRNAs w/seed 
AAGGCAC) 
mature microRNA Inhibited -3.6 3.7E-03 
miR-16-5p (and other 
miRNAs w/seed 
AGCAGCA) 
mature microRNA Inhibited -2.6 1.9E-02 
let-7 microRNA Inhibited -2.6 3.7E-02 
SOCS1 other Inhibited -2.6 9.0E-03 
Irgm1 other Inhibited -2.0 1.3E-02 
INSIG1 other Inhibited -2.4 3.3E-02 
MYD88 other Activated 2.4 3.6E-02 
CD24 other Activated 2.0 4.4E-02 
NUPR1 transcription 
regulator 
Inhibited -5.0 1.9E-05 
TWIST1 transcription 
regulator 
Activated 2.5 4.1E-05 
SMAD7 transcription 
regulator 
Inhibited -2.2 9.2E-05 
MYC transcription 
regulator 
Activated 2.1 1.4E-04 
SOX11 transcription 
regulator 
Inhibited -2.1 2.7E-04 
FOXM1 transcription 
regulator 
Activated 2.6 9.0E-04 
TBX2 transcription 
regulator 
Activated 2.4 2.6E-03 
CCND1 transcription 
regulator 
Activated 2.0 4.2E-03 
TRIM24 transcription 
regulator 
Inhibited -2.6 4.6E-03 
SPDEF transcription 
regulator 
Inhibited -2.4 5.1E-03 
IRF3 transcription 
regulator 
Activated 2.0 5.5E-03 
SOX1 transcription 
regulator 
Inhibited -2.4 6.3E-03 
XBP1 transcription 
regulator 
Activated 3.0 6.4E-03 
GMNN transcription 
regulator 
Inhibited -2.4 8.9E-03 
SOX3 transcription 
regulator 
Inhibited -2.4 8.9E-03 
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IRF5 transcription 
regulator 
Activated 2.2 1.2E-02 
JUN transcription 
regulator 
Activated 2.6 1.7E-02 
CEBPB transcription 
regulator 
Activated 2.2 2.0E-02 
POU5F1 transcription 
regulator 
Activated 2.5 2.5E-02 
SOX2 transcription 
regulator 
Inhibited -2.2 2.9E-02 
CDKN2A transcription 
regulator 
Inhibited -2.8 3.1E-02 
ISL1 transcription 
regulator 
Activated 2.2 3.5E-02 
MTPN transcription 
regulator 
Activated 2.2 3.5E-02 
BTNL2 transmembrane 
receptor 
Activated 2.4 6.8E-03 
 
The pathways and genes significantly associated E. faecalis+ CRCs are strikingly 
similar to those seen following infection of IL10-/- mice with Enterococcus spp. (E. 
faecalis and E. faecium), including a significant increase in IL-6, TNF and IFN-γ, the 
Antigen Presentation Pathway and pathways related to inflammatory disease and 
immune response440. Given the role of the E. faecalis virulence factors including 
lipoteichoic acid, AS and bacteriocin in stimulating production of TNF-β, IFN-γ and 
TNF-α441, strains that possess these virulence factors may be particularly relevant in the 
pathogenesis of E. faecalis+ CRCs.  
In Chapter 7 several DNA and protein damage response-related processes were shown 
to be significantly increased in B group B CRCs. Since E. faecalis is known to induce 
DNA damage through the production of ROS, it is tempting to speculate that E. faecalis 
causes these responses in E. faecalis+ CRCs. However, these pathways were not 
exclusively altered in E. faecalis+ CRCs. Nevertheless, given that group B CRCs are 
significantly enriched with E. faecalis, and that Barnett et al. reported Enterococcus-
specific alterations in the Cell Cycle: G2/M DNA Damage Checkpoint Regulation 
pathway in IL10-/- mice440, it seems plausible that E. faecalis contributes to a ROS-
induced DNA damage response in E. faecalis+ group B cancers. 
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An increase in the canonical pathway CRC Metastasis Signaling (Table 3a) and in the 
diseases and functions categories: metastasis, cell movement of colon cancer cell lines 
and migration of colon cancer cell lines (Table 3c) were found in E. faecalis+ CRCs. 
These results may suggest a more aggressive phenotype for E. faecalis-infected CRCs, 
irrespective of the involvement of E. faecalis therein (Table 3c).  
Table 3c. Diseases and functions associated with E. faecalis colonisation (p≤0.05, |z-score| ≥ 2). Italicised 
entries were also significant in the comparison between group A vs. group B CRCs in Chapter 7. 




Connective Tissue Disorders, 
Developmental Disorder, Skeletal and 
Muscular Disorders 
craniofacial abnormality 2.8E-03 -2.4 
Inflammatory Disease, Respiratory Disease pulmonary emphysema 1.5E-02 -2.2 
Developmental Disorder, Immunological 
Disease 
hypoplasia of thymus 
gland 
1.8E-02 -2.6 
Cellular Growth and Proliferation proliferation of cells 1.7E-04 3.9 
Cellular Development, Skeletal and 
Muscular System Development and 
Function, Tissue Development 
differentiation of smooth 
muscle cells 
3.9E-04 2.2 
Cancer metastasis 9.5E-04 3.1 
Cellular Movement invasion of tumor cell lines 9.7E-04 2.9 
Cellular Movement invasion of cells 6.9E-03 2.8 
Cellular Development epithelial-mesenchymal 
transition 
7.0E-03 2.6 
Cellular Movement invasion of breast cancer 
cell lines 
7.4E-03 2.1 
Cardiovascular System Development and 
Function 
neovascularization 8.6E-03 2.0 
Cancer neoplasia of cells 1.1E-02 2.2 
Organismal Development size of body 1.3E-02 3.9 
Cellular Development epithelial-mesenchymal 
transition of tumor cell 
lines 
1.5E-02 2.3 
Cellular Movement cell movement of colon 
cancer cell lines 
1.8E-02 2.6 
Cellular Movement migration of colon cancer 
cell lines 
1.9E-02 2.4 
Cellular Development, Skeletal and 
Muscular System Development and 
Function, Tissue Development 
differentiation of muscle 
cells 
2.1E-02 2.2 
Cell-To-Cell Signaling and Interaction, 
Tissue Development 
adhesion of epithelial cells 2.3E-02 2.0 
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Genomic alterations associated with high-level colonisation by Fusobacterium in CRCs 
In the comparison between CRCs colonized by high levels of Fusobacterium (FB-H) vs. 
those with low/no colonisation by Fusobacterium (as defined in Chapter 4), only three 
genes were significantly differentially expressed. Interestingly all three belonged to the 
regenerating islet-derived (REG) family of genes. These were REG1A, REG3A and 
REG1P––all were highly and significantly overexpressed 23-, 15-fold, and 7-fold, 
respectively in CRCs with high-level colonisation by Fusobacterium, while REG1B 
showed a 12-fold increase, but was not significant after multiple testing correction 
(Table 4).  
Table 4: Genes differentially expressed at an FDR ≤ 0.25 in Fusobacterium-high vs. Fusobacterium-
low/negative tumours. 
Gene ID Gene 
symbol 
Gene name P value FDR FC (FB-H 
vs. FB-L/N) 
8053341 REG3A regenerating islet-derived 3 alpha 1.1E-07 2.3E-03 15.4 
8042986 REG1A regenerating islet-derived 1 alpha 6.5E-07 7.2E-03 22.8 
8053337 REG1P regenerating islet-derived 1 
pseudogene 
1.6E-06 1.2E-02 6.7 
8097335 HSPA4L heat shock 70kDa protein 4-like 1.4E-05 7.6E-02 4.1 
7957338 SYT1 synaptotagmin I 2.3E-05 1.0E-01 -1.7 
7985213 CHRNA
5 
cholinergic receptor, nicotinic, 
alpha 5 (neuronal) 
3.6E-05 1.3E-01 3.1 
8156935 ZNF189 zinc finger protein 189 5.0E-05 1.6E-01 1.7 
8053330 REG1B regenerating islet-derived 1 beta 6.2E-05 1.7E-01 12.2 
7918026 EXTL2 exostosin-like glycosyltransferase 
2 
8.8E-05 2.1E-01 1.7 
8096704 NPNT nephronectin 1.1E-04 2.4E-01 2.4 
7902913 CDC7 cell division cycle 7 1.4E-04 2.5E-01 1.8 
8129947 NMBR neuromedin B receptor 1.4E-04 2.5E-01 -1.5 
8138381 AGR2 anterior gradient 2 homolog 
(Xenopus laevis) 
1.5E-04 2.5E-01 2.0 
FB: Fusobacterium; H: high-level infection; L: low-level infection; N: no infection 
REG proteins are members of the C-type lectin superfamily and have important roles in 
proliferation and differentiation in a range of cell types. Of the REGs, only REG4 is 
constitutively expressed in the colon but several REG proteins are aberrantly expressed 
in inflammatory pathologies including IBD where REG1A, REG1B and REG3A are all 
expressed at the intestinal crypt base by metastatic Paneth cells384. REG1A and REG1B 
have also been found to be concomitantly upregulated in CRC457.  
Back to table of contents 201 
Considering that both REG1A and REG3A are expressed in metaplastic Paneth cells of 
inflamed IBD crypts384; that REG1A is a downstream target of Wnt pathway 
activation458; that H. pylori induces REG1A expression through the induction of IL-8374 
and that Fusobacterium spp. are associated with increased IL-8 in vitro196 and in vivo218, 
suggests that the upregulation of REG genes seen here may be mediated by increased 
penetrance by pro-inflammatory bacteria such as Fusobacterium of colonic crypts at the 
tumour interface. This idea is supported by the finding that REG1 is highly expressed at 
the tumour interface (the zone between the tumour and the adjacent normal mucosa)––
more so than in the tumour itself459 and the finding that Fusobacterium do enter colonic 
crypts in the normal mucosa of CRC patients195. 
From a pathological perspective, REG1A is associated with poor prognosis in CRC460, 
and correlates with recurrence and/or distant metastasis as well as a short median 
survival in patients with MSI+ tumors401. Importantly, the upregulation of REG1A and 
REG3A seen here appear to be specific to Fusobacterium-high tumours as opposed to 
MSI+ tumours, since these genes were not significantly differentially expressed in 
MSI+ vs. MSI- tumours in our cohort (data not shown). 
In normal tissue, although only three normal samples were classified as Fusobacterium-
high, REG1B (p=0.03, FC=2.5) and REG1P (p=0.002, FC=2.7) were also associated 
with Fusobacterium-high, albeit to a lesser degree compared to tumour samples. Taken 
together, these results reveal a link between high-level colonisation by Fusobacterium 
spp. and the expression of several of the REG-family genes, which may be important in 
the pathogenesis of a subset of CRCs. The potential role of Fusobacterium in regulating 
the expression of these genes warrants further investigation. 
Discussion and conclusions 
Although E. faecalis is a normal constituent of the human microbiome, it is also a 
common source of infection, a disparity most likely explained by strain-specific 
virulence factors. Gene expression and pathway analysis of CRCs stratified by E. 
faecalis infection, revealed genes and pathways that had previously been associated 
with E. faecalis colonisation in vitro or in mouse models, as well as novel genes 
(particularly SLRPs and BMI1) and pathways related to CRC progression. 
Back to table of contents 202 
Pathway analysis of genes differentially expressed in association with E. faecalis 
colonisation uncovered pathways related to immune function (in particular antigen 
presentation and microbial pattern recognition), inflammation and CRC progression, 
which may indicate an important role in the pathogenesis of a subset of CRCs. 
A substantial increase in the expression of REG-family gene members, particularly in 
REG1A and REG3A, was seen in CRCs infected with high-level Fusobacterium, which 
may have important repercussions for progression and metastases of these cancers.  
Given the ability of Fusobacterium to enter colonic crypts195 in CRC patients, and the 
relative increase in REG1 expression at the tumour interface compared to the tumour 
itself459, the increased expression of these genes seen here could plausibly be mediated 
by increased penetrance of colonic crypts at the tumour interface by pro-inflammatory 
bacteria such as Fusobacterium.  
Recently, Kostic et al. identified a pro-inflammatory signature of Fusobacterium 
colonisation in CRCs, which included COX-2, IL-1β, IL-6, IL-8, TNF-α, and MMP3. 
Here, these genes were not significantly differentially expressed in CRCs with high-
level Fusobacterium. However, this signature shows significant overlap with the gene- 
and/or pathway-level profiles of B group B CRCs (COX-2, IL-8, IL-1β, IL-6 and TNF) 
and with E. faecalis+ CRCs (IL-1β, IL-6, TNF-α), which may suggest a more complex 
pattern of bacterial involvement associated with this pro-inflammatory signature that is 
not limited to Fusobacterium colonisation but rather represents a signature of dysbiosis 
that may be characterised by increased colonisation of the host mucosa by CRC-
associated pathogens. 
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Chapter 9: Summary, conclusions and future perspectives 
 
Sporadic CRC has been linked to various lifestyle factors and is one of most extensively 
characterised cancers, both at a molecular and ‘omic level; nevertheless, the precise 
mechanism driving CRC initiation remains unknown. Importantly, the relationship 
between currently known CRC-associated bacteria, clinicopathological features of CRC 
and genomic subtypes of CRC has not been concurrently investigated. Given the poor 
outcome of late-stage CRCs and the poor rates of colonoscopy-based screening, it is 
imperative to focus on novel diagnostic and preventative strategies––a process that will 
be greatly aided by a better understanding of the etiological basis of different CRC 
subtypes. In this regard, and given the apparent multitude of factors, both exogenous 
and endogenous to the host that may drive CRC, a systems biology approach, where 
clinical, ‘omic and molecular data are considered in parallel for each patient, will likely 
play a key role in detailing the yet unknown molecular origins of CRCs, or at least in 
generating new hypotheses. In this study the relationships between CRC-associated 
bacteria and transcriptomic and methylation profiles of CRC patients was therefore 
determined with the aim of gaining insight, and driving future research regarding the 
potential contribution of these bacteria in the aetiopathogenesis of CRC.  
Here, a transcriptomic subtype of colorectal cancer, characterised by an increase in CpG 
island methylation displays an increased frequency of colonisation by E. faecalis and by 
high levels of Fusobacterium was identified. At the pathway-level, this subtype is 
enriched for pathways related to DNA and protein damage response, infection, 
inflammation and cellular proliferation; notably, these findings were confirmed in a 
well-defined publically available CRC gene expression dataset (GSE13294) of 
colorectal adenocarcinomas (N=155). These findings suggest that specific bacterial 
colonisation underlie a distinct genomic subtype of colorectal cancer that is 
characterised by inflammatory-related gene expression changes.  
One of the major technical challenges (which commonly arises when using clinical 
samples) of this study was variable RNA integrity between samples; this issue was 
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addressed by establishing a thorough quality control and data analysis pipeline whereby 
low-integrity samples were either excluded from downstream analysis, or included 
following suitable adjustment of the data to account for known or unknown sources of 
variation, such as array quality- and batch- effects using ComBat or Surrogate Variable 
Analysis. This approach will be useful for transcriptomic studies conducted on the 
Affymetrix Gene 1.0 ST array platform using samples with variable RNA integrity 
scores. 
 
In addition to characterising the aforementioned genomic subtypes of CRC, we were 
interested in identifying transcriptome, methylome and pathway-level profiles that were 
specifically altered in CRCs colonised by each of the bacteria studied here. Regarding 
DNA methylation, EPEC-colonised CRCs had intriguing alterations in CpG island 
methylation, and notably, hypermethylation of the MLH1 promoter was exclusively 
identified in these CRCs. Meanwhile, specific genes and pathways that had previously 
been associated with E. faecalis infection in vitro or in mouse models were confirmed in 
E. faecalis-infected CRCs– specifically upregulation of CXCL10 and predicted 
upstream regulation by IL-6, TNF and IFN-γ as well as the Antigen presentation 
pathway was found; novel genes significantly associated with E. faecalis colonisation in 
CRCs included SLRPs (lumican, decorin, biglycan and asporin) and BMI1. In CRCs 
infected with high-level Fusobacterium a substantial increase in the expression of REG-
family gene members, particularly in REG1A and REG3A, was noted. 
Further, the associations of each bacterium studied here, with various 
clinicopathological features of CRC was determined–observations from previous 
studies such as the significant enrichment with Fusobacterium in CRC compared to 
adjacent normal mucosa samples, as well as the relative increase in the level of 
Fusobacterium in MSI-H CRCs were confirmed; additionally, novel observations were 
made, including the increased frequency of ETBF and Fusobacterium in late stage 
cancers; the increased frequency of ETBF and afaC+ E. coli in the colon compared to 
the rectum; and the association between increased levels of colonisation by 
Fusobacterium in black patients and in younger patients.  
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Conclusion 
This is the first study to quantify CRC-associated pathogens across a single cohort and 
to link colonisation by specific bacteria to a transcriptomic subtype of colorectal cancer, 
and, although we cannot yet prove causality, the enrichment with both E. faecalis and 
Fusobacterium, together with the relative increase in MSI+, CIMP+ and inflamed 
samples in this subtype, suggests that these bacteria are likely an important aspect of 
colonic tumourigenesis. Moreover, our findings support previous studies suggesting that 
polymicrobial colonisation of the colonic epithelium and/or tumour may be an 
important aspect of colonic tumourigenesis (at least in a subset of CRCs) that warrants 
further investigation.  
Our findings underscore the value of quantifying suspected oncogenic bacteria in 
parallel with transcriptomic and clinicopathological data in elucidating molecular 
origins and optimal therapeutic strategies by colorectal cancer subtype. Importantly, the 
subtype-specific pathway level alterations seen in our cohort (N=19) were confirmed in 
a large publically available cohort (N=155), which suggests broader applicability of our 
findings.  
Taken together, these findings provide additional support for the role of specific 
bacteria in the aetiopathogenesis of CRC and provide important clues that will 
hopefully drive future research on the role of host-pathogen interaction in CRC.  
Future perspectives 
This study (and previous studies) demonstrates that the level of colonisation by 
Fusobacterium may be relevant to the pathogenesis of CRC; a consistent method of 
defining high-level vs. low-level Fusobacterium colonisation will be required for 
reproducibility and comparibility between studies. Future studies should be aimed at 
validating our findings in a larger cohort, with a higher proportion of MSI+; black; and 
young patients since high-level colonisation by Fusobacterium (and by EPEC with 
regards to MSI-status) appear to be particularly relevant to these patients. In addition, 
because high-level colonisation by Fusobacterium could plausibly facilitate colonisation 
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by other potential oncopathogens, species-level metagenomic profiling of these CRCs 
will be of particular interest. 
Given the pathway-level evidence for an increased response to DNA and protein 
damage in group B CRCs, investigating the level of ROS and NOS by CRC subtype, as 
well as CRC risk factors other than bacteria that have inflammatory or pro-oxidative 
potential, including viral infection, cigarette smoking, alcohol- and red meat-
consumption, may shed further light on the pathogenesis of these CRCs.  
Patients developing group B CRCs have seemingly distinct clinical, microbial and 
genomic characteristics. However, the evidence presented here is not sufficient to prove 
that these bacteria cause CRC initiation and/or progression, and further research should 
be conducted to validate and extend the findings presented here. If these bacteria do 
prove to play a causal role in CRC initiation/progression, individuals should be 
screened for these bacteria alongside other CRC screening tools such as colonoscopies 
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Appendix A 
Table 1: Participant-level characteristics table 1/2. FF = fresh-frozen; FFPE = formalin-fixed paraffin embedded; Tissue type: N=matched normal mucosa, T = 








Patient Age Ethnicity RT Gender BMI Stage Location Site 
10N FF Sporadic N 10 63 MA N M 24.7 NA Distal Descending colon 
10T FF Sporadic T 10 63 MA N M 24.7 III Distal Descending colon 
11N FF Sporadic N 11 84 C N M 28.7 NA Proximal Transverse colon 
11T FF Sporadic T 11 84 C N M 28.7 I Proximal Transverse colon 
13N FF HNPCC N 13 46 MA N F 22.3 NA Proximal Ceacum 
13T FF HNPCC T 13 46 MA N F 22.3 II Proximal Ceacum 
14N FF Sporadic N 14 80 MA N M 23.5 NA Distal Sigmoid colon 
14T FF Sporadic T 14 80 MA N M 23.5 IV Distal Sigmoid colon 
15N FF Sporadic N 15 74 I N M 24.2 NA Distal Rectum 
15T FF Sporadic T 15 74 I N M 24.2 II Distal Rectum 
16N FF Sporadic N 16 76 C N M NA NA Proximal Ascending colon 
16T FF Sporadic T 16 76 C N M NA I Proximal Ascending colon 
17N FF Sporadic N 17 79 C N M 22.7 NA Distal Sigmoid colon 
17T FF Sporadic T 17 79 C N M 22.7 III Distal Sigmoid colon 
18N FF HNPCC N 18 44 MA N F NA NA Proximal Transverse colon 
18T FF HNPCC T 18 44 MA N F NA I Proximal Transverse colon 
1N FF HNPCC N 1 58 MA N F 29.6 NA Proximal Transverse colon 
1T FF HNPCC T 1 58 MA N F 29.6 IV Proximal Transverse colon 
20N FF HNPCC N 20 NA MA N F NA NA Proximal Ceacum 
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20T FF HNPCC T 20 NA MA N F NA NA Proximal Ceacum 
23N FF Sporadic N 23 70 MA N F NA NA Distal Splenic flexure 
23T FF Sporadic T 23 70 MA N F NA III Distal Splenic flexure 
33N FF Sporadic N 33 69 MA N F 28.7 NA Distal Rectum 
33T FF Sporadic T 33 69 MA N F 28.7 III Distal Rectum 
34N FF Sporadic N 34 70 MA N F 25.4 NA Distal Rectum 
34T FF Sporadic T 34 70 MA N F 25.4 III Distal Rectum 
37N FF Sporadic N 37 49 B N M 20 NA Distal Proximal descending 
colon 
37T FF Sporadic T 37 49 B N M 20 III Distal Proximal descending 
colon 
3N FF Sporadic N 3 70 MA N M 29.5 NA Distal RSJ 
3T FF Sporadic T 3 70 MA N M 29.5 III Distal RSJ 
41N FF Sporadic N 41 71 MA N F 31.6 NA Distal Rectum 
41T FF Sporadic T 41 71 MA N F 31.6 II Distal Rectum 
44N FF Sporadic N 44 36 B N M 18.2 NA Proximal Ceacum 
44T FF Sporadic T 44 36 B N M 18.2 III Proximal Ceacum 
48N FF Sporadic N 48 37 MA N M 30.7 NA Distal NA 
48T FF Sporadic T 48 37 MA N M 30.7 IV Distal NA 
4N FF HNPCC N 4 44 MA N F 26.7 NA Proximal Ceacum 
4T FF HNPCC T 4 44 MA N F 26.7 III Proximal Ceacum 
55N FF Sporadic N 55 64 MA N M 25.8 NA Distal NA 
55T FF Sporadic T 55 64 MA N M 25.8 III Distal NA 
56N FF Sporadic N 56 54 MA N F 26.9 NA Distal RSJ 
56T FF Sporadic T 56 54 MA N F 26.9 III Distal RSJ 
60N FF Sporadic N 60 65 MA N M NA NA Distal RSJ 
60T FF Sporadic T 60 65 MA N M NA II Distal RSJ 
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63N FF Sporadic N 63 78 C N F 26.8 NA Proximal Hepatic flexure 
63T FF Sporadic T 63 78 C N F 26.8 II Proximal Hepatic flexure 
8N FF Sporadic N 8 61 C N M 25 NA Distal Rectum 
8T FF Sporadic T 8 61 C N M 25 III Distal Rectum 
19N FF Sporadic N 19 62 MA Y F NA NA Distal Rectum 
19T FF Sporadic T 19 62 MA Y F NA I Distal Rectum 
21N FF Sporadic N 21 61 MA N F 40.5 NA Distal Rectum 
21T FF Sporadic T 21 61 MA N F 40.5 NA Distal Rectum 
24N FF Sporadic N 24 42 MA Y M NA NA Distal Rectum 
24T FF Sporadic T 24 42 MA Y M NA III Distal Rectum 
25N FF Sporadic N 25 67 MA Y F NA NA Distal Rectum 
25T FF Sporadic T 25 67 MA Y F NA I Distal Rectum 
26N FF Sporadic N 26 73 C N F NA NA Distal Rectum 
26T FF Sporadic T 26 73 C N F NA I Distal Rectum 
28N FF Sporadic N 28 79 I Y M NA NA Distal Rectum 
28T FF Sporadic T 28 79 I Y M NA II Distal Rectum 
29N FF Sporadic N 29 73 B Y M 25.8 NA Distal Rectum 
29T FF Sporadic T 29 73 B Y M 25.8 III Distal Rectum 
2N FF Sporadic N 2 67 MA Y M NA NA Distal Rectum 
2T FF Sporadic T 2 67 MA Y M NA II Distal Rectum 
30N FF Sporadic N 30 25 B Y M NA NA Distal Rectum 
30T FF Sporadic T 30 25 B Y M NA II Distal Rectum 
35N FF Sporadic N 35 68 MA Y M NA NA Distal Rectum 
35T FF Sporadic T 35 68 MA Y M NA II Distal Rectum 
39N FF Sporadic N 39 51 MA Y F 36.3 NA Distal Rectum 
39T FF Sporadic T 39 51 MA Y F 36.3 II Distal Rectum 
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45N FF Sporadic N 45 36 B Y F NA NA Distal Rectum 
45T FF Sporadic T 45 36 B Y F NA II Distal Rectum 
47N FF HNPCC N 47 25 MA Y M NA NA Distal Descending colon 
47T FF HNPCC T 47 25 MA Y M NA III Distal Descending colon 
54N FF Sporadic N 54 60 MA N M NA NA NA NA 
54T FF Sporadic T 54 60 MA N M NA NA NA NA 
58N FF Sporadic N 58 71 MA Y NA NA NA Distal Rectum 
58T FF Sporadic T 58 71 MA Y NA NA NA Distal Rectum 
61N FF Sporadic N 61 61 MA N F NA NA Distal Sigmoid colon 
61T FF Sporadic T 61 61 MA N F NA NA Distal Sigmoid colon 
62N FF Sporadic N 62 40 MA Y F NA NA Distal Rectum 
62T FF Sporadic T 62 40 MA Y F NA II Distal Rectum 
65N FF Sporadic N 65 73 C Y M NA NA Distal Rectum 
65T FF Sporadic T 65 73 C Y M NA III Distal Rectum 
66N FF Sporadic N 66 59 MA Y F NA NA Distal Rectum 
66T FF Sporadic T 66 59 MA Y F NA III Distal Rectum 
67N FF Sporadic N 67 64 MA N M 23.8 NA Distal Rectum 
67T FF Sporadic T 67 64 MA N M 23.8 III Distal Rectum 
69N FF Sporadic N 69 NA NA NA F NA NA NA NA 
69T FF Sporadic T 69 NA NA NA F NA NA NA NA 
6N FF Sporadic N 6 23 B Y F NA NA Distal Rectum 
6T FF Sporadic T 6 23 B Y F NA III Distal Rectum 
7N FF Sporadic N 7 52 MA N M 27.9 NA Distal Rectum 
7T FF Sporadic T 7 52 MA N M 27.9 III Distal Rectum 
22N FF Sporadic N 22 49 MA Y M NA NA Distal Rectum 
22T FF Sporadic T 22 49 MA Y M NA III Distal Rectum 
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40N FF Sporadic N 40 47 MA Y F NA NA Distal Rectum 
40T FF Sporadic T 40 47 MA Y F NA II Distal Rectum 
43N FF Sporadic N 43 67 MA Y F NA NA Distal Rectum 
43T FF Sporadic T 43 67 MA Y F NA II Distal Rectum 
51N FF Sporadic N 51 47 MA Y M NA NA Distal Rectum 
51T FF Sporadic T 51 47 MA Y M NA II Distal Rectum 
57N FF Sporadic N 57 45 MA N M 25.7 NA Distal RSJ 
57T FF Sporadic T 57 45 MA N M 25.7 III Distal RSJ 
59N FF Sporadic N 59 79 C Y F NA NA NA NA 
59T FF Sporadic T 59 79 C Y F NA II NA NA 
64N FF Sporadic N 64 69 MA Y F NA NA Distal Rectum 
64T FF Sporadic T 64 69 MA Y F NA II Distal Rectum 
31N FF Sporadic N 31 54 MA Y F NA NA Distal Rectum 
31T FF Sporadic T 31 54 MA Y F NA II Distal Rectum 
71T FFPE Sporadic T 71 41 NA N F NA II Proximal Hepatic flexure 
71N FFPE Sporadic N 71 41 NA N F NA NA Proximal Hepatic flexure 
72T FFPE Sporadic T 72 43 B N M NA III Proximal Ceacum 
72N FFPE Sporadic N 72 43 B N M NA NA Proximal Ceacum 
73T FFPE Sporadic T 73 30 NA N F NA III Proximal Ceacum 
73N FFPE Sporadic N 73 30 NA N F NA NA Proximal Ceacum 
74T FFPE Sporadic T 74 41 NA Y F NA IV Distal Rectum 
74N FFPE Sporadic N 74 41 NA Y F NA NA Distal Rectum 
75T FFPE Sporadic T 75 NA NA NA NA NA NA NA NA 
76T FFPE Sporadic T 76 41 B N M NA II Proximal Ceacum 
76N FFPE Sporadic N 76 41 B N M NA NA Proximal Ceacum 
77T FFPE Sporadic T 77 NA NA NA NA NA NA NA NA 
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78T FFPE Sporadic T 78 NA NA NA NA NA NA NA NA 
79T FFPE HNPCC T 79 NA NA NA NA NA NA NA NA 
80T FFPE Sporadic T 80 NA NA NA NA NA NA NA NA 
81T FFPE Sporadic T 81 NA NA NA NA NA III NA NA 
82T FFPE Sporadic T 82 NA NA NA NA NA NA NA NA 
83T FFPE Sporadic T 83 NA NA NA NA NA NA NA NA 
84T FFPE Sporadic T 84 NA NA NA NA NA NA NA NA 
85T FFPE Sporadic T 85 35 NA N M NA III Distal Sigmoid colon 
85N FFPE Sporadic N 85 35 NA N M NA NA Distal Sigmoid colon 
86T FFPE Sporadic T 86 NA NA NA NA NA NA NA NA 
87T FFPE Sporadic T 87 NA NA NA NA NA NA NA NA 
88T FFPE HNPCC T 88 NA NA NA NA NA NA NA NA 
 
Table 2: Participant characteristics, table 2/2. Bacterial quantitation data expressed as bacteria/50ng human DNA; EPEC limit of detection (LOD) & 
Fusobacterium LOD: for FFPE tissue these are the estimated LOD's based on normalisation against COX1; MSI method: PCR = Bethesda panel of markers; 
MLH1 meth. = MLH1 methylation testing by methylation-specific PCR; MMR prot. = MMR protein(s) with known methylation or absence of staining by 
immunohistochemistry (IHC) of MLH1, MSH2 and MSH6; FB = Fusobacterium; EF = E. faecalis. NA no data for that entry available, whereas 0 means that 0 
bacterial copies were detected for the relevant species noted 










ETBF EPEC EPEC 
LOD 




10N MSS PCR NA NA N 12 0 10 NA 8 2 2177 0 
10T MSS PCR NA NA N 139 0 10 0 1 2 170 0 
11N MSS PCR N NA N 0 0 10 0 0 2 0 0 
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11T MSS PCR N NA N 0 0 10 0 0 2 0 0 
13N MSI-H PCR N NA Y 374 0 10 0 65 2 3787 0 
13T MSI-H PCR N MLH1 Y 3186 0 10 1 3273 2 19200 0 
14N MSS PCR N NA N 3423 0 10 331 67 2 261 0 
14T MSS PCR N NA N 987 0 10 151 271 2 729 0 
15N MSS PCR N NA N 2 0 10 0 9 2 4787 1172 
15T MSS PCR N NA N 0 0 10 0 17 2 9887 1707 
16N MSS PCR N NA Y 0 0 10 0 1953 2 319000 1780 
16T MSS PCR N NA Y 0 0 10 0 21 2 2043 0 
17N MSS PCR N NA N 130 0 10 0 48 2 15 0 
17T MSS PCR N NA N 486 0 10 0 833 2 81 0 
18N MSI-H PCR N NA NA 0 0 10 5 377 2 1937 0 
18T MSI-H PCR N NA NA 0 0 10 3 2610 2 7593 994 
1N MSS PCR N NA N  4 0 10 0 12 2 12 0 
1T MSS PCR N NA N  2 0 10 0 276 2 47 0 
20N MSI-H PCR N NA NA 3 0 10 NA 0 2 0 0 
20T MSI-H PCR N NA NA 13 0 10 NA 2 2 0 0 
23N MSS PCR N NA Y 5 0 10 1 26 2 0 0 
23T MSS PCR N NA Y 3 0 10 250 4820 2 0 0 
33N MSS PCR N NA N 0 0 10 0 3 2 0 677 
33T MSS PCR N NA N 0 0 10 0 14 2 0 622 
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34N MSS PCR N NA N 0 52 10 0 25 2 30900 1263 
34T MSS PCR N NA N 3 63 10 1 289 2 33433 1400 
37N MSS PCR N NA Y 1620 0 10 NA 1897 2 0 3693 
37T MSS PCR N NA Y 35300 0 10 0 4773 2 0 1800 
3N MSS PCR N NA N  0 0 10 0 1 2 0 0 
3T MSS PCR N NA N  0 0 10 0 3 2 0 0 
41N MSS PCR N NA N  0 0 10 NA 69 2 0 0 
41T MSS PCR N NA N  0 0 10 NA 213 2 2 0 
44N MSI-H PCR N NA Y 0 3037 10 0 1110 2 1197 36 
44T MSI-H PCR Y NA Y 0 1111 10 0 68700 2 156 0 
48N MSS PCR N NA N 2328 0 10 0 1 2 0 0 
48T MSS PCR N NA N 1106 0 10 0 44 2 0 0 
4N MSI-H PCR N NA N 0 0 10 0 20 2 195 0 
4T MSI-H PCR N NA N 3 0 10 0 60767 2 6537 0 
55N MSI-L PCR N NA N 4 0 10 0 99 2 0 5777 
55T MSI-L PCR N NA N 3 0 10 0 9 2 0 536 
56N MSS PCR N NA N 698 0 10 0 46 2 0 0 
56T MSS PCR N NA N 648 0 10 0 378 2 0 0 
60N MSI-H PCR N NA N 20 0 10 0 3 2 2750 78 
60T MSI-H PCR N NA N 0 0 10 0 22 2 5237 69 
63N MSI-H PCR N NA N 0 0 10 NA 73 2 0 0 
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63T MSI-H PCR Y NA N 0 13 10 4 2730 2 0 0 
8N MSS PCR N NA N 12 0 10 4 0 2 592 0 
8T MSS PCR N NA N 14 0 10 2 37 2 619 0 
19N NA NA NA NA NA 0 0 10 0 0 2 0 0 
19T NA NA NA NA NA 0 0 10 0 0 2 0 0 
21N MSS PCR NA NA NA 0 0 10 NA 0 2 0 0 
21T MSS PCR N NA NA 0 0 10 NA 0 2 1 0 
24N NA NA NA NA NA 0 0 10 0 21 2 0 0 
24T NA NA NA NA NA 0 0 10 NA 57 2 0 0 
25N NA NA NA NA NA 0 0 10 0 8 2 0 0 
25T NA NA NA NA NA 0 0 10 0 0 2 0 0 
26N MSI-L PCR N NA N 0 0 10 4 333 2 0 34 
26T MSI-L PCR N NA N 0 0 10 NA 40 2 0 0 
28N NA NA NA NA NA 0 0 10 0 1 2 0 0 
28T NA NA NA NA NA 0 0 10 0 0 2 0 0 
29N MSS PCR NA NA N 0 14 10 0 69 2 0 0 
29T MSS PCR NA NA N 0 31 10 0 6678 2 19 0 
2N NA NA NA NA NA 0 0 10 0 71 2 0 0 
2T NA NA NA NA NA 0 0 10 0 1026 2 0 0 
30N NA NA NA NA NA 0 0 10 4 1543 2 0 22800 
30T NA NA NA NA NA 0 0 10 0 106 2 0 0 
35N NA NA NA NA NA 0 0 10 0 422 2 0 0 
35T NA NA NA NA NA 0 0 10 1 1353 2 0 0 
Back to table of contents 247 
39N NA NA NA NA N 0 0 10 NA 11 2 0 0 
39T NA NA NA NA N 0 0 10 NA 49 2 0 0 
45N NA NA NA NA NA 0 0 10 0 0 2 0 0 
45T NA NA NA NA NA 0 51 10 0 5 2 0 0 
47N NA NA NA NA Y 5 0 10 0 187 2 0 0 
47T NA NA NA NA Y 0 0 10 0 125 2 0 0 
54N MSS PCR N NA NA 0 0 10 0 0 2 0 516 
54T MSS PCR N NA NA 0 0 10 0 8 2 0 316 
58N NA NA NA NA NA 0 0 10 0 1 2 2 0 
58T NA NA NA NA NA 0 0 10 0 0 2 2 0 
61N MSI-L PCR N NA Y 0 0 10 0 36 2 25 0 
61T MSI-L PCR N NA Y 0 0 10 0 14 2 20 60 
62N NA NA NA NA NA 0 0 10 NA 5 2 0 0 
62T NA NA NA NA NA 0 0 10 NA 78 2 0 0 
65N NA NA NA NA NA 0 0 10 8 340 2 10 3617 
65T NA NA NA NA NA 0 0 10 131 1353 2 0 3497 
66N NA NA N NA NA 0 0 10 0 38 2 0 0 
66T NA NA N NA NA 0 0 10 1 8990 2 0 0 
67N MSS PCR N NA N 0 0 10 NA 217 2 0 0 
67T MSS PCR N NA N 0 0 10 12 1483 2 0 0 
69N NA NA NA NA NA 0 0 10 0 0 2 29 0 
69T NA NA NA NA NA 0 0 10 0 240 2 23 0 
6N MSS PCR NA NA NA 0 0 10 0 273 2 0 0 
6T MSS PCR NA NA NA 0 0 10 0 2417 2 0 0 
7N MSS PCR N NA N 0 0 10 0 1397 2 0 44 
7T MSS PCR N NA N 0 0 10 0 8497 2 0 62 
22N NA NA NA NA NA 0 0 10 NA 4 2 0 0 
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22T NA NA NA NA NA 0 41 10 NA 5740 2 0 7373 
40N NA NA NA NA NA 0 0 10 NA 5 2 0 0 
40T NA NA NA NA NA 0 0 10 NA 3 2 0 0 
43N NA NA NA NA NA NA 0 10 NA 4 2 0 0 
43T NA NA NA NA NA 0 0 10 NA 9 2 0 0 
51N NA NA NA NA NA 0 0 10 NA NA 2 0 0 
51T NA NA NA NA NA 0 0 10 NA 9 2 0 0 
57N NA NA NA NA N NA NA 10 NA 2 2 NA NA 
57T NA NA NA NA N NA NA 10 NA NA 2 NA NA 
59N NA NA NA NA NA 0 0 10 NA 28 2 0 0 
59T NA NA NA NA NA 0 0 10 NA 47 2 0 0 
64N NA NA NA NA NA 0 0 10 NA 8 2 0 0 
64T NA NA NA NA NA 0 0 10 NA 10 2 0 0 
31N NA NA NA NA NA 0 0 10 NA 0 2 0 0 
31T NA NA NA NA NA 0 0 10 NA 4 2 NA 0 
71T MSI-H IHC NA MSH6, 
MSH2 
Y NA NA 36 NA 107 164 NA NA 
71N MSI-H IHC NA  Y NA NA 56 NA NA 252 NA NA 
72T MSI-H IHC NA MSH2 N NA NA 13 NA 260 59 NA NA 
72N MSI-H IHC NA  N NA NA 35 NA 4091 156 NA NA 
73T MSI-H IHC NA MSH6 N NA NA 19 NA NA 87 NA NA 
73N MSI-H IHC NA  N NA NA 18 NA NA 79 NA NA 
74T MSI-H IHC NA MSH6 NA NA NA 3 NA NA 14 NA NA 
74N MSI-H IHC NA  NA NA NA 9 NA NA 39 NA NA 
75T MSI-H IHC NA MSH6 NA NA NA 86 NA 526 385 NA NA 
76T MSI-H IHC NA MLH1 N NA NA 42 NA 124 188 NA NA 
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76N MSI-H IHC NA  N NA NA 61 NA NA 276 NA NA 
77T MSI-H IHC NA MLH1 NA NA NA 77 NA NA 346 NA NA 
78T MSI-H IHC NA MLH1 NA NA NA 5 NA 27291 24 NA NA 
79T MSI-H IHC NA MLH1 NA NA NA 55 NA 1888 248 NA NA 
80T MSI-H IHC NA MLH1 NA NA NA 457 NA 1587 2056 NA NA 
81T MSI-H IHC NA MLH1 NA NA NA 82 NA 221 367 NA NA 
82T MSI-H IHC NA MLH1, 
MSH2 
NA NA NA 2968 NA NA 13356 NA NA 
83T MSI-H IHC NA MSH2, 
MSH6 
NA NA NA 242 NA NA 1088 NA NA 
84T MSI-H IHC NA MSH2 NA NA NA 26 NA 262 117 NA NA 
85T MSI-H IHC NA MSH2 Y NA NA 43 NA 6642 194 NA NA 
85N MSI-H IHC NA NA Y NA NA 91 NA 22818 410 NA NA 
86T MSI-H IHC NA MSH2, 
MLH1 
NA NA NA 74 NA NA 331 NA NA 
87T MSS IHC NA NA Y NA NA 21 NA NA 94 NA NA 
88T MSI-H IHC NA MLH1 NA NA NA 25 NA 342 112 NA NA 
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Table 3: qPCR conditions used. 
Bacteria Reagent qPCR conditions Number of 
cycles 
    
ETBF   2 min @ 95°C   
  SensiFAST SYBR No Rox Mix (1x) 1 s @ 95°C x45 
  F (200 nM final) 5 s @ 65-55°C; decrease 
0.5 °C/cycle 
  R (200 nM final) acquire 1 s @ 80°C 
  template: 50 ng human DNA     
  H20    
  total = 20 μl     
      
    
E. 
faecalis 
  10 min @ 95°C   
  Maxima SYBR qPCR Master Mix (1x) 15 s @ 95°C x50 
  F (900 nM final) 60 s @ 60°C 
  R (900 nM final) acquire @ 72°C 
  template: 50 ng human DNA     
  H20    
  total = 25 μl     




  2 min @ 95°C   
  SensiFAST SYBR No Rox Mix (1x) 5 s @ 95°C x60 
  F (200 nM final) 10 s @ 60-50°C, decrease 
0.5 °C/cycle 
  R (200 nM final) acquire @ 80°C 
  template: 50 ng human DNA     
  H20    
  total = 20 μl     
    
    
EPEC 
(bfpA) 
  2 min @ 95°C   
  SensiFAST SYBR No Rox Mix (1x) 5 s @ 95°C x60 
  F (200 nM final) 7 s @ 70-64°C; decrease 
0.5 °C/cycle 
  R (200 nM final) acquire @ 80°C 
  template: 50 ng human DNA     
  H20    
  total = 20 μl     
    
    
EPEC 
(eae) 
PCR buffer 2 min @ 95°C   
  SensiFAST SYBR No Rox Mix (1x) 5 s @ 95°C x55 
  F (200 nM final) 7 s @ 70-60°C; decrease 
0.5 °C/cycle 
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  R (200 nM final) acquire @ 80°C 
  template: 50 ng human DNA      
  H20    
  total = 20 μl     
    
EHEC 
(stx1) 
  2 min @ 95°C   
  SensiFAST SYBR No Rox Mix (1x) 5 s @ 95°C x60 
  F (600 nM final) 10 s @ 70-60°C; decrease 
0.5 °C/cycle 
  R (600 nM final) acquire @ 80°C 
  template: 50 ng human DNA      
  H20    
  total = 20 μl     
    
EHEC 
(stx2) 
  1 min @ 95°C   
  SensiFAST SYBR No Rox Mix (1x) 1 s @ 95°C x55 
  F (400 nM final) 5 s @ 70-60°C; decrease 
0.5 °C/cycle 
  R (400 nM final) acquire @ 80°C 
  template: 50 ng human DNA      
  H20    
  total = 20 μl     
    
Fusobacterium spp. 10 min @ 95   
 Maxima SYBR qPCR Master Mix (1x) 15 s @ 95°C x50 
  F (300 nM final) 45 s @ 60°C 
  R (300 nM final) acquire @ 72°C  
  template: 50 ng human DNA      
  H20    
  total = 25 μl     
    
AIEC 
(afaC) 
  10 min @ 95   
 Maxima SYBR qPCR Master Mix (1x) 15 s @ 95°C x50 
  F (900 nM final) 60 s @ 65-60 decrease 
0.5 °C/cycle. 
  R (900 nM final)  acquire at 72°C 
  template: 50 ng human DNA      
  H20    
  total = 25 μl     
    
AIEC 
(ClB) 
  10 min @ 95   
 Maxima SYBR qPCR Master Mix (1x) 15 s @ 95°C x60 
  F (600 nM final)  60 s @ 60°C 
  R (600 nM final) acquire at 72°C 
  template: 50 ng human DNA      
  H20    
  total = 25 μl     
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Appendix B 
 
Figure 1: Predicting CIMP-H using an array-based marker panel. RPMM-based clustering of probes 
mapping to CpG islands in the Hinoue CIMP-H marker panel (FAM78A, FSTL1, KCNC1, MYOCD, and 
SLC6A4). Sample 63T is considered to be CIMP-H. The scale on the right represents beta values (0–1) 
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Table 1: Region-specific detail of the 35 genes that are differentially methylated and differentially expressed in EPEC+ CRCs. CpG islands = 1; non-CpG 
islands = 0; EPEC+/- median: median beta values in each group; EPEC+ vs. EPEC- diff.: difference in median beta values between groups; Target: Refseq 
gene target and region(s) to which each probe map. 




















cg02128087 C12orf68 12 48577366 48579709 1 3.10E-02 0.87 0.07 0.31 0.24 NM_0010136
35:TSS1500 
cg03272292 C12orf68 12 48577366 48579709 1 1.60E-02 0.87 0.07 0.3 0.23 NM_0010136
35:TSS200 
cg05376611 C12orf68 12 48577366 48579709 1 5.50E-03 0.71 0.1 0.33 0.23 NM_0010136
35:TSS1500 
cg11201894 C6orf223 6 43968337 43973694 0 4.00E-02 0.87 0.7 0.43 -0.27 NM_153246:3
'UTR 
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cg17011964 EFNB2 13 -
107142079 
-107187388 0 4.40E-02 0.87 0.61 0.85 0.23 NM_004093:3
'UTR 




1 1.60E-02 0.87 0.12 0.46 0.35 NM_017549:
Body 




1 2.00E-02 0.87 0.08 0.55 0.46 NM_017549:1
stExon 




1 4.40E-03 0.68 0.07 0.4 0.32 NM_017549:
Body 




1 1.20E-02 0.84 0.09 0.56 0.48 NM_017549:
Body 




1 9.50E-03 0.79 0.12 0.57 0.46 NM_017549:1
stExon 




cg02934930 EPHB1 3 134514099 134979307 1 6.90E-06 0.02 0.09 0.48 0.4 NM_004441:T
SS1500 
cg04891921 EPHB1 3 134514099 134979307 1 2.60E-04 0.18 0.1 0.4 0.31 NM_004441:T
SS200 




0 7.10E-04 0.32 0.72 0.5 -0.21 NM_014883:
Body 
cg02098413 HACE1 6 -
105175968 
-105307794 0 2.20E-02 0.87 0.58 0.85 0.27 NM_020771:T
SS1500 




















cg24761195 LRP11 6 -
150139894 










1 3.30E-02 0.87 0.09 0.32 0.23 NM_0011361
60:TSS1500; 
NM_0011361


















cg23076591 MN1 22 -28144265 -28197486 1 4.30E-02 0.87 0.08 0.33 0.25 NM_002430:T
SS200 
cg25803927 MN1 22 -28144265 -28197486 1 3.40E-06 0.01 0.06 0.44 0.38 NM_002430:T
SS1500 
cg20612002 MYEF2 15 -48431629 -48470558 1 2.10E-02 0.87 0.09 0.35 0.26 NM_016132:
Body 





1 1.10E-02 0.81 0.28 0.5 0.21 NM_020443:1
stExon 



































Back to table of contents 256 
NM_0010053
89:5'UTR 
cg00936907 NOG 17 54671060 54672951 1 6.10E-03 0.73 0.08 0.35 0.27 NM_005450:1
stExon 






cg22629987 QPCT 2 37571753 37600465 0 3.50E-03 0.65 0.2 0.46 0.26 NM_012413:T
SS200 



























1 1.50E-02 0.87 0.1 0.49 0.39 NM_0010069
32:TSS1500 







1 2.00E-02 0.87 0.11 0.48 0.37 NM_0010069
32:TSS1500 







0 2.00E-03 0.53 0.18 0.43 0.25 NM_0010069
32:TSS1500 
cg13364903 SCUBE3 6 35182190 35218609 1 1.10E-05 0.03 0.11 0.34 0.24 NM_152753:T
SS1500 
cg21604042 SCUBE3 6 35182190 35218609 1 1.30E-02 0.84 0.21 0.42 0.21 NM_152753:T
SS1500 
cg27301032 SOX1 13 112721913 112726020 1 2.40E-02 0.87 0.11 0.42 0.31 NM_005986:T
SS1500 




0 2.60E-02 0.87 0.05 0.28 0.23 NM_0010254
36:TSS1500; 
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214149103 NM_024532:T
SS1500 
cg22674613 SPATS1 6 44310397 44344904 1 2.00E-02 0.87 0.17 0.4 0.23 NM_145026:T
SS200 




cg12964144 WSCD1 17 5973934 6027747 1 2.20E-04 0.16 0.1 0.4 0.29 NM_015253:5
'UTR 
cg14097019 ZNF287 17 -16453631 -16472520 1 3.20E-02 0.87 0.08 0.32 0.24 NM_020653:T
SS200 
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cg23190994 ZNF546 19 40502943 40523514 1 3.50E-02 0.87 0.13 0.46 0.32 NM_178544:5
'UTR 
cg08397818 ZNF606 19 -58488441 -58514714 1 1.60E-03 0.49 0.17 0.51 0.33 NM_025027:5
'UTR 




















Back to table of contents 259 
Appendix C 
 
Figure 1: Hierarchical clustering of the 5334 most variable PARADIGM IPLs. Two main clusters can be 
distinguished that are identical to the RPMM gene-expression clusters except for 18T. The scale on the 
right represents row-scaled expression values. 
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Figure 2: RPMM clustering of gene expression of Wnt pathway antagonists known to be methylated in 
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Figure 3: CRC classification for genes from the CRCassigner-786 classifier associated with the transit-
amplifying subtype according to Sadanandam et al. The scale on the right represents log2 expression 
values. 
 
Table 1: The 100 most significant PARADIGM genes or gene families of the 712 differentially activated 
between group A and B CRCs in our cohort. Genes have been sorted by the difference in activation 
scores between group B and A. 











FOXM1 1.7E-06 1.8E-04 3.92 -5.06 8.97 
MIR17_(miRNA) 1.8E-08 5.2E-06 3.70 -2.32 6.02 
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MIR9-3_(miRNA) 1.8E-08 5.2E-06 3.70 -2.32 6.02 
MIR141_(miRNA) 1.8E-08 5.2E-06 3.70 -2.32 6.02 
MIR338_(miRNA) 1.8E-08 5.2E-06 3.70 -2.32 6.02 
MIR429_(miRNA) 1.8E-08 5.2E-06 3.70 -2.32 6.02 
MIR200A_(miRNA) 1.8E-08 5.2E-06 3.70 -2.32 6.02 
MYC 8.1E-07 1.1E-04 2.68 -1.16 3.84 
MAX 1.6E-06 1.8E-04 2.37 -1.25 3.62 
ATF6 2.6E-07 4.9E-05 1.83 -1.73 3.56 
CCNB2 3.1E-10 2.3E-07 0.56 -1.16 1.72 
H2AFZ 4.1E-06 3.7E-04 0.54 -1.18 1.72 
SSR1 3.8E-06 3.4E-04 0.48 -1.23 1.72 
CALR 2.1E-06 2.2E-04 0.41 -1.27 1.68 
HSP90B1 4.3E-06 3.8E-04 0.37 -1.30 1.67 
HELLS 3.9E-07 7.2E-05 0.49 -1.15 1.64 
CDK1 2.2E-16 1.9E-12 0.51 -1.11 1.63 
E2F1_targets_(family) 3.5E-06 3.2E-04 0.49 -1.13 1.62 
DUSP10 2.6E-08 6.2E-06 0.48 -1.14 1.62 
TOP2A 4.2E-12 3.8E-09 0.49 -1.11 1.60 
ECT2 5.3E-15 1.8E-11 0.43 -1.15 1.58 
ACTL6A 2.4E-06 2.4E-04 0.36 -1.14 1.50 
ME1 2.1E-08 5.3E-06 0.36 -1.13 1.49 
EBNA1BP2 4.3E-06 3.8E-04 0.34 -1.15 1.49 
FANCI 2.2E-13 2.4E-10 0.39 -1.10 1.48 
YWHAE 4.5E-06 3.9E-04 0.33 -1.15 1.48 
VBP1 4.6E-14 1.3E-10 0.39 -1.08 1.48 
HNRNPC 6.6E-14 1.6E-10 0.40 -1.07 1.48 
RPL6 4.5E-06 3.9E-04 0.33 -1.15 1.48 
POT1 1.9E-13 2.4E-10 0.39 -1.09 1.48 
HSP90AB1 2.1E-08 5.3E-06 0.37 -1.11 1.47 
NUF2 2.0E-08 5.3E-06 0.37 -1.10 1.47 
RPS15A 9.7E-09 4.0E-06 0.35 -1.12 1.47 
SUZ12 2.1E-08 5.3E-06 0.36 -1.11 1.47 
MND1 2.6E-06 2.5E-04 0.34 -1.13 1.47 
PSMB6 4.5E-06 3.9E-04 0.33 -1.14 1.47 
TUBGCP4 4.5E-06 3.9E-04 0.32 -1.14 1.46 
ZNF484 9.7E-09 4.0E-06 0.35 -1.12 1.46 
PSMD14 1.8E-06 1.9E-04 0.32 -1.15 1.46 
PSMB5 2.7E-06 2.6E-04 0.33 -1.13 1.46 
SUMO1 2.1E-08 5.3E-06 0.37 -1.10 1.46 
C1QBP 2.1E-08 5.3E-06 0.35 -1.11 1.46 
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PSMD1 2.1E-08 5.3E-06 0.35 -1.11 1.46 
CHAF1B 2.8E-06 2.6E-04 0.33 -1.13 1.46 
EEF2 2.1E-08 5.3E-06 0.35 -1.10 1.46 
CENPN 2.1E-08 5.3E-06 0.36 -1.10 1.46 
BUB1 9.9E-18 1.7E-13 0.37 -1.08 1.45 
MED21 1.5E-06 1.7E-04 0.36 -1.10 1.45 
KIF20A 3.3E-15 1.4E-11 0.39 -1.06 1.45 
NCAPG 2.9E-15 1.4E-11 0.39 -1.06 1.45 
SSB 2.8E-06 2.7E-04 0.32 -1.13 1.45 
SKA1 3.9E-09 2.0E-06 0.34 -1.10 1.45 
NEDD1 9.2E-09 4.0E-06 0.36 -1.09 1.45 
LAMB1 2.8E-06 2.6E-04 0.32 -1.12 1.44 
CENPQ 9.5E-09 4.0E-06 0.35 -1.09 1.44 
HNRNPK 1.6E-06 1.8E-04 0.33 -1.11 1.43 
NDC80 1.6E-06 1.8E-04 0.32 -1.11 1.43 
CENPE 7.5E-06 5.7E-04 0.38 -1.04 1.43 
NDUFAB1 1.7E-06 1.8E-04 0.32 -1.11 1.43 
HIST1H1B 6.1E-06 5.1E-04 0.38 -1.04 1.43 
CCT2 1.6E-06 1.8E-04 0.33 -1.10 1.43 
COPS2 7.5E-06 5.7E-04 0.38 -1.04 1.43 
KIF15 1.7E-06 1.9E-04 0.32 -1.11 1.42 
NUP43 9.5E-09 4.0E-06 0.35 -1.08 1.42 
KIF11 3.6E-09 2.0E-06 0.35 -1.07 1.42 
KIF18A 3.7E-09 2.0E-06 0.35 -1.07 1.42 
SMC2 6.2E-06 5.1E-04 0.38 -1.03 1.42 
PARP2 5.1E-07 8.1E-05 0.35 -1.07 1.41 
MED17 5.3E-07 8.3E-05 0.35 -1.07 1.41 
NUDT21 3.8E-09 2.0E-06 0.34 -1.07 1.41 
XPO1 8.3E-07 1.1E-04 0.32 -1.08 1.41 
OIP5 8.6E-07 1.2E-04 0.32 -1.09 1.41 
STT3A 8.7E-07 1.2E-04 0.32 -1.09 1.41 
MSH2 3.3E-06 3.1E-04 0.36 -1.05 1.40 
SNUPN 4.9E-07 8.1E-05 0.34 -1.06 1.40 
PLK4 9.0E-07 1.2E-04 0.32 -1.08 1.40 
GAPDH 6.6E-06 5.3E-04 0.19 -1.21 1.39 
CCT6A 6.7E-06 5.3E-04 0.17 -1.17 1.35 
UBE2R2 6.7E-06 5.3E-04 0.17 -1.17 1.35 
EXOC6 6.7E-06 5.3E-04 0.16 -1.17 1.34 
CKAP5 2.3E-06 2.4E-04 0.19 -1.13 1.31 
UBE2T 2.1E-08 5.3E-06 0.35 -0.96 1.31 
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RMI1 2.3E-06 2.4E-04 0.18 -1.12 1.30 
SLC11A2 7.0E-08 1.6E-05 0.13 -1.15 1.27 
GDI2 4.1E-06 3.7E-04 0.00 -1.18 1.18 
CHEK1 3.5E-07 6.4E-05 0.15 -0.36 0.50 
CHK1-2_(family) 6.0E-06 5.0E-04 0.15 -0.32 0.47 
NEB 6.6E-06 5.3E-04 -1.17 0.00 -1.17 
TLX2 6.5E-06 5.3E-04 -1.18 0.00 -1.18 
AMN 1.3E-06 1.5E-04 -1.10 0.35 -1.45 
LOC440461 2.4E-06 2.4E-04 -1.12 0.36 -1.49 
MIR26A2_(miRNA) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
DLEU2_(rna) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
MIR26B_(miRNA) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
DLEU1_(rna) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
MIR23B_(miRNA) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
MIR26A1_(miRNA) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
MIRLET7G_(miRNA) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
MIR22_(miRNA) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
MIR146A_(miRNA) 1.8E-08 5.2E-06 -3.70 2.32 -6.02 
 
Table 2: The 100 most significant PARADIGM complexes of the 711 differentially activated between 
group A and B CRCs in our cohort. Complexes have been sorted by the difference in activation scores 
between group B and A. 










MYC/Max_(complex) 6.0E-09 2.9E-06 7.06 -6.34 13.40 
MYC/Max/HDAC3_(complex) 9.7E-07 1.3E-04 2.01 -1.11 3.12 
Myc/Max_heterodimer_(complex) 3.1E-09 1.8E-06 1.60 -1.43 3.02 
MYC/Max/RPL11_(complex) 5.8E-07 8.8E-05 1.77 -0.67 2.45 
MYC/Max/DNA_replication_preinitiati
on_complex_(complex) 
8.2E-08 1.8E-05 1.60 -0.81 2.42 
MYC/Max/HBP1_(complex) 6.5E-06 5.3E-04 1.73 -0.68 2.40 
ATF6-alpha/BiP_(complex) 6.8E-06 5.4E-04 0.70 -1.66 2.37 
MYC/Max/P-TEFb_(complex) 3.2E-07 6.1E-05 1.54 -0.78 2.33 
MYC/Max/NF-Y_(complex) 3.0E-06 2.8E-04 1.44 -0.89 2.33 
MYC/Max/PML4_(complex) 8.7E-08 1.9E-05 1.54 -0.66 2.20 
FANCD2/FANCI_(complex) 1.2E-12 1.1E-09 0.50 -1.58 2.08 
Cyclin_B2/phospho-
Cdc2(Thr_14_Thr_161)_(complex) 
4.9E-11 3.9E-08 0.71 -1.36 2.06 
Cyclin_B2/phospho-
Cdc2(Thr_161)_(complex) 
4.9E-11 3.9E-08 0.71 -1.36 2.06 
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Cyclin_A2/phospho-
Cdc2(Thr_161)_(complex) 
7.5E-09 3.5E-06 0.61 -1.42 2.02 
Cyclin_B/phospho-
Cdc2(Thr_14)_(complex) 
2.6E-09 1.6E-06 0.63 -1.39 2.02 
Cyclin_B/Cdk1_complex_(complex) 2.6E-09 1.6E-06 0.63 -1.39 2.02 
Cyclin_B/Cdc2_complex_(complex) 2.6E-09 1.6E-06 0.63 -1.39 2.02 
Cyclin_A/CDK1-2_(complex) 1.9E-06 2.0E-04 0.50 -1.44 1.94 
calnexin/calreticulin_(complex) 4.8E-07 8.1E-05 0.51 -1.38 1.88 
BUB1/BUB3_(complex) 6.3E-08 1.4E-05 0.49 -1.37 1.85 
nuclear_Cyclin_B1/Cdc2_complexes_(f
amily) 
4.1E-07 7.4E-05 0.67 -1.16 1.83 
cytoplasmic_Cyclin_B1/Cdc2_complexe
s_(family) 
4.1E-07 7.4E-05 0.67 -1.16 1.83 
EIF2A/14-3-3_E_(complex) 6.1E-07 9.2E-05 0.40 -1.43 1.82 
MYC/Max/p14ARF_(complex) 1.0E-07 2.2E-05 1.44 -0.39 1.82 
MAD2*CDC20_complex_(complex) 3.4E-06 3.1E-04 0.48 -1.33 1.81 
Centralspindlin_(complex) 1.2E-06 1.4E-04 0.39 -1.41 1.81 
active_nuclear_Cyclin_B1/Cdc2_compl
exes_(family) 
4.5E-07 7.9E-05 0.66 -1.14 1.80 
RAD51/BRCA2_(complex) 1.1E-06 1.3E-04 0.49 -1.28 1.77 
RAD51/BRCA2_complex_(complex) 1.1E-06 1.3E-04 0.49 -1.28 1.77 
BRCA2/Rad51_(complex) 1.1E-06 1.3E-04 0.49 -1.28 1.77 
Cyclin_B1/CDK1_(complex) 2.2E-06 2.3E-04 0.35 -1.35 1.70 
Cyclin_B1/phospho-
Cdc2_(_Thr_14)_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
phospho-Cyclin_B1/phospho-
Cdc2(Thr_161)_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
nuclear_Cyclin_B1/phospho-
Cdc2_(_Thr_14)_complexes_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
phospho-Cyclin_B1(CRS)/phospho-
Cdc2_(Thr_161)_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
phospho-cyclin_B1(CRS)/phosph-
Cdc2(Thr_161)_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
Cyclin_B1/phospho-
Cdc2(Thr_161)_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
Phospho-Cyclin_B1_(CRS)/phospho-
Cdc2(Thr_161)_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
Cyclin_B1/phospho-
Cdc2_(Thr_14_Thr_161)_(complex) 
2.4E-06 2.4E-04 0.36 -1.34 1.70 
ORC_complex_bound_to_origin_(comp
lex) 




2.7E-06 2.6E-04 0.36 -1.22 1.59 
SKP2/p27Kip1_(complex) 4.6E-06 3.9E-04 0.60 -0.92 1.52 
Centromeric_Chromatin/CENPH-
I_Complex_(complex) 
2.0E-07 3.9E-05 0.82 -0.69 1.51 
unfolded_protein/(Glc)1_(GlcNAc)2_( 5.0E-07 8.1E-05 0.47 -1.03 1.50 
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Man)9_(Asn)1/chaperone_(complex) 
Laminin-1_(EHS_laminin)_(complex) 5.9E-06 5.0E-04 0.44 -1.05 1.49 
Laminin_1_(complex) 5.9E-06 5.0E-04 0.44 -1.05 1.49 
Cyclin_A/Cdc2_(complex) 2.0E-13 2.4E-10 0.46 -1.01 1.47 
Cyclin_A/phospho-
Cdc2(Thr_14)_(complex) 
2.0E-13 2.4E-10 0.46 -1.01 1.47 
Cyclin_A/phospho-
Cdc2(Thr_161)_complex_(complex) 
2.0E-13 2.4E-10 0.46 -1.01 1.47 
Cyclin_A/phospho-
Cdc2(Thr_161)_(complex) 
2.0E-13 2.4E-10 0.46 -1.01 1.47 
phospho-
Cdc2(Thr_14)/Cyclin_A_(complex) 




2.0E-13 2.4E-10 0.46 -1.01 1.46 
Cyclin_A/phospho-
Cdc2(Thr_14_Thr_161)_(complex) 
2.0E-13 2.4E-10 0.46 -1.01 1.46 
ORC/origin_(complex) 9.1E-07 1.2E-04 0.68 -0.75 1.43 
ORC_(complex) 1.2E-06 1.5E-04 0.54 -0.86 1.41 
MKLP2/PLK1_(complex) 2.7E-08 6.2E-06 0.56 -0.83 1.39 
EIF-2-alpha(P)/EIF-2-gamma/EIF-2-
beta_(complex) 
4.5E-07 7.9E-05 0.89 -0.48 1.38 
PICH/PLK1_(complex) 3.4E-06 3.1E-04 0.50 -0.86 1.36 
eIF2/GDP_(complex) 4.1E-06 3.7E-04 0.87 -0.45 1.33 
eIF2/GTP_(complex) 4.1E-06 3.7E-04 0.87 -0.45 1.33 
14-3-3E_homodimer_(complex) 5.4E-06 4.6E-04 0.25 -1.07 1.32 
AZIN1_bound_OAZ/ODC_complex_(c
omplex) 
5.2E-06 4.4E-04 0.57 -0.75 1.32 
C1q_binding_protein_tetramer_(comple
x) 
2.2E-08 5.3E-06 0.28 -1.03 1.30 
eEF2/GDP_(complex) 2.2E-08 5.3E-06 0.28 -1.03 1.30 
eEF2/GTP_(complex) 2.2E-08 5.3E-06 0.28 -1.03 1.30 
KIF18A_dimer_(complex) 5.0E-09 2.5E-06 0.28 -0.99 1.27 
Kinesin-5_homotetramer_(complex) 4.9E-09 2.5E-06 0.28 -0.99 1.27 




1.8E-07 3.5E-05 0.48 -0.78 1.27 
PML/SUMO1_(complex) 1.7E-07 3.3E-05 0.54 -0.73 1.26 
ORC/CDC6/CDT1_(complex) 7.2E-08 1.6E-05 0.78 -0.44 1.22 
Emi1/Cdc20_complex_(complex) 5.5E-07 8.5E-05 0.43 -0.78 1.21 
DNA_Pol_alpha/primase_(complex) 1.0E-06 1.3E-04 0.70 -0.49 1.19 
CCT/TriC(ATP)/unfolded_tubulin_com
plex_(complex) 
7.5E-07 1.0E-04 0.63 -0.52 1.15 
Sumo_target_protein/SUMO_1_(comple
x) 
2.2E-08 5.3E-06 0.24 -0.89 1.13 
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CCT/TriC(ADP)_(complex) 1.3E-06 1.5E-04 0.66 -0.46 1.12 
CCT/TriC(ATP)_(complex) 1.3E-06 1.5E-04 0.66 -0.46 1.12 
FANCD2/FANCI/H2AX_(complex) 2.3E-09 1.6E-06 0.84 -0.26 1.10 
SMN_complex_(complex) 1.4E-06 1.7E-04 0.36 -0.66 1.01 
Nup107-160_complex_(complex) 6.1E-07 9.2E-05 0.45 -0.56 1.01 
Cdt1/geminin_(complex) 1.3E-06 1.5E-04 0.21 -0.78 0.99 
p27Kip1/KPNA1_(complex) 1.9E-06 2.1E-04 0.48 -0.44 0.92 
p27Kip1/14-3-3_family_(complex) 1.9E-06 2.1E-04 0.48 -0.44 0.92 
Shelterin_Complex/Apollo_(complex) 6.7E-06 5.3E-04 0.51 -0.41 0.91 
Rev/importin-beta/B23/Ran-
GTP_complex_(complex) 
1.3E-06 1.5E-04 0.38 -0.52 0.90 
FANCD2/FANCI/BRCA2/PALB2_(co
mplex) 
1.4E-08 5.2E-06 0.78 -0.11 0.89 
mono-
ubiquitinated_FANCD2_(complex) 









1.1E-07 2.2E-05 0.58 -0.27 0.85 
mono-ubiquitinated_FANCI_(complex) 4.6E-11 3.9E-08 0.20 -0.61 0.82 
BRCA1/BRCA2/PALB2_(complex) 1.1E-07 2.3E-05 0.48 -0.29 0.77 
Rev_multimer-bound_HIV-
1_mRNA/CRM1_complex_(complex) 
7.2E-07 9.9E-05 0.18 -0.57 0.75 
Ku/Artemis/DNA-PKcs_(complex) 5.7E-06 4.8E-04 0.46 -0.25 0.71 
alpha7X1/beta1D_Integrin/Laminin_1_(
complex) 
6.3E-06 5.2E-04 0.35 -0.31 0.66 
FANCD_and_ub-FANCI-
bound_chromatin_(complex) 
4.0E-13 4.1E-10 0.29 -0.36 0.65 
RNA_primer-
DNA_primer/origin_duplex_(complex) 
1.1E-07 2.3E-05 0.47 -0.16 0.63 
RNA_primer-DNA_primer/G-
strand_extended_telomere_(complex) 
1.1E-07 2.3E-05 0.47 -0.16 0.63 
43s_Ribosome_subunit_(complex) 1.2E-06 1.5E-04 0.40 -0.07 0.47 
SUMO-1/ubiquitin_(complex) 1.1E-06 1.4E-04 0.04 -0.42 0.47 
Viral_RNA_dependent_RNA_polymera
se_(complex) 
1.5E-06 1.7E-04 0.14 -0.20 0.35 
 
Table 3: The 41 PARADIGM abstract processes differentially activated between group A and B CRCs in 
our cohort (FDR ≤ 0.05). IDs have been sorted by the magnitude of the difference between group B vs. 
group A samples. 
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positive_regulation_of_Wnt_receptor_
signaling_pathway_(abstract) 
1.4E-03 2.3E-02 2.14 -1.51 3.65 
negative_regulation_of_DNA_binding
_(abstract) 
1.9E-04 6.3E-03 1.37 -1.32 2.68 
G1/S_transition_of_mitotic_cell_cycle
_(abstract) 
2.1E-03 3.0E-02 1.15 -1.33 2.48 
anoikis_(abstract) 2.9E-03 3.7E-02 0.62 -1.57 2.20 
regulation_of_centriole_replication_(a
bstract) 
2.0E-06 2.1E-04 0.43 -1.64 2.07 
protein_catabolic_process_(abstract) 1.2E-05 8.2E-04 1.32 -0.63 1.95 
G2/M_transition_DNA_damage_chec
kpoint_(abstract) 
1.4E-03 2.3E-02 1.68 -0.24 1.92 
response_to_radiation_(abstract) 4.2E-03 4.7E-02 0.62 -1.05 1.67 
DNA_damage_checkpoint_(abstract) 2.1E-05 1.3E-03 0.39 -1.26 1.65 




1.9E-05 1.2E-03 0.39 -1.14 1.53 
positive_regulation_of_telomere_main
tenance_(abstract) 
2.4E-03 3.2E-02 0.18 -1.27 1.45 
MRN_complex_relocalizes_to_nuclear
_foci_(abstract) 
1.6E-03 2.6E-02 0.26 -1.12 1.38 
prostaglandin_biosynthetic_process_(a
bstract) 
1.5E-03 2.4E-02 0.43 -0.92 1.35 
centrosome_localization_(abstract) 3.7E-04 9.8E-03 0.58 -0.76 1.34 
chromosome_segregation_(abstract) 2.6E-03 3.4E-02 0.52 -0.70 1.22 
microtubule-based_process_(abstract) 5.2E-08 1.2E-05 0.55 -0.67 1.22 
spindle_assembly_(abstract) 1.1E-03 2.0E-02 0.48 -0.72 1.20 
regulation_of_mitotic_centrosome_sep
aration_(abstract) 
9.1E-05 3.7E-03 0.39 -0.80 1.19 
protein_folding_(abstract) 4.7E-05 2.2E-03 0.00 -1.17 1.17 
transcription_from_RNA_polymerase_
III_promoter_(abstract) 
5.8E-04 1.3E-02 0.96 -0.09 1.04 
G1/S_transition_checkpoint_(abstract) 3.2E-04 8.8E-03 0.14 -0.89 1.04 
Golgi_organization_(abstract) 2.9E-04 8.3E-03 0.31 -0.72 1.03 
positive_T_cell_selection_(abstract) 3.3E-04 9.0E-03 -0.09 -0.92 0.83 
activation_of_caspase_activity_by_cyt
ochrome_c_(abstract) 
1.7E-03 2.6E-02 0.22 -0.57 0.79 
DNA_replication_termination_(abstrac
t) 
3.3E-05 1.7E-03 0.66 -0.04 0.69 
G2/M_transition_of_mitotic_cell_cycl
e_(abstract) 
1.4E-03 2.3E-02 0.46 -0.12 0.58 
degradation_(abstract) 1.7E-03 2.6E-02 0.12 -0.45 0.57 
negative_regulation_of_cell_proliferati
on_(abstract) 
6.9E-04 1.5E-02 0.49 0.00 0.49 
negative_regulation_of_transcription_
during_mitosis_(abstract) 
4.3E-07 7.6E-05 0.14 -0.33 0.47 
transcription_termination_(abstract) 1.7E-05 1.1E-03 0.14 -0.30 0.44 
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regulation_of_DNA_replication_(abstr
act) 
1.1E-06 1.4E-04 0.30 -0.11 0.41 
chromatin_modification_(abstract) 5.3E-04 1.2E-02 0.23 -0.10 0.33 
regulation_of_DNA_replication_initiat
ion_(abstract) 
1.6E-03 2.6E-02 0.29 -0.04 0.33 
translational_initiation_(abstract) 3.3E-04 9.0E-03 0.23 -0.08 0.30 
DNA_repair_(abstract) 9.9E-04 1.9E-02 0.27 -0.04 0.30 
mitotic_spindle_organization_(abstract
) 
3.0E-03 3.8E-02 0.11 -0.17 0.28 
S_phase_of_mitotic_cell_cycle_(abstr
act) 
9.3E-04 1.8E-02 0.14 -0.12 0.27 
neural_crest_cell_migration_(abstract) 2.5E-04 7.6E-03 -0.83 0.27 -1.10 
cell_cycle_arrest_(abstract) 2.2E-03 3.1E-02 -1.14 0.06 -1.20 
ribosome_biogenesis_(abstract) 2.4E-03 3.2E-02 -2.69 0.22 -2.91 
 
Table 4: The top 100 of 1922 most significantly differentially activated PARADIGM genes and gene 
families between group A and B CRCs of the Jorissen cohort (FDR ≤ 0.05). IDs have been sorted by the 
magnitude of the difference between group B vs. group A samples. 
 
ID P value FDR Group A Group B Group B 
vs. 
Group A 
TP53 1.9E-20 7.0E-18 -2.84 4.14 6.98 
XBP1-2 8.6E-18 1.2E-15 -2.95 2.21 5.16 
CAV1 1.1E-18 2.3E-16 -0.66 1.84 2.50 
SNAI2 3.5E-19 8.9E-17 -0.71 1.67 2.38 
GJA1 1.4E-15 9.8E-14 -0.84 1.43 2.27 
VCAN 2.2E-18 3.8E-16 -0.64 1.62 2.26 
ENO1 2.5E-19 6.6E-17 -1.42 0.76 2.18 
KDELR3 6.8E-19 1.5E-16 -1.58 0.48 2.06 
HIF1A 8.7E-17 8.5E-15 -0.47 1.57 2.04 
ADM 2.1E-17 2.5E-15 -1.13 0.90 2.02 
C19orf10 3.5E-20 1.1E-17 -1.57 0.44 2.02 
DNAJB9 1.6E-16 1.5E-14 -1.55 0.47 2.01 
COL18A1 1.0E-19 3.1E-17 -0.81 1.19 2.00 
CXCR4 1.8E-21 9.9E-19 -1.02 0.98 2.00 
PFKFB3 7.5E-16 5.8E-14 -1.10 0.82 1.92 
EGLN1 6.7E-17 6.9E-15 -1.17 0.70 1.87 
RCHY1 3.0E-23 2.7E-20 -0.88 0.85 1.73 
TGFB1 3.0E-17 3.4E-15 -1.02 0.71 1.73 
ITGB2 1.1E-28 1.8E-24 -1.01 0.70 1.71 
MCL1 4.8E-18 7.7E-16 -1.00 0.60 1.59 
DUSP1 5.2E-16 4.1E-14 -0.61 0.92 1.53 
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FAS 4.1E-28 3.2E-24 -0.71 0.80 1.50 
CSF1R 9.8E-21 4.0E-18 -0.66 0.79 1.46 
DUSP5 8.9E-17 8.6E-15 -0.58 0.68 1.26 
PPP3CA 1.6E-16 1.4E-14 -1.03 0.19 1.22 
SLC2A3 6.7E-19 1.5E-16 -0.88 0.32 1.20 
TCF7L2 2.2E-16 1.9E-14 -0.71 0.47 1.18 
SERPINB5 3.3E-19 8.6E-17 -0.59 0.54 1.13 
HIV-1_(rna) 2.2E-19 6.1E-17 -0.61 0.46 1.07 
CSRP2 4.9E-16 3.9E-14 -0.90 0.17 1.07 
HMOX1 1.2E-15 8.5E-14 -0.69 0.37 1.07 
BNIP3L 3.4E-18 5.5E-16 -0.62 0.43 1.05 
CCR5 2.0E-16 1.7E-14 -0.79 0.26 1.05 
NT5E 4.7E-19 1.1E-16 -0.81 0.22 1.03 
TNFRSF10B 1.4E-15 1.0E-13 -0.81 0.19 0.99 
NDRG1 1.2E-16 1.1E-14 -0.54 0.45 0.99 
ARF4 1.8E-20 6.6E-18 -0.73 0.21 0.94 
CTSD 1.1E-17 1.5E-15 -0.57 0.35 0.92 
PHF23 2.5E-18 4.2E-16 -0.67 0.25 0.92 
CD86 5.7E-17 5.9E-15 -0.65 0.26 0.91 
HCLS1 2.0E-18 3.7E-16 -0.60 0.30 0.90 
SNX2 2.8E-20 9.0E-18 -0.66 0.24 0.90 
TAF13 1.5E-21 8.5E-19 -0.68 0.22 0.90 
ARFGAP3 5.4E-18 8.4E-16 -0.62 0.27 0.90 
CDC27 3.6E-25 6.2E-22 -0.64 0.25 0.89 
FBXO8 1.1E-22 8.8E-20 -0.66 0.23 0.89 
TYROBP 5.6E-18 8.6E-16 -0.61 0.28 0.89 
CD14 1.0E-20 4.0E-18 -0.61 0.28 0.89 
HPSE 1.4E-16 1.3E-14 -0.59 0.30 0.89 
FPR3 7.6E-16 5.8E-14 -0.61 0.28 0.88 
NRBF2 4.9E-17 5.3E-15 -0.65 0.23 0.88 
UBE2D3 1.9E-23 1.8E-20 -0.64 0.25 0.88 
FCGR2A 7.7E-17 7.6E-15 -0.65 0.23 0.88 
SEC24A 1.5E-17 2.0E-15 -0.62 0.26 0.88 
SLC30A7 4.9E-17 5.3E-15 -0.67 0.21 0.88 
PAFAH1B1 8.1E-18 1.2E-15 -0.68 0.20 0.88 
SSR3 4.4E-21 2.1E-18 -0.61 0.27 0.88 
RNF19B 2.8E-18 4.8E-16 -0.61 0.27 0.88 
ATP6V1B2 5.3E-18 8.4E-16 -0.63 0.24 0.87 
SRGN 2.4E-18 4.2E-16 -0.58 0.29 0.87 
GNS 1.3E-20 5.1E-18 -0.60 0.26 0.87 
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C1QA 5.2E-17 5.6E-15 -0.59 0.28 0.87 
NUP50 1.4E-15 9.7E-14 -0.63 0.23 0.86 
ATP5A1 4.2E-16 3.3E-14 -0.77 0.09 0.86 
KAT2B 1.1E-17 1.5E-15 -0.61 0.25 0.86 
ARHGAP30 2.8E-20 9.0E-18 -0.61 0.24 0.86 
PTPRC 1.6E-19 4.7E-17 -0.60 0.26 0.86 
FCER1G 8.2E-23 6.9E-20 -0.58 0.28 0.85 
CSF2RB 7.1E-18 1.1E-15 -0.58 0.27 0.85 
C1QB 2.6E-19 6.7E-17 -0.58 0.27 0.85 
Ubiquitin_conjugating_enzyme_(fa
mily) 
1.0E-18 2.2E-16 -0.60 0.21 0.82 
TLR8 4.7E-17 5.2E-15 -0.63 0.18 0.81 
CDC40 3.8E-16 3.1E-14 -0.62 0.17 0.80 
CXCR4_protein_(family) 1.5E-19 4.3E-17 -0.20 0.55 0.75 
CXCL8_(family) 8.3E-17 8.1E-15 -0.12 0.60 0.71 
VEGF 1.2E-22 8.9E-20 -0.21 0.48 0.69 
P55269 4.6E-26 1.6E-22 -0.29 0.36 0.66 
MDM2 4.3E-16 3.4E-14 -0.25 0.40 0.65 
CCR5/CXCR4_(family) 5.5E-28 3.2E-24 -0.32 0.33 0.65 
Active_caspases_(family) 9.8E-17 9.4E-15 -0.31 0.15 0.47 
MEK1-2_(family) 7.5E-16 5.8E-14 -0.20 0.22 0.41 
IGFBP3 1.8E-16 1.5E-14 -0.11 0.31 0.41 
C13orf15 2.5E-25 4.9E-22 -0.21 0.20 0.41 
PMS2 2.5E-25 4.9E-22 -0.21 0.20 0.41 
MEK1/MEK2_(family) 9.0E-16 6.7E-14 -0.19 0.21 0.40 
Caspase-2_p12_subunit_(family) 2.3E-16 1.9E-14 -0.24 0.11 0.35 
Caspase-2_precursor_(family) 2.3E-16 1.9E-14 -0.24 0.11 0.35 
Caspase-2_p18_subunit_(family) 2.3E-16 1.9E-14 -0.24 0.11 0.35 
Procaspase2/3_(family) 1.6E-16 1.5E-14 -0.22 0.10 0.32 
PKM2 7.6E-17 7.6E-15 -0.05 0.27 0.31 
PLA2G4B 1.7E-17 2.1E-15 -0.15 0.13 0.28 
SULT1A3 1.7E-17 2.1E-15 -0.15 0.13 0.28 
RORA-4 5.1E-17 5.4E-15 -0.03 0.25 0.28 
GPX2 1.1E-19 3.1E-17 0.29 -0.55 -0.84 
CD9 8.9E-21 4.0E-18 0.23 -0.61 -0.84 
ZMIZ2 8.0E-18 1.2E-15 0.19 -0.67 -0.86 
TRIM24 3.9E-17 4.3E-15 0.23 -0.68 -0.90 
RPA4 2.3E-16 1.9E-14 0.29 -0.62 -0.91 
SCAP 9.8E-18 1.4E-15 0.20 -0.71 -0.92 
USP7 1.3E-16 1.2E-14 0.20 -0.78 -0.98 
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Table 5: The top 100 of 1609 significantly differentially activated PARADIGM complexes between 
group A and B CRCs of the Jorissen cohort (FDR ≤ 0.05). IDs have been sorted by the magnitude of the 
difference between group B vs. group A samples. 









p53_(tetramer)_(complex) 2.1E-20 7.6E-18 -3.58 5.96 9.54 
HIF1A/ARNT_(complex) 6.7E-22 3.9E-19 -3.67 2.74 6.42 
JUN/FOS_(complex) 4.6E-19 1.1E-16 -2.48 3.88 6.35 
p53_tetramer_(complex) 3.9E-19 9.7E-17 -0.90 2.21 3.10 
MYC/Max/MIZ-1_(complex) 2.0E-19 5.5E-17 -1.68 1.27 2.95 
p53/BCL2_subfamily_(complex) 2.0E-19 5.6E-17 -0.62 1.92 2.55 
p53/mSin3A_(complex) 1.8E-18 3.3E-16 -0.43 1.93 2.37 
p53/PIN1_(complex) 1.5E-17 2.0E-15 -0.48 1.86 2.33 
p53_(tetramer)/SP1_(complex) 6.1E-18 9.2E-16 -0.01 1.89 1.90 
enolase_1_dimer_(alpha)_(complex) 1.3E-17 1.7E-15 -1.22 0.67 1.90 
p53/SIRT1_(complex) 4.6E-19 1.1E-16 -0.39 1.50 1.89 
Glucocorticoid_receptor/Dexamethas
one_Complex_(complex) 
1.7E-17 2.2E-15 -0.72 1.10 1.82 
HIF1A/ARNT/Cbp/p300_(complex) 3.0E-16 2.5E-14 -0.82 0.99 1.80 
p53/NEDD8_(complex) 8.8E-19 1.9E-16 -0.23 1.57 1.80 
Caveolin-
1_bound_to_Basigin_(complex) 
2.0E-17 2.5E-15 -0.27 1.52 1.79 
p53/SP1_(complex) 8.2E-18 1.2E-15 -0.33 1.46 1.79 
CXCR4_(dimer)_(complex) 5.9E-21 2.8E-18 -0.92 0.87 1.79 
Dexamethasone/glucocorticoid_rece
ptor_(complex) 
2.3E-17 2.7E-15 -0.72 1.06 1.78 
p53_(tetramer)/NF-Y_(complex) 3.4E-17 3.9E-15 -0.04 1.74 1.78 
glucocorticoid/glucocorticoid_recept
or_(complex) 
1.9E-17 2.3E-15 -0.72 1.05 1.78 




4.1E-22 2.4E-19 -0.83 0.84 1.67 
MYC/Max/MIZ-
1/DNMT3A/GFI1_(complex) 
1.2E-16 1.1E-14 -0.73 0.93 1.66 
HIF1A/JAB1_(complex) 2.4E-20 8.2E-18 -0.22 1.43 1.66 
HIF1A/p53_(complex) 9.5E-21 4.0E-18 -0.25 1.40 1.64 
JUN/FOS/GATA2_(complex) 4.5E-16 3.6E-14 -0.03 1.59 1.62 
BAK/p53_(complex) 3.1E-18 5.2E-16 -0.24 1.34 1.59 
MIZ-1/IRF8_(complex) 1.8E-16 1.6E-14 -1.24 0.34 1.58 
p53_(tetramer)/Drosha/DGCR8/p68_
helicase_(complex) 
1.3E-18 2.6E-16 -0.04 1.47 1.51 
AR/GR_(complex) 4.1E-16 3.3E-14 -0.56 0.88 1.44 
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HIF-1-alpha/ARNT_(complex) 7.6E-19 1.7E-16 -0.52 0.91 1.43 
FAS_(trimer)_(complex) 3.7E-27 1.6E-23 -0.65 0.74 1.39 
Phospho-COP1(Ser-
387)/p53_complex_(complex) 
1.1E-16 1.0E-14 -0.14 1.16 1.30 
TLR1/MD2_(complex) 4.1E-16 3.3E-14 -0.93 0.34 1.27 
ERM/c-JUN_(complex) 4.9E-17 5.3E-15 -0.83 0.34 1.17 
SMAD2-3/SMAD4/MYC/Max/MIZ-
1_(complex) 
2.8E-17 3.2E-15 -0.50 0.63 1.13 
GLUT3_tetramer_(complex) 7.1E-19 1.6E-16 -0.81 0.29 1.10 
C1q_(complex) 1.5E-16 1.4E-14 -0.54 0.56 1.10 
C1Q_subunit_(C1QA/C1QB/C1QC_
heterotrimer)_(complex) 
1.5E-16 1.4E-14 -0.54 0.56 1.10 
alphaD/beta2_Integrin_(complex) 3.6E-22 2.2E-19 -0.67 0.41 1.08 
Integrin_alphaDbeta2_(complex) 3.6E-22 2.2E-19 -0.67 0.41 1.08 
SDF1/CXCR4_(dimer)_(complex) 1.2E-18 2.4E-16 -0.15 0.87 1.03 
BAK/MCL1_(complex) 2.8E-16 2.3E-14 -0.64 0.38 1.02 
Integrin_alphaLbeta2_(LFA-
1)_(complex) 
1.5E-25 3.6E-22 -0.65 0.36 1.01 
alphaL/beta2_Integrin_(complex) 1.5E-25 3.6E-22 -0.65 0.36 1.01 
alphaX/beta2_Integrin_(complex) 3.0E-22 2.0E-19 -0.64 0.37 1.01 
alphaX/beta2_Integrin/heparin_(com
plex) 
3.0E-22 2.0E-19 -0.64 0.37 1.01 
Integrin_alphaXbeta2_(complex) 3.0E-22 2.0E-19 -0.64 0.37 1.01 
alphaM/beta2_Integrin_(complex) 1.4E-18 2.7E-16 -0.65 0.33 0.98 




4.9E-19 1.2E-16 -0.75 0.20 0.95 
TRAIL_receptor-
2/TRAIL_Trimer_(complex) 
3.3E-21 1.7E-18 -0.57 0.37 0.94 
PAFAH/LIS1_(complex) 1.4E-23 1.4E-20 -0.93 0.00 0.93 
MAD/Max_(complex) 5.1E-17 5.4E-15 -0.62 0.27 0.89 
Mad/Max_(complex) 4.9E-17 5.3E-15 -0.62 0.27 0.89 
LFA-1/ICAM_1-4_(complex) 6.7E-25 1.1E-21 -0.43 0.45 0.88 
ARF4/GTP_(complex) 2.5E-20 8.2E-18 -0.70 0.16 0.86 
ARF4/GDP_(complex) 2.2E-20 7.8E-18 -0.68 0.17 0.85 
Cathepsin_D/ceramide_(complex) 1.0E-17 1.4E-15 -0.54 0.30 0.84 
alphaM/beta2_Integrin/P-
Selectin/PSGL1_(complex) 
5.9E-16 4.6E-14 -0.28 0.53 0.82 
LPS_complexed_with_secreted_CD1
4_(complex) 
1.0E-20 4.0E-18 -0.57 0.24 0.81 
LPS_complexed_with_GPI-
anchored_CD14_(complex) 
1.0E-20 4.0E-18 -0.57 0.24 0.81 
CXCR4/g-alpha-q_(complex) 6.2E-20 1.9E-17 -0.62 0.18 0.79 
FceRI_gamma_dimer_(complex) 8.3E-23 6.9E-20 -0.54 0.25 0.79 
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SDF1/CXCR4_(complex) 7.3E-21 3.4E-18 -0.34 0.44 0.79 
CSF2RB_(dimer)_(complex) 7.8E-18 1.2E-15 -0.55 0.24 0.78 
signal_recognition_particle_endoplas
mic_reticulum_targeting_(complex) 
1.1E-17 1.6E-15 -0.47 0.31 0.78 
C1Q_(complex) 3.3E-16 2.7E-14 -0.31 0.46 0.77 
LPS_complexed_with_CD14_(famil
y) 
1.0E-20 4.0E-18 -0.55 0.22 0.77 
p-PECAM1/p-PECAM1_(complex) 6.8E-16 5.3E-14 -0.52 0.23 0.74 
Integrin_alphaXbeta2/AMICA1_(co
mplex) 
2.2E-18 3.9E-16 -0.37 0.37 0.74 
Integrin-alpha/Integrin-
beta/Caveolin-1/FYN_(complex) 
3.4E-16 2.8E-14 -0.07 0.67 0.74 
full_length_TLR8_(complex) 1.7E-16 1.5E-14 -0.58 0.13 0.72 
KIR2DS2_complexed_with_DAP12
_(complex) 
5.6E-18 8.6E-16 -0.50 0.21 0.72 
TRAIL_receptor-
2/TRAIL_complex_(complex) 
1.9E-18 3.4E-16 -0.71 0.00 0.71 
p53/MDM2_(complex) 3.3E-18 5.4E-16 -0.01 0.69 0.70 
CD4/CD4/CXCR4_(complex) 1.2E-17 1.7E-15 -0.70 0.00 0.70 




1.3E-18 2.5E-16 -0.44 0.25 0.69 
LIS1/Poliovirus_Protein_3A_(compl
ex) 
1.3E-17 1.7E-15 -0.55 0.14 0.69 
VEGF/VEGF_R_(complex) 3.4E-21 1.7E-18 -0.12 0.56 0.69 
FPRL2/FPRL2_ligands_(complex) 2.7E-17 3.2E-15 -0.50 0.18 0.68 
alphaM/beta2_Integrin/JAM-B/JAM-
C_(complex) 
1.9E-16 1.7E-14 -0.31 0.37 0.68 
IL3RB/Jak2_(complex) 8.2E-18 1.2E-15 -0.48 0.20 0.68 
TRAIL/TRAILR2/FADD/TRADD/R
IP_(complex) 
2.9E-18 4.8E-16 -0.34 0.34 0.68 
HIV-1/VIF_(complex) 7.1E-17 7.3E-15 -0.29 0.39 0.68 
Ca2+/CaM_(complex) 1.4E-16 1.3E-14 -0.18 0.47 0.65 
LFA-1/JAM-A_(complex) 1.2E-17 1.6E-15 -0.31 0.26 0.57 
TRAIL/TRAILR2_(complex) 6.1E-17 6.4E-15 -0.08 0.48 0.57 
CCR5/g-alpha-q_(complex) 1.7E-18 3.3E-16 -0.56 0.00 0.56 
active_Caspase-2_(complex) 7.3E-17 7.4E-15 -0.36 0.18 0.53 
C1_complex_(complex) 8.8E-18 1.3E-15 -0.06 0.47 0.53 
p-SLP-76/NCK1_(complex) 1.1E-17 1.5E-15 -0.44 0.00 0.44 
SNX1/SNX2_(complex) 4.3E-17 4.7E-15 -0.43 0.00 0.43 
alphaD/beta2_Integrin/ICAM3_(com
plex) 
3.2E-17 3.7E-15 -0.21 0.22 0.43 
VCAN/TLR2/TLR1_(complex) 2.4E-16 2.0E-14 -0.05 0.38 0.43 
cIAP1/UbcH5C_(complex) 6.4E-20 2.0E-17 -0.41 0.00 0.41 
Complement_activator/C1_complex_ 2.1E-17 2.5E-15 -0.04 0.36 0.40 




7.3E-17 7.4E-15 -0.04 0.24 0.28 
TL_phenol_transferase_1A3_homodi
mer_(complex) 
2.1E-17 2.5E-15 -0.14 0.12 0.25 
 
Table 6: The 88 significantly differentially activated PARADIGM abstract processes between group A 
and B CRCs of the Jorissen cohort (FDR ≤ 0.05). IDs have been sorted by the magnitude of the difference 
between group B vs. group A samples. 









DNA_damage_(abstract) 5.3E-09 6.9E-08 -3.53 2.90 6.44 
anoikis_(abstract) 2.1E-18 3.7E-16 -1.11 2.16 3.27 
negative_regulation_of_DNA_bindin
g_(abstract) 
4.9E-18 7.8E-16 -0.68 1.95 2.63 
response_to_radiation_(abstract) 3.4E-19 8.6E-17 -0.63 1.66 2.29 
gap_junction_assembly_(abstract) 1.3E-15 9.1E-14 -0.79 1.43 2.22 
G2/M_transition_DNA_damage_che
ckpoint_(abstract) 
7.8E-17 7.8E-15 -0.02 1.59 1.61 
osteoclast_differentiation_(abstract) 5.6E-10 8.9E-09 -0.46 1.14 1.59 
primary_microRNA_processing_(abs
tract) 
4.9E-18 7.8E-16 -0.03 1.32 1.34 
extracellular_matrix_organization_(a
bstract) 
1.3E-11 3.2E-10 -0.59 0.70 1.29 
protein_catabolic_process_(abstract) 3.4E-17 3.8E-15 -0.22 1.00 1.21 
regulation_of_cell_cycle_(abstract) 1.1E-07 1.1E-06 -0.70 0.51 1.21 
activation_of_caspase_activity_by_c
ytochrome_c_(abstract) 




4.8E-09 6.2E-08 -0.72 0.20 0.92 




5.5E-19 1.3E-16 -0.58 0.32 0.91 
monocyte_activation_(abstract) 1.3E-08 1.6E-07 -0.59 0.29 0.88 
dendritic_cell_antigen_processing_a
nd_presentation_(abstract) 
5.9E-17 6.2E-15 -0.55 0.32 0.87 
cytotoxic_T_cell_degranulation_(abs
tract) 
3.1E-08 3.4E-07 -0.62 0.25 0.87 
protein_folding_(abstract) 1.7E-04 7.3E-04 -0.62 0.25 0.86 
pseudopodium_formation_(abstract) 1.3E-09 1.9E-08 -0.61 0.23 0.84 
lipid_biosynthetic_process_(abstract) 1.8E-03 5.6E-03 -0.65 0.19 0.84 
Antiviral_Response_(abstract) 5.0E-06 3.2E-05 -0.65 0.15 0.79 
Antibacterial_Response_(abstract) 5.0E-06 3.2E-05 -0.65 0.15 0.79 
neutrophil_chemotaxis_(abstract) 5.6E-12 1.5E-10 -0.59 0.20 0.79 
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DNA_biosynthetic_process_(abstract
) 
1.9E-05 1.0E-04 -0.77 0.00 0.77 
positive_regulation_of_leukocyte_mi
gration_(abstract) 








7.8E-06 4.8E-05 -0.65 0.07 0.71 
Immunoregulation_(abstract) 7.8E-06 4.8E-05 -0.65 0.07 0.71 
prostaglandin_biosynthetic_process_
(abstract) 
3.3E-08 3.6E-07 -0.74 -0.04 0.70 
phosphatidic_acid_metabolic_proces
s_(abstract) 





2.2E-11 5.0E-10 -0.49 0.18 0.67 
stress_fiber_assembly_(abstract) 1.4E-04 5.9E-04 -0.45 0.21 0.66 
neuron_apoptosis_(abstract) 2.9E-07 2.5E-06 -0.41 0.22 0.63 
negative_regulation_of_T_cell_prolif
eration_(abstract) 
5.2E-04 1.9E-03 -0.33 0.25 0.58 
Golgi_organization_(abstract) 1.9E-02 4.3E-02 -0.26 0.32 0.57 
cholesterol_biosynthetic_process_(ab
stract) 
5.2E-03 1.4E-02 -0.55 0.03 0.57 




2.1E-10 3.7E-09 -0.28 0.29 0.57 
regulation_of_transcription_(abstract
) 
1.8E-04 7.6E-04 -0.47 0.10 0.57 
necrosis_(abstract) 1.0E-15 7.5E-14 -0.27 0.25 0.53 
Schwann_cell_development_(abstrac
t) 
1.3E-12 4.2E-11 -0.25 0.19 0.44 
Metastasis_(abstract) 4.9E-03 1.4E-02 -0.08 0.33 0.42 
positive_regulation_of_phagocytosis
_(abstract) 
1.9E-12 5.9E-11 -0.24 0.17 0.41 
skeletal_muscle_tissue_development
_(abstract) 
1.2E-05 6.9E-05 0.22 0.63 0.41 
actin_cytoskeleton_organization_(ab
stract) 




5.0E-04 1.8E-03 -0.03 0.38 0.41 
JNK_cascade_(abstract) 6.0E-07 4.8E-06 -0.11 0.25 0.37 
G1/S_transition_checkpoint_(abstrac
t) 
4.2E-04 1.6E-03 -0.51 -0.15 0.36 
neutrophil_activation_(abstract) 1.1E-05 6.5E-05 -0.35 0.00 0.35 
regulation_of_interleukin-
6_production_(abstract) 
3.9E-15 2.4E-13 -0.04 0.28 0.32 
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respiratory_burst_involved_in_infla
mmatory_response_(abstract) 
1.2E-07 1.2E-06 -0.32 0.00 0.32 
G1_phase_of_mitotic_cell_cycle_(ab
stract) 
3.5E-04 1.4E-03 -0.25 0.07 0.32 
positive_regulation_of_cell_migratio
n_(abstract) 
1.2E-04 5.3E-04 -0.47 -0.16 0.31 
natural_killer_cell_activation_(abstra
ct) 
1.2E-08 1.4E-07 -0.13 0.18 0.31 
clathrin-
independent_pinocytosis_(abstract) 
9.7E-06 5.8E-05 -0.18 0.12 0.30 
positive_regulation_of_endocytosis_
(abstract) 
9.7E-06 5.8E-05 -0.18 0.12 0.30 
liver_development_(abstract) 9.7E-06 5.8E-05 -0.18 0.12 0.30 
regulation_of_epithelial_cell_migrati
on_(abstract) 
9.7E-06 5.8E-05 -0.18 0.12 0.30 
regulation_of_mitotic_centrosome_s
eparation_(abstract) 
1.3E-02 3.2E-02 -0.29 0.00 0.29 
The_NLRP3_inflammasome_(abstra
ct) 
1.1E-04 5.0E-04 -0.17 0.12 0.28 
positive_regulation_of_JNK_cascade
_(abstract) 
9.8E-13 3.3E-11 -0.16 0.12 0.28 
cell_growth_and/or_maintenance_(a
bstract) 
1.6E-03 5.1E-03 -0.23 0.05 0.28 
apoptosis_(abstract) 2.2E-05 1.2E-04 -0.04 0.24 0.27 
positive_regulation_of_cell_prolifera
tion_(abstract) 
1.2E-03 4.0E-03 -0.32 -0.05 0.26 
calcium_ion-
dependent_exocytosis_(abstract) 
4.0E-02 8.3E-02 -0.12 0.14 0.26 
membrane_fusion_(abstract) 4.0E-02 8.3E-02 -0.12 0.14 0.26 
tube_development_(abstract) 2.6E-05 1.4E-04 -0.13 0.12 0.25 
actin_filament_polymerization_(abst
ract) 
2.4E-03 7.3E-03 0.17 -0.09 -0.26 
axonogenesis_(abstract) 3.9E-02 8.2E-02 -0.21 -0.49 -0.27 
embryonic_digit_morphogenesis_(ab
stract) 
1.1E-07 1.0E-06 0.03 -0.25 -0.28 




8.3E-04 2.9E-03 0.06 -0.28 -0.34 
positive_regulation_of_Wnt_receptor
_signaling_pathway_(abstract) 
2.5E-02 5.6E-02 0.20 -0.17 -0.37 
chromatin_remodeling_(abstract) 2.7E-02 6.0E-02 -0.28 -0.66 -0.38 
heart_development_(abstract) 1.8E-03 5.8E-03 0.03 -0.45 -0.48 
myoblast_fusion_(abstract) 4.8E-06 3.1E-05 0.52 0.00 -0.52 
membrane_budding_(abstract) 2.2E-07 1.9E-06 0.03 -0.48 -0.52 
cell_cycle_arrest_(abstract) 2.4E-07 2.1E-06 0.00 -0.52 -0.52 
cytokine_production_involved_in_in
flammatory_response_(abstract) 
2.1E-10 3.7E-09 0.28 -0.29 -0.57 
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negative_regulation_of_cell_cycle_(
abstract) 
2.3E-02 5.2E-02 0.43 -0.19 -0.62 
BMP_signaling_pathway_(abstract) 1.8E-03 5.6E-03 0.77 0.00 -0.77 
regulation_of_isotype_switching_to_
IgG_isotypes_(abstract) 
5.1E-06 3.3E-05 0.21 -0.59 -0.80 
apoptotic_nuclear_changes_(abstract
) 
1.9E-07 1.7E-06 0.17 -0.63 -0.80 
virus_assembly_(abstract) 1.6E-13 6.7E-12 0.59 -0.25 -0.84 
megakaryocyte_differentiation_(abst
ract) 
2.0E-05 1.1E-04 0.29 -0.60 -0.89 
Bergmann_glial_cell_differentiation
_(abstract) 
8.4E-11 1.7E-09 0.32 -0.97 -1.29 
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for Affymetrix Gene 1.0 ST arrays with variable
RNA integrity
Katie S Viljoen and Jonathan M Blackburn*Abstract
Background: RNA and microarray quality assessment form an integral part of gene expression analysis and,
although methods such as the RNA integrity number (RIN) algorithm reliably asses RNA integrity, the relevance of
RNA integrity in gene expression analysis as well as analysis methods to accommodate the possible effects of
degradation requires further investigation. We investigated the relationship between RNA integrity and array quality
on the commonly used Affymetrix Gene 1.0 ST array platform using reliable within-array and between-array quality
assessment measures. The possibility of a transcript specific bias in the apparent effect of RNA degradation on the
measured gene expression signal was evaluated after either excluding quality-flagged arrays or compensation for
RNA degradation at different steps in the analysis.
Results: Using probe-level and inter-array quality metrics to assess 34 Gene 1.0 ST array datasets derived from
historical, paired tumour and normal primary colorectal cancer samples, 7 arrays (20.6%), with a mean sample RIN of
3.2 (SD = 0.42), were flagged during array quality assessment while 10 arrays from samples with RINs < 7 passed
quality assessment, including one sample with a RIN < 3. We detected a transcript length bias in RNA degradation
in only 5.8% of annotated transcript clusters (p-value 0.05, FC ≥ |2|), with longer and shorter than average
transcripts under- and overrepresented in quality-flagged samples respectively. Applying compensatory measures
for RNA degradation performed at least as well as excluding quality-flagged arrays, as judged by hierarchical
clustering, gene expression analysis and Ingenuity Pathway Analysis; importantly, use of these compensatory
measures had the significant benefit of enabling lower quality array data from irreplaceable clinical samples to be
retained in downstream analyses.
Conclusions: Here, we demonstrate an effective array-quality assessment strategy, which will allow the user to
recognize lower quality arrays that can be included in the analysis once appropriate measures are applied to
account for known or unknown sources of variation, such as array quality- and batch- effects, by implementing
ComBat or Surrogate Variable Analysis. This approach of quality control and analysis will be especially useful for
clinical samples with variable and low RNA qualities, with RIN scores ≥ 2.
Keywords: Gene expression profiling, Microarray, RNA quality, RNA integrity number, Quality control, ComBat,
Surrogate variable analysis, Non-biological experimental variance* Correspondence: jonathan.blackburn@uct.ac.za
Institute of Infectious Disease and Molecular Medicine, University of Cape
Town, Anzio Road, Observatory, Cape Town 7925, South Africa
© 2013 Viljoen and Blackburn; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Viljoen and Blackburn BMC Genomics 2013, 14:14 Page 2 of 13
http://www.biomedcentral.com/1471-2164/14/14Background
RNA degradation is a common concern in gene expres-
sion analysis, especially for clinical samples where RNA
degradation may occur before sample collection [1]. A
wealth of archival material, either snap frozen or formalin
fixed and paraffin embedded (FFPE), could potentially be
used for gene expression analysis, given an appropriate
method to evaluate and account for the effect of RNA
degradation on the quality of downstream gene expression
data. Methods such as the RNA integrity number (RIN)
algorithm reliably assesses RNA integrity by extracting
features from the RNA electropherogram. The RIN algo-
rithm was developed using learning tools to identify
regions (features) indicative of RNA integrity in the elec-
tropherogram, which are then used to compile the RNA
integrity number on a scale of 1 to 10. However, the rele-
vance of RNA integrity in gene expression analysis, espe-
cially when there is large variability between samples,
requires further investigation and validation on a platform
specific basis. The impact of RNA integrity on gene ex-
pression analysis has been investigated on both qRT-PCR
and certain microarray platforms [2-7]. Opitz et al investi-
gated the impact of RNA degradation on Agilent 44 k
gene expression profiling by subjecting RNA from clinical
biopsies to temperature-induced RNA degradation and
comparing gene expression to the original, intact samples.
Notably, less than 1% of genes were affected, even after
substantial RNA degradation, where control and test sam-
ples had RINs of 9 and 5 respectively. The affected tran-
scripts were relatively shorter, had lower GC content, or
had probes relatively closer to the 5' region of the gene
compared to more robust genes [6]. Although the process
of RNA degradation is not fully understood, both exo-
nuclease and endonuclease activity is likely to play an im-
portant role [6]. Classical oligo-dT based cDNA synthesis,
which starts at the poly-A tail, will most certainly be com-
promised by exonuclease activity. In contrast random
priming does not rely on full length mRNA and therefore
is in theory at least partially relieved from the affects of
RNA degradation [6-9].
When using semi-degraded RNA for gene expression
studies, reliable measures of array quality provide valuable
information that can be used to guide downstream ana-
lysis. Microarray data quality may be defined in terms of
accuracy (systematic bias between the true and measured
value), precision (the uncertainty in replicated measures),
specificity (the selective power of the measurement to
respond only to the specific targets) and sensitivity (the
expression range potentially covered by the measurement)
[10]. Any attempt to utilise array quality results to guide
downstream analysis should ideally take into account the
possible effects of RNA degradation on sensitivity, specifi-
city and accuracy. In previous work, Binder et al proposed
a single-array preprocessing method that allows correctionfor systematic biases such as RNA degradation by utilising
information on the 3'/5'-amplification bias and the sample-
specific calling rate [10]. Lassmann et al proposed using a
data adjustment method to allow comparative analysis of
microarray datasets derived from fresh frozen vs. FFPE
samples by centering the log intensities of each probe set
independently to a mean of zero in both groups [8]. Chow
et al evaluated the suitability of different quality control
and preprocessing strategies for use with partially degraded
RNA samples on the Illumina DASL-based gene expres-
sion assay using mean inter-array correlation and multi-
variate distance matrix regression (MDMR) as a measure
of success [11]. Unfortunately none of these studies are
directly applicable to one of the most commonly used
human transcriptomic microarray platforms, namely Affy-
metrix Gene 1.0 ST arrays, either because they do not use
a random priming approach or because the design of the
microarray platform differs substantially from Gene 1.0 ST
arrays. We therefore identified two alternative approaches
that might be used as compensatory methods: Firstly,
Johnson et al developed an empirical Bayes algorithm,
ComBat, to directly adjust for non-biological experimental
variation. As the name implies, this method is most often
used to adjust for batch effects i.e. when microarrays are
processed on different dates [12]. Secondly, Leek et al
developed a method called Surrogate Variable Analysis
(SVA), which examines the contribution of sources ofsignal
due to unknown (surrogate) variables in high-dimensional
data sets, which may confound the biological signal of
interest [13]. The surrogate variables are constructed dir-
ectly from the gene expression data where groups of genes
that are affected by each source of variation are identified,
factors are then estimated for each array which can be
included in a linear model to adjust for unknown sources
of noise e.g. RNA- or array-quality.
Here, we investigate the relationship between RNA integ-
rity and array quality on Affymetrix Gene 1.0 ST arrays for
34 paired colorectal tumour and adjacent normal biopsies
of highly variable RNA integrity. We assume that at a cer-
tain point on the RIN scale, RNA will be degraded to the
extent where fragments are too small to analyse reliably
and for the purpose of this analysis we arbitrarily select a
RIN cutoff of 2. We describe the within- and between-array
quality control measures and analysis methods that we
found most relevant for gene expression analysis of samples
with highly variable RINs on Affymetrix Gene 1.0 ST arrays.
We then investigate the possibility of a transcript-length
dependency in RNA degradation. Finally, we apply array
quality information to either exclude quality-flagged arrays,
to directly adjust the data using the ComBat algorithm, or
to account for unknown sources of variation (such as RNA
integrity or array quality) in the model fitting process using
SVA. The data discussed, have been submitted to ArrayEx-
press, with accession number E-MEXP-3715.
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Array quality
We assessed array quality using within- and between-
array measures – the former to assess raw data quality
(Figure 1a & 1b), and the latter to assess the quality of
an array relative to a large publically available collection
of high quality Gene 1.0 ST arrays (Figure 1c). Raw array
quality was investigated at the probe level by calculating
the difference between the means of perfect match- and
background-probes for each array as well as the coeffi-
cient of variation (CV) across all probes for each array.
Preprocessed data quality was assessed using the global
normalised, unscaled standard error (GNUSE) [14]. See
Methods section for details.
The 34 RNA samples used in this study had a mean
RIN of 6.3 and a standard deviation of 2.0. Samples that
failed all three measures of quality had RINs between 2
and 3.3 as summarised in Table 1. Samples were ranked
by GNUSE median and we found a good concordance in
terms of ranking between the different quality control
metrics. Samples that failed at least two out of the three
quality measures were flagged for downstream analysis,
resulting in 7 out of 34 samples being flagged (mean
RIN = 3.2; SD = 0.42). Interestingly, for one sample with
a RIN of 2.6, array quality was not compromised, jud-
ged by our quality measures. The possibility of a RIN-
independent RNA quality factor, such as chemical purity,
was investigated by performing a two-tailed Student’s t-test,
comparing A260/230 ratios between quality-flagged and
quality-passed sample groups but no significant association
was found (p-value = 0.14).
Transcript-dependent effects of RNA degradation on
accuracy
To investigate a possible probe-positional intensity bias
































































































































Figure 1 Array quality metrics. a) Raw coefficient of variation across all p
is calculated as 2SD from the mean of CVs for arrays with RINs > 6. b) Raw
unscaled errors (GNUSE) across probes for each array. Samples that were flaintensity from the 5'- to 3' end of the sequence using
4644/32321 (14.4%) of transcript clusters for Gene 1.0
ST arrays and 54130/54675 (99%) of probesets for
HGU133-plus2 arrays. The number of probes per set
varies for GeneST arrays, so we selected the largest
group (N = 4664), which had exactly 25 probes/set.
Interestingly, from the 4644 transcript clusters displayed
in Figure 2, Gene ST 1.0 arrays, do not display the same
probe-positional intensity bias typically seen in oligo-dT
based arrays such as the HGU133-plus2 arrays.
We next investigated which genes were most affected
in our quality-flagged category and identified 1994 out
of 21943 annotated transcript clusters (with 1172
uniquely identified genes) that were significantly diffe-
rent (fold change ≥ |2|, adjusted p-value ≤ 0.05) between
the two quality categories previously discussed. Of the
1172 uniquely identified genes, 1032 and 140 showed
decreased or increased intensity in the quality-flagged
category respectively (Figure 3a). To investigate tran-
script characteristics in the genes most affected, we com-
pared transcript lengths (taken as the median cDNA
length for each gene) between the different groups. Com-
pared to the unaffected genes, median cDNA lengths of
genes that showed increased intensity were significantly
shorter (p-value < 2.2 e − 16) while those with decreased
intensity significantly longer (p-value = 2.9 e − 9) with
regards to quality, judged using the Mann Whitney test
(Figure 3b).
Quality dependent methods of data adjustment and
analysis
After assigning samples to two categories according to
array quality measures, we next assessed the performance
of the five preprocessing and analysis methods. Broadly
speaking, the data was either directly adjusted for quality
































































































































robes by sample, the red line represents our chosen threshold which
perfect match mean - background mean c) Global normalised
gged during quality assessment are highlighted in red.
Table 1 Array quality assessment summary
Sample ID RIN RNA 260/230 ratio GNUSE probe-level CV PM-BG Array weight
44N 3 2.41 fail (1) fail (3) fail (1) 0.22 (1)
33T 2.8 2.08 fail (2) fail (5) fail (2) 0.28 (2)
60N 3.2 2.03 fail (3) fail (1) fail (3) 0.42 (3)
63T 3 2.2 fail (4) fail (4) pass 0.59 (6)
10T 3.2 2.18 fail (5) fail (2) fail (4) 0.60 (7)
56T 3.3 1.87 fail (6) fail (10) fail (5) 0.42 (4)
41T 4.2 2.21 fail (7) fail (9) pass 0.78 (8)
13N 4.6 2.24 pass fail (7) pass 0.82 (9)
15T 4.8 2.15 pass fail (8) pass 1.07 (15)
4N 2.6 1.62 pass pass pass 0.44 (5)
18N 7.1 1.66 pass pass pass 0.83 (10)
8T 8.5 2.16 pass pass pass 0.85 (11)
56N 6.5 1.94 pass pass pass 0.95 (12)
20T 7.4 1.6 pass pass pass 1.02 (13)
44T 6.9 1.72 pass pass pass 1.03 (14)
11T 8.6 2.16 pass pass pass 1.07 (16)
60T 6.4 1.64 pass pass pass 1.09 (17)
14T 6.4 1.76 pass pass pass 1.09 (18)
13T 8.3 2 pass pass pass 1.11 (19)
23T 7 2.17 pass pass pass 1.18 (20)
8N 7.1 2.22 pass pass pass 1.25 (21)
18T 7.4 1.85 pass pass pass 1.26 (22)
33N 8.1 1.82 pass pass pass 1.45 (23)
34T 8 2.25 pass pass pass 1.49 (24)
11N 6.8 1.94 pass pass pass 1.50 (25)
20N 7.3 2.11 pass pass pass 1.50 (26)
63N 7.5 2.13 pass pass pass 1.61 (27)
23N 8.4 2.02 pass pass pass 1.61 (28)
34N 8.3 2.21 pass pass pass 1.61 (29)
14N 8.1 2.36 pass pass pass 1.74 (30)
41N 5.4 2.07 pass pass pass 1.76 (31)
10N 7.3 1.78 pass pass pass 1.78 (32)
15N 6.9 2.16 pass pass pass 1.90 (33)
4T 8.4 2.25 pass pass pass 2.14 (34
Array performance is ranked for each measure with 1 considered the worst quality. Samples highlighted in bold were flagged for downstream analysis.
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addressed by including known or unknown sources of
non-biological variance in the linear model fit to assess
differential expression.
The five methods of data preprocessing and analysis,
further detailed in the Methods section, were: 1) Estimat-
ing array quality weights which were then included in the
linear model fit; 2) Excluding quality-flagged arrays from
the analysis; 3) Applying a batch correction algorithm,
ComBat, [12] to directly adjust the data according to qua-
lity, where arrays were divided into two categories accor-
ding to the array quality assessment; 4) “Quality” and“batch” were included as a factors in the linear model
together with disease status; 5) Possible unknown sources
of non-biological variance, such as quality, was estimated
by SVA, with the output incorporated into the linear
model fit [13].
To assess the effect of using ComBat for direct data
adjustment, hierarchical clustering using Euclidian dis-
tance was performed before and after direct adjustment
(Figure 4). We chose to use Euclidian distance based on
research by Gibbons et al who demonstrated that, for log-
transformed expression data, using Euclidian distance is
more appropriate than Pearson’s correlation coefficients
RNA degradation plot
5' <−−−−−> 3'
























a RNA degradation plot
5' <−−−−−> 3'


























Figure 2 Mean probe intensity by probe position. Each line represents an array for a) Gene 1.0 ST arrays: transcript clusters with exactly 25
probes (N = 4644) and b) HGU133-plus2 arrays previously analysed with a subset of the cohort: probesets with exactly 11 probes per probeset.
Viljoen and Blackburn BMC Genomics 2013, 14:14 Page 5 of 13
http://www.biomedcentral.com/1471-2164/14/14[15]. Before adjustment, samples that were flagged during
quality assessment cluster closely together, irrespective of
the disease status of the samples. After adjustment, the
maximum distance between samples is greatly reduced,
and quality-flagged samples no longer cluster together.
Also, samples segregate more clearly by disease status
after adjustment. Furthermore, applying ComBat clearly
has a stabilising effect on the transcript clusters most
affected by RNA quality (Figure 5b & 5c).
SVA identified two surrogate variables that were subse-
quently used in downstream analysis. Plotting the estimates
of these surrogate variables for each sample revealed a pat-
tern whereby samples were clearly grouped by batch and
quality (Figure 6). Importantly, SVA identified these two















Figure 3 Characteristics of genes most affected by RNA degradation.
a) Fold change distribution of annotated transcript clusters comparing sam
uniquely identified genes. Expression signal significantly increased (Up) or d
a Mann-Whitney test. Adjusted p-value ≤ 0.01, |fold change| > 2.To evaluate the performance of each method, we first
compared the number of differentially expressed genes
detected between tumour and normal samples at a strin-
gent p-value of 0.01. For our analysis, we did not use a fold
change cutoff since we feel that artificial fold change cut-
offs, which exclude subtle changes in the expression of
many genes, may result in the loss of valuable biological
information, or worse, affect the interpretation of the data
– this is particularly true for applications such as network/
pathway analysis [16].
SVA and ComBat detected 2137 and 1945 genes
(p-value ≤ 0.01), respectively. The top four methods
had 1117 differentially expressed genes in common
(Figure 7). At the commonly used p-value- and fold






















p−val = 2.9e−9 p−val < 2.2e−16
Unaffected (18851) Down (1032) Up (140)
b
Comparison of samples that either passed or were flagged during QC.
ples that were flagged vs. samples that passed QC b) Gene lengths of






































































































































Figure 4 Expression profiles of samples clustered using average linkage hierarchical clustering. a) Sample clustering after preprocessing.
b) Sample clustering after preprocessing and correction for batch and quality using ComBat. Samples that were flagged during quality
assessment are highlighted in red. The dissimilarity measure (height) used was 1- Pearson correlation of the log2-transformed expression values.
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duced 447, 475, 461 and 521 differentially expressed
genes respectively, suggesting similar performance
under these criteria. We next assessed the relevance
of these differentially expressed genes in colorectal
cancer using Ingenuity Pathway Analysis where, sta-
tistically significant over-representation of our listed
genes in a given process such as “colorectal tumour”
or “infection of embryonic cell lines” is scored by
p-value.
We considered the top 10 functions for each method
(Table 2) from which it was clear that the 615 and 423 addi-
tional genes identified as differentially expressed by SVA
and ComBat, compared to that obtained when excluding



























































































































Figure 5 Boxplots of frma expression. a) All transcript clusters. b) Genes
Samples that were flagged during quality assessment are highlighted in recancer. Using IPA, we considered the top 10 upstream reg-
ulators (highest absolute activation z-scores) when compa-
ring tumour vs. normal samples, to further investigate the
utility of SVA or ComBat as suitable analysis methods when
including low-RIN samples (Table 3). We found conside-
rable overlap in the identity and direction of activation of
these upstream regulators between the methods compared.
qRT-PCR validation of select genes
In order to ascertain whether or not data obtained by
microarray analysis with low-RIN samples were comparable
to the results obtained using the method designed by Anto-
nov et al for qPCR analysis of low-RIN samples, we selected
two genes, dipeptidase 1 (DPEP1) and claudin 1 (CLDN1),























































































































most affected by quality (adjusted p-value ≤ 0.01, |fold change| > 2. c)
d.


























































Figure 6 Surrogate variable analysis results. Samples that were flagged during quality assessment are highlighted in red. Two latent variables















A (1522) B (2137)
C (1945) D (1638)
Figure 7 Venn diagram of unique differentially expressed genes (tumour vs. normal) with adjusted p-values ≤ 0.01 for the four best-
performing methods. A - removing quality-flagged arrays before analysis. B - applying SVA to batch corrected data. C - ComBat used to correct
for batch and quality. D - Array weights included in the linear model.
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Table 2 P-values for evidence for overrepresentation in the functions listed for each method
Functions A B C D E
Cancer 7.72E-29 NA 8.15E-24 NA 3.38E-23
cancer NA 2.58E-25 NA 2.70E-26 NA
carcinoma 8.64E-37 2.52E-33 1.87E-34 2.87E-32 5.56E-30
colon cancer 1.30E-26 1.19E-36 1.10E-26 1.99E-21 3.29E-21
colon tumor 1.10E-26 4.31E-37 3.65E-27 1.80E-21 7.28E-22
colorectal cancer 2.27E-26 4.74E-29 2.43E-26 1.11E-21 1.98E-23
colorectal tumor 2.28E-26 6.80E-29 2.97E-26 4.67E-22 1.72E-23
digestive organ tumor 2.68E-31 6.82E-32 1.24E-28 7.27E-27 2.72E-29
epithelial tumor 2.16E-38 NA 2.27E-35 NA 1.11E-30
gastrointestinal tract cancer 2.35E-25 2.42E-28 4.00E-24 3.19E-21 5.31E-22
intestinal cancer 2.02E-26 5.77E-29 2.58E-26 1.03E-21 1.55E-23
neoplasia NA 1.63E-24 NA 1.10E-25 NA
solid tumor 3.31E-35 8.07E-32 6.80E-33 4.65E-31 3.88E-29
tumorigenesis NA 1.55E-26 NA 3.31E-28 NA
uterine serous papillary cancer 3.46E-21 1.71E-20 8.61E-25 1.26E-22 1.14E-15
A - excluding quality-flagged arrays from the analysis. B - applying SVA to batch corrected data. C - ComBat used to correct for batch and quality. D - Array
weights included in the linear model. E - including batch and quality as factors in the linear model.
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integrity, we wished to compare microarray and qPCR data
for genes that were apparently unaffected by RNA integrity;
DPEP1 and CLDN1 were found to be significantly differen-
tially expressed in our microarray data by all of the five
methods used and, in addition, there is strong literature evi-
dence for their differential expression between tumour and
normal samples. From reference genes previously cited as
suitable for colorectal cancer studies, we selected those
most stably expressed in our cohort using the Normfinder
algorithm (UBC, B2M, ATP5E) [17-21]. We found good
correlations, for both CLDN1 (Adjusted R2 = 0.81) and
DPEP1 (Adjusted R2 = 0.83), between qRT-PCR- and
microarray-based fold change values (Figure 8), irrespective
of RIN score.
Discussion
RNA is extremely vulnerable to degradation and as such
has the potential to introduce a systematic bias in gene
expression measures. Reliable measures of sample and
data quality are therefore essential to evaluate the effects
of RNA integrity on accuracy, sensitivity and specificity
of gene expression results. From previous studies as well
as our own, it is now clear that the level of acceptable
RNA degradation within an experiment depends largely
on the experimental design, platform and application.
Multiple studies have demonstrated an improvement in
microarray and qRT-PCR performance by using random
priming when RNA integrity is in doubt. Here we
observed a direct association between RINs and array
quality in the majority of cases. To gauge the con-
sequences of using these arrays in downstream analysis,
we compared quality-flagged to quality-passed arraysand found a relatively small subset of genes, 1172/20019,
to be significantly affected (p-value 0.05, FC ≥ |2|) in our
samples on the Gene 1.0 ST platform. It is of course
possible that the exact identity and proportion of the
affected genes may differ between studies on Gene 1.0
ST arrays but, based on our data, we suggest that the
overall proportion of affected genes is unlikely to be sig-
nificantly different to that observed here. Depending on
the application, this may or may not have an effect on
the study outcome. However, the most common micro-
array applications such as finding differentially expressed
genes between two conditions, pathway analysis, and
clustering do not rely on interrogating specific genes
and appear to be largely robust to the effects of RNA
degradation on this platform (Table 2).
Using within- and between-array quality measures, we
investigated the relationship between RNA integrity and
array quality on Affymetrix Gene 1.0 ST arrays. We found
a combination of within- and between-array quality mea-
sures useful to rank samples by array quality. However,
the single most useful array quality measure appears to be
GNUSE, since it provides a more general measure of array
quality relative to a large set of publically available arrays.
We found that 86% of samples with RINs ≤ 3.3 were
flagged by at least two of our quality control measures.
One sample with RIN score < 3 passed all three quality
measures, although it did have relatively low array quality
weight. Furthermore, 10 out of 17 samples with RIN
scores ≤ 7 passed at least 2 out of 3 quality measures, sug-
gesting that the widely used RIN cutoff of 7 is too strin-
gent for Gene 1.0 ST arrays.
We then examined the genes most affected by RNA
degradation and demonstrated a relationship between
Table 3 Top 10 IPA-derived upstream regulators, by absolute activation z-score
A
Upstream Regulator Log Ratio Molecule Type Predicted Activation State Activation z-score p-value of overlap
TP53 transcription regulator Inhibited −4.88 1.05E-16
CDKN1A −0.469 kinase Inhibited −3.274 4.20E-10
TRAF2 enzyme Activated 2.804 3.06E-06
CCNK other Activated 2.905 3.83E-04
TNF cytokine Activated 2.935 7.69E-04
IL1B cytokine Activated 2.952 1.76E-01
TP63 transcription regulator Activated 3.181 8.37E-10
TREM1 other Activated 3.352 3.69E-05
FOXM1 1.37 transcription regulator Activated 4.28 3.71E-17
Mek group Activated 4.336 2.38E-07
B
Upstream Regulator Log Ratio Molecule Type Predicted Activation State Activation z-score p-value of overlap
TP53 0.622 transcription regulator Inhibited −5.749 6.48E-12
TGM2 enzyme Inhibited −4.243 3.64E-02
CDKN1A −0.485 kinase Inhibited −3.548 1.85E-10
KDM5B transcription regulator Inhibited −3.126 3.31E-08
NFkB (complex) complex Activated 3.034 3.59E-03
TREM1 other Activated 3.073 2.18E-05
TP63 transcription regulator Activated 3.63 6.25E-06
IL1B cytokine Activated 3.686 4.13E-01
FOXM1 1.29 transcription regulator Activated 3.925 5.82E-11
Mek group Activated 4.771 7.08E-08
C
Upstream Regulator Log Ratio Molecule Type Predicted Activation State Activation z-score p-value of overlap
TP53 transcription regulator Inhibited −5.126 1.30E-13
CDKN1A −0.496 kinase Inhibited −3.534 5.99E-10
TGM2 enzyme Inhibited −3.402 4.25E-02
miR-483-3p mature microRNA Inhibited −3.153 6.49E-03
EGFR kinase Activated 3.104 4.43E-03
IL1B cytokine Activated 3.281 1.73E-01
TP63 transcription regulator Activated 3.524 1.48E-09
TREM1 other Activated 3.845 5.74E-06
FOXM1 1.398 transcription regulator Activated 4.386 4.18E-16
Mek group Activated 4.654 9.72E-08
A - excluding quality-flagged arrays from the analysis. B - applying SVA to batch corrected data. C - ComBat used to correct for batch and quality.
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http://www.biomedcentral.com/1471-2164/14/14accuracy and length of the original transcript, with both
longer than average, and very short transcripts being
under- and overrepresented in quality-flagged samples
respectively. This is in contrast to the findings by Opitz
et al who found that short transcripts were more vulner-
able to the perceived effects of degradation, whereas
long transcripts were more stable relative to the average
length transcript [6]. Interestingly, of the genes that were
overrepresented in quality-flagged samples, 70% were
small non-protein coding RNAs, including 94 small nu-
cleolar RNAs, and 4 microRNAs, consistent with reportsthat microRNAs are more robust to RNA degradation
compared to mRNA [22], perhaps because they are more
thermodynamically stable than mRNAs.
Without excluding any genes, we then compared the
orthogonal approaches of either excluding quality-flagged
arrays or compensating for RNA degradation at different
steps in the analysis. Sample clustering showed that when
using ComBat adjustment, quality-flagged samples no
longer clustered together. Furthermore, samples tend to
segregate more clearly by disease status following adjust-
ment, which suggests that the algorithm is not introducing































Figure 8 DPEP1 and CLDN1 tumour vs. normal fold change (FC) results for qRT-PCR and microarray results. Samples that were flagged
during quality assessment are highlighted in red.
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diagnosed with a hereditary form of CRC (HNPCC) – it is
therefore not surprising that the ‘normal’ samples from
these patients form a separate cluster.
Irrespective of sample/array quality, applying compen-
satory measures for RNA degradation performed at least
as well as excluding arrays that were flagged during
quality assessment, as judged by gene expression analysis
and IPA. At a p-value of 0.01, SVA and Combat detected
the highest number of differentially expressed genes
between tumour and normal samples and the top four
methods applied here had 1117 differentially expressed
genes in common. To evaluate the biological plausibility
of the genes deemed significantly differentially expressed
between tumour and normal samples, we harnessed the
results from IPA to show that, in terms of the top sco-
ring biological functions and upstream regulators, there
is considerable overlap in the identity and direction of
biological activation when comparing analysis methods
that either excluded or included quality-flagged arrays.
These results suggest that our analysis strategies are bio-
logically sound and not biased by non-biological variance.
The relevance of each method will depend on the
downstream application and the proportion of quality-
flagged arrays: If a small percentage of arrays are flagged,
there might not be much benefit in including them for
downstream analysis. However, if a large proportion of
the arrays are affected by RNA quality – which is likely
to often be the case where the RNA is derived from irre-
placeable historical clinical samples – the ability to re-
tain all arrays and to account for these effects in the
analysis will be valuable. Here, ComBat may be useful if
direct data adjustment is required, e.g. for sample/gene
clustering. On the other hand, for analysis of differential
expression, especially when the source of non-biologicalvariance is not immediately apparent, SVA may be most
useful since it does not require supervision; notably, in
our hands SVA was able to identify two surrogate va-
riables which closely corresponded to “batch” and “qua-
lity” factors, judged by the grouping of samples. To
establish whether the measures used here to compensate
for quality-effects are superior to excluding these arrays
from the analysis will require a controlled study with
known true- and false-positives where the discriminatory
power of each method can be objectively investigated.
However, the significant overlap observed between the
differentially expressed genes identified by the different
approaches used here, combined with the considerable
overlaps in both biological function and upstream regula-
tors identified by pathway analysis of the resultant data,
argues against a simple expansion of false positives when
lower quality array data is included in the analyses. The
quality assessment and data analysis methods discussed
here should in principle be as useful for Affymetrix Exon
ST array analysis as well.Conclusions
In conclusion, array quality measures can be used to set
quality thresholds, to provide valuable information that
can be used to improve the linear model of differential ex-
pression, or to correct expression signal prior to assessing
differential expression. We suggest that accounting for
known or unknown sources of variation, such as variable
RNA integrity and batch, by implementing ComBat or
Surrogate Variable Analysis for analysis of differential gene
expression enables robust analysis of microarray datasets
derived from variable and low quality RNA, thereby
extending the range of clinical samples that are suitable
for microarray analysis.
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Sample collection and storage
Paired colorectal patient samples (diseased tumour tissue
and adjacent healthy gut epithelial tissue) were collected
during surgical resection of previously untreated patients
at the Groote Schuur Hospital, Cape Town, South Africa.
The samples were frozen immediately in liquid nitrogen
and stored at -80°C. Ethical consent was obtained (UCT
HREC REF 416/2005) and each patient provided written
informed consent to donate samples from the tissues left
over after surgical resection to subsequent molecular
studies.Sample preparation and quality control
Frozen samples were transitioned to RNAWlater-ICE
(Ambion), an RNA stabilisation solution, using dry ice
to prevent thawing of the tissue at any stage. RNA was
extracted using a Dounce homogenizer and the AllPrep
DNA/RNA/Protein kit (Qiagen) including DNAse treat-
ment. RNAseZap (Ambion) was used to eliminate
RNAse from the work surface, pipettes and glassware.
RNA integrity assessment was conducted on an Agilent
Bioanalyser 2100.Quantitative real-time PCR
From a biological perspective, we used the stability of
expression of housekeeping genes to investigate the
effect of RNA integrity on array- and qRT-PCR perform-
ance. Gene candidates were selected from those previ-
ously been specifically identified as good reference genes
for colorectal cancer [17-21]. Expression stabilities were
ranked using the Normfinder algorithm [23] and three
genes were selected for use as reference genes. All pri-
mers except those for b2m [24] were designed using
Primer-BLAST - sequences are shown in Table 4. Ex-
periments were performed in triplicate on a Roche
LightCyclerW 480 Real-Time PCR System in 96-well for-
mat. Efficiency was determined for each primer pair
using a two-fold dilution series across five points for five
patient samples of varying RNA integrity. For each pa-
tient, tumour vs. normal fold change was determined
based on the method of Antonov et al whereby the Ct of
the test gene is normalised by the geometric mean ofTable 4 Primers used for qRT-PCR analysis






atp5e CTGGACTCAGCTACATCCGAmultiple control genes [9]. Since our efficiencies were
quite low in some cases, we adapted the Antonov et al
method to include primer efficiency as shown in the
equation below:
eΔCt tð Þffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
eΔCt ið Þi  eΔCt iþ1ð Þiþ1 . . . eΔCt iþnð Þiþnnþ1
q
where t represents the test gene, e represents efficiency
and i represents the control gene(s).
Microarray analysis: Affymetrix HuGene 1.0 ST expression
arrays
Thirty-four samples with A260/230 ratios of at least 1.6,
RINs of at least 2 and no sign of genomic DNA contami-
nation, were selected for microarray analysis. The samples
were amplified from 200ng of total RNA in accordance
with the AmbionW WT Expression assay kit and fragmen-
ted and end labeled in accordance with the AffymetrixW
GeneChipW WT Terminal Labeling protocol. The prepared
targets were hybridized overnight to Affymetrix Human
Gene 1.0 ST arrays. Following hybridization, the arrays
were washed and stained using the GeneChip Fluidics Sta-
tion 450 and scanned using the GeneChipW Scanner 3000
7G. Arrays were processed in two batches - batch one had
10 arrays, and batch two 24. Individual patient pairs were
not split across batches.
Microarray quality assessment and data analysis
Standard Affymetrix quality control was conducted
using Expression ConsoleW Software: The quality of
cDNA preparation and array hybridisation was assessed
using appropriate spike-in controls at each stage.
Raw array quality was investigated at the probe level by
1) the difference between the mean of the perfect match
probes and the mean of the background probes for each
array as well as 2) the coefficient of variation (CV) across
all probes for each array. A threshold for the CV across
probes was set as two standard deviations from the mean
CV, where the mean was calculated from arrays with RINs
> 6. The data was preprocessed in R using the Bioconduc-
tor packages frma [25], oligo [26], and the ComBat algo-
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http://www.biomedcentral.com/1471-2164/14/14was assessed using the global normalised, unscaled stan-
dard error (GNUSE) [14]. The SE estimates are norma-
lized such that for each probe set, the median standard
error across all arrays is equal to 1. Since most genes are
not expected to be differentially expressed, boxplots for
each array should be centered around 1. Samples with a
median GNUSE of greater than 1.25 were flagged for
downstream analysis. This threshold is fairly arbitrary and
has not been validated for the Gene 1.0 ST platform but
roughly equates to having a precision that is on average
25% worse than the average Gene 1.0 ST array [14].
Five comparative methods for analysis of differential
expression were individually applied to the preprocessed
data: 1) The arrayWeights function in the Bioconductor
package limma [27] was used to estimate array quality
weights which were then included in the linear model fit;
2) Arrays that were flagged in array quality assessment
were excluded from the analysis; 3) The ComBat algo-
rithm [12] for batch correction was applied to directly
adjust the data according to quality, where arrays were
divided into two categories according to the array quality
assessment; 4) “Quality” and “batch” were included as a
factors in the linear model together with disease status; 5)
Surrogate variable analysis was applied to frma-processed
data without any direct adjustment, the output from SVA
being incorporated into the linear model fit [13].
To rank genes by evidence for differential expression, the
eBayes function in limma was applied to compute mode-
rated t-statistics, moderated F-statistic, and log-odds of dif-
ferential expression by empirical Bayes shrinkage of the
standard errors towards a common value [27]. Next, using
the topTable function in limma, p-values were adjusted for
multiple hypothesis testing using the Benjamini and
Hochberg method [28]. Transcript clusters were annotated
in R using the Bioconductor package hugene10sttran-
scriptcluster.db (Affymetrix Human Gene 1.0-ST Array
Transcriptcluster Revision 8 annotation data, assembled
using data from public repositories).
The subset of genes differentially affected by RNA qual-
ity was similarly obtained, now using array quality for
grouping, instead of disease status. Genes with adjusted
p-values ≤ 0.05 and FCs ≥ |2| were included in the analysis.
Transcript length was obtained for all annotated transcript
clusters using the Bioconductor package goseq [29]. Hier-
archical clustering with average linkage and Euclidian
distance as distance measure was performed in R using the
hclust function.
For Ingenuity Pathway Analysis, genes that were found to
be significantly differentially expressed for each method
(adjusted p-value ≤ 0.01), were used as input for IPAs “Core
Analysis”. Here, statistically significant over-representation
of our listed genes in a given process such as “colorectal
tumour” or “infection of embryonic cell lines” is scored by
p-value, using the right-tailed Fisher’s Exact Test. In thecase of upstream regulators, the predicted activation state
and activation z-score is based on the direction of fold
change values for genes in the input dataset for which an
experimentally observed causal relationship has been estab-
lished. Performance was assessed using the top 10 func-
tions in terms of p-values for each method while taking
into account the relevance of the function to colorectal
cancer.
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